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A B S T R A C T
Background
Child and adolescent obesity has increased globally, and can be associated with significant short- and long-term health consequences.
Objectives
To assess the efficacy of drug interventions for the treatment of obesity in children and adolescents.
Search methods
We searched CENTRAL, MEDLINE, Embase, PubMed (subsets not available on Ovid), LILACS as well as the trial registers ICTRP
(WHO) and ClinicalTrials.gov. Searches were undertaken from inception to March 2016. We checked references and applied no
language restrictions.
Selection criteria
We selected randomised controlled trials (RCTs) of pharmacological interventions for treating obesity (licensed and unlicensed for this
indication) in children and adolescents (mean age under 18 years) with or without support of family members, with a minimum of
three months’ pharmacological intervention and six months’ follow-up from baseline. We excluded interventions that specifically dealt
with the treatment of eating disorders or type 2 diabetes, or included participants with a secondary or syndromic cause of obesity. In
addition, we excluded trials which included growth hormone therapies and pregnant participants.
Data collection and analysis
Two review authors independently assessed trial quality and extracted data following standard Cochrane methodology. Where necessary
we contacted authors for additional information.
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Main results
We included 21 trials and identified eight ongoing trials. The included trials evaluated metformin (11 trials), sibutramine (six trials),
orlistat (four trials), and one trial arm investigated the combination ofmetformin and fluoxetine. The ongoing trials evaluatedmetformin
(four trials), topiramate (two trials) and exenatide (two trials). A total of 2484 people participated in the included trials, 1478 participants
were randomised to drug intervention and 904 to comparator groups (91 participants took part in two cross-over trials; 11 participants
not specified). Eighteen trials used a placebo in the comparator group. Two trials had a cross-over design while the remaining 19 trials
were parallel RCTs. The length of the intervention period ranged from 12 weeks to 48 weeks, and the length of follow-up from baseline
ranged from six months to 100 weeks.
Trials generally had a low risk of bias for random sequence generation, allocation concealment and blinding (participants, personnel
and assessors) for subjective and objective outcomes. We judged approximately half of the trials as having a high risk of bias in one or
more domain such as selective reporting.
The primary outcomes of this review were change in body mass index (BMI), change in weight and adverse events. All 21 trials
measured these outcomes. The secondary outcomes were health-related quality of life (only one trial reported results showing no
marked differences; very low certainty evidence), body fat distribution (measured in 18 trials), behaviour change (measured in six trials),
participants’ views of the intervention (not reported), morbidity associated with the intervention (measured in one orlistat trial only
reporting more new gallstones following the intervention; very low certainty evidence), all-cause mortality (one suicide in the orlistat
intervention group; low certainty evidence) and socioeconomic effects (not reported).
Intervention versus comparator for mean difference (MD) in BMI change was -1.3 kg/m2 (95% confidence interval (CI) -1.9 to -0.8;
P < 0.00001; 16 trials; 1884 participants; low certainty evidence). When split by drug type, sibutramine, metformin and orlistat all
showed reductions in BMI in favour of the intervention.
Intervention versus comparator for change in weight showed a MD of -3.9 kg (95% CI -5.9 to -1.9; P < 0.00001; 11 trials; 1180
participants; low certainty evidence). As with BMI, when the trials were split by drug type, sibutramine, metformin and orlistat all
showed reductions in weight in favour of the intervention.
Five trials reported serious adverse events: 24/878 (2.7%) participants in the intervention groups versus 8/469 (1.7%) participants in
the comparator groups (risk ratio (RR) 1.43, 95% CI 0.63 to 3.25; 1347 participants; low certainty evidence). A total 52/1043 (5.0%)
participants in the intervention groups versus 17/621 (2.7%) in the comparator groups discontinued the trial because of adverse events
(RR 1.45, 95% CI 0.83 to 2.52; 10 trials; 1664 participants; low certainty evidence). The most common adverse events in orlistat and
metformin trials were gastrointestinal (such as diarrhoea, mild abdominal pain or discomfort, fatty stools). The most frequent adverse
events in sibutramine trials included tachycardia, constipation and hypertension. The single fluoxetine trial reported dry mouth and
loose stools. No trial investigated drug treatment for overweight children.
Authors’ conclusions
This systematic review is part of a series of associated Cochrane reviews on interventions for obese children and adolescents and has
shown that pharmacological interventions (metformin, sibutramine, orlistat and fluoxetine) may have small effects in reduction in BMI
and bodyweight in obese children and adolescents. However,many of these drugs are not licensed for the treatment of obesity in children
and adolescents, or have been withdrawn. Trials were generally of low quality with many having a short or no post-intervention follow-
up period and high dropout rates (overall dropout of 25%). Future research should focus on conducting trials with sufficient power and
long-term follow-up, to ensure the long-term effects of any pharmacological intervention are comprehensively assessed. Adverse events
should be reported in a more standardised manner specifying amongst other things the number of participants experiencing at least
one adverse event. The requirement of regulatory authorities (US Food and Drug Administration and European Medicines Agency)
for trials of all new medications to be used in children and adolescents should drive an increase in the number of high quality trials.
P L A I N L A N G U A G E S U M M A R Y
Drug interventions for the treatment of obesity in children and adolescents
Review question
Do drug (medicine) interventions reduce weight in obese children and adolescents and are they safe?
Background
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Across the world more children and adolescents are becoming overweight and obese. These children and adolescents are more likely
to have health problems, both while as children or adolescents and in later life. More information is needed about what works best for
treating this problem recognising that so-called lifestyle changes (diet, exercise and counselling) have limited efficacy.
Study characteristics
We found 21 randomised controlled studies (clinical studies where people are randomly put into one of two or more treatment groups)
comparing various drugs plus a behaviour changing intervention such as diet, exercise or both (= intervention groups) usually with
placebo (a pretend drug) plus a behaviour changing intervention (= control groups). We also identified eight ongoing studies (studies
which are currently running but not completed yet). A total of 2484 children and adolescents took part in the included studies. The
length of the intervention period ranged from 12 weeks to 48 weeks, and the length of follow-up ranged from six months to 100 weeks.
Key results
The included studies investigated metformin (10 studies), sibutramine (six studies), orlistat (four studies) and one study group evaluated
the combination of metformin and fluoxetine. The ongoing studies are investigating metformin (four studies), topiramate (two studies)
and exenatide (two studies).
Most studies reported on body mass index (BMI) and bodyweight: BMI is a measure of body fat and is calculated from weight and
height measurements (kg/m2). In children, BMI is often measured in a way that takes into account sex, weight and height as children
grow older (BMI z score). The average change in BMI across control groups was between a 1.8 kg/m2 reduction to a 0.9 kg/m2
increase, while across all intervention groups the average reduction was more pronounced (1.3 kg/m2 reduction). The same effect
was observed for weight change: on average, children and adolescents in the intervention groups lost 3.9 kg more weight than the
children and adolescents in the control groups. Study authors reported an average of serious side effects in 24 per 1000 participants
in the intervention groups compared with an average of 17 per 1000 participants in the control groups. The numbers of participants
dropping out of the study because of side effects were 40 per 1000 in the intervention groups and 27 per 1000 in the control groups.
The most common side effects in the orlistat and metformin studies were gut (such as diarrhoea and mild tummy pain). Common side
effects in the sibutramine trials included increased heart rate (tachycardia), constipation and high blood pressure. The fluoxetine study
reported dry mouth and loose stools. One study reported health-related quality of life (a measure of physical, mental, emotional and
social functioning) and found no marked differences between intervention and control. No study reported the participants’ views of the
intervention or socioeconomic effects. Only one study reported on morbidity (how often a disease occurs in a specific area) associated
with the intervention, where there were more gallstones after the orlistat treatment. Study authors reported one suicide in the orlistat
intervention group. However, studies were not long enough to reliably investigate death from any cause. No study investigated drug
treatment for children who were only overweight (obese children have a much higher weight, BMI or BMI z score than children being
overweight).
This evidence is up to date to March 2016.
Quality of the evidence
The overall certainty of the evidence was low or very low, mainly because there were only a few studies per outcome measurement, the
number of included children or adolescents was small, and due to variation in the results of the studies. In addition, many children or
adolescents left the studies before the study had finished.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Drug interventions for the treatment of obesity in children and adolescents
Population: obese children and adolescents
Settings: mainly outpat ient sett ings
Intervention: metform in, orlistat , sibutramine usually combined with behaviour changing intervent ions
Comparison: placebo or no placebo usually with behaviour changing intervent ions
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Comparator Pharmacological inter-
vention
a. BM I (kg/ m2)
Follow-up: 6 months
(14 trials) - 12 months
(2 trials)
b. Body weight (kg)
Follow-up: 6 months
(10 trials) - 12 months
(1 trial)
a. The mean reduct ion
in BMI ranged across
control groups f rom -1.
8 to +0.9
b. The mean reduct ion
in weight ranged across
control groups f rom -3.
8 kg to +4.9 kg
a. The mean reduct ion
in BMI in the inter-
vent ion groups was -1.
3 higher (-1.9 to -0.8
higher)
b. The mean reduct ion
in weight in the inter-
vent ion groups was - 3.
9 kg higher (-5.9 kg to -
1.9 kg higher)
- a. 1884 (16)
b. 1180 (11)
a.
⊕⊕©©
L owa
b.
⊕⊕©©
Lowa
-
Adverse events
a. Serious adverse
events
b. Discont inuat ion of
trial because of adverse
events
Follow-up: most ly 6
months, maximum 100
weeks (1 trial)
a. 17 per 1000
b. 27 per 1000
a. 24 per 1000 (11 to
55)
b. 40 per 1000 (23 to
69)
a.RR 1.43 (0.63 to 3.25)
b.RR 1.45 (0.83 to 2.
52)
a. 1347 (5)
b. 1664 (10)
a.
⊕⊕⊕©
L owb
b.
⊕⊕⊕©
Lowb
All t rials reported if ad-
verse events occurred;
however, only 7/ 20 tri-
als reported the num-
ber of part icipants who
experienced at least 1
adverse event
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Health- related quality
of life
3 quest ionnaires (1
trial) and SF-36 (1 trial)
Follow-up: 6 months
See comment See comment See comment 86 (2) ⊕©©©
V ery lowc
Results were only re-
ported for SF-36 (1 trial
on sibutramine, 46 chil-
dren), there were no
marked dif ferences be-
tween intervent ion and
comparator groups
All- cause mortality
Follow-up: most ly 6
months, maximum 100
weeks (1 trial)
See comment See comment See comment 2176 (20) ⊕⊕⊕©
L owd
1 suicide in the orlistat
intervent ion group
M orbidity See comment See comment See comment 533 (1) ⊕©©©
V ery lowe
Only 1 trial invest igated
morbidity def ined as ill-
ness or harm associ-
ated with the interven-
t ion (Chanoine 2005).
In the orlistat group 6/
352 (1.7%) part icipants
developed new gall-
stones compared with
1/ 181 (0.6%) in the
placebo group
Socioeconomic effects See comment See comment See comment See comment See comment Not reported
* The basis for the assumed risk (e.g. the median control group risk across trials) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is based
on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
BM I: body mass index; CI: conf idence interval; RR: risk rat io; SF-36: Short-Form Health Survey 36 items.
GRADE Working Group grades of evidence
High certainty: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate certainty: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low certainty: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low certainty: We are very uncertain about the est imate.
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* Assumed risk was derived f rom the event rates in the comparator groups.
aDowngraded by two levels because of potent ial other risk of bias, inconsistency and imprecision (see Appendix 13).
bDowngraded by two levels because of potent ial report ing bias, inconsistency and imprecision (see Appendix 13).
cDowngraded by three levels because of one trial only with a small number of part icipants and imprecision (see Appendix 13).
dDowngraded by two levels because of short follow-up periods and no trial was powered to invest igate mortality (see Appendix
13).
eDowngraded by three levels because of one trial only and imprecision (see Appendix 13).
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
The prevalence of overweight and obese children and adolescents
has increased throughout the world, presenting a global public
health crisis (Ng 2014; WHO 2015). It is not only a problem in
high-income countries, but a high prevalence has also been found
in low- andmiddle-income countries (Wang 2012). Evidence sug-
gests that rates are slowing down or plateauing in high-income
countries; however, they are still rising in low- or middle-income
countries and prevalence continues to remain high in both (Olds
2011; Rokholm 2010). TheGlobal Burden of Disease Study 2013
reported a mean of 24% of boys and 23% of girls from high-
income countries to be overweight or obese, whilst the estimated
percentages of boys and girls in low- or middle-income countries
who are overweight or obese are 13% each (Ng 2014). This report
used the International Obesity Task Force (IOTF) age and sex
standardised cut points (Cole 2000). Furthermore, young children
also have a high prevalence of being overweight or obese with an
estimated 42 million overweight or obese children under five years
of age in 2010 (approximately 35 million living in low- or middle-
income countries - De Onis 2010); these statistics were based on
theWorld Health Organization (WHO) growth standard (WHO
2006).
An additional concern in some high-income countries, such as the
USA (Kelly 2013; Skinner 2014) and England (CMO 2014; Ells
2015a), is the rise in severe paediatric obesity. In England during
2012/2013, 2.9% of girls and 3.9% of boys, aged 10 to 11 years,
were classified as severely obese (body mass index (BMI) UK90
99.6th centile or greater - Ells 2015a). In the USA from 2011
to 2012, 2.1% of youths (aged 2 to 19 years) were categorised as
class 3 obese (Centers for Disease Control and Prevention growth
charts: BMI 140% of greater of the 95th percentile or BMI 40 kg/
m2 or greater - Skinner 2014).
Whilst the IOTF published an international definition for pae-
diatric severe (morbid) obesity in 2012 (Cole 2012), often severe
obesity prevalence is reported using country-specific cut points
making international comparisons difficult. Data from the USA
(Skinner 2014) and England (Ells 2015a) have shown that severe
paediatric obesity prevalence varies by socioeconomic status and
ethnicity, andmay result in greater risk of adverse cardio-metabolic
events and severe obesity in adulthood (Kelly 2013).
The prevalence of overweight and obese children is influenced by
inequalities, where rates are higher in children from areas of high
deprivation in high-income countries (Knai 2012; Shrewsbury
2008), and from more affluent areas in low- or middle-income
countries (Lobstein 2004; Wang 2012). Other variables are also
likely to influence obesity prevalence including age, sex and eth-
nicity, with varying rates found in different groups in the USA
(Freedman 2006; Skinner 2014), England (HSCIC 2014), and
New Zealand (Rajput 2014).
Description of the condition
Being overweight or obese in childhood is associated with many
conditions which may affect both physical and psychosocial
health. Such conditions include hypertension, insulin resistance
and hyperlipidaemia in obese children and adolescents, also in-
cluding very young children (Bocca 2013; Freedman 1999; Reilly
2003; Weiss 2004). The prevalence of type 2 diabetes has contin-
ued to increase in children and adolescents, with recent projections
in the USA suggesting a potential quadrupling from 2010 to 2050
in the number of youths (aged less than 20 years old) with type
2 diabetes (Imperatore 2012; Pinhas-Hamiel 2005). Being over-
weight or obese in early childhood has also been linked to increased
cardiovascular risk factors, such as high systolic blood pressure
(Falaschetti 2010), with such risks factors also beingpresent in peo-
ple with type 2 diabetes (Maahs 2014). In addition medical condi-
tions such as sleep apnoea, polycystic ovarian syndrome (PCOS)
and poor pulmonary function have also been linked to childhood
obesity (Dietz 1998; Ebbeling 2002; Lobstein 2004; Reilly 2003).
Furthermore, childhood obesity has been shown to be strongly
associated with nonalcoholic fatty liver disease (NAFLD), which
is the most common cause of chronic liver disease in children and
adolescents (Aggarwal 2014; Berardis 2014).
The condition can also affect the child’s mental health and lead
to early discrimination, low self-esteem and depression (Dietz
1998; Puhl 2007; Tang-Peronard 2008). There is also evidence
that childhood obesity also tracks into adulthood (Parsons 1999;
Singh 2008; Whitaker 1997), and hence is associated with an
increased risk of ill health in later life (Reilly 2011).
Description of the intervention
Since childhood obesity can potentially have serious consequences
on a child’s health and well-being, it is very important to identify
interventions which can treat obesity in both the short- and long-
term. The purposes of such interventions are similar to treatment
in adultswhereby the primary aims are: to reduce energy intake, in-
crease energy expenditure and decrease sedentary behaviour. How-
ever, the child’s age and baseline degree of obesity should be taken
into consideration before deciding the type, length and intensity
of the intervention. This will allow the intervention to bemore tai-
lored to the target population and potentially increase the chances
of success and reduce the likelihood of adverse events.
In recent years, only three drugs have been licensed for the treat-
ment of adult obesity: rimonabant, sibutramine and orlistat.How-
ever, none of these were licensed for use in children (Petkar 2013).
Rimonabant was withdrawn from the market due to psychiatric
adverse events and sibutramine was suspended by the European
Medicine Agency (EMA) and was withdrawn by the US Food and
Drug Administration (FDA) in 2010 due to cardiovascular ad-
verse effects; however, sibutramine is still licensed for treatment of
obesity in Brazil. Orlistat has been approved by the FDA but only
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for people over the age of 12 years (Sherafat-Kazemzadeh 2013).
In England, National Institute for Health and Care Excellence
(NICE) guidance recommends that orlistat should only be used
in children under 12 years old in exceptional circumstances where
severe comorbidities exist. Moreover, in children who are 12 years
or older, treatment is only recommended if there are physical co-
morbidities such as sleep apnoea or severe psychological comor-
bidities (NICE 2014).
Metformin has been approved by the FDA to treat type 2 diabetes
mellitus in both adults and children over the age of 10 years but
does not have approval for treating obesity in children or adults
(McDonagh 2014). However, an analysis of prescribing data in
the UK in 2011 showed metformin has regularly been prescribed
to treat childhood obesity, the main indication being PCOS (
Hsia 2011). Other drugs which have also previously been used
off-licence to treat obesity in children and adolescents include
antidepressants such as fluoxetine and bupropion (Petkar 2013).
While weight loss alone may be of clinical and psychological bene-
fit, additional health benefits may be achieved by the amelioration
of obesity-related disorders, such as hyperglycaemia in type 2 dia-
betes (Pandey 2015), pain andmobility in osteoarthritis (Widhalm
2016), and improvement in obstructive sleep apnoea (Nespoli
2013). Weight loss may also reduce the risk factors for cardio-
vascular and metabolic disease (Halpern 2010), or even prevent
the development of disease, for example type 2 diabetes (Power
2014). While registration of drugs usually does not require such
clinical endpoints, people and health economic considerations in-
creasingly demand evidence on more than just weight or BMI re-
duction, data that would be more difficult to establish in children
and adolescents and have been poorly, if at all, studied.
Adverse effects of the intervention
One systematic review of pharmacological options for managing
paediatric obesity stated that the most common adverse events
when taking orlistat were gastrointestinal problems related to
increased fat excretion (e.g. fatty or oily stools, increased defe-
cation, soft stools, flatus, faecal leakage). Other adverse events
included long-term fat-soluble deficiencies, decrease in vitamin
D concentrations and asymptomatic gallstones (Boland 2015).
The most frequent adverse events associated with metformin are
gastrointestinal, some of which can be intolerable (McCreight
2016). A change in dose or duration may resolve these ad-
verse effects (McDonagh 2014). Common adverse effects of sibu-
tramine included dry mouth, headaches, constipation and insom-
nia (Cheung 2013). However, the drug has also been linked to in-
creased risk of nonfatal stroke ormyocardial infarction, as shown in
the Sibutramine Cardiovascular Outcomes (SCOUT) trial (James
2010). Consequently, the drug was withdrawn from the market
in numerous countries including the UK, USA and Australia.
How the intervention might work
Sibutramine is a serotonin and norepinephrine reuptake inhibitor.
It works by reducing hunger and improving satiety leading to de-
creased food intake (Catoira 2010). Orlistat leads to the excre-
tion of approximately 30% of ingested fat; it works by acting as a
gastrointestinal lipase inhibitor (Yanovski 2014). Metformin is a
biguanide derivative which activates adenosine monophosphate-
activated protein kinase leading to the reduction of glucose pro-
duction and absorption in the intestines and increasing insulin
sensitivity. It is thought to reduce bodyweight by inhibiting fat cell
lipogenesis and potentially may decrease food intake by increasing
glucagon-like peptide (Matson 2012). Fluoxetine is an antidepres-
sant which works by inhibiting serotonin re-uptake. It can result
in weight loss by decreasing appetite and therefore inhibiting en-
ergy intake (Ye 2011). Hence, it is important to recognise that any
drug that produces aversive taste or gastrointestinal adverse effects
could produce weight loss by such adverse effects (Halford 2010).
Why it is important to do this review
In 2003, a systematic Cochrane Review was published entitled
“Interventions for treating obesity in children” which assessed
the effects of lifestyle interventions (dietary, physical activity, be-
havioural, or a combination of these) and included the analysis
of childhood obesity treatment trials published up to July 2001
(Summerbell 2003). The second version of this Cochrane Review
was published in 2009 providing an update to the 2003 review,
and assessing the effects of pharmacological and surgical interven-
tions (Oude Luttikhuis 2009).
To reflect the rapid growth in this field, the third update to this
review has been split across six reviews focusing on the follow-
ing treatment approaches: “Surgery for the treatment of obesity
in children and adolescents” (Ells 2015b); “Drug interventions
for the treatment of obesity in children and adolescents”; “Parent-
only interventions for childhood overweight or obesity in chil-
dren aged 5 to 11 years” (Loveman 2015); “Diet, physical activity,
and behavioural interventions for the treatment of overweight or
obesity in preschool children up to the age of 6 years” (Colquitt
2016); “Diet, physical activity and behavioural interventions for
the treatment of overweight or obesity in school children from the
age of 6 to 11 years”; and “Diet, physical activity, and behavioural
interventions for the treatment of overweight or obesity in ado-
lescents aged 12 to 17 years”. This review in this series focuses
on the efficacy of pharmacological interventions for obese chil-
dren and adolescents. The review complements the Cochrane Re-
view of “Long-term pharmacotherapy for obesity and overweight”
(Padwal 2003), which does not provide randomised controlled
trial (RCT) data on pharmacological interventions for children
and adolescents.
The results of this current review and other systematic reviews in
this series will provide information on which to underpin clinical
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guidelines and health policy on the treatment of children and
adolescents who are overweight or obese.
O B J E C T I V E S
To assess the effects of drug interventions for the treatment of
obesity in children and adolescents.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included RCTs where the length of the intervention had to be
at least three months and the length of follow-up from baseline
had to be a least six months.
Types of participants
We included trials evaluating obese children and adolescents with
a mean age of less than 18 years at the commencement of the
intervention. We excluded trials with pregnant or critically ill par-
ticipants. We excluded interventions that specifically dealt with
the treatment of eating disorders or type 2 diabetes, or included
participants with a secondary or syndromic cause of obesity.
Types of interventions
We investigated any pharmacological intervention which aimed
to treat paediatric obesity, using any of the following intervention
versus control sequences, where the same letters indicate direct
comparisons.
Intervention
• (a) Pharmacological intervention.
• (b) Pharmacological intervention plus other therapy.
Comparator
• (a1) Placebo.
• (a2) Usual care.
• (b1) Placebo plus other therapy.
• (b2) Usual care plus other therapy.
Concomitant therapies were required to be the same in both the
intervention and comparator groups.
Summary of specific exclusion criteria
• Trials which included a growth hormone therapy as
treatment for obesity.
• Trials which included pregnant participants.
• Trials which included participants who were critically ill.
• Trials where participants had a secondary or syndromic
cause of obesity.
• Interventions that specifically dealt with the treatment of
eating disorders or type 2 diabetes.
• Trials in which the aim was not to treat obesity in children
or adolescents.
• Duration of intervention less than three months.
• Duration of follow-up less than six months.
Types of outcome measures
Primary outcomes
• Body mass index (BMI) and bodyweight.
• Adverse events.
Secondary outcomes
• Health-related quality of life and self-esteem.
• Body fat distribution.
• Behaviour change.
• Participants’ views of the intervention.
• Morbidity.
• All-cause mortality.
• Socioeconomic effects.
Timing of outcome measurement
• BMI: defined as weight (kg) divided by height (m) squared,
and bodyweight (kg): measured at baseline, 6, 12, 24 and more
than 24 months.
• Adverse events: defined as an adverse outcome that
occurred during or after the intervention but was not necessarily
caused by it, and measured at any time during the trial.
• Health-related quality of life and self-esteem: evaluated by a
validated instrument such as the Paediatric Quality of Life
Inventory and measured at baseline, 6, 12, 24 and more than 24
months.
• Body fat distribution: defined by validated tools such as
dual energy X-ray absorptiometry (DEXA), waist circumference,
skin fold thickness, waist-to-hip ratio and bioelectrical
impedance analysis and measured at baseline, 6, 12, 24 and more
than 24 months.
• Behaviour change: evaluated by a validated instrument and
measured at baseline, 6, 12, 24 and more than 24 months.
• Participants’ views of the intervention: defined as
documented accounts from participant feedback and measured
at baseline, 6, 12, 24 and more than 24 months.
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• Morbidity: defined as illness or harm associated with the
intervention and measured at baseline, 6, 12, 24 and more than
24 months.
• All-cause mortality: defined as any death that occurred
during or after the intervention and measured at any time during
the trial.
• Socioeconomic effects: defined as a validated measure of
socioeconomic status such as parental income or educational
status and measured at baseline, 6, 12, 24 and more than 24
months.
’Summary of findings’ table
Wepresented a ’Summary of findings’ table to report the following
outcomes, listed according to priority.
• BMI and bodyweight.
• Adverse events.
• Health-related quality of life.
• All-cause mortality.
• Morbidity.
• Socioeconomic effects.
Search methods for identification of studies
Electronic searches
We searched the following sources on 15March 2016 from incep-
tion to the specified date.
• Cochrane Central Register of Controlled Trials
(CENTRAL) via Cochrane Register of Studies Online (CRSO).
• Ovid MEDLINE(R) In-Process & Other Non-Indexed
Citations and Ovid MEDLINE(R) (1946 to 15 March 2016).
• PubMed (subsets not available on Ovid) (15 March 2016).
• Embase 1974 to 2016 Week 11.
• LILACS (15 March 2016).
• ClinicalTrials.gov (15 March 2016).
• WHO International Clinical Trials Registry Platform
(ICTRP; apps.who.int/trialsearch/) (15 March 2016).
For detailed search strategies, see Appendix 1. We continuously
applied an email alert service for MEDLINE via OvidSP to iden-
tify newly published trials using the search strategy detailed in
Appendix 1. If we detected additional relevant key words during
any of the electronic or other searches, we modified the electronic
search strategies to incorporate these terms and documented the
changes. We placed no restrictions on the language of publication
when searching the electronic databases or reviewing reference lists
of identified trials.
Searching other resources
We attempted to identify other potentially eligible trials or ancil-
lary publications by searching the reference lists of retrieved in-
cluded trials, (systematic) reviews, meta-analyses and health tech-
nology assessment reports.
Data collection and analysis
Selection of studies
To determine the trials to be assessed further, two review authors
(of EM, LE, CO) independently scanned the abstract, title, or
both, of every record retrieved by the searches. We obtained full-
text articles of all those trials deemed potentially relevant for in-
clusion. We resolved any differences in opinion by consultation
of a third review author (of GA, EC, LE). If there was an out-
standing issue with the trial, we added the article to those ’await-
ing assessment’ and we contacted trial authors for clarification.
We presented an adapted PRISMA flow diagram of trial selection
(Figure 1) (Liberati 2009).
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Figure 1. Trial flow diagram.
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Data extraction and management
For trials that fulfilled the inclusion criteria, two review authors
(of EM, LE, GA, NF, EC, LB, CO) independently extracted key
participant and intervention characteristics and reported data on
efficacy outcomes and adverse events using standard data extrac-
tion templates. We resolved any disagreements by discussion, or,
if required, by consultation with a third review author (of NF,
EC, LB, GA) (for details see Table 1; Appendix 2; Appendix 3;
Appendix 4; Appendix 5; Appendix 6; Appendix 7; Appendix 8;
Appendix 9; Appendix 10; Appendix 11).
We provided information, including trial identifier, about po-
tentially relevant ongoing trials in the Characteristics of ongoing
studies table and in Appendix 5. We tried to obtain the protocol
of each included trial, either in trial registers or in publications of
trial designs, or both, and specified the data Appendix 5.
We sent an email to all authors of included trials to enquire
whether they were willing to answer questions regarding their tri-
als. Appendix 12 shows the results of this survey. Thereafter, we
sought relevant missing information on the trial from the primary
author(s) of the article, if required.
Dealing with duplicate and companion publications
In the event of duplicate publications, companion documents or
multiple reports of a primary trial, we tried to maximise yield
of information by collating all available data and used the most
complete data set aggregated across all known publications. In case
of doubt, we gave priority to the publication reporting the longest
follow-up associated with our primary or secondary outcomes.
Assessment of risk of bias in included studies
Two review authors (of EM, LE, GA, NF, EC, LB, CO) indepen-
dently assessed the risk of bias of each included trial. We resolved
possible disagreements by consensus, or with consultation of a
third party. In cases of disagreement, the rest of the group were
consulted and a judgement was made based on consensus.
We assessed risk of bias using Cochrane’s ’Risk of bias’ tool
(Higgins 2011a; Higgins 2011b). We used the following criteria.
• Random sequence generation (selection bias).
• Allocation concealment (selection bias).
• Blinding (performance bias and detection bias), separated
for blinding of participants and personnel and blinding of
outcome assessment.
• Incomplete outcome data (attrition bias).
• Selective reporting (reporting bias).
• Other bias.
We assessed outcome reporting bias by integrating the results of
’Examination of outcome reporting bias’ (Appendix 6), ’Matrix of
trial endpoints (publications trial documents)’ (Appendix 5), and
section ’Outcomes (outcomes reported in abstract of publication)’
of the Characteristics of included studies table (Kirkham 2010).
This analysis formed the basis for the judgement of selective re-
porting (reporting bias).
We judged risk of bias criteria as ’low risk’, ’high risk’ or ’un-
clear risk’ and evaluated individual bias items as described in the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011a). We presented a ’Risk of bias’ graph and a ’Risk of bias’
summary figure.
We assessed the impact of individual bias domains on trial results
at endpoint and trial levels.
For blinding of participants and personnel (performance bias),
detection bias (blinding of outcome assessors) and attrition bias
(incomplete outcome data), we intended to evaluate risk of bias
separately for subjective and objective outcomes (Hróbjartsson
2013). We considered the implications of missing outcome data
from individual participants.
We defined the following endpoints as self-reported outcomes.
• All self-reported data such as a self-reported health-related
quality of life questionnaires.
We defined the following endpoints as investigator-assessed out-
comes.
• All measured data such as assessor measured height and
weight.
Measures of treatment effect
We expressed continuous data as mean differences (MD) with
95% confidence intervals (CI). We expressed dichotomous data
as odds ratios (ORs) or risk ratios (RRs) with 95% CIs. We used
ComprehensiveMeta Analysis (CMA) version 3 and ReviewMan-
ager 5 (RevMan 2014) to conduct the meta-analyses.
Unit of analysis issues
We tried to consider the level at which randomisation occurred,
such as cross-over trials, cluster-randomised trials and multiple
observations for the same outcome.
Dealing with missing data
We obtained relevant missing data from trial authors, if feasible,
and evaluated important numerical data such as screened, eligi-
ble, randomised participants as well as intention-to-treat (ITT),
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as-treated and per-protocol (PP) populations. We investigated at-
trition rates, for example dropouts, losses to follow-up and with-
drawals, and critically appraised issues of missing data and impu-
tation methods (e.g. last observation carried forward (LOCF)).
Where standard deviations (SD) for outcomes were not reported,
we imputed these values by assuming the SD of the missing out-
come to be the mean of the SDs from those trials where this infor-
mation was reported. We investigated the impact of imputation
on meta-analyses by means of sensitivity analyses.
Assessment of heterogeneity
In the event of substantial clinical or methodological heterogene-
ity, we did not report trial results as meta-analytically pooled effect
estimates. We identified heterogeneity by visual inspection of the
forest plots and by using a standard Chi2 test with a significance
level of α = 0.1, in view of the low power of this test. We examined
heterogeneity using the I2 statistic, which quantifies inconsistency
across trials to assess the impact of heterogeneity on themeta-anal-
ysis (Higgins 2002; Higgins 2003), where an I2 statistic of 75%
or more indicates a considerable level of inconsistency (Higgins
2011a). We also calculated Tau2, another statistic that provides
information about heterogeneity.
When we found heterogeneity, we attempted to determine po-
tential reasons for it by examining individual trial and subgroup
characteristics.
We expected the following characteristics to introduce clinical het-
erogeneity.
• Differences in the age of trial population.
• Differences in the trial population demographics.
• Differences in the types of drugs.
• Differences in BMI at baseline.
Assessment of reporting biases
If we included 10 trials or more for a given outcome, we used
funnel plots to assess small-trial effects. Due to several explanations
for funnel plot asymmetry, we interpreted results carefully (Sterne
2011).
Data synthesis
Unless there was good evidence for homogeneous effects across
trials, we primarily summarised low risk of bias data by means of
a random-effects model (Wood 2008). We interpreted random-
effectsmeta-analyses with due consideration of the whole distribu-
tion of effects, ideally by presenting a prediction interval (Higgins
2009). A prediction interval specifies a predicted range for the true
treatment effect in an individual trial (Riley 2011). In addition,
we performed statistical analyses according to the statistical guide-
lines referenced in the latest version of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011a).
Quality of evidence
Wepresented the overall certainty of the evidence for each outcome
specified under ’Types of outcome measures: Summary of findings
table’ according to the GRADE approach which considers issues
not only related to internal validity (risk of bias, inconsistency,
imprecision, publication bias) but also to external validity such as
directness of results.Two review authors (EM, GA) independently
rated the certainty for each outcome. We presented a summary of
the evidence in Summary of findings for the main comparison,
which provides key information about the best estimate of the
magnitude of the effect, in relative terms and absolute differences
for each relevant comparison of alternativemanagement strategies,
numbers of participants and trials addressing each important out-
come and the rating of the overall confidence in effect estimates
for each outcome. We created the Summary of findings for the
main comparison based on the methods described in theCochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011a).
We presented results on the outcomes as described in Types of
outcomemeasures. If meta-analysis was not possible, we presented
results in a narrative form in Summary of findings for the main
comparison.
In addition, we established an appendix ’Checklist to aid con-
sistency and reproducibility of GRADE assessments’ (Meader
2014) to help with standardisation of ’Summary of findings’ tables
(Appendix 13).
Subgroup analysis and investigation of heterogeneity
We planned to carry out the following subgroup analyses and
investigated interactions.
• Length of follow-up.
• Impact and nature of maintenance periods.
• The impact of comparator/control: whether concomitant
therapy or no treatment (true control).
• The impact of population demographics.
Sensitivity analysis
We planned to performed sensitivity analyses to explore the influ-
ence of the following factors on effect size.
• Restricting the analysis to published trials.
• Restricting the analysis considering risk of bias, as specified
in the Assessment of risk of bias in included studies section.
• Restricting the analysis to very long or large trials (more
than 300 participants in total) to establish how much they
dominated the results.
• Restricting the analysis to trials using the following filters:
diagnostic criteria, language of publication, source of funding
(industry versus other), country.
We also tested the robustness of the results by repeating the analysis
using different measures of effect size (RR, OR, etc.) and different
statistical models (fixed-effect and random-effects models).
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R E S U L T S
Description of studies
For a detailed description of trials, see the Characteristics
of included studies, Characteristics of excluded studies and
Characteristics of ongoing studies tables.
Results of the search
Our comprehensive literature searches identified 4995 records;
from these, 199 full-text papers or clinical trial records were iden-
tified for further examination. We excluded trials based on their
titles or abstracts because they did not meet the inclusion crite-
ria or were not relevant to the question under trial (see Figure 1
for the amended PRISMA flow diagram). After screening the full
text of the selected publications, 21 completed trials (33 publica-
tions) met the inclusion criteria and were included in the quali-
tative synthesis of this review. All trials were published in English
apart from Franco 2014 (Portuguese) and Prado 2012 (Spanish).
We contacted all trial authors of the included trials and received
a reply from all but four authors (Atabek 2008; Berkowitz 2003;
Berkowitz 2006; Ozkan 2004). We sought additional informa-
tion from the authors of all 21 trials, 12 authors responded to
these requests and provided further data (Chanoine 2005; Clarson
2009; Franco 2014; Freemark 2001; Godoy-Matos 2005; Maahs
2006; Mauras 2012; NCT00001723; Prado 2012; Rezvanian
2010; Srinivasan 2006; Van Mil 2007). We also identified eight
ongoing trials, and an additional seven trials were placed in the
’awaiting classification’ section because we could not source the
full publication, the trial was completed but there was not yet
enough information to include it in this review or the publication
was identified when a final draft of the review had been completed
(NCT01487993).
Included studies
Adetailed description of the characteristics of included trials is pre-
sented elsewhere (seeCharacteristics of included studies; Appendix
2; Appendix 3; Appendix 4). The following is a succinct overview.
Source of data
The literature search identified all 21 included trials in the review
and all but one (NCT00001723) were published trials. Ten out
of 21 trials were included in the previous review (Oude Luttikhuis
2009), and information relating to these 10 trials was extracted
from the 2009 review - two review authors extracted any missing
information from the publication. All ongoing trials were found
from searching online clinical trial registers.
Comparisons
Of the 21 included trials, 11 used metformin in their intervention
arm; four of these trials gave metformin plus a behaviour changing
programme to the intervention group and used a placebo plus a
behaviour changing programme in the comparator group (Prado
2012; Wiegand 2010; Wilson 2010; Yanovski 2011). Two tri-
als compared metformin plus a behaviour changing programme
against a behaviour changing programme alone without using a
placebo (Clarson 2009; Mauras 2012). Four trials compared met-
formin plus a behaviour changing intervention against placebo
plus a behaviour changing intervention (Atabek 2008; Kendall
2013;Rezvanian 2010; Srinivasan 2006). Rezvanian 2010 also had
two additional intervention arms: metformin plus fluoxetine plus
healthy eating plus physical activity advice; and fluoxetine plus
healthy eating plus physical activity advice. The remaining trial
compared metformin with placebo; hence, there was no lifestyle
component included in either arm (Freemark 2001).
Six trials used sibutramine as the pharmacological intervention;
three trials compared sibutramine plus a behaviour changing pro-
gramme with placebo plus a behaviour changing programme
(Berkowitz 2003; Berkowitz 2006; Van Mil 2007). The other
three trials compared sibutramine plus dietary/exercise advice with
placebo plus dietary/exercise advice (Franco 2014;García-Morales
2006; Godoy-Matos 2005).
Four trials investigated orlistat. Chanoine 2005,Maahs 2006, and
NCT00001723 examined orlistat plus a behaviour changing in-
tervention versus placebo plus a behaviour changing intervention.
Ozkan 2004 did not include a placebo in their comparator group;
hence, they compared orlistat plus a behaviour changing interven-
tion with a behaviour changing intervention only.
Overview of trial populations
A total of 2484 children and adolescents participated in the 21 in-
cluded trials. A total of 1851 participants finished the trial (74.5%)
and hence we measured at the study’s endpoint. In 10 studies, the
dropout rates were higher in the placebo group than the inter-
vention group, potentially showing some dissatisfaction with the
control condition. The individual trial sample size ranged from
24 to 539 participants.
The 11 metformin trials included 885 participants. The individ-
ual trial sample size ranged from 26 to 155 participants. One met-
formin trial also included two additional intervention arms of flu-
oxetine and fluoxetine plus metformin (45 randomised partici-
pants in each intervention arm).
The six sibutramine trials included 778 participants. The individ-
ual trial sample size ranged from 24 to 498 participants.
The four orlistat trials included 821 participants. The individual
trial sample size ranged from 40 to 539 participants.
Trial design
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Trials were RCTs. Nineteen trials adopted a parallel group su-
periority design and two were cross-over trials (Franco 2014;
Srinivasan 2006). All but three trials used a placebo compara-
tor (Clarson 2009; Mauras 2012; Ozkan 2004). Five trials were
multicentred (Berkowitz 2006; Chanoine 2005; Kendall 2013;
Wiegand 2010; Wilson 2010), with the number of centres rang-
ing from two (Wiegand 2010) to 33 (Berkowitz 2006). In terms
of blinding, 14 trials were double-blinded for participants and
personnel (Berkowitz 2003; Berkowitz 2006; Chanoine 2005;
Franco 2014; Freemark 2001; Godoy-Matos 2005; Maahs 2006;
NCT00001723; Prado 2012; Rezvanian 2010; Srinivasan 2006;
Van Mil 2007; Wilson 2010; Yanovski 2011), no trials were sin-
gle-blinded for participants, and four trials did not define blind-
ing (Atabek 2008; García-Morales 2006; Kendall 2013; Ozkan
2004). Thirteen trials blinded outcome assessors (Berkowitz 2003;
Berkowitz 2006; Chanoine 2005; Franco 2014; Freemark 2001;
Godoy-Matos 2005; Maahs 2006; NCT00001723; Rezvanian
2010; Srinivasan 2006; Van Mil 2007; Wiegand 2010; Wilson
2010; Yanovski 2011). Trialswere published between the 2001 and
2014; all but one sibutramine trial were published before the drug
was withdrawn by the FDA - Franco 2014 was conducted in Brazil
where the drug is still licensed. All metformin trials were published
between 2006 and 2012 apart from Freemark 2001. Orlistat trials
were published between 2004 and 2006, but one trial did not have
any publications available and only posted results on a clinical trial
website and in a conference abstract (NCT00001723).
The durationof interventions ranged from12weeks to 17months,
with a mean duration of 28 weeks. The duration of follow-up
(from end of intervention) ranged from0 to 52weeks, with amean
follow-up period of 12 weeks. Participants in nine trials received
the intervention/comparator for six months with no additional
follow-up; in three trials, participants received the intervention/
comparator for six months, which was then followed by an open-
label period for six months (Berkowitz 2003; NCT00001723;
Yanovski 2011); two trials received the intervention for 12months
with no additional follow-up (Berkowitz 2006; Chanoine 2005);
two cross-over trials included a six-month intervention or control
condition followed by a washout period, then each participant
crossed over into the alternative condition for an additional six
months (Franco 2014; Srinivasan 2006); three trials included an
intervention/comparator period for three months (or 12 weeks)
then a follow-up period for an additional three months (or 12
weeks) (Prado 2012 Rezvanian 2010; Van Mil 2007); one trial
gave the intervention or comparator condition for 48 weeks, then
included an additional follow-up period for another 48 weeks (
Wilson 2010); andfinally in one trial the length of the intervention
and follow-up varied across participants (Ozkan 2004).
Five trials had a run-in period, of which three included a placebo
run-in phase (Chanoine 2005;Godoy-Matos 2005;Wilson2010),
with a duration varying from two to four weeks; Freemark 2001 in-
cluded 48-hour inpatient tests as their run-in period; two trial gave
dietetic advice/counselling (García-Morales 2006; Godoy-Matos
2005); Wilson 2010 also included a lifestyle modification pro-
gramme in their run-in period. Outcomes were not assessed in
these run-in periods. Furthermore, three trials included an open-
label phase six months after randomisation where both groups re-
ceived the drug intervention (Berkowitz 2003; NCT00001723;
Yanovski 2011); these open-label phases were not included in our
analyses. Participants in one of these trials were also followed up
for two years after the open-label phase (NCT00001723). None
of the included trials were terminated before regular end; however,
two trials that we identified from ClinicalTrials.gov were termi-
nated before enrolment and have been placed in the excluded trials
section (see Characteristics of excluded studies table).
Settings
Nine of the 21 trials were conducted in the USA (Berkowitz 2003;
Berkowitz 2006; Chanoine 2005; Freemark 2001; Maahs 2006;
Mauras 2012; NCT00001723; Wilson 2010; Yanovski 2011).
The other trials were completed in Turkey (Atabek 2008; Ozkan
2004), Canada (Chanoine 2005; Clarson 2009), Brazil (Franco
2014; Godoy-Matos 2005), Mexico (García-Morales 2006), the
UK (Kendall 2013), Australia (Srinivasan 2006), Chile (Prado
2012), Iran (Rezvanian 2010), the Netherlands (Van Mil 2007),
Germany (Wiegand 2010), and Switzerland (Wiegand 2010). All
trials were performed in an outpatient setting apart from three tri-
als which had both an inpatient and outpatient setting (Freemark
2001; Maahs 2006; Yanovski 2011).
Participants
The participating population consisted of the following: mainly
obese children or adolescents (Maahs 2006 also included over-
weight participants). The mean age of the participants in the
trials ranged from 10.1 to 16.3 years with only two trials hav-
ing a mean age less than 12 years old (Atabek 2008; Yanovski
2011). Two studies required all participants to be postmenar-
chal (Berkowitz 2003; Prado 2012), while Yanovski 2011 only
included children who were prepubertal or early pubertal. Fif-
teen trials included participants from high-income countries, and
six recruited participants from middle-income countries (Atabek
2008; Franco 2014; García-Morales 2006; Godoy-Matos 2005;
Ozkan 2004; Rezvanian 2010) - based on the World Bank list
of economies July 2015 (World Bank 2015). Ethnic groups were
distributed as follows: six trials did not report on ethnic groups
(Atabek 2008; Franco 2014; Ozkan 2004; Prado 2012; Rezvanian
2010; Van Mil 2007); one trial reported all their participants
were white (Clarson 2009), three trials reported approximately
75% of their population were white (Chanoine 2005; Kendall
2013; Wiegand 2010); five trials reported approximately half of
their population were white (Berkowitz 2003; Berkowitz 2006;
Freemark 2001; Mauras 2012; Wilson 2010); one trial reported
that approximately 60%of their populationwereHispanic (Maahs
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2006); one trial reported approximately 50% of their popula-
tion were non-Hispanic (Yanovski 2011); 63% of participants
in one trial were non-Hispanic black people while the remain-
ing were non-Hispanic white people (NCT00001723); and one
trial reported that 64% of their participants came from ethnic
backgrounds with a high prevalence of insulin resistance and
metabolic syndrome (Srinivasan 2006). Participants’ sex was not
distributed evenly in 11 trials (Berkowitz 2003; Berkowitz 2006;
Chanoine 2005; Freemark 2001; Godoy-Matos 2005; Kendall
2013;Maahs 2006; NCT00001723; Prado 2012;Wiegand 2010;
Wilson 2010). Three trials reported glycosylated haemoglobin
A1c (HbA1c) at baseline and the mean HbA1c ranged from
5.3% to 5.6% (Freemark 2001; Maahs 2006; Wilson 2010).
The mean BMI at baseline for the interventions groups ranged
from 26.5 kg/m2 to 41.5 kg/m2. The BMI at baseline for the
comparator groups ranged from 26.2 kg/m2 to 41.7 kg/m2.
Thirteen trials reported comorbidities of participants at baseline
(Atabek 2008; Berkowitz 2006; Chanoine 2005; Clarson 2009;
Freemark 2001; García-Morales 2006; Kendall 2013; Mauras
2012; NCT00001723; Prado 2012; Srinivasan 2006; Wiegand
2010; Yanovski 2011), all but one trial (Freemark 2001) reported
cointerventions in participants, and four trials had comedications
used by participants (NCT00001723; Ozkan 2004;Wilson 2010;
Yanovski 2011). Criteria for entry into the individual trials are
outlined in the Characteristics of included studies table. Major
trial exclusion criteria were major illnesses such as type 1 or 2 dia-
betes mellitus or cardiovascular disease; pregnancy; major psychi-
atric disorders; taking or previously taken medication known to
influence body composition or contradiction to the drug therapy;
cigarette smoking or alcohol use; obesity associated with genetic
disorders; and eating disorders such as bulimia. Adherence/com-
pliance with the intervention was reported in most trials as good
(70% or more) and was usually assessed by pill counts.
Diagnosis
All trials included participants who were defined as obese at base-
line according to the growth reference they used, apart from one
trial (Maahs 2006), which also included overweight children in
their inclusion criteria. Seven trials define obesity using the 95th
percentile or greater cut-off on the Centers for Disease Control
and Prevention (CDC; Kuczmarski 2000) charts (Atabek 2008;
Clarson 2009; García-Morales 2006; Mauras 2012; Rezvanian
2010; Wilson 2010; Yanovski 2011), but Wilson 2010 also re-
quired their participants to weigh less than 136 kg. One trial used
greater than 85th percentile (to include also overweight partici-
pants) (Maahs 2006), while VanMil 2007 used the 97th percentile
or greater but also further selected for triceps skinfold thickness
97th percentile or greater for age and sex. NCT00001723 defined
obesity by BMI for age and triceps skinfold above the 95th per-
centile (determined by National Health and Nutrition Examina-
tion Survey (NHANES) I age-, sex- and race-specific data) and
all participants were required to be over 60 kg in bodyweight.
Alternatively two trials used the definition of obesity given by
Rosner 1998 of two units more than the US weightedmean of the
95th percentile but no greater than 44 kg/m2 (Berkowitz 2006;
Chanoine 2005). One trial used the IOTF (Cole 2000) defini-
tions for obesity (Srinivasan 2006), while another used theWHO
(WHO 1995) growth standards cut-off (Franco 2014). Kendall
2013 used the UK BMI growth charts (Cole 1995), and used the
98th centile as the cut-off for obesity. One trial usedGerman refer-
ences (Kromeyer-Hausschild 2001) to define obesity using greater
than 97th percentile (Wiegand 2010). Three trials used raw BMI
to define obesity: BMI greater than 30 kg/m2 (Freemark 2001);
BMI 32 kg/m2 to 44 kg/m2 (Berkowitz 2003); and BMI 30 kg/m
2 to 45 kg/m² (Godoy-Matos 2005). In two trials, it was unclear
which growth reference charts theywere referring to (Ozkan 2004;
Prado 2012). Participants were diagnosed with type 1 or 2 dia-
betes mellitus in none of our included trials. However, some trials
included additional inclusion criteria other than age and obesity:
Atabek 2008 required all participants to have hyperinsulinaemia;
Clarson 2009 only includedparticipantswhowere insulin resistant
(defined by homeostasis model assessment (HOMA) for insulin
resistance values greater than 3); Godoy-Matos 2005 required all
participants to have an adult bone age determined by left hand
radiography (Greulich-Pyle method); Kendall 2013 only included
participants who had impaired glucose tolerance or hyperinsuli-
naemia; NCT00001723 only recruited participants who had co-
morbidities at baseline and these included hypertension, hyperin-
sulinaemia and hepatic steatosis; Srinivasan 2006 only included
participants where there was a suspicion of insulin resistance (fast-
ing insulin to glucose ratio greater than 4.5 or presence of acan-
thosis nigricans); Prado 2012 required all participants to present
with at least one risk factor for type 2 diabetes (e.g. first- or second-
degree relative with history of type 2 diabetes); Mauras 2012 only
included participants who had normal glucose tolerance but also
had elevated highly sensitive C-reactive protein (hsCRP), fibrino-
gen concentrations or both; Freemark 2001 inclusion criteria in-
cluded a fasting insulin concentration exceeding 15 IU/mL and at
least one first- or second-degree relative with type 2 diabetes; and
Yanovski 2011 required all participants to have hyperinsulinaemia
(defined as fasting insulin 15 IU/mL or greater). All participants in
Wiegand 2010 presented with comorbidities at baseline (features
of the metabolic syndrome); however, this did not appear to be an
inclusion criterion.
Interventions
Eleven trials used metformin as their pharmacological interven-
tion (Atabek 2008; Clarson 2009; Freemark 2001; Kendall 2013;
Mauras 2012; Prado 2012; Rezvanian 2010; Srinivasan 2006;
Wiegand 2010; Wilson 2010; Yanovski 2011). The intervention
was administered orally and varied between one and four times per
day. Between trials, the daily dosage of metformin varied between
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500 mg and 2000 mg, with a mean daily dosage of 1364 mg. Four
metformin trials reported treatment before the start of the trial
(Kendall 2013; Rezvanian 2010; Wiegand 2010; Wilson 2010);
this included a healthy ’lifestyle’ advice sheet, lifestyle modifica-
tion treatment and a six-month multiprofessional lifestyle inter-
vention. Seven trials had a titration period, consisting of increasing
the number of tablets taken over a period of weeks until the maxi-
mum dosage was tolerated (Clarson 2009; Kendall 2013; Mauras
2012; Rezvanian 2010; Srinivasan 2006; Wilson 2010; Yanovski
2011). Two trials did not have a matching placebo in the com-
parator group - participants received a lifestyle intervention only
(Clarson 2009; Mauras 2012). The duration of treatment ranged
from 12 weeks/three months to six months with a mean treatment
duration of 5.5 months.
Six trials used sibutramine as their intervention (Berkowitz 2003;
Berkowitz 2006; Franco 2014; García-Morales 2006; Godoy-
Matos 2005; Van Mil 2007). In all six trials, the drug was admin-
istered orally once daily. The daily dosage of sibutramine varied
between 5 mg and 15 mg, with a mean daily dose of 11 mg. Three
trials reported that participants received treatment before the start
of the trial (Franco 2014; García-Morales 2006; Godoy-Matos
2005); this included dietetic advice/counselling and a six-month
lifestyle intervention. Two trials had a titration period (Berkowitz
2003; Van Mil 2007). All trials had a matching placebo as the
comparator intervention. The duration of treatment ranged from
12 weeks to 12 months, with a mean treatment duration of 6.5
months.
Four trials gave orlistat to their intervention group (Chanoine
2005; Maahs 2006; NCT00001723; Ozkan 2004). The drug was
administered orally three times per day and the daily dosage of
orlistat was 360 mg in all four trials. No trials gave participants
any treatment before the trial. One trial did not give a match-
ing placebo to the comparator group - participants received a
lifestyle intervention only (Ozkan 2004). The duration of treat-
ment ranged from six months to 12 months, with a mean treat-
ment duration of 8.9 months.
One trial also included two additional intervention arms: met-
formin plus fluoxetine and fluoxetine only (Rezvanian 2010). The
drugs were given by the oral route once daily. The daily dose of
fluoxetine was 20 mg. Participants were also given lifestyle modifi-
cation treatment before the start of the trial. They also had a titra-
tion period. The comparator group received a matching placebo.
The duration of treatment was 12 weeks.
Outcomes
Fourteen trials explicitly stated a primary endpoint in the publica-
tion (Berkowitz 2003; Berkowitz 2006; Chanoine 2005; Clarson
2009; García-Morales 2006; Godoy-Matos 2005; Kendall 2013;
Maahs 2006; Mauras 2012; Prado 2012; VanMil 2007; Wiegand
2010; Wilson 2010; Yanovski 2011), 10 trials reported ’sec-
ondary’ endpoints (Berkowitz 2003; Berkowitz 2006; Chanoine
2005; García-Morales 2006; Godoy-Matos 2005; Kendall 2013;
Maahs 2006; Wiegand 2010; Wilson 2010; Yanovski 2011).
NCT00001723 had no publication attached; however, the trial
authors reported both a primary and secondary endpoint on the
clinical trials website. The most commonly defined primary out-
comes in publications were change in absolute BMI, change in
BMI z score/standard deviation score (SDS) and change in body-
weight. The most commonly defined primary outcomes in trial
protocols were change in BMI from baseline and per cent change
in BMI.
Reporting of endpoints
Twenty-one trials collected a mean of 14 (range four to 25) out-
comes. All 21 trials measured raw BMI. Ten trials reported change
in BMI z score/SDS (Berkowitz 2003; Clarson 2009; Freemark
2001; Kendall 2013; NCT00001723; Srinivasan 2006; Van Mil
2007; Wiegand 2010; Wilson 2010; Yanovski 2011). All 21 trials
reported on whether adverse events occurred. Of those trials which
reported adverse events, some reported the total number of ad-
verse events whilst others reported the total number of participants
who experienced at least one adverse event. We asked all authors
to provide further details on adverse events, such as how many
participants experienced severe adverse events and if so, whether
they were hospitalised. Two trials measured health-related quality
of life with validated questionnaires (García-Morales 2006;Maahs
2006). Seventeen trials reported that theymeasured body fat distri-
bution. Fifteen trialsmeasuredwaist circumference, hip circumfer-
ence, or both (Berkowitz 2003; Berkowitz 2006; Chanoine 2005;
Clarson 2009; Franco 2014; García-Morales 2006; Godoy-Matos
2005; Kendall 2013; Mauras 2012; Prado 2012; Rezvanian 2010;
Srinivasan 2006; Wiegand 2010; Wilson 2010; Yanovski 2011).
Seven trials measured body fat mass by DEXA (Chanoine 2005;
Mauras 2012; NCT00001723; Srinivasan 2006; Van Mil 2007;
Wilson 2010; Yanovski 2011). Two trials also measured body fat
mass by bioelectrical impedance (Maahs 2006; Wiegand 2010).
Six trials measured behaviour change (Atabek 2008; Berkowitz
2003; García-Morales 2006; Kendall 2013; Maahs 2006; VanMil
2007). Five trials measured food consumption through dietary
records or questionnaires (Atabek 2008; García-Morales 2006;
Kendall 2013; Maahs 2006; Van Mil 2007), and one trial mea-
sured the feeling of hunger (Berkowitz 2003). Two trials measure
changes in physical activity: Kendall 2013 used a physical activity
questionnaire and Van Mil 2007 measured total energy expendi-
ture which accounts for level of physical activity. Only one trial in-
vestigated morbidity defined as illness or harm associated with the
intervention (Chanoine 2005). One trial reported a death from
suicide (Maahs 2006). Berkowitz 2006 reported two suicide at-
tempts which did not result in death.
No trials assessed participants’ views or socioeconomic effects as
outcomes. For a summary of all outcomes assessed in each trial,
see Appendix 5.
17Drug interventions for the treatment of obesity in children and adolescents (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Excluded studies
We excluded 135 trials or trial records after careful evaluation
of the full publication. The main reasons for exclusion were the
participants were adults or had a mean age of more than 18 years,
the trial design was not an RCT, the duration of treatment was less
than three months or the duration of follow-up was less than six
months. For further details, see Characteristics of excluded studies
table.
Risk of bias in included studies
For details on risk of bias of included trials see Characteristics of
included studies table. For an overview of review authors’ judge-
ments about each risk of bias item for individual trials and across
all trials, see Figure 2 and Figure 3. We investigated performance
bias, detection bias and attrition bias separately for objective and
subjective outcome measures.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included trials.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
trial.
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Allocation
Fifteen trials reported allocation was concealed (Berkowitz
2006; Chanoine 2005; Franco 2014;Freemark 2001; García-
Morales 2006; Godoy-Matos 2005; Kendall 2013; Mauras
2012; NCT00001723; Prado 2012; Rezvanian 2010; Srinivasan
2006; Wiegand 2010; Wilson 2010; Yanovski 2011); two tri-
als did not conceal allocation (Clarson 2009; Ozkan 2004).
It was unclear whether four trials concealed allocation (Atabek
2008; Berkowitz 2003; Rezvanian 2010;Wiegand 2010) ). Four-
teen trials reported an adequate random sequence generation
(Berkowitz 2006; Chanoine 2005; Clarson 2009; Franco 2014;
Freemark 2001; García-Morales 2006; Kendall 2013; Mauras
2012; NCT00001723; Prado 2012; Rezvanian 2010; Srinivasan
2006; Wilson 2010; Yanovski 2011). Two trials reported random
sequence generation was inadequate; hence, would have likely of
introduced bias (Maahs 2006; Ozkan 2004).Five trials did not de-
scribe the randomisation process (Atabek 2008; Berkowitz 2003;
Godoy-Matos 2005; Van Mil 2007; Wiegand 2010).
Blinding
All 21 trials reported both objective and subjective outcomes. The
main objectives outcomes were BMI, weight, waist or hip circum-
ference, blood pressure, cholesterol insulin, glucose and triglyc-
erides, whilst the main subjective outcomes were adverse events,
food consumption and health-related quality of life. Subjective
outcomes tended to be self-reported (e.g. quality of life and dietary
questionnaires), while objective measures usually were investiga-
tor-assessed (e.g. BMI, waist circumference). Adverse events could
be either self-reported or investigator assessed.
Ten trials explicitly stated that blinding of the participants, per-
sonnel and outcome assessors was undertaken (Berkowitz 2003;
Berkowitz 2006; Franco 2014; Maahs 2006; NCT00001723;
Rezvanian 2010; Srinivasan 2006; Van Mil 2007; Wilson 2010;
Yanovski 2011). Seven trials reported that double blinding took
place (Atabek 2008; Chanoine 2005; Freemark 2001; García-
Morales 2006; Godoy-Matos 2005; Kendall 2013; Wiegand
2010), but only three of the trials’ authors confirmed this meant
blinding was undertaken of participants, personnel and outcomes
assessors (Chanoine 2005; Freemark 2001; Godoy-Matos 2005).
No trials reported that single blinding was undertaken. Six trials
did not provide sufficient information about blinding procedures
(Atabek 2008; García-Morales 2006; Kendall 2013; Ozkan 2004;
Prado 2012; Wiegand 2010).
Incomplete outcome data
Twenty trials that had losses to follow-up described the num-
ber of trial withdrawals (Berkowitz 2003; Berkowitz 2006;
Chanoine 2005; Clarson 2009; Franco 2014; Freemark 2001;
García-Morales 2006; Godoy-Matos 2005; Kendall 2013; Maahs
2006; Mauras 2012; NCT00001723; Ozkan 2004; Prado 2012;
Rezvanian 2010; Srinivasan 2006; Van Mil 2007; Wiegand 2010;
Wilson 2010; Yanovski 2011). Twelve trials used ITT analy-
ses (Berkowitz 2003; Berkowitz 2006; Chanoine 2005; García-
Morales 2006; Godoy-Matos 2005; Kendall 2013; Maahs 2006;
NCT00001723; Rezvanian 2010; Van Mil 2007; Wilson 2010;
Yanovski 2011). One trial did not report whether there were any
losses to follow-up (Atabek 2008). Five trials did not provide de-
tailed descriptions of participants’ withdrawals and reasons un-
derpinning them (Atabek 2008; Franco 2014; Freemark 2001;
García-Morales 2006;Mauras 2012). Four trials had attrition rates
greater than 30%with possible impact on the outcomes(Chanoine
2005; Franco 2014; Mauras 2012; Prado 2012;Wilson 2010).
Selective reporting
Only nine trials provided a clinical trial identifier or reference
to a protocol (Berkowitz 2003; Berkowitz 2006; Kendall 2013;
Mauras 2012; NCT00001723; Srinivasan 2006; Wiegand 2010;
Wilson 2010; Yanovski 2011); however, we were unable to source
the clinical trial entry of one trial (Wiegand 2010). Three trials
had a high risk of reporting bias after failure to report results for
one or more outcomes they described as having measured (Atabek
2008; García-Morales 2006; Maahs 2006), and a further trial had
a high risk due to differences in results reported on the clinical
trial website and in a conference abstract (NCT00001723). The
remaining trials had unclear risk of reporting bias due to no pro-
tocol being available.
Other potential sources of bias
Seven trials were at high risk of other biases. These biases in-
cluded: the trial not including a power calculation (Atabek 2008;
Clarson 2009; Franco 2014; Freemark 2001; Godoy-Matos 2005;
Ozkan 2004), the trial lacking methodological detail (Atabek
2008; Franco 2014) and the trial not adjusting for baseline differ-
ences (Freemark 2001;Ozkan 2004), The remaining 14 trials were
at unclear risk of other potential sources of bias. It is important
to note that the trials which do not include a power calculation
may not be powered to detect differences in their primary out-
come. BMI or weight was the primary outcome in all but two trials
(Mauras 2012; Wiegand 2010) that included a power calculation.
Mauras 2012 and Wiegand 2010 may not have been adequately
powered to detect differences in BMI or weight. With regards to
adverse events and the review’s secondary outcomes (e.g. morbid-
ity), it is likely that most trials would not have been powered to
detect differences in these outcomes. Hence, these results should
be interpreted with caution.
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Effects of interventions
See: Summary of findings for the main comparison Drug
interventions for the treatment of obesity in children and
adolescents
Baseline characteristics
For details of baseline characteristics, see Appendix 3 andAppendix
4.
Pharmacological intervention versus comparators
We performed the meta-analyses with CMA software version 3
and aligned with the data in the Review Manager 5 (RevMan
2014) meta-analyses. Because the cross-over design did not appear
suitable for our research question due to inadequate washout pe-
riods and noncomparable baseline measures in the two cross-over
periods, we excluded Franco 2014 and Srinivasan 2006 from all
meta-analyses. We also excluded Rezvanian 2010 from the meta-
analyses because the reported SDs were unreliably small in com-
parison to all other published SDs of included trials and probably
denoted standard errors. We excluded two further trials because of
substantial methodological concerns (Ozkan 2004; Prado 2012).
In addition, Prado 2012 did not report change in BMI from base-
line to follow-up and Ozkan 2004 did not have a consistent fol-
low-up time frame across all participants.
Primary outcomes
Body mass index and bodyweight
We included 16 trials in the meta-analysis of BMI. Most of the
BMI data were from the publications, except for Chanoine 2005
and Freemark 2001, where raw BMI, SDs or both were not avail-
able; hence, we obtained additional data from the trial authors.
We extracted data for NCT00001723 from the ClinicalTrials.gov
website. In themeta-analysis, we included trials which had either a
six-month or 12-month follow-up frombaseline (Berkowitz 2006;
Wilson 2010), which was the endpoint in most of the trials. How-
ever, even though Chanoine 2005 had a 12-month follow-up, we
only had data available at six months from baseline. Wilson 2010
provided data at 100weeks’ follow-up butwe did not include these
in the meta-analysis.
The summary estimate across all pharmacological interventions
versus all comparators (metformin, orlistat or sibutramine mostly
versus placebo - usually combined with behaviour changing inter-
ventions) showed a MD in BMI change of -1.3 kg/m2 (95% CI
-1.9 to -0.8; P < 0.00001; 16 trials; 1884 participants; low cer-
tainty evidence - Analysis 1.1) in favour of the drug interventions.
Heterogeneity was considerable (I2 = 77%).
InWilson 2010, which reported a BMI change at 100 weeks from
baseline (48 weeks of metformin or placebo treatment, then a
48-week drug-free period), the metformin group increased their
BMI during the drug-free period (+0.5) while the placebo group
decreased their BMI (-0.8), measured as the difference between
52 and 100 weeks from baseline. In the metformin plus fluoxetine
trial, the fluoxetine only group had a decrease in BMI of -0.6 (SD
0.1) and the metformin plus fluoxetine group had a decrease in
BMI of -0.9 (SD 0.02), compared to an increase of 0.2 (SD 0.04)
in the placebo group at 24 weeks from baseline.
Only 11 trials reported weight data at baseline or follow-up (or
change from baseline) in their publications; hence, we only in-
cluded these trials in the meta-analysis. Data were reported at
six months from baseline apart from one trial (Berkowitz 2006),
which reported the change in weight at 12 months from baseline.
The summary estimate across all pharmacological interventions
versus comparators (metformin, orlistat or sibutraminemostly ver-
sus placebo - usually combined with behaviour changing inter-
ventions) showed an MD in change in weight of -3.9 kg (95% CI
-5.9 to -1.9; P < 0.00001; 11 trials; 1180 participants; low cer-
tainty evidence - Analysis 2.1) in favour of the drug interventions.
Heterogeneity was considerable (I2 = 79%).
Adverse events
Only three trials had sufficiently long exposure times to evaluate
adverse events possibly associated with drug interventions for obe-
sity in children and adolescents: one trial with 39 participants ran-
domised to metformin treatment for 100 weeks (Wilson 2010),
one trial with 368 participants randomised to sibutramine treat-
ment for 12 months (Berkowitz 2006), and one trial with 357 par-
ticipants randomised to orlistat treatment for 54 weeks (Chanoine
2005).
Adverse events were reported to have occurred in all 11 metformin
trials except from Clarson 2009, which reported that metformin
was well tolerated, and the author clarified no adverse events oc-
curred. Gastrointestinal adverse events were most commonly re-
ported with one metformin trial reporting that gastrointestinal
adverse events were statistically more prevalent in the intervention
group compared to the control group (Yanovski 2011). However,
Wiegand 2010 reported such events occurred more frequently in
the placebo group. Kendall 2013 reported adverse events were
more common in the metformin group and were mainly gastroin-
testinal. Atabek 2008 reported that two metformin-treated partic-
ipants experienced diarrhoea, mild abdominal pain/discomfort, or
both. Freemark 2001 also reported three participants experienced
transient abdominal discomfort or diarrhoea, however so did one
placebo participant. Wilson 2010 reported that the most com-
mon adverse events included headache, nausea, vomiting, upper
respiratory tract infection and musculoskeletal complaints; how-
ever, none were statistically different between the metformin and
placebo groups. One trial showed the fatigue was more common
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in the metformin-treated children (Yanovski 2011). Furthermore,
Freemark 2001 reported one case of an exacerbation of migraine
and one case of transient nausea in the metformin arm. Nausea
was reported in the Srinivasan 2006 trial where two participants
were unable to tolerate a higher dose of metformin (1 g); however,
they tolerated a lower dose and continued in the trial. Yanovski
2011 also reported that levels of serum vitamin B12 were reduced
in the metformin group compared with an increase in the placebo
group - this difference was statistically significant. Rezvanian 2010
reported two cases of headache, two cases of abdominal pain and
three cases of loose stools in the metformin arm but they were
all minor and tolerable. Mauras 2012 reported metformin was
well tolerated and safe, and the author added that the adverse ef-
fects between groups were comparable. Prado 2012 reported met-
formin was well tolerated by participants and both groups showed
a significant increase in alanine transaminase (ALT) and aspartate
transaminase (AST), and a reduction in haemoglobin levels, but
these were within the normal ranges.
Three of six trials on sibutramine therapy reported on adverse
events: one large trial showed tachycardia, dry mouth, constipa-
tion, dizziness, insomnia and hypertension were all reported more
frequently by sibutramine participants than by placebo partici-
pants (Berkowitz 2006). Sibutramine-treated participants also had
a higher blood pressure and pulse rate at 12 months’ follow-up
compared to the placebo-treated participants (Berkowitz 2006).
However, another trial reported that there was no statistically sig-
nificant difference between changes in heart rate or blood pressure
between the sibutramine and placebo groups, although abdominal
cramps were significantly higher in the sibutramine group (Van
Mil 2007). Godoy-Matos 2005 showed constipation was signifi-
cantly higher in the sibutramine group compared to the placebo
group.
All four orlistat trials reported on adverse events: gastrointestinal
problems such as fatty stools, oily spotting and fecal urgency, along
with headaches and upper respiratory tract infections, were the
most common adverse effects. In the NCT00001723 trial, the
prevalence of some gastrointestinal problems was higher in the
orlistat group compared to the placebo group and this included:
fatty-appearing stools, bloating/gas, frequent urge for bowelmove-
ment and uncontrolled passage of stool or oil. Chanoine 2005 re-
ported that gastrointestinal tract-related adverse events were more
common in the orlistat group compared to the placebo group;
however, most were classed as mild to moderate intensity. Maahs
2006 also reported that the orlistat group had significantly in-
creased gastrointestinal adverse events (e.g. soft stools, oily spot-
ting) compared to the placebo group. Mild gastrointestinal com-
plaints (frequent stools) were experienced by all orlistat-receiving
participants in theOzkan 2004 trial. Chanoine 2005 also reported
that 10 orlistat and one placebo participant showed abnormalities
detected on electrocardiograms; however, an independent cardi-
ologist concluded that none were connected to the treatment; in
addition, levels of oestradiol in girls decreased in the orlistat group
versus a slight increase in the placebo group (P = 0.05). Symp-
tomatic gallstones were also seen in six orlistat participants which
were not seen at baseline (five of these participants had lost large
amounts of weight).
In the trial which included a fluoxetine arm, there were five adverse
events with regards to the drug which included three cases of dry
mouth and two cases of loose stool; these were all considered as
minor and tolerable, and reported as transient (Rezvanian 2010).
Serious/severe adverse events were also investigated: most trials
did not report how they defined a serious/severe adverse event.
It was also unclear in four trials whether a serious/severe adverse
event actually occurred (Berkowitz 2003; Ozkan 2004; Van Mil
2007; Wiegand 2010). Only five trials reported that a serious or
severe adverse event occurred (Berkowitz 2006; Chanoine 2005;
Maahs 2006; NCT00001723; Wilson 2010); the remaining 12
trials reported that there were no serious or severe adverse events.
Across all trials the RR for serious adverse events comparing drug
interventions with comparators was 1.43 (95% CI 0.63 to 3.25; P
= 0.39; 5 trials; 1347 participants; low certainty evidence - Analysis
3.1). Absolute numbers experiencing a serious adverse event were
24/878 (2.7%) participants in the drug intervention groups versus
8/469 (1.7%) participants in the comparator groups.
In the metformin trials, only one trial reported that there were se-
rious adverse events and these included one case of appendectomy
and one case of leg vein thrombosis in the metformin group, but
these were both seen as unrelated to the drug (Wilson 2010). One
sibutramine trial reported that 2.7% of sibutramine-treated par-
ticipants experienced serious adverse events which included one
case of excessive nausea and vomiting, one suicide attempt and
five depression cases (Berkowitz 2006). The placebo group had
one case of suicide attempt and one case of depression. Chanoine
2005 reported 3% of participants experienced at least one serious
adverse event: the five events in the placebo group included acute
demyelinating encephalomyelitis, facial palsy, pneumonia, wors-
ening of asthma and pain in the right side; and the 11 events in
the orlistat group included pilonidal abscess, depression, asthma
attack, seizure, admission for repair of deviated nasal septum, ap-
pendicitis, cholelithiasis, gallbladder disorder followed by chole-
cystectomy, adenoidal hypertrophy and aseptic meningitis. It was
only the case of cholelithiasis in the orlistat participant which was
seen to be possibly related to the trial medication potentially due
to rapid weight loss. Another orlistat trial reported two serious
adverse events in the placebo group and these were one case of
hypoglycaemia and one case of left lower quadrant pain and vom-
iting (NCT00001723).
In the sibutramine trials, 32 participants (24 in the intervention
groups and eight in the control groups) left the trial because of
adverse events. Berkowitz 2006 reported that withdrawals due to
tachycardia were similar in both groups but hypertension led to
the withdrawal of five participants in the sibutramine group versus
none in the placebo group. Two cases of attempted suicide (one
intervention and one placebo) also led to discontinuation but were
22Drug interventions for the treatment of obesity in children and adolescents (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
considered unlikely to be related to the trial drug; one case of
excessive nausea and vomiting in the sibutramine group also led to
withdrawal and may have been related to the drug. Van Mil 2007
had one withdrawal from the sibutramine group due to symptoms
of clinical depression and Berkowitz 2003 had one withdrawal
from the placebo group.
In the metformin trials, nine participants withdrew due to adverse
events (five in intervention group and four in placebo group).
Wilson 2010 reported one participant from the metformin group
withdrew due to nausea which was probably related to the drug,
and a further twometformin andone placeboparticipants dropped
out of the trial due to elevated levels of ALT. Gastrointestinal
symptoms caused 6% of participants (one in metformin group
and three in placebo group) to drop out of theWiegand 2010 trial.
In addition, Yanovski 2011 reported one participant dropped out
of the metformin group due to medication intolerance.
Across all trials the RR for discontinuing the trial because of ad-
verse events comparing drug interventions with comparators was
1.45 (95% CI 0.83 to 2.52; P = 0.19; 10 trials; 1664 participants;
low certainty evidence - Analysis 3.2). Absolute numbers discon-
tinuing the trial because of an adverse event were 52/1043 (5.0%)
participants in the drug intervention groups versus 17/621 (2.7%)
participants in the comparator groups.
All four orlistat trials had dropouts due to adverse events; 28 par-
ticipants (23 in the intervention group and five in the placebo
group). Chanoine 2005 reported 12 dropouts (3%) in the orlis-
tat group and three dropouts (2%) in the placebo group, mainly
due to gastrointestinal adverse events. Ozkan 2004 reported seven
participants (32%) dropped out of the orlistat group due to gas-
trointestinal complaints. Maahs 2006 reported two participants in
the orlistat group discontinued due to adverse events (assumed to
be gastrointestinal) and one participant in the orlistat group com-
mitted suicide. NCT00001723 reported one participant in the
orlistat group and two participants in the placebo group dropped
out of the trial due to medication intolerance.
For further details, see Appendix 9, Appendix 10, and Appendix
11.
Secondary outcomes
Health-related quality of life
Two trials measured health-related quality of life; the certainty
of the evidence was very low. García-Morales 2006 used the 36-
Item Short-Form Health Survey (SF-36) questionnaire and found
changes in the total score were slightly higher in the sibutramine
group compared to the placebo group, but this difference was
not statistically significant. Maahs 2006 used three questionnaires
to assess health-related quality of life, but found no statistically
significant differences between the orlistat and placebo group from
baseline to six months. For further details on the health-related
quality of life measurements, see Appendix 14.
Body fat distribution
Eighteen trials reported outcomes which measured body fat dis-
tribution. Fifteen of these trials measured waist, hip, or both cir-
cumferences at baseline and follow-up. In the metformin trials,
Mauras 2012 found greater decreases in waist circumference in
the metformin plus diet plus exercise group compared with the
diet plus exercise group at six months’ follow-up. However, this
trial was not placebo controlled. In addition, Srinivasan 2006,
a cross-over trial, reported a beneficial treatment effect on waist
circumference in participants taking metformin for six months,
when compared to six months of placebo. However, there was
no statistically significant difference in waist circumference be-
tween the drug and control groups in Clarson 2009 and Prado
2012 trials at six months’ follow-up. Wilson 2010 measured waist
circumference but did not report results. Two metformin trials
also measured waist-to-hip ratio and found no statistically signifi-
cant difference between groups at six months’ follow-up (Kendall
2013; Wiegand 2010). Yanovski 2011 also measured abdominal
and hip circumference at six months’ follow-up, and found a sta-
tistically significant difference betweenmetformin and placebo, in
favour of the intervention. In the metformin plus fluoxetine trial,
only the metformin plus fluoxetine arm had a statistically signifi-
cant between-group difference in waist circumference at 24 weeks
from baseline (Rezvanian 2010). In the sibutramine trials, there
was a statistically significant difference in waist circumference in
favour of the intervention in five trials (Berkowitz 2003; Berkowitz
2006; Franco 2014; García-Morales 2006; Godoy-Matos 2005).
Godoy-Matos 2005 also reported a statistically significant reduc-
tion in hip circumference in the sibutramine group compared to
the placebo group; however, there was no statistically significant
difference for waist-to-hip ratio at six months. Only one orlistat
trial measured waist circumference and found it increased in the
placebo group but decreased in the orlistat group at one year’ fol-
low-up (difference statistically significant); this was also seen for
hip circumference (Chanoine 2005).
Seven trials measured body composition by DEXA. Four met-
formin trials and twoorlistat trialsmeasured body fat usingDEXA.
Three metformin trials found no statistically significant difference
between groups in the percentage of body fat lost (Mauras 2012;
Srinivasan 2006;Wilson 2010). However, one trial observed a sta-
tistically significant difference of 1.4 kg between the metformin
and placebo groups, in favour of the intervention group at six
months’ follow-up (Yanovski 2011). One sibutramine trial as-
sessed body composition using underwater weighing and DEXA;
however, there was no statistically significant difference in per-
centage of fat mass between groups. Chanoine 2005 reported they
measured fat mass by DEXA in a subgroup of participants as a
safety measure and the orlistat group lost more fat mass compared
to the placebo group (P = 0.03). NCT00001723 found a slightly
greater decrease in body fat (kg) in the orlistat group compared
to the placebo group. Two trials estimated fat mass from bioim-
pedence analysis: one orlistat trial (Maahs 2006) and one met-
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formin trial (Wiegand 2010), but they reported no statistically
significant difference between intervention and placebo groups.
Yanovski 2011measured fat mass by air displacement plethysmog-
raphy and found metformin participants had statistically signifi-
cant decreases in their fat mass compared to placebo participants;
they also measured intra-abdominal fat by magnetic resonance
imaging but found no statistically significant difference between
groups. Srinivasan 2006 also used magnetic resonance imaging
and found a beneficial treatment effect of metformin over placebo
for subcutaneous abdominal adipose tissue but not visceral ab-
dominal adipose tissue; Mauras 2012 also used this technique and
found that intrahepatic fat only decreased in the nonplacebo con-
trol group. Wiegand 2010 used abdominal computer tomography
(CT) scans to evaluate abdominal fat content but also found no
statistically significant difference between metformin and placebo
participants in the results.
Behaviour change
Six trials measured behaviour change; however, only two trials re-
ported the results. Participants in three trials all completed a food
frequency questionnaire at the beginning and end of the trial;
however, no results were presented (Atabek 2008; García-Morales
2006; Maahs 2006). Kendall 2013 assessed dietary habits and ex-
ercise levels through three previously validated questionnaires but
were unable to analyse the data due to insufficient resources. Van
Mil 2007 measured total energy expenditure, using theMaastricht
protocol and included data from a seven-day dietary record; how-
ever, the difference between the sibutramine and control groups af-
ter 12 weeks of intervention was not statistically significant. Physi-
cal activity level was also measured using an activity questionnaire,
but there was no statistically significant difference between groups
at 12 weeks. Changes in total energy expenditure and physical ac-
tivity levels were not measured at 24-week follow-up due to un-
availability of equipment.
Participants’ views of the intervention
No trials investigated participants’ views of the intervention.
Morbidity
Only one trial investigated morbidity defined as illness or harm
associated with the intervention (Chanoine 2005). In the orlistat
group, 6/352 (1.7%) participants developed new gallstones com-
pared with 1/181 (0.6%) in the placebo group. The certainty of
the evidence was very low.
Some trials investigated various risk indicators, mainly insulin re-
sistance or insulin sensitivity andhyperinsulinaemia (Atabek 2008;
Clarson 2009; Freemark 2001; Kendall 2013; Srinivasan 2006;
Wiegand 2010; Yanovski 2011). García-Morales 2006 investi-
gated changes in blood pressure, glucose and triglycerides. Prado
2012 investigated glycaemia, insulin resistance and lipid profiles.
Mauras 2012 investigated changes in hsCRP and fibrogen con-
centrations.
All-cause mortality
One trial reported a death from suicide (Maahs 2006); the cer-
tainty of evidence was low. The authors reported that quality of
life factors were screened extensively and the participant gave neg-
ative responses to quality of life questions specific to suicide and
was also under the care of a psychiatrist for depression at the time
of the trial. Berkowitz 2006 reported two suicide attempts (one in
the intervention group and one in the placebo group).
Socioeconomic effects
No trials investigated socioeconomic effects.
For a summary of all outcomes assessed in each trial, see Appendix
5. For further explanation on how trial outcomes were defined,
see Appendix 7 and Appendix 8.
Subgroup analyses
We performed subgroup analyses on our primary outcomes of
BMI and weight. In our protocol, we specified we would analyse
length of follow-up; however, only two trials provided data at a
time point greater than six months. There was too much hetero-
geneity to analyse the maintenance periods and most trials ended
on completion of the intervention. In addition, there were only
two trials which did not use a placebo; hence, we did not per-
form subgroup analyses based on type of control given. However,
we performed subgroup analyses on BMI for the following fac-
tors: drug type (Analysis 1.2), dropout rates (Analysis 1.3), ITT
analysis (Analysis 1.4), funding source (Analysis 1.5), publication
date (Analysis 1.6), quality of trial (Analysis 1.7), country income
(Analysis 1.8), and mean age of participants (Analysis 1.9).
Only two interaction tests for subgroup differences indicated sta-
tistically significant differences.
Comparing dropout rates less than 20% showed an MD in BMI
change of -1.1 kg/m2 (95%CI -1.8 to -0.4; 9 trials), with dropout
rates 20% or greater showed an MD in BMI change of -1.4 kg/m
2 (95% CI -2.3 to -0.5; 6 trials), and with unclear dropout rates
showed an MD in BMI change of -2.7 kg/m2 (95% CI -3.7 to -
1.7; 1 trial). The P value for interactionwas 0.03 and heterogeneity
was substantial (I2 = 71%).
Comparing middle-income countries with high-income countries
showed anMD inBMI change of -2.4 kg/m2 (95%CI -3.1 to -1.7;
3 trials) versus -1.1 kg/m2 (95% CI -1.6 to -0.6; 13 trials). The P
value for interactionwas 0.004 and heterogeneity was considerable
(I2 = 88%).
For the outcome measure change in weight, only drug type could
be used for a subgroup analysis and the interaction test for sub-
group differences was not statistically significant (P = 0.52, I2 =
0%).
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We also explored the effects of participant sex on the BMI point
estimate, using a meta-regression model in CMA. The proportion
of boys at follow-up (or baseline if not reported) in each study was
selected as a covariate. We found that the coefficient of determina-
tion (r2) from this model was zero. The 95% CI for the meta-re-
gression slope was extremely wide either side of zero (-6.3 to 4.1).
We noted that some study authors only reported the percentage
of boys and girls in the total sample at baseline and not at follow-
up.
Sensitivity analyses
Table 2 shows the sensitivity analyses on BMI change. Our first
analysis removed the trials which only reported pre- and post-BMI
(not change scores) (Kendall 2013;Wiegand 2010), and hence re-
quired the use of a correlation coefficient of 0.78 (Bayer 2011) to
predict the point estimates. This made very little difference in the
point estimate. Only two trials had larger sample sizes (Berkowitz
2006; Chanoine 2005); however, when we removed these trials
from the meta-analysis the point estimate did not change. Fur-
thermore, all trials in the meta-analysis were published and were
in English; hence, we could not perform a sensitivity analysis on
these criteria. However, we performed a sensitivity analysis with
allocation bias, blinding bias (participant and trial personnel, and
assessor) and attrition bias by removing the high risk or unclear
risk trials, and did not find substantial differences. This was also
the case when we removed trials with higher drug dose and 12
months’ follow-up, as well as when we removed the trials with an
active lifestyle intervention.
We performed similar analyses for weight change (Table 3).We re-
moved trials which did not report change in weight (Atabek 2008;
Kendall 2013; Maahs 2006), and this resulted in a slightly greater
reduction in the point estimate. We used the same correlation co-
efficient to calculate the mean change in weight (in the interven-
tion and comparator groups) as we did for the BMI outcome (r
= 0.78), although we were able to calculate an exact correlation
coefficient in one trial (Maahs 2006) by using their reported BMI
at baseline, follow-up and change score (r = 0.975). Reductions
in point estimates increased slightly when we removed trials with
blinding (participant and trial personnel, and assessor) and attri-
tion bias. This also occurred when we restricted the analysis to
trials which also included a high-dose behaviour change interven-
tion. In the sensitivity analyses where we removed trials with high
allocation concealment bias, high drug dose, large sample size or
follow-up greater than six months, point estimate reductions were
slightly less than in the original analysis.
Assessment of reporting bias
We drew a funnel plot in CMA version 3 and Review Manager
5 for change in BMI as there was a sufficient number of trials
(16) (Figure 4). The Egger’s regression intercept was -0.75 (95%
CI -3.2 to 1.7; P = 0.52); this suggests there was no evidence of
reporting bias.
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Figure 4. Funnel plot of comparison: 1 Body mass index (BMI): pharmacological interventions versus
comparators, outcome: 1.1 Change in BMI (all trials) (kg/m2).
There was a similar finding when we drew a funnel plot for change
in weight (11 trials) (Egger’s regression intercept 1.7, 95% CI -3.5
to 6.8; P = 0.48) (Figure 5).
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Figure 5. Funnel plot of comparison: 2 Weight: pharmacological interventions versus comparators,
outcome: 2.1 Change in weight (all trials) (kg).
Ongoing trials
We found eight ongoing RCTs with four receiving met-
formin in the intervention group (EUCTR2010-023061-21;
NCT00889876;NCT01677923;NCT02274948), two receiving
topiramate (NCT01859013; NCT02273804), and two receiving
exenatide (EUCTR2015-001628-45-SE;NCT02496611). Three
trials, originally identified as ongoing, have been moved into the
’awaiting classification’ section because the trial has been com-
pleted but no results are available on the clinical trial website
or through a publication (ISRCTN08063839; NCT00934570;
NCT00940628). In addition, one trial which was originally clas-
sified as ongoing was moved to the ’awaiting classification’ sec-
tion because during the final stages of conducting the review we
identified a new publication (via the MEDLINE email alert ser-
vice), which included results from 18-month follow-up (van der
Aa 2016, seeNCT01487993 for a summary of the results). Results
from this trial will be incorporated in the next update of the review.
For two trials, we were unable to locate the source (Golebiowska
1981; Linquette 1971). In addition, we identified one confer-
ence abstract (Pastor 2014a, see EUCTR2010-023061-21) and
one conference poster (Smetanina 2015). We attempted to con-
tact both authors but only received a reply from Smetanina 2015,
who confirmed the trial had been completed but these data were
still being analysed.
D I S C U S S I O N
Summary of main results
We included 21 published RCTs and eight ongoing RCTs in this
review. The included trials evaluated metformin (11 trials), sibu-
tramine (six trials), orlistat (four trials), and one trial arm investi-
gating the combination of metformin plus fluoxetine. The ongo-
ing trials included four metformin, two topiramate and two exe-
natide trials. There were 2484 participants in the included trials,
1478 participants were randomised to drug intervention groups
and 904 to comparator groups. All trials but three used a placebo
in the comparator group. Two trials had a cross-over design while
the remaining 19 trials were parallel RCTs. The length of the inter-
vention period ranged from 12 weeks to 48 weeks, and the length
of follow-up from baseline ranged from six months to 100 weeks.
27Drug interventions for the treatment of obesity in children and adolescents (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Overall there were small reductions in BMI (MD -1.3, 95% CI -
1.9 to -0.8) and bodyweight change (MD -3.9 kg. 95% CI -5.9 to
-1.9) in favour of the drug interventions. Five trials reported se-
rious adverse events (24/878 (2.7%) participants in the interven-
tion groups versus 8/469 (1.7%) participants in the comparator
groups; RR1.43, 95%CI 0.63 to 3.25; 1347 participants; low cer-
tainty evidence). A total of 52/1043 (5.0%) participants in the in-
tervention groups versus 17/621 (2.7%) in the comparator groups
discontinued the trial because of adverse events (RR 1.45, 95%CI
0.83 to 2.52; 10 trials; 1664 participants; low certainty evidence).
The most common adverse events in orlistat and metformin tri-
als were gastrointestinal. Common adverse effects in sibutramine
trials included tachycardia, constipation and hypertension. The
fluoxetine trial reported dry mouth and loose stools. One trials re-
ported health-related quality of life showing nomarked differences
between intervention and comparator. No trial reported the par-
ticipants’ views of the intervention or socioeconomic effects. Only
one trial reported on morbidity associated with the intervention
where there were more gallstones after the orlistat treatment. Trial
authors reported one suicide in one of the orlistat intervention
groups. However, the trials were not sufficiently long to investigate
all-cause mortality reliably. No trial investigated drug treatment
for overweight children.
Overall completeness and applicability of
evidence
We faced problems in meta-analysing BMI as some trials did not
report the rawdatawe required; therefore, we had to try and obtain
this from the trial authors. In addition, age and sex are usually
taken into account when measuring the weight status of a child
because they are growing. However, in this review, we only assessed
changes in raw BMI because previous research has shown short-
term changes in adiposity are best represented by changes in raw
BMI units compared to BMI z scores or BMI centiles (Cole 2005;
Kakinami 2014). Furthermore, only 10 trials reported changes in
BMI z scores; therefore, we thought it was more appropriate to
only meta-analyse raw BMI, then this change could be converted
into change in BMI z score (using the desired growth reference) -
which we have done in the conclusion section of this review.
All 21 trialsmeasured adverse events; however, some trials reported
the total number of participants who experienced at least one ad-
verse event whilst others only reported the number of specific ad-
verse events. Hence, we also had to attempt to obtain this infor-
mation from the trial authors. Of the six trials which measured
behaviour change, only two trials reported the results at follow-
up. Only two trials reported health-related quality of life and they
used different methods. Hence, more trials are needed to investi-
gate how drugs used to treat obesity affect the participants’ health-
related quality of life. No trials reported differences in participant
views or socioeconomic effects.
Quality of the evidence
Based on the GRADE criteria, we rated the outcomes BMI, body
weight, all-cause mortality and adverse events as low. We down-
graded the levels of evidence because of potential other risk of bias
or reporting bias, inconsistency and imprecision. We rated health-
related quality of life and morbidity as very low certainty evidence,
mainly because of the small number of participants, one trial only
and imprecision.
Potential biases in the review process
We decided to perform unplanned subgroup analyses looking at
funding and country as there were enough trials to divide them
into groups. We were unable to analyse length of follow-up, im-
pact of maintenance periods and type of control group in the sub-
group analyses as there were too few trials or too much hetero-
geneity. The meta-analyses for BMI and weight included trials
which differed in follow-up length, behavioural interventions and
drug dose. However, when sensitivity analyses were performed,
the changes in point estimates were small.
We did not restrict our search strategy to any date, hence we have
sifted through trials ranging back to the 1960s. However, we did
not undertake any searches of the grey literature.We had some cor-
respondence with most of trial authors, and some have supplied us
with additional information including raw BMI data. Only seven
trials gave clinical trial identifiers or protocols available; hence, it
was difficult to assess whether reporting bias occurred. However,
from the trials where a protocol/clinical trial entry was available,
there was little evidence to suggest a source of reporting bias. We
excluded a large number of trials because of follow-up times less
than six months, especially older trials, and this may have im-
pacted on the overall findings from this review. In addition, we
had difficulties calculating the number of adverse events in each
trial due to different reporting metrics; for example, some trials
reported the total number of adverse events in each group whilst
others reported the total number of participants who suffered at
least one adverse event. Despite our attempts to contact authors
for additional information, we were still unable to meta-analyse
most of these findings.
Agreements and disagreements with other
studies or reviews
Since the previous review (Oude Luttikhuis 2009), we identified
one new orlistat trial; however, the reduction in BMI was similar
to what was found previously. The reduction in BMI for the sibu-
tramine trials found in this review was smaller than the change
reported in the previous review; however, these data still favour the
intervention. This difference is likely to be due to the inclusion of
three extra sibutramine trials in the meta-analysis. The previous
review did not include a meta-analysis of metformin trials.
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Another review and meta-analysis of the effect of orlistat and sibu-
tramine on adolescent weight loss derived a difference in BMI of
-2.3 kg/m2 for sibutramine (95% CI -2.9 to -1.8; 5 trials; 770
participants) and -1.7 kg/m2 for orlistat (95% CI -3.5 to 0.2; 3
trials; 621 participants) (Czernichow 2010). These point estimates
reductions are greater than the ones derived in our review. How-
ever, the orlistat point estimate in the Czernichow 2010 review
includes the Ozkan 2004 trial with a large BMI weight reduction
which we excluded from the meta-analysis in our review for not
having a common follow-up time across participants. In addition,
the sibutramine analysis included data from a secondary analysis
of white and African-American participants from Berkowitz 2003
which may explain why the point estimate was different. In an
earlier review, there was an MD of -0.7 kg/m2 (95% CI -1.2 to -
0.3) in orlistat participants compared to placebo, which is consis-
tent with our findings (McGovern 2008). There was a reduction
of -2.4 kg/m2 (95% CI -3.1 to -1.8) in sibutramine trials, which
is higher than the reduction we found (McGovern 2008). There
were similar findings also found in another meta-analysis where
the reduction for sibutramine was an MD of -2.2 kg/m2 (95%
CI -2.8 to -1.6; 4 trials; 686 participants) and the reduction for
orlistat was an MD of -0.8 (95% CI -1.2 to -0.5; 2 trials; 573
participants) (Viner 2010).
In metformin trials, McDonagh 2014 determined an effect size
of an MD of -1.2 kg/m2 (95% CI -1.6 to -0.7; 13 trials), which
is similar to the point estimate found in this review. In addition,
Bouza 2012 found a reduction of a MD of -1.2 kg/m2 (95% CI
-1.8 to -0.5; 7 trials), in favour of metformin. An earlier review
found a reduction of -1.4 kg/m2 (95% CI -2 to -0.8; 5 trials; 320
participants) in metformin trials (Park 2009); however, the review
only included five trials and we excluded one of the trials in this
review (Love-Osborne 2008).
Overall findings from meta-analyses of metformin, sibutramine
and orlistat trials are similar to the ones presented in this review,
and reasons for any differences are likely to derive from different
inclusion criteria and our inclusion of more recent trials.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This systematic review highlights the paucity of both the avail-
ability of reliable pharmacotherapy options for the treatment of
obese children and adolescents, and the clinical trial evidence to
support efficacy and safety. Trial quality and reporting overall was
poor, with high dropout and discontinuation rates. Many of the
trials assessed the efficacy of drugs which have now been with-
drawn (sibutramine) or are not recommended for obesity treat-
ment (metformin) in many countries.
In this review, we found an overall reduction in body mass index
(BMI) of 1.3 kg/m2 in favour of the drug interventions. Using
the International Obesity Task Force (IOTF) BMI cut-offs for
overweight and obesity (Cole 2012), a 12-year-old boy would
have a cut-off of 21.2 kg/m2 for being overweight, 26.02 kg/m
2 for being obese and 31.21 kg/m2 for being morbidly obesity.
Therefore, it would be possible for a 12-year-old boy who reduces
his BMI by 1.3 kg/m2 to move down a weight status category -
but only if they happen to lie just above the cut-off points. This is
also similar for girls and older children. In terms of a standardised
meandifference (SMD), the reduction inBMI found in this review
would equate to a reduction of 0.28 between-individuals standard
deviation scores.
Whilst this finding suggests that drug interventions can result in
a small BMI and weight reduction over the short term, it is not
known whether this is:
• sustainable over the longer term, which is an important
consideration given evidence from the pharmacological
management of adult obesity demonstrating a need for
continued medication to maintain weight loss (Yanovski 2014),
that is, drug withdrawal is followed by weight regain, which
occurred in Rezvanian 2010, Van Mil 2007, and Wilson 2010
during the drug-free follow-up.
• has any impact on existing or future clinical risk factors or
disease. Additionally, though all trials reported adverse events,
quantitative data were only available in the minority of the
included trials. This is particularly important as none of the
included trials collected data on participants’ views.
Implications for research
As new pharmacotherapies for the treatment of adult obesity be-
come available (phentermine plus topiramate extended release; li-
raglutide 3.0 mg; bupropion plus naltrexone; lorcaserin), there
may be a demand for an evaluation of their efficacy within an
obese paediatric population. The requirement of regulatory au-
thorities (US Food and Drug Administration (FDA) and Euro-
pean Medicines Agency (EMA)) for trials of all new medications
to be used in children and adolescents should drive more and bet-
ter trials. Hence, any future trials should ensure they are evaluated
over the longer term (i.e. longer than one year) and collect data
on cardiovascular and metabolic parameters, morbidities, health-
related quality of life, social and psychological well-being, diet
and physical activity behaviours, participant views and socioeco-
nomic effects. It is also important that new trials’ protocols reduce
all possible sources of bias and provide accurate interpretation of
findings, by ensuring power calculations and intention-to-treat
analyses are described and conducted, and robust sequence allo-
cation, allocation concealment methods and blinding measures
are used and comprehensively described. All new trial protocols
should also be registered and published to ensure reporting bias
can be assessed. There should also be standardisation in report-
ing to ensure all trials report a raw BMI score and adverse events
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per participant. As evidence from adult weight management indi-
cates the intensity of adjunctive lifestyle interventions can impact
on weight loss and associated outcomes, future trials should aim
to ensure they maximise and adequately report any concomitant
behaviour changing programme. Participant retention is also an
issue that needs addressing with improved and novel mechanisms
to reduce dropout rates and ensure treatment concordance. Since
overweight and obesity is developing at an increasingly early age,
future evaluation and trials may need to consider recruiting young,
prepubertal participants in whom clearly high levels of safety will
need to be established.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [author-defined order]
Atabek 2008
Methods Parallel randomised controlled trial, randomisation ratio 3:1 (intervention:control), su-
periority design
Participants Inclusion criteria:
• BMI ≥ 95th percentile for age and sex based on the standards of the CDC
Exclusion criteria:
• children were excluded if they had prior major illness, including type 1 or type 2
diabetes mellitus
• took medications or had a condition known to influence body composition,
insulin action, or insulin secretion
• none of the participants had a history of diabetes mellitus
Diagnostic criteria: see above
Interventions Intervention: metformin + diet and physical activity advice
Comparator: placebo + diet and physical activity advice
Number of trial centres: 1
Treatment before trial: none
Titration period: no
Outcomes Outcomes reported in abstract of publication: BMI, fasting insulin, 120-min insulin
levels, FGIR, HOMA-IR, QUICKI
Study details Run-in period: no
Trial terminated early: no
Publication details Language of publication: English
Funding: no information given
Publication status: peer-reviewed journal
Stated aim for study Quote from publication: ”To determine whether metformin treatment for 6 months is
effective in reducing body weight and hyperinsulinaemia and also ameliorating insulin
sensitivity indices in obese adolescents with hyperinsulinaemia“
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: no description of randomisa-
tion process
Allocation concealment (selection bias) Unclear risk Comment: no description of how alloca-
tion was concealed
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Atabek 2008 (Continued)
Blinding of participants and personnel
(performance bias)
Objective outcomes
Unclear risk Quote: ”a 6 month, randomized, double-
blind placebo-controlled, parallel-group,
prospective clinical trial“
Comment: unsure who was blinded
Blinding of participants and personnel
(performance bias)
Subjective outcomes
Unclear risk Quote: ”a 6 month, randomized, double-
blind placebo-controlled, parallel-group,
prospective clinical trial“
Comment: unsure who was blinded
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk Quote: ”a 6 month, randomized, double-
blind placebo-controlled, parallel-group,
prospective clinical trial.“
Comment: unsure who was blinded
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Unclear risk Quote: ”a 6 month, randomized, double-
blind placebo-controlled, parallel-group,
prospective clinical trial“
Comment: unsure who was blinded
Incomplete outcome data (attrition bias)
Objective outcomes
Unclear risk Comment: the trial did not report the
number of dropouts, or clarify there were
no dropouts
Incomplete outcome data (attrition bias)
Subjective outcomes
Unclear risk Comment: the trial did not report the
number of dropouts, or clarify there were
no dropouts
Selective reporting (reporting bias) High risk Quote: ”A detailed questionnaire on food
consumption was completed at the begin-
ning and at the end of the trial medication
period“
Comment: no results shown for food con-
sumption data. Also, very unclear on the
number lost to follow-up and what type of
analyses were conducted
Other bias High risk Comment: there was uncertainty to
whether this was a randomised controlled
trial or a matched controlled trial. Concern
arose over a lack of description about ran-
domisation, blinding and allocation. No
rationale for the size of intervention group
and no calculation of power. They also do
not declare who funded the trial
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Berkowitz 2003
Methods Parallel randomised controlled clinical trial, randomisation ratio 1:1, superiority design
Participants Inclusion criteria:
• boys and postmenarchal girls aged 13 to 17 years who had a BMI (calculated as
weight (kg) divided by height squared (m2) of 32 to 44 kg/m2
Exclusion criteria:
• contraindications to participation included cardiovascular disease (including
arrhythmias)
• type 1 or 2 diabetes mellitus
• major psychiatric disorders
• pregnancy
• use of a weight-loss medication or a weight loss of ≥ 5 kg in the prior 6 months
• use of medications promoting weight gain (e.g. oral steroids)
• use of medications contraindicated with use of sibutramine or cigarette smoking
Diagnostic criteria: see above
Interventions Intervention: behavioural programme + sibutramine
Comparator: behavioural programme + placebo
Number of trial centres: 1
Treatment before trial: none
Titration period: in medication-treated participants, sibutramine was increased to 10
mg/day at week 3, and to 15 mg/day at week 7
Outcomes Outcomes reported in abstract of publication: weight (kg), BMI (kg/m2), reductions
in hunger, number of participants who reduced dose or discontinued
Study details Run-in period: no
Trial terminated early: no
Publication details Language of publication: English
Commercial funding and noncommercial funding
Publication status: peer-reviewed journal
Stated aim for study Quote from publication: ”To increase weight loss in obese adolescents by combining a
comprehensive behavioral program with pharmacotherapy“
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: no description of the randomi-
sation process
Allocation concealment (selection bias) Unclear risk Comment: trial did not describe how allo-
cation was concealed
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Blinding of participants and personnel
(performance bias)
Objective outcomes
Low risk Quote: ”Participants, parents, and all study
personnel were blinded to treatment con-
dition during phase 1. Only the research
pharmacist was aware of treatment status“
Comment: risk of performance bias likely
to be low due to blinding of participants,
parents and trial personnel
Blinding of participants and personnel
(performance bias)
Subjective outcomes
Low risk Quote: ”Participants, parents, and all study
personnel were blinded to treatment con-
dition during phase 1. Only the research
pharmacist was aware of treatment status“
Comment: risk of performance bias likely
to be low due to blinding of participants,
parents and trial personnel
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: ”Participants, parents, and all study
personnel were blinded to treatment con-
dition during phase 1. Only the research
pharmacist was aware of treatment status“
Comment: risk of detection bias likely to
be low due to blinding of all trial personnel
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk Quote: ”Participants, parents, and all study
personnel were blinded to treatment con-
dition during phase 1. Only the research
pharmacist was aware of treatment status“
Comment: risk of detection bias likely to
be low due to blinding of all trial personnel
Incomplete outcome data (attrition bias)
Objective outcomes
Unclear risk Comment: whilst dropout numbers were
small, a more appropriate imputation
method could have been used to strengthen
data analysis. Imputation method only
used for primary outcome measures
(weight and waist circumference, which
were objectively measured)
Incomplete outcome data (attrition bias)
Subjective outcomes
Unclear risk Comment: whilst dropout numbers were
small, a more appropriate imputation
method could have been used to strengthen
data analysis. Imputation method only
used for primary outcome measures
(weight and waist circumference, which
were objectively measured)
Selective reporting (reporting bias) Low risk Comment: no differences found between
clinical trial entry and publication
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Other bias Unclear risk Comment: trial was partly funded by 2
pharmaceutical companies. The trial de-
clared these companies had no involvement
in the design, analysis or interpretation of
the data; however, still could have influ-
enced the reporting of results in some way
Berkowitz 2006
Methods Parallel randomised controlled clinical trial, randomisation ratio 3:1 (sibutramine:
placebo), superiority design
Participants Inclusion criteria:
• adolescents 12 to 16 years of age with a BMI (calculated as weight (kg) divided by
height squared (m2)) that was at least 2 units more than the US weighted mean of the
95th percentile based on age and sex and was not more than 44 kg/m2
• adolescents with stable hypertension who were receiving therapy
Exclusion criteria:
• cardiovascular disease (including arrhythmias)
• type 1 or 2 diabetes mellitus
• major psychiatric disorders
• pregnancy
• use of a weight loss medication or participation in structured weight loss
programmes for > 2 weeks
• medication use promoting weight gain or contraindicated with sibutramine or
cigarette smoking
• candidates with SBP > 130 mmHg, DBP > 85 mmHg, or pulse rate > 95 beats/
min were excluded
Diagnostic criteria: see above
Interventions Intervention: behaviour therapy programme + sibutramine
Comparator: behaviour therapy programme + placebo
Number of trial centres: 33
Treatment before trial: no
Titration period: no
Outcomes Outcomes reported in abstract of publication: BMI, weight, triglyceride levels, high-
density lipoprotein cholesterol levels, insulin levels, insulin sensitivity, rate of tachycardia,
completion rate
Study details Run-in period: no
Trial terminated early: no
Publication details Language of publication: English
Commercial funding
Publication status: peer-reviewed journal
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Stated aim for study Quote from publication: ”To see whether sibutramine reduced weightmore than placebo
in obese adolescents who were receiving a behavior therapy program“
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”The randomization schedule was
stratified by center and baseline BMI (≤37
kg/m2 or >37 kg/m2) and was computer-
generated in blocks of 4 by the sponsor.
Each site was responsible for assigning se-
quential treatments within each stratum“
Comment: an adequate randomisation
method was used
Allocation concealment (selection bias) Low risk Quote: ”The sponsor kept allocation codes
sealed and secure until the database was
locked before analysis“
Comment: allocation concealment was
sufficient to protect against bias
Blinding of participants and personnel
(performance bias)
Objective outcomes
Low risk Quote: ”Participants, their parents, and
study personnel were blinded to treatment“
Comment: risk of performance bias likely
to be low due to blinding of participants,
parents and trial personnel
Blinding of participants and personnel
(performance bias)
Subjective outcomes
Low risk Quote: ”Participants, their parents, and
study personnel were blinded to treatment“
Comment: risk of performance bias likely
to be low due to blinding of participants,
parents and trial personnel
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: ”Participants, their parents, and
study personnel were blinded to treatment“
Comment: risk of performance bias likely
to be low due to blinding of participants,
parents and trial personnel
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk Quote: ”Participants, their parents, and
study personnel were blinded to treatment“
Comment: risk of performance bias likely
to be low due to blinding of participants,
parents and trial personnel
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Incomplete outcome data (attrition bias)
Objective outcomes
Unclear risk Comment: LOCFwas only used to replace
BMI missing data; other objective out-
come data were expressed for completers
only. Dropout rate was fairly moderate and
higher in the placebo group compared to
the drug group. Difficult to access level of
attrition bias based on these factors
Incomplete outcome data (attrition bias)
Subjective outcomes
Unclear risk Comment: LOCFwas only used to replace
BMI missing data only
Selective reporting (reporting bias) Low risk Comment: same outcomes reported in
both clinical trial register and publication
Other bias Unclear risk Quote: ”the Statistics Department of Ab-
bott Global Pharmaceutical Research and
Development (including Ms. Hewkin) was
responsible for data management and sta-
tistical analysis“
Comment: potential influence of the fund-
ing body (Abbot Global Pharmaceuticals)
Chanoine 2005
Methods Parallel randomised controlled clinical trial, randomisation ratio 2:1 (orlistat: placebo),
superiority design
Participants Inclusion criteria:
• adolescents (aged 12 to 16 years) were eligible for enrolment if they:
◦ had a BMI (calculated as weight (kg) divided by height squared (m2)) ≥ 2
units than the US weighted mean for the 95th percentile based on age and sex
◦ had a parent or guardian prepared to attend trial visits with them
◦ were willing to be actively involved in behavioural modification
Exclusion criteria:
• BMI ≥ 44 (to increase homogeneity of the group)
• bodyweight ≥ 130 kg or < 55 kg
• weight loss ≥ 3 kg within 3 months prior to screening
• diabetes requiring antidiabetic medication
• obesity associated with genetic disorders
• history or presence of psychiatric disease
• use of dexamphetamine or methylphenidate
• active gastrointestinal tract disorders
• ongoing bulimia or laxative abuse
• use of anorexiants or weight-reduction treatments during the 3 months before
randomisation
Diagnostic criteria: see above
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Interventions Intervention: orlistat + diet + exercise + behaviour therapy
Comparator: placebo + diet + exercise + behaviour therapy
Number of trial centres: 32
Treatment before trial: no
Titration period: no
Outcomes Outcomes reported in abstract of publication: BMI, weight, fat mass (DEXA), waist
circumference, adverse events
Study details Run-in period: placebo was given for 2 weeks before treatment began in the intervention
group
Trial terminated early: no
Publication details Language of publication: English
Commercial funding
Publication status: peer-reviewed journal
Stated aim for study Quote from publication: ”To determine the efficacy and safety of orlistat in weight
management of adolescents“
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”Patients were randomized cen-
trally according to a computer-generated
randomization schedule prepared by the
study’s sponsor, with stratification by body
weight (<80 kg or≥80 kg) on day 1 and by
weight loss during the lead-in period (<1
kg or ≥1 kg)“
Comment: an adequate randomisation
method was used
Allocation concealment (selection bias) Low risk Quote: ”The allocation process was triple-
blind; the allotted treatment group was
obtained through an automated telephone
system“
Comment: allocation concealment was
sufficient to protect against bias
Blinding of participants and personnel
(performance bias)
Objective outcomes
Low risk Quote: ”double-blind study“
Comment: the author confirmed all par-
ticipants, trial personnel and outcome as-
sessors were blinded
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Blinding of participants and personnel
(performance bias)
Subjective outcomes
Low risk Quote: ”double-blind study“
Comment: the author confirmed all par-
ticipants, trial personnel and outcome as-
sessors were blinded
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: ”double-blind study“
Comment: the author confirmed all par-
ticipants, trial personnel and outcome as-
sessors were blinded
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk Quote: ”double-blind study“
Comment: the author confirmed all par-
ticipants, trial personnel and outcome as-
sessors were blinded
Incomplete outcome data (attrition bias)
Objective outcomes
Unclear risk Comment: even though an imputation
method was used (LOCF), dropout rates
were high. Effect on objective outcomes
unclear
Incomplete outcome data (attrition bias)
Subjective outcomes
Unclear risk Comment: even though an imputation
method was used (LOCF), dropout rates
were high. Effect on subjective outcomes
unclear
Selective reporting (reporting bias) Unclear risk Comment: unable to assess if all outcomes
were reported due to the trial protocol not
previously been published
Other bias Unclear risk Quote: ”Hoffmann-LaRochewas involved
in the study design and conduct and in the
analysis and interpretation of the data. All
data were independently reanalyzed by an
academic statistician“
Comment: potential influence from the
funding body (Hoffmann-La Roche). No
rationale to explain the imbalance in the
number of participants in the 2 groups
Clarson 2009
Methods Parallel randomised controlled clinical trial, randomisation ratio 1:1, superiority design
Participants Inclusion criteria:
• obese participants aged 10 to 16 years, defined as BMI > 95th percentile for age
and sex, and who were also insulin resistant (defined by HOMA > 3.0, calculated as
fasting plasma insulin (mU/L) x fasting serum blood glucose (mmol/L)/22.5) were
enrolled over a 15-month period between 2005 and 2007. All the participants were
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assessed to be in puberty throughout the trial. HOMA values > 3 in adolescents are
indicative of insulin resistance
Exclusion criteria:
• fasting blood glucose > 6.0 mmol/L
• contraindications to metformin therapy
Diagnostic criteria: see above
Interventions Intervention: metformin + lifestyle intervention
Comparator: lifestyle intervention
Number of trial centres: 1
Treatment before trial: no
Titration period: started metformin therapy at 500 mg/day, increasing by 500 mg/day
every 7 days to a maximum tolerated dose of 500 mg x 3 per day
Outcomes Outcomes reported in abstract of publication: BMI, HOMA, adiponectin-to-leptin
ratio, dyslipidaemic profiles, metabolic risk factors e.g. plasma lipids and adipocytokines
Study details Run-in period: no
Trial terminated early: no
Publication details Language of publication: English
Noncommercial funding
Publication status: peer-reviewed journal
Stated aim for study Quote from publication: ”To access the efficacy of adding metformin to a structured
lifestyle intervention in reducing BMI in obese adolescents with insulin resistance“
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”subjects were randomized using
computer random number generation to
lifestyle intervention alone or lifestyle in
combination with metformin“
Comment: an adequate randomisation
method was used
Allocation concealment (selection bias) High risk Comment: author confirmed allocation
was not concealed
Blinding of participants and personnel
(performance bias)
Objective outcomes
High risk Quote: ”limitations to this study include
the relatively small sample size and the ab-
sence of a placebo control group“
Comment: the absence of a placebo in
the control group meant participant and
personnel blinding could not have been
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achieved. Author confirmed participants
and personnel were not blinded
Blinding of participants and personnel
(performance bias)
Subjective outcomes
High risk Quote: ”limitations to this study include
the relatively small sample size and the ab-
sence of a placebo control group“
Comment: the absence of a placebo in
the control group meant participant and
personnel blinding could not have been
achieved. Author confirmed participants
and personnel were not blinded
Blinding of outcome assessment (detection
bias)
Objective outcomes
High risk Comment: outcomes assessment was not
blinded as confirmed by the author
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk Comment: outcomes assessment was not
blinded as confirmed by the author
Incomplete outcome data (attrition bias)
Objective outcomes
Unclear risk Comment: trial dropouts were fairly low;
however, no imputation method was used
Incomplete outcome data (attrition bias)
Subjective outcomes
Unclear risk Comment: trial dropouts were fairly low;
however, no imputation method was used
Selective reporting (reporting bias) Unclear risk Comment: no previously published pro-
tocol; therefore, unable to access reporting
bias
Other bias High risk Quote: ”limitations to this study include
the relatively small sample size and the ab-
sence of a placebo control group“
Comment: a power calculation was not
performed, therefore likely the trial was
underpowered. No placebo given to the
control group. Unclear whether there were
baseline differences
Franco 2014
Methods Cross-over randomised controlled clinical trial, randomisation ratio 1:1, superiority de-
sign
Participants Inclusion criteria:
• aged 10 to 18 years
• diagnosis of obesity (classification according to the World Health Organization)
• ability to understand the guidelines
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• the adolescent’s consent and the legal guardian
• for initial inclusion, the participant needed to have already carried out some
conventional treatments (diet/behavioural) prior, for at least 6 months
Exclusion criteria:
• cardiovascular problems and or arrhythmias
• history of anorexia, bulimia and or psychiatric disorders
• hypertension
• chronic diseases
• prior use of any other medication that interfered with the weight change, genetic
syndromes, neuropsychomotor development delay, or a combination
• glaucoma
• use of illicit drugs, tobacco or alcohol
• pregnant girls or that they had sexual intercourse without contraceptives
Diagnostic criteria: see above
Interventions Intervention: sibutramine + dietary guidance
Comparator: placebo + dietary guidance
Number of trial centres: 1
Treatment before trial: all participants had to have under gone at least 6 months of
lifestyle intervention prior to recruitment
Titration period: none
Outcomes Outcomes reported in abstract of publication: % of participants who lost 10% of
initial weight, weight, BMI
Study details Run-in period: no
Trial terminated early: no
Publication details Language of publication: Portuguese
Noncommercial funding
Publication status: peer-reviewed journal
Stated aim for study Quote from publication: ”The aim of this study was to evaluate the efficacy and safety
of sibutramine in association with a multidisciplinary program for treatment of obesity
and check its influence on metabolic laboratory changes“
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk From author: ”patients were distributed
according to a table of random numbers“
Comment: randomisation process assessed
as low risk
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Allocation concealment (selection bias) Low risk From author: ”the study was double-
blind placebo-controlled. Patients received
placebo or sibutramine for 6 months, 1
month washout and in the next six months
who received placebo began receiving sibu-
tramine and vice verse. The researchers had
no knowledge who was getting the drug
and who was getting the placebo“
Comment: allocation was concealed
Blinding of participants and personnel
(performance bias)
Objective outcomes
Low risk Quote: ”This study was double blinded
placebo controlled cross-over type with du-
ration of 13 months“
Comment: author confirmed participants,
trial personnel and outcome assessors were
all blinded
Blinding of participants and personnel
(performance bias)
Subjective outcomes
Low risk Quote: ”This study was double blinded
placebo controlled cross-over type with du-
ration of 13 months“
Comment: author confirmed participants,
trial personnel and outcome assessors were
all blinded
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: ”This study was double blinded
placebo controlled cross-over type with du-
ration of 13 months“
Comment: author confirmed participants,
trial personnel and outcome assessors were
all blinded
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk Quote: ”This study was double blinded
placebo controlled cross-over type with du-
ration of 13 months“
Comment: author confirmed participants,
trial personnel and outcome assessors were
all blinded
Incomplete outcome data (attrition bias)
Objective outcomes
High risk Quote: ”of the 63 patients who initiated
the study only 23 patients completed the
study“
Comment: high attrition rate likely to af-
fect objective outcomes
Incomplete outcome data (attrition bias)
Subjective outcomes
High risk Quote: ”of the 63 patients who initiated
the study only 23 patients completed the
study“
Comment: high attrition rate likely to af-
fect subjective outcome (i.e. adverse effects)
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Selective reporting (reporting bias) Unclear risk Comment: no protocol available so risk
was unclear
Other bias High risk Comment: lacked appropriate method-
ological detail and the failed to present the
results in a meaningful and balanced man-
ner. The cross-over nature of the trial added
to the difficulty in deciphering the results
with such a high attrition rate. No power
calculation performed
Freemark 2001
Methods Parallel randomised controlled clinical trial, randomisation ratio 1:1, superiority design
Participants Inclusion criteria:
• aged 12 to 19 years and had a BMI > 30 kg/m2. Criteria for enrolment included:
◦ a fasting insulin concentration > 15 mU/mL
◦ ≥ 1 first- or second-degree relative (parent, sibling or grandparent) with type
2 diabetes
Exclusion criteria: -
Diagnostic criteria: see above
Interventions Intervention: metformin
Comparator: placebo
Number of trial centres: 1
Treatment before trial: none
Titration period: no
Outcomes Outcomes reported in abstract of publication: BMI, serum leptin, fasting blood glu-
cose, fasting insulin levels, insulin sensitivity, glucose effectiveness, haemoglobin A1c,
serum lipids, serum lactate, adverse events
Study details Run-in period: 48 hours’ inpatient tests
Trial terminated early: no
Publication details Language of publication: English
Commercial funding and noncommercial funding
Publication status: peer-reviewed journal
Stated aim for study Quote from publication: ”We reasoned that drugs that increase glucose tolerance in
diabetic patients might prove useful in preventing the progression to glucose intolerance
in high-risk patients“
Notes
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”patients were randomized to the
metformin and placebo groups by a re-
search pharmacist using computer-gener-
ated randomization tables“
Comment: an appropriate randomisation
method was used
Allocation concealment (selection bias) Low risk Quote: ”the allocation was made by the
research pharmacist at the first medication
visit. The pill bottles were coded - thus the
pharmacist was blinded to the medication“
Comment: author confirmed allocation
was concealed
Blinding of participants and personnel
(performance bias)
Objective outcomes
Low risk Quote: ”We conducted a double-blind,
placebo-controlled study“
Comment: author confirmed all partici-
pants and trial personnel were blinded
Blinding of participants and personnel
(performance bias)
Subjective outcomes
Low risk Quote: ”We conducted a double-blind,
placebo-controlled study“
Comment: author confirmed all partici-
pants and trial personnel were blinded
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: ”We conducted a double-blind,
placebo-controlled study“
Comment: author confirmed all partici-
pants and trial personnel were blinded
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk Quote: ”We conducted a double-blind,
placebo-controlled study“
Comment: author confirmed all partici-
pants and trial personnel were blinded
Incomplete outcome data (attrition bias)
Objective outcomes
Unclear risk Comment: a missing data method was not
used; however, dropout rateswere fairly low
Incomplete outcome data (attrition bias)
Subjective outcomes
Unclear risk Comment: a missing data method was not
used; however, dropout rateswere fairly low
Selective reporting (reporting bias) Unclear risk Comment: since no protocol was pub-
lished before trial was completed, it is un-
clear whether all outcomes were reported
Other bias High risk Quote: ”the study involved a small num-
ber of patients and the results must be con-
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firmed in a larger sample“
Comment: the trial did not perform a
power calculation and the sample size was
small. It is likely the trial was underpow-
ered. Potential influence of a commercial
funding source. Baseline differences iden-
tified and not adjusted for in the analysis
García-Morales 2006
Methods Parallel randomised controlled clinical trial, randomisation ratio: 1:1, superiority design
Participants Inclusion criteria:
• all the participants were Mestizo living in the metropolitan area of Mexico City.
• male and female participants aged 14 to 18 years with a sex-specific BMI for age
and sex > 95th percentile (obesity) to be enrolled in the trial after written informed
consent had been obtained from both parents and oral informed consent was obtained
from the participants
Exclusion criteria:
• lactating or pregnant females
• females who were sexually active without using acceptable contraceptive methods
• SBP ≥140 mm Hg or DBP ≥ 90 mm Hg
• history of anorexia nervosa or bulimia
• received treatment in the previous 30 days with corticosteroids, monoamine
oxidase inhibitors, antidepressants, lithium, drugs for weight loss, nasal or respiratory
anticongestives, migraine treatment, gastrointestinal prokinetics or antihistaminics
• using alcohol or recreational drugs
• history of depression or weight loss treatment in the last 6 months
• genetic disease associated with obesity, hypothyroidism, cancer, blood disease,
gastrointestinal surgery, psychiatric disease, a history of work or school problems,
weight loss ≥ 3 kg in the last 3 months, or who were unable to follow the protocol (i.e.
they did not attend or were late for visits, or they failed to follow the directions of the
investigators)
Diagnostic criteria: see above
Interventions Intervention: sibutramine + diet + exercise
Comparator: placebo + diet + exercise
Number of trial centres: 1
Treatment before trial: participants received dietetic advice 15 days before the beginning
of the medications. In addition, clinical control visits also occurred before the start of
the trial
Titration period: no
Outcomes Outcomes reported in abstract of publication:mean weight loss, net weight loss, waist
circumference, % BMI loss, SBP, DBP, heart rate, adverse events
Study details Run-in period: yes - dietetic advice
Trial terminated early: no
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Publication details Language of publication: English
Commercial funding
Publication status: peer-reviewed journal
Stated aim for study Quote from publication: ”The goal of this article was to assess the efficacy and safety of
sibutramine in obese Mexican adolescents“
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”Patients were block-randomized
by using a computer generated list“
Comment: an appropriate randomisation
method was used
Allocation concealment (selection bias) Low risk Quote: ”Patients were block-randomized
by using a computer generated list. All the
materials for a patient were identified by
the patient number. The placebo and drug
capsules were identical in appearance and
smell. The trial medications were prepared
by one author (A.B.), whodidnot know the
identity of the patients. Another author (L.
M.G.-M.) received the trial materials with-
out any knowledge of the procedures or or-
der in the random number list“
Comment: allocation was appropriately
concealed
Blinding of participants and personnel
(performance bias)
Objective outcomes
Unclear risk Quote: ”This was a 6 month, randomized,
double blind, placebo-controlled, prospec-
tive clinical trial of sibutramine QD“
Comment: unclear who was blinded
Blinding of participants and personnel
(performance bias)
Subjective outcomes
Unclear risk Quote: ”This was a 6 month, randomized,
double blind, placebo-controlled, prospec-
tive clinical trial of sibutramine QD“
Comment: unclear who was blinded
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk Quote: ”This was a 6 month, randomized,
double blind, placebo-controlled, prospec-
tive clinical trial of sibutramine QD“
Comment: unclear who was blinded
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Blinding of outcome assessment (detection
bias)
Subjective outcomes
Unclear risk Quote: ”This was a 6 month, randomized,
double blind, placebo-controlled, prospec-
tive clinical trial of sibutramine QD“
Comment: unclear who was blinded
Incomplete outcome data (attrition bias)
Objective outcomes
Unclear risk Quote: ”the last observation replaced the
missing values“
Comment: LOCF and modified inten-
tion-to-treat analysis was used to replace
missing data for the primary outcomes.
However, the 5 participants who dropped
out before the first month were not in-
cluded
Incomplete outcome data (attrition bias)
Subjective outcomes
Unclear risk Comment: baseline and follow-up data for
subjective outcomes were not reported in
the publication
Selective reporting (reporting bias) High risk Quote: ”A detailed questionnaire on food
consumption was completed at the begin-
ning and end of the trial“
Comment: data on food consumption
were not provided in the publication
Other bias Unclear risk Quote: ”This trial was supported by Ab-
bott Laboratories de Mexico, S.A. de C.
V., Mexico City, D.F, Mexico. Dr. Berber
was the medical manager of sibutramine
in Mexico from 1995 to April 2004. The
protocol was designed by all the authors;
the study was conducted by the non indus-
try authors; and analysis and publication
formalities were performed by Drs. Gar-
cia-Morales, Del-Rio-Navarro, and Berber.
The non industry authors had access to all
the data generated“
Comment: the trial sponsor (Abbot Labo-
ratories) may have influenced the trial’s re-
sults
Godoy-Matos 2005
Methods Parallel randomised controlled clinical trial, randomisation ratio 1:1, superiority design
Participants Inclusion criteria:
• boys and girls, aged 14 to 17 years, with a BMI of 30 to 45 (BMI calculated as
weight (kg) divided by height squared (m)). To avoid growth variation, all participants
were required to have adult bone age, as determined by left hand radiography
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(Greulich- Pyle method)
Exclusion criteria:
• diabetes mellitus
• endocrine diseases predisposing to obesity (e.g. Cushing’s syndrome)
• severe hyperlipidaemia (total cholesterol 300 mg/dL or triglycerides 500 mg/dL)
• systemic or major psychiatric disorders
• history of bulimia or anorexia
• uncontrolled hypertension (DBP 110 mm Hg) or other cardiovascular diseases
• weight loss ≥ 3 kg within 2 months or use of weight loss or weight gain drugs
within 3 months before recruitment
• drug or alcohol abuse
• recent tobacco cessation or intention to quit during trial period
• pregnancy or lactation
Diagnostic criteria: see above
Interventions Intervention: sibutramine + hypocaloric diet + exercise
Comparator: placebo + hypocaloric diet + exercise
Number of trial centres: 1
Treatment before trial: during the run-in period all participants received dietary coun-
selling to achieve an energy deficit of 500 kcal/day. They also all received placebo capsules
Titration period: no
Outcomes Outcomes reported in abstract of publication: weight loss, mean BMI reduction,
adverse events
Study details Run-in period: a single-blind, 4-week, placebo run-in period
Trial terminated early: no
Publication details Language of publication: English
Commercial funding
Publication status: peer-reviewed journal
Stated aim for study Quote from publication: ”The aim of this study was to determine the efficacy and safety
of sibutramine in obese adolescents“
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”Patients were allocated in a ran-
dom block fashion to placebo or sibu-
tramine“
Comment: details of the randomisation
process was provided by the author - pro-
cess seems adequate
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Allocation concealment (selection bias) Low risk Quote: ”Bymeans of a sealed envelopewith
a coded number. A container with boxes
for each patient displaying the code num-
ber were provided. Each box had blisters
for each visit with 40 capsules (similar for
placebo or active drug). Patients were sup-
plied in each visit with a new box. Adher-
ence was judged by counting used capsules“
Comment: allocation was concealed as
confirmed by the author
Blinding of participants and personnel
(performance bias)
Objective outcomes
Low risk Quote: ”a randomised, double-blind,
placebo-controlled trial“
Comment: author confirmed all partici-
pants and personnel were blinded
Blinding of participants and personnel
(performance bias)
Subjective outcomes
Low risk Quote: ”a randomised, double-blind,
placebo-controlled trial“
Comment: author confirmed all partici-
pants and personnel were blinded
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: ”a randomised, double-blind,
placebo-controlled trial“
Comment: author confirmed all partici-
pants and personnel were blinded
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk Quote: ”a randomised, double-blind,
placebo-controlled trial“
Comment: author confirmed all partici-
pants and personnel were blinded
Incomplete outcome data (attrition bias)
Objective outcomes
Unclear risk Comment: dropout fairly low; however,
was higher in the placebo group.Only com-
pleters results shown
Incomplete outcome data (attrition bias)
Subjective outcomes
Unclear risk Comment: dropout fairly low; however,
was higher in the placebo group.Only com-
pleters results shown
Selective reporting (reporting bias) Unclear risk Comment: a protocol was not published
before the trial was completed, therefore it
is unclear whether all outcomes were re-
ported
Other bias High risk Quote: ”thisworkwas supported by a grant
from Abbott Laboratories“
Comment: the trial did not highlight how
involved Abbott Laboratories were the trial
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design, analysis and interpretation of the
results
Quote: ”Conclusions regarding treatment
group differences are somewhat limited by
the small sample size“
Comment: the trial did not perform a
power calculation. Likely the trial was un-
derpowered
Kendall 2013
Methods Parallel randomised controlled clinical trial, randomisation ratio 1:1, superiority design
Participants Inclusion criteria:
• BMI > 98th centile on UK BMI centile charts
• impaired glucose tolerance, i.e. OGTT 2-hour plasma glucose value 7.8 to 11.1
mmol/L (with or without impaired fasting glucose 6.1 to 7.0 mmol/L) or
hyperinsulinaemia, i.e. fasting insulin > 26 mIU/L or 120-min insulin > 89 mIU/L
(pubertal/ postpubertal children); fasting insulin > 15 mIU/L or 120-min insulin > 89
mIU/L (prepubertal children)
Exclusion criteria:
• glycosuria, ketonuria, other chronic illness or chromosomal abnormality or
syndrome, e.g. Prader-Willi, renal insufficiency, hepatic dysfunction, raised ALT (> 7.0
IU/L), chronic diarrhoea and a previous episode of lactic acidosis
Diagnostic criteria: see above
Interventions Intervention: metformin + healthy lifestyle advice
Comparator: placebo + healthy lifestyle advice
Number of trial centres: 6
Treatment before trial: all participants were provided with standardised healthy lifestyle
advice at the start in a 1-to-1 session, including a healthy diet advice sheet and increased
levels of exercise (available upon request)
Titration period: participants were instructed to gradually increase the dose by taking
1 pill with breakfast for 1 week and then 1 pill with breakfast and the evening meal the
next week and then 2 pills with breakfast and 1 pill with the evening meal thereafter (1.
5 g/day)
Outcomes Outcomes reported in abstract of publication: BMI-SDS, fasting glucose, ALT, ALR
Study details Run-in period: no
Trial terminated early: no
Publication details Language of publication: English
Noncommercial funding
Publication status: peer-reviewed journal
Stated aim for study Quote from publication: ”The objective of the study was to assess the effect of metformin
on body mass index SD score (BMI-SDS), metabolic risk factors, and adipokines“
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Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”Independent pharmacists dis-
pensed either metformin or placebo ac-
cording to a computer-generated random-
ization list for each stratification group“
Comment: an appropriate randomisation
method was used
Allocation concealment (selection bias) Low risk Quote: ”The third party, concealed alloca-
tion process ensured that participants and
all investigators were unaware of the allo-
cated treatment“
Comment: allocation was concealed
Blinding of participants and personnel
(performance bias)
Objective outcomes
Unclear risk Quote: ”This was a prospective, ran-
domized, double-blind, placebo-controlled
trial“
Comment: unclear who was blinded
Blinding of participants and personnel
(performance bias)
Subjective outcomes
Unclear risk Quote: ”This was a prospective, ran-
domized, double-blind, placebo-controlled
trial“
Comment: unclear who was blinded
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk Quote: ”This was a prospective, ran-
domized, double-blind, placebo-controlled
trial“
Comment: unclear who was blinded
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Unclear risk Quote: ”This was a prospective, ran-
domized, double-blind, placebo-controlled
trial“
Comment: unclear who was blinded
Incomplete outcome data (attrition bias)
Objective outcomes
High risk Quote: ”There were a number of limita-
tions to the MOCA [Metformin in Obese
Children and Adolescents] trial including
the dropout rate“
Comment: dropout rate was high and no
imputation method was used to replace
missing data
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Incomplete outcome data (attrition bias)
Subjective outcomes
High risk Quote: ”There were a number of limi-
tations to the MOCA trial including the
dropout rate“
Comment: dropout rate was high and no
imputation method was used to replace
missing data
Selective reporting (reporting bias) Unclear risk Quote: ”In the MOCA trial, three pre-
viously validated questionnaires (food fre-
quency, diet and eating behavior, and phys-
ical activity) were completed by each child
at the start and end of the trial. This
amounted to a large amount of data, and
resources were unfortunately insufficient to
allow analysis of these data for inclusion in
this paper“
Comment: behaviour change results were
not reported; however, the publication did
give a valid reason to why
Other bias Unclear risk Comment: insufficient information to as-
sess whether an important risk of bias exists
Maahs 2006
Methods Parallel randomised controlled clinical trial, randomisation ratio: 1:1, superiority design
Participants Inclusion criteria:
• aged 14 to 18 years
• BMI > 85th percentile for age and sex
Exclusion criteria:
• known secondary causes for obesity (e.g. hypothyroidism, daily corticosteroid
exposure > 30 days, history of significant exposure to corticosteroids for chronic illness
during the past year and known genetic causes of obesity)
Diagnostic criteria: see above
Interventions Intervention: orlistat + diet and exercise therapy
Control: placebo + diet and exercise therapy
Number of trial centres: 1
Treatment before trial: none
Titration period: no
Outcomes Outcomes reported in abstract of publication: BMI reduction, adverse effects, labo-
ratory measurements
Study details Run-in period: no
Trial terminated early: no
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Publication details Language of publication: English
Noncommercial funding
Publication status: peer-reviewed journal
Stated aim for study Quote from publication: ”To evaluate the efficacy of orlistat to enhance weight loss in
obese adolescents“
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: ”The GCRC [General Clinical Re-
search Center] statistician generated the
randomization sequence before the start of
the study“
”Two sets of subjects (a sister-sister pair and
a girlfriend-boyfriend pair) were assigned
to the same cohort, as determined by the
order of entry of the first member of the
pair; the next paired subject was blocked
into the same cohort and given the next
available number in that cohort“
Comment: not all participants were ran-
domised
Allocation concealment (selection bias) Low risk Quote: ”The list of randomization assign-
mentswas sealed and sent to the study phar-
macist, who had no contact with study sub-
jects“
Comment: allocation was concealed
Blinding of participants and personnel
(performance bias)
Objective outcomes
Low risk Quote: ”Only the research pharmacist was
aware of treatment status“
Comment: participants and personnel
were blinded
Blinding of participants and personnel
(performance bias)
Subjective outcomes
Low risk Quote: ”Only the research pharmacist was
aware of treatment status“
Comment: participants and personnel
were blinded
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: ”Only the research pharmacist was
aware of treatment status“
Comment: participants and personnel
were blinded
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Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk Quote: ”Only the research pharmacist was
aware of treatment status“
Comment: participants and personnel
were blinded
Incomplete outcome data (attrition bias)
Objective outcomes
Unclear risk Comment: an imputation method was
not used to replace missing data; however,
dropout was fairly low
Incomplete outcome data (attrition bias)
Subjective outcomes
Unclear risk Comment: unable to access effect on sub-
jective outcomes as quality of life results
were not reported
Selective reporting (reporting bias) High risk Comment: results from the quality of life
questionnaires were not reported
Other bias Unclear risk Comment: unclear if any other bias exists
Mauras 2012
Methods Parallel randomised controlled clinical trial, randomisation ratio 1:1, superiority design
Participants Inclusion criteria:
• uncomplicated (exogenous) obesity defined as BMI > 95th percentile for US
standards for < 5 years
• normal blood pressure, glucose tolerance and total cholesterol
Exclusion criteria:
• chronic illness, medications, alcohol use and smoking
Diagnostic criteria: see above
Interventions Intervention: metformin + diet/exercise intervention
Comparator: diet/exercise intervention
Number of trial centres: 1
Treatment before trial: no
Titration period: metformin was started at 250 mg orally, twice daily, before meals
titrating up to 500 mg twice daily in children < 12 years old and 1000 mg twice daily as
tolerated in older children
Outcomes Outcomes reported in abstract of publication: weight loss, hsCRP, fibrinogen, intra-
hepatic fat
Study details Run-in period: no
Trial terminated early: no
Publication details Language of publication: English
Noncommercial funding
Publication status: peer-reviewed journal
69Drug interventions for the treatment of obesity in children and adolescents (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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Stated aim for study Quote frompublication: ”To determine ifmetformin improvesmarkers of inflammation,
thrombosis, and intrahepatic fat contents in children with uncomplicated obesity“
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (from the author): ”randomisation
assignments were balanced for pubertal sta-
tus. We used sealed envelopes with equal
amount of labels organized at random for
pubertal and pre-pubertal kids to choose
from at their CRC visit (baseline)“
Comment: adequate randomisation pro-
cess
Allocation concealment (selection bias) Low risk Comment: the author of the trial con-
firmed allocation was concealed via the
sealed envelopes
Blinding of participants and personnel
(performance bias)
Objective outcomes
High risk Comment: no placebo was given to the
control group, therefore the participants
would not have been blinded
Blinding of participants and personnel
(performance bias)
Subjective outcomes
High risk Comment: no placebo was given to the
control group, therefore the participants
would not have been blinded
Blinding of outcome assessment (detection
bias)
Objective outcomes
High risk Comment: author confirmed the outcome
assessors were not blinded
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk Comment: author confirmed the outcome
assessors were not blinded
Incomplete outcome data (attrition bias)
Objective outcomes
High risk Comment: there was a high number of
dropouts and no imputation method was
used to replace missing data
Incomplete outcome data (attrition bias)
Subjective outcomes
High risk Comment: there was a high number of
dropouts and no imputation method was
used to replace missing data
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Selective reporting (reporting bias) Low risk Quote: ”The study was registered at http:/
/www.clinicaltrials.gov (NCT00139477)“
Comment: all outcomes reported on the
clinical trial register page were reported in
the publication
Other bias Unclear risk Comment: unable to access if any other
bias were present
NCT00001723
Methods Type of trial: interventional, randomised controlled trial
Allocation: randomised
Intervention model: parallel assignment
Masking: double blind (participant, carer, investigator, outcomes assessor)
Primary purpose: treatment
Participants Condition:
• diabetes mellitus
• hypertension
• metabolic disease
• obesity
• sleep apnoea syndrome
Enrolment: 200
Inclusion criteria:
• good general health. People taking medications for obesity-related comorbid
conditions not excluded
• obesity: BMI for age and triceps skinfold > 95th percentile (determined by
National Health and Nutrition Examination Survey I age-, sex- and race-specific data).
All participants > 60 kg in bodyweight
• evidence for a quantifiable obesity-related comorbidity. Examples include: systolic
or diastolic hypertension (determined by age-specific charts); frank type 2 diabetes,
impaired glucose tolerance assessed by OGTT; hyperinsulinaemia (fasting insulin > 15
mIU/mL); significant hyperlipidaemia (total cholesterol > 200 mg/dL, low-density
lipoprotein cholesterol > 129 mg/dL or fasting triglycerides > 200 mg/dL); hepatic
steatosis (ALT or AST above normal range with negative hepatitis trials) or sleep
apnoea documented by a sleep trial
• aged 12 to 17 years at the start of the trial
• for girls with childbearing potential, a negative pregnancy test before taking and
while taking trial medication. Sexually active females used an effective form of
contraception, including. total abstinence, oral contraceptives, an intrauterine device,
levonorgestrel implants or medroxyprogesterone acetate injections. If one of these
could not be used, contraceptive foam with a condom
• race of all 4 grandparents self-identified as either all Caucasian or all African-
American
Exclusion criteria:
• presence of renal, hepatic (other than obesity-related steatosis), gastrointestinal,
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most endocrinological (e.g. Cushing’s syndrome), or pulmonary disorders (other than
either asthma not requiring continuous medication or sleep apnoea-related disorders)
• pregnancy, breastfeeding or having unprotected intercourse
• had, or had parent or guardians who had, current substance abuse or a psychiatric
disorder or other condition which, in the opinion of the investigators, would impede
competence or compliance or possibly hinder completion of the trial
• regularly used prescription medications unrelated to the complications of obesity.
Oral contraceptive use permitted, provided the contraceptive was used for at least 2
months before starting trial medication. Use of nonprescription and prescription
medications reviewed on a case-by-case basis; depending on the medication,
participants who have continued to take prescription medication for at least 3 months
prior to trial entry were eligible
• recent use (within 6 months) of anorexiant medications for weight reduction
• inability to undergo magnetic resonance imaging (e.g. volunteers with metal
within their bodies including cardiac pacemakers, neural pacemakers, aneurysmal clips,
shrapnel, ocular foreign bodies, cochlear implants, nondetachable electronic or
electromechanical devices such as infusion pumps, nerve stimulators, bone growth
stimulators, etc. that are contraindications)
Interventions Intervention: orlistat
Comparator: placebo
Outcomes Primary outcome: change in BMI SDS (baseline to 6 months)
Secondary outcomes:
• change in bodyweight
• change in BMI
• change in body fat, body fat distribution measures obtained from DEXA
• effect of race on change in weight, difference in change of weight according to
race (non-Hispanic white participants versus non-Hispanic black participants)
Study details NCT number: NCT00001723
Other trial ID numbers: 980111, 98-CH-0111
Publication details ”Safety and Efficacy of Orlistat (Xenical, Hoffmann LaRoche) in African American and
Caucasian Children and Adolescents with Obesity-Related Comorbid Conditions“
Stated aim for study Quote: ”Researchers propose to determine the safety, tolerability, and efficacy of Xenical
[orlistat] in 12-17 year old severely obese African American and Caucasian children and
adolescents who have one or more obesity-related disease (hypertension, hyperlipidemia,
sleep apnea, hepatic steatosis, insulin resistance, impaired glucose tolerance, or Type 2
diabetes)“
Notes The trial was completed when identified.
Trial collaborators:
• Eunice Kennedy Shriver National Institute of Child Health and Human
Development (NICHD)
• Roche Pharma AG
Results presented on the clinicaltrials.gov website and in a conference abstract
Results from ClinicalTrials.gov Results Database: change in BMI SDS orlistat: -0.12 ±
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0.02 and placebo: -0.06 ± 0.02. ANCOVA differences between groups P value = 0.007.
Change in bodyweight orlistat: -2.9 ± 0.7 and placebo: -0.6 ± 0.7. No statistical analysis
provided. Change in BMI orlistat: -1.44 ± 0.26 and placebo: -0.50 ± 0.20. No statistical
analysis provided. 95/100 participants in orlistat and 94/100 in placebo group experi-
enced adverse events with the most common being gastrointestinal disorders. No serious
adverse events in orlistat group. In placebo group, 1 participant had hypoglycaemia and
1 participant had left lower quadrant pain and vomiting, and was admitted to hospital
overnight
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote from author (via email): ”We
randomized participants in a 1:1 fashion
to orlistat 120 mg or identical appear-
ing placebo thrice daily with meals plus a
daily multivitamin (Centrum, Whitehall-
Robins Healthcare, Madison, NJ) contain-
ing 5000 IU vitamin A (80% as retinol,
20% as beta carotene), 400 IU vitamin D
as ergocalciferol, 30 IU vitamin E (as di-
α tocopheryl acetate), and 25 mcg vita-
min K (as phytonadione). Investigators as-
signed consecutive code numbers to par-
ticipants from pre-specified lists that were
stratified by race (Caucasian versus African
American), sex (Male, Female), and degree
of pubertal development (3 strata for boys:
testes <15ml, testes 15-20mL, and testes
>20mL; for girls: Breast Tanner stage I-III;
Tanner stage IV, and Tanner stage V). The
NIH CRC Pharmaceutical Development
Section used permuted blocks with strati-
fication to generate allocations that trans-
lated code numbers into trial group assign-
ments by using a pseudo-random number
program“
Comment: randomisation process de-
scribed
Allocation concealment (selection bias) Low risk Quote from author (via email): ”Phar-
macy personnel not involved with the con-
duct of the study, dispensed identical-ap-
pearing study capsules in containers that
differed only by participant code number.
During the trial, no participant, investiga-
tor, or other medical or nursing staff inter-
acting with participants was aware of study
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group assignments“
Comment: allocation was concealed
Blinding of participants and personnel
(performance bias)
Objective outcomes
Low risk Quote: ”Masking: Double Blind (Subject,
Caregiver, Investigator, Outcomes Asses-
sor)“
Comment: participants and personnel
were blinded
Blinding of participants and personnel
(performance bias)
Subjective outcomes
Low risk Quote: ”Masking: Double Blind (Subject,
Caregiver, Investigator, Outcomes Asses-
sor)“
Comment: participants and personnel
were blinded
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: ”Masking: Double Blind (Subject,
Caregiver, Investigator, Outcomes Asses-
sor)“
Comment: assessors were blinded
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk Quote: ”Masking: Double Blind (Subject,
Caregiver, Investigator, Outcomes Asses-
sor)“
Comment: assessors were blinded
Incomplete outcome data (attrition bias)
Objective outcomes
Low risk Comment: according toClinicalTrials.gov,
87% of orlistat participants completed the
trial, 84% completed placebo arm
Incomplete outcome data (attrition bias)
Subjective outcomes
Low risk Comment: according toClinicalTrials.gov,
87% of orlistat participants completed the
trial, 84% completed placebo arm
Selective reporting (reporting bias) High risk Comment: there are differences in the re-
sults reported on theClinicalTrial.govweb-
site and in the conference abstract
Other bias Unclear risk Comment: unclear as limited information
available
Ozkan 2004
Methods Parallel randomised controlled clinical trial, randomisation ratio 1:1, superiority design
Participants Inclusion criteria:
• severe exogenous obesity, described as weight for height index > 140% in
otherwise healthy participants, not associated with endocrinopathy, genetic syndromes
or medications
• adolescents (Tanner stage 2 or higher) aged 10 to 16 years, and informed consent
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for the trial
Exclusion criteria: -
Diagnostic criteria: see above
Interventions Intervention: conventional treatment + orlistat
Control: conventional treatment
Number of trial centres: 1
Treatment before trial: no
Titration period: no
Outcomes Outcomes reported in abstract of publication: adverse effects, bodyweight loss, %
bodyweight lost, BMI
Study details Run-in period: no
Trial terminated early: no
Publication details Language of publication: English
Noncommercial funding
Publication status: peer-reviewed journal
Stated aim for study Quote from publication: ”To investigate the efficacy and tolerability of orlistat in obese
adolescents, a prospective, open-label, randomised, controlled pilot trial was performed“
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: ”Randomisation was done by alter-
nation of successive patients, who met the
inclusion criteria, to receive conventional
treatment alone or orlistat in addition to
conventional treatment“
Comment: an inappropriate randomisa-
tion method was used
Allocation concealment (selection bias) High risk Comment: allocation was likely not con-
cealed due to the randomisation method
used
Blinding of participants and personnel
(performance bias)
Objective outcomes
High risk Quote: ”the true benefit of orlistat versus
conventional therapy remains to be deter-
mined in a larger placebo-controlled study“
Comment: the control group did not re-
ceive a placebo therefore could not have
been blinded
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Blinding of participants and personnel
(performance bias)
Subjective outcomes
High risk Quote: ”the true benefit of orlistat versus
conventional therapy remains to be deter-
mined in a larger placebo-controlled study“
Comment: the control group did not re-
ceive a placebo therefore could not have
been blinded
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk Comment: unclear if outcome assessors
were blinded
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Unclear risk Comment: unclear if outcome assessors
were blinded
Incomplete outcome data (attrition bias)
Objective outcomes
High risk Comment: an imputation method to re-
placemissing datawere not performed, and
dropout rate was moderate
Incomplete outcome data (attrition bias)
Subjective outcomes
High risk Comment: an imputation method to re-
placemissing datawere not performed, and
dropout rate was moderate
Selective reporting (reporting bias) Unclear risk Comment: BMI was reported in different
formats; median BMI at baseline and mean
BMI at follow-up. No protocol published
Other bias High risk Comment: there were significant differ-
ences in baseline BMI between groups
which were not accounted for. A power cal-
culation was not performed, therefore trial
may have been underpowered
Prado 2012
Methods Parallel randomised controlled trial, randomisation ratio 1:1, superiority design
Participants Inclusion criteria:
• obese adolescents (BMI > 95th percentile for age and sex)
• postmenarchal
• aged 13 to 19 years
• ≥ 1 risk factor for type 2 diabetes
Exclusion criteria:
• diagnosis of diabetes mellitus type 1 or 2
• kidney diseases
• liver or respiratory alcoholism
• eating disorders
• other psychiatric disorders that could diminish adherence to treatment
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• hypersensitivity to metformin
• pharmacological treatments by metabolic or nutritional impact during the last 3
months
• pregnancy
Diagnostic criteria: obesity defined as BMI > 95th percentile for age and sex. Risk
factors for type 2 diabetes include first- or second-degree relative with a history of type
2 diabetes, or alteration in the results of the following examinations within the past 6
months: glycaemia fasting ≥ 100 mg/dL, postload glucose ≥ 140 mg/dL or HOMA >
3.0
Interventions Intervention: metformin + nutritional guide + exercise programme
Comparator: placebo + nutritional guide + exercise programme
Number of trial centres: 1
Treatment before trial: none
Titration period: no
Outcomes Outcomes reported in abstract of publication: weight, BMI, metabolic risk profile
Study details Run-in period: no
Trial terminated early: no
Publication details Language of publication: Spanish
Noncommercial funding
Publication status: peer-reviewed journal
Stated aim for study Quote from publication: ”To analyze the anthropometric and metabolic impact of met-
formin in obese adolescents at risk for type 2 diabetes“
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”Recruited adolescents were ran-
domly assigned into two groups (A and
B) through a sequence computational ran-
domization“
Comment: an appropriate randomisation
method was used
Allocation concealment (selection bias) Low risk Quote: ”An external laboratory was in
charge of packing and labelling bottles,
keeping content knowledge in confidence
until the study ended“
Comment: there was allocation conceal-
ment
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Blinding of participants and personnel
(performance bias)
Objective outcomes
Low risk Comment: author confirmed participants
and trial personnel were blinded
Blinding of participants and personnel
(performance bias)
Subjective outcomes
Low risk Comment: author confirmed participants
and trial personnel were blinded
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk Comment: unclear if outcome assessment
was blinded and if this would have results
in detection bias for the objective outcomes
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Unclear risk Comment: unclear if outcome assessment
was blinded and if thiswould have results in
detection bias for the subjective outcomes
Incomplete outcome data (attrition bias)
Objective outcomes
High risk Comment: there was no imputation
method to replace missing data and
dropout rates were fairly high
Incomplete outcome data (attrition bias)
Subjective outcomes
High risk Comment: there was no imputation
method to replace missing data and
dropout rates were fairly high
Selective reporting (reporting bias) Unclear risk Comment: do not give follow-up data for
some outcomes such as blood pressure
Other bias Unclear risk Comment: unable to make an assessment
on other bias due to lack of information
Rezvanian 2010
Methods Parallel randomised controlled trial, randomisation ratio: 1:1:1:1, superiority design
Participants Inclusion criteria:
• aged 10 to 18 years
• failure in weight loss after 3 months of nonpharmacological treatment (by lifestyle
modification advised in study author’s clinic)
• BMI ≥ age- and sex-specific 95th percentile according to the revised CDC
growth charts
Exclusion criteria:
• people with syndromal obesity, endocrine disorders, any physical disability,
history of chronic medication use, using monoamine oxidase inhibitors, history of
mood disorder in parents and first-degree relatives (depression or bipolar), history of
any chronic diseases (e.g. kidney disorders, lung diseases, hepatitis or a combination)
Diagnostic criteria: see above
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Interventions Intervention 1: metformin + healthy eating + physical activity advice
Intervention 2: fluoxetine + healthy eating + physical activity advice
Intervention 3: metformin + fluoxetine + healthy eating + physical activity advice
Comparator: placebo + healthy eating + physical activity advice
Number of trial centres: 1
Treatment before trial: 3 months of nonpharmacological treatment (by lifestyle modi-
fication advised in study author’s clinic)
Titration period: metformin dosage increased weekly from 500 mg/day to 1500 mg/
day. Fluoxetine dosage of 10 mg/day increased to 20 mg/day after 3 weeks
Outcomes Outcomes reported in abstract of publication: BMI, waist circumference, adverse
effects
Study details Run-in period: no
Trial terminated early: no
Publication details Language of publication: English
Noncommercial funding
Publication status: peer-reviewed journal
Stated aim for study Quote frompublication: ”We aimed to compare the effects of three types of drug regimens
and placebo on generalized and abdominal obesity among obese children and adolescents
who did not succeed to lose weight 3 months after lifestyle modification (diet and
exercise)“
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”Sequence was generated by com-
puter generated random number table“
Comment: randomisationwas an adequate
method
Allocation concealment (selection bias) Unclear risk Comment: unclear if allocation was con-
cealed
Blinding of participants and personnel
(performance bias)
Objective outcomes
Low risk Quote: ”triple-masked randomized clinical
trial“
Comment: participants and personnel
would have been blinded
Blinding of participants and personnel
(performance bias)
Subjective outcomes
Low risk Quote: ”triple-masked randomized clinical
trial“
Comment: participants and personnel
would have been blinded
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Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: ”triple-masked randomized clinical
trial“
Comment: outcomes assessors would have
been blinded
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk Quote: ”triple-masked randomized clinical
trial“
Comment: outcomes assessors would have
been blinded
Incomplete outcome data (attrition bias)
Objective outcomes
Unclear risk Comment: an imputation method was
not used to replace missing data; however,
dropout rate was fairly low
Incomplete outcome data (attrition bias)
Subjective outcomes
Unclear risk Comment: an imputation method was
not used to replace missing data; however,
dropout rate was fairly low
Selective reporting (reporting bias) Unclear risk Comment: unable to assess if all outcomes
were reported due to the unavailability of a
protocol
Other bias Unclear risk Comment: unable to access if any other
bias was present
Srinivasan 2006
Methods Cross-over randomised controlled clinical trial, randomisation ratio 1:1, superiority de-
sign
Participants Inclusion criteria:
• aged 9 to 18 years referred to the endocrine clinic at The Children’s Hospital at
Westmead between March 2002 and March 2003 with obesity, as defined by the
International Obesity Task Force, and clinical suspicion of insulin resistance, as defined
by either a fasting insulin (milliunits per litre) to glucose (millimoles per litre) ratio > 4.
5 (15) or the presence of acanthosis nigricans
Exclusion criteria:
• known type 1 or type 2 diabetes mellitus,
• contraindications to metformin therapy or magnetic resonance imaging scanning
(or both) and weight > 120 kg due to technical difficulties with DEXA scans
Diagnostic criteria: see above
Interventions Intervention: metformin + ”standardised information on healthy eating and exercise“
Comparator: placebo + ”standardised information on healthy eating and exercise“
Number of trial centres: 1
Treatment before trial: no
Titration period: both metformin and placebo doses were gradually built up over a 3-
week period to a final dose of 1 g twice daily
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Outcomes Outcomes reported in abstract of publication:mean age, median BMI z score, weight,
BMI, waist circumference, subcutaneous abdominal adipose tissue, fasting insulin
Study details Run-in period: no
Trial terminated early: no
Publication details Language of publication: English
Noncommercial funding
Publication status: peer-reviewed journal
Stated aim for study Quote from publication: ”We assessed the effect of metformin on body composition and
insulin sensitivity in pediatric subjects with exogenous obesity“
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”Block randomization (blocks of
four) with stratification by pubertal stage
(Tanner 1-2 or Tanner 3-5) was performed
by computer generated random number al-
location“
Comment: an adequate randomisation
method was used
Allocation concealment (selection bias) Low risk Quote (from the author): ”randomisation
was performed in the hospital pharmacy by
random number generation and only re-
vealed for data analysis“
Comment: allocation was likely concealed
Blinding of participants and personnel
(performance bias)
Objective outcomes
Low risk Quote: ”All participants and investigators
were blinded to the intervention“
Comment: participants and personnel
were blinded
Blinding of participants and personnel
(performance bias)
Subjective outcomes
Low risk Quote: ”All participants and investigators
were blinded to the intervention“
Comment: participants and personnel
were blinded
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: ”All participants and investigators
were blinded to the intervention“
Comment: participants and personnel
were blinded
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Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk Quote: ”All participants and investigators
were blinded to the intervention“
Comment: participants and personnel
were blinded
Incomplete outcome data (attrition bias)
Objective outcomes
Unclear risk Comment: an imputation method was
not used to replace missing data; however,
dropout rates were fairly low
Incomplete outcome data (attrition bias)
Subjective outcomes
Unclear risk Comment: an imputation method was
not used to replace missing data; however,
dropout rates were fairly low
Selective reporting (reporting bias) Unclear risk Comment: the publication did not report
raw data for some of the outcomes, but a
clinical trial entry was available and there
were no differences
Other bias Unclear risk Comment: no power calculation was per-
formed; therefore, the trial may have been
underpowered
Van Mil 2007
Methods Parallel controlled clinical trial, randomisation ratio 1:1, superiority design
Participants Inclusion criteria:
• aged 12 to 18 years, initially selected for BMI ≥ 97th percentile, and further
selected for triceps skinfold thickness ≥ 97th percentile for age and sex with persisting
obesity despite previous professionally supervised weight loss attempts (97.5th
percentile is equivalent to 2 SD)
Exclusion criteria:
• endocrine causes or other secondary causes of obesity
• significant physical or medical illness that could influence the results of the trial
Diagnostic criteria: see above
Interventions Intervention: sibutramine + energy-restricted diet and exercise plan
Comparator: placebo + energy-restricted diet and exercise plan
Number of trial centres: 1
Treatment before trial: no
Titration period: 5 mg placebo or sibutramine, taken once daily in the morning. After
2 weeks, the dose was increased to 10 mg/day
Outcomes Outcomes reported in abstract of publication: BMI-SDS, BMI, % fat mass, BMRadj,
total energy expenditure
Study details Run-in period: no
Trial terminated early: no
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Van Mil 2007 (Continued)
Publication details Language of publication: English
Commercial funding
Publication status: peer-reviewed journal
Stated aim for study Quote from publication: ”The objective of this trial was to examine the effect of treat-
ment with sibutramine (10 mg) on body composition and energy expenditure in obese
adolescents“
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”Randomisation was performed by
Knoll Pharmaceuticals. Boxeswithmedica-
tion for each visit were numbered for each
subject. Subjects received their number and
the boxes with medication that belonged
to that number. The numbers/medication
was handed out in order of inclusion in the
study“
Comment: author clarified randomisation
process; however, it was unclear if the pro-
cess would have introduced selection bias
Allocation concealment (selection bias) Low risk Quote: ”Knoll Pharmaceuticals BV [cur-
rently Abbott Laboratories (Hoofddorp,
TheNetherlands)], manufactured and pro-
vided code-numbered placebo and sibu-
tramine capsules. Subjects received their
trial and medication code according to or-
der of entrance into the study, without
stratification“
Comment: allocation was concealed
Blinding of participants and personnel
(performance bias)
Objective outcomes
Low risk Comment: author confirmed participants
and personnel were blinded
Blinding of participants and personnel
(performance bias)
Subjective outcomes
Low risk Comment: author confirmed participants
and personnel were blinded
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Comment: author confirmed outcome as-
sessment was blinded
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Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk Comment: author confirmed outcome as-
sessment was blinded
Incomplete outcome data (attrition bias)
Objective outcomes
Unclear risk Comment: an imputation method was
used; however, results only shown for com-
pleters. Dropout rates fairly low
Incomplete outcome data (attrition bias)
Subjective outcomes
Unclear risk Comment: an imputation method was
used; however, results only shown for com-
pleters. Dropout rates fairly low
Selective reporting (reporting bias) Unclear risk Comment: unclear whether all outcomes
were reported due to no previously pub-
lished protocol
Other bias Unclear risk Quote: ”E.G.A.H.V.M. was previously
employed by Maastricht University, partly
on a research grant from Knoll, currently
Abbott Pharmaceuticals, TheNetherlands“
Comment: potential influence of funding
source
Wiegand 2010
Methods Parallel randomised controlled trial, randomisation ratio 1:1, superiority design
Participants Inclusion criteria:
• obese
• aged 10 to 17 years
• HOMA IR > 3 or > 95th percentile according to Allard et al
• nondiabetic
• normal liver and kidney function
• already were enrolled in the trial
Exclusion criteria:
• pre-existing diabetes
• pregnancy
• liver enzymes > 1.5 times the upper limit of normal or elevated creatinine > 1.5
mg/dL
• severe chronic or mental illness
Diagnostic criteria: obesity (not defined)
Interventions Intervention: metformin + multiprofessional lifestyle intervention
Comparator: placebo + multiprofessional lifestyle intervention
Number of trial centres: 2
Treatment before trial: 6-month multiprofessional lifestyle intervention
Titration period: no
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Outcomes Outcomes reported in abstract of publication: BMI, HOMA-IR, fasting insulin,
insulin sensitivity index, metabolic syndrome
Study details Run-in period: no
Trial terminated early: no
Publication details Language of publication: English
Commercial and noncommercial funding
Publication status: peer-reviewed journal
Stated aim for study Quote from publication: ”To study whether metformin reduces obesity, homeostasis
model assessment for insulin resistance index (HOMA-IR), and themetabolic syndrome
(MtS) in obese European adolescents in addition to previous unsuccessful lifestyle inter-
vention“
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: no description of the randomi-
sation process
Allocation concealment (selection bias) Unclear risk Comment: unclear if allocation was con-
cealed
Blinding of participants and personnel
(performance bias)
Objective outcomes
Unclear risk Quote: ”we performed adouble-blind, ran-
domized controlled clinical trial“
Comment: unclear who was blinded
Blinding of participants and personnel
(performance bias)
Subjective outcomes
Unclear risk Quote: ”we performed adouble-blind, ran-
domized controlled clinical trial“
Comment: unclear who was blinded
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk Quote: ”we performed adouble-blind, ran-
domized controlled clinical trial“
Comment: unclear who was blinded
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Unclear risk Quote: ”we performed adouble-blind, ran-
domized controlled clinical trial“
Comment: unclear who was blinded
Incomplete outcome data (attrition bias)
Objective outcomes
Unclear risk Comment: no imputation method was
used to replace missing data; however,
dropout was fairly low
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Incomplete outcome data (attrition bias)
Subjective outcomes
Unclear risk Comment: no imputation method was
used to replace missing data; however,
dropout was fairly low
Selective reporting (reporting bias) Unclear risk Comment: unable to find the clinical trial
entry; hence, it is unclear whether selective
reporting occurred
Other bias High risk Quote: ”The study was supported in part
by BMBF Research grant 01 GS 0825 and
by MERCK SANTE S.A.S, Lyon, France
(10’000,- Euro)“
Comment: trial was partly funded by a
pharmaceutical company. The authors do
not declare their involvement in the design,
analysis and interpretation of the results
Wilson 2010
Methods Parallel randomised controlled clinical trial, randomisation ratio 1:1, superiority design
Participants Inclusion criteria:
• BMI ≥ 95th percentile for age and sex but weighed < 136 kg (weight limit for
DEXA table)
Exclusion criteria:
• previous diagnosis of diabetes mellitus
• had ever used a medication to treat diabetes or insulin resistance or weight loss
• were taking any medications known to increase metformin levels
• received recent glucocorticoid therapy
• had any identified syndrome or medical disorder predisposing to obesity
• had surgical therapy of obesity
• attended formal weight loss programme in last 6 months
• had significant alcohol use in last 6 months
• had elevated creatinine or liver enzymes
• had untreated disorders of the thyroid
• impaired mobility
• had ever been pregnant
Diagnostic criteria: see above
Interventions Intervention: metformin + lifestyle intervention programme
Comparator: placebo + lifestyle intervention programme
Number of trial centres: 6
Treatment before trial: 4-week placebo run-in phase, during which participants were
required to attend at least 2 of 3 scheduled lifestylemodification sessions and demonstrate
80% compliance with daily placebo treatment (pill count) for subsequent randomisation
Titration period: participants either given metformin XR or identical placebo tablets
and instructed to take 1 tablet/day (metformin hydrochloride XR 500 mg or placebo)
orally before dinner for 2 weeks, then 2 tablets/day for 2 weeks, then 4 tablets/day from
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week 8 to week 52
Outcomes Outcomes reported in abstract of publication: mean adjusted BMI, body composi-
tions, abdominal fat, insulin indices
Study details Run-in period: 4-week placebo run-in phase (see above)
Trial terminated early: no
Publication details Language of publication: English
Noncommercial funding
Publication status: peer-reviewed journal
Stated aim for study Quote from publication: ”to test the hypothesis that 48 weeks of daily metformin hy-
drochloride extended release (EX) will reduce body mass index in obese adolescents, as
compared with placebo“
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”Subjects who successfully com-
pleted the run-in period were randomized
to metformin XR or placebo treatment ac-
cording to random sequences constructed
at the Data Coordinating Center. To en-
sure balance across major factors, the ran-
domization was stratified by site and sex“
”To ensure nonpredictability of assign-
ment, the randomization sequence was
grouped in randomly permuted blocks of
2 and 4, and assignments were randomly
permuted within block“
Comment: an adequate randomisation
method was used
Allocation concealment (selection bias) Low risk Quote: ”Subjects who successfully com-
pleted the run-in period were randomized
to metformin XR or placebo treatment ac-
cording to random sequences constructed
at the Data Coordinating Center“
Comment: adequate allocation conceal-
ment
Blinding of participants and personnel
(performance bias)
Objective outcomes
Low risk Quote: ”Subjects and study personnel were
blinded to assignment throughout the en-
tire study“
Comment: performance bias likely to be
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reduced by blinding participants and trial
personnel
Blinding of participants and personnel
(performance bias)
Subjective outcomes
Low risk Quote: ”Subjects and study personnel were
blinded to assignment throughout the en-
tire study“
”Unblinded data were seen only by the
Data and Safety Monitoring Board and
study statistician“
Comment: performance bias likely to be
reduced by blinding participants and trial
personnel
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: ”Subjects and study personnel were
blinded to assignment throughout the en-
tire study“
”Unblinded data were seen only by the
Data and Safety Monitoring Board and
study statistician“
Comment: outcomes assessors blinded
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk Quote: ”Subjects and trial personnel were
blinded to assignment throughout the en-
tire study“
”Unblinded data were seen only by the
Data and Safety Monitoring Board and
study statistician“
Comment: outcomes assessors blinded
Incomplete outcome data (attrition bias)
Objective outcomes
High risk Quote: ”Ninety-two subjects
were screened and 77 were randomized, 39
to metformin XR, 38 to placebo; 27 and
19 in each group were measured at weeks
52 and 100, respectively“
Comment: dropout fairly high in each
group and no imputation method was per-
formed to replace missing data
Incomplete outcome data (attrition bias)
Subjective outcomes
High risk Quote: ”Ninety-two subjects
were screened and 77 were randomized, 39
to metformin XR, 38 to placebo; 27 and
19 in each group were measured at weeks
52 and 100, respectively“
Comment: dropout fairly high in each
group and no imputation method was per-
formed to replace missing data
Selective reporting (reporting bias) Low risk Comment: all outcomes reported
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Other bias Unclear risk Comment: baseline means seemed to be
adjusted
Yanovski 2011
Methods Parallel randomised controlled clinical trial, randomisation ratio 1:1, superiority design
Participants Inclusion criteria:
• BMI ≥ 95th percentile according to the CDC 2000 growth charts for the US
• prepubertal or early pubertal (defined as breast Tanner stage I to III for girls; testes
< 8 mL for boys)
• fasting hyperinsulinaemia, defined as fasting insulin ≥ 15 mU/mL, the 99th
percentile for fasting insulin among 224 nonobese 6- to 12-year-old children studied as
outpatients at the National Institutes of Health with the same insulin assay
Exclusion criteria:
• impaired fasting glucose
• diabetic
• diagnosed renal, cardiac, endocrine, pulmonary or hepatic disease that might alter
bodyweight
• baseline creatinine > 1 mg/dL and for ALT or AST > 1.5 times the upper limit of
the laboratory normal range
Diagnostic criteria: see above
Interventions Intervention: metformin + dietitian-administered weight-reduction programme
Comparator: placebo + dietitian-administered weight-reduction programme
Number of trial centres: 1
Treatment before trial: no
Titration period: once baseline assessments were completed, participant’s trial medica-
tion dose was progressively increased according to a prespecified algorithm over a 3-week
period, starting with 500 mg twice daily and increasing to a maximum dose of 1000 mg
twice daily
Outcomes Outcomes reported in abstract of publication: BMI, bodyweight, BMI z score, fat
mass, fasting plasma glucose, HOMA-IR, adverse events
Study details Run-in period: no
Trial terminated early: no
Publication details Language of publication: English
Commercial and noncommercial funding
Publication status: peer-reviewed journal
Stated aim for study Quote from publication: ”To determine whether metformin treatment causes weight loss
and improves obesity related comorbidities in obese children, who are insulin resistant“
Notes -
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”We randomly assigned partici-
pants in a 1:1 randomization ratio to re-
ceive metformin hydrochloride or placebo,
twice daily with meals. Investigators as-
signed consecutive code numbers to partic-
ipants from prespecified lists stratified by
race/ethnicity, sex, and degree of pubertal
development“
Comment: an adequate randomisation
method was used
Allocation concealment (selection bias) Low risk Quote: ”The CRC Pharmaceutical De-
velopment Section used permuted blocks
with stratification to generate allocations
that translated code numbers into study
group assignments by using a pseudo-ran-
dom number program and prepared iden-
tically appearing placebo and metformin
capsules“
Comment: allocation was concealed
Blinding of participants and personnel
(performance bias)
Objective outcomes
Low risk Quote: ”No participant, investigator, or
other medical or nursing staff interacting
with participants was aware of study group
assignments during the trial“
Comment: both the participants and per-
sonnel were blinded
Blinding of participants and personnel
(performance bias)
Subjective outcomes
Low risk Quote: ”No participant, investigator, or
other medical or nursing staff interacting
with participants was aware of study group
assignments during the trial“
Comment: both the participants and per-
sonnel were blinded
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: ”No participant, investigator, or
other medical or nursing staff interacting
with participants was aware of study group
assignments during the trial“
Comment: both the participants and per-
sonnel were blinded
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk Quote: ”No participant, investigator, or
other medical or nursing staff interacting
with participants was aware of study group
90Drug interventions for the treatment of obesity in children and adolescents (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Yanovski 2011 (Continued)
assignments during the trial“
Comment: both the participants and per-
sonnel were blinded
Incomplete outcome data (attrition bias)
Objective outcomes
Low risk Quote: ”We assessed efficacy in the in-
tention-to-treat sample of all randomly as-
signed participants using a multiple impu-
tationmodel for missing data under amiss-
ing-at-random assumption“
Comment: low risk of attrition bias for ob-
jective outcomes
Incomplete outcome data (attrition bias)
Subjective outcomes
Low risk Quote: ”We assessed efficacy in the in-
tention-to-treat sample of all randomly as-
signed participants using a multiple impu-
tationmodel for missing data under amiss-
ing-at-random assumption“
Comment: low risk of attrition bias for
subjective outcomes
Selective reporting (reporting bias) Low risk Comment: all outcomes reported from
protocol
Other bias Unclear risk Comment: unclear if any other bias was
present
”-“ denotes not reported.
ALR: adiponectin-to-leptin ratio; ALT: alanine transaminase; AST: aspartate transaminase; BMI: body mass index; BMIadj: adjusted
body mass index: BMI-SDS: body mass index standardised score; BMRadj: adjusted basal metabolic rate; CDC: Centers for Disease
Control and Prevention; DBP: diastolic blood pressure; DEXA: dual energy X-ray absorptiometry; FGIR: fasting glucose insulin ratio;
HbA1c: glycosylated haemoglobin A1c; HOMA-IR: homeostasis model assessment for insulin resistance index; hsCRP: highly sensitive
C-reactive protein; LOCF: last observation carried forward; min: minute; OGTT: oral glucose tolerance test; QUICKI: quantitative
insulin check index; SBP: systolic blood pressure; SD: standard deviation; SDS: standard deviation score
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Andelman 1967 Duration of treatment only 11 weeks
Ardizzi 1996 Duration of drug treatment only 2 months
Arman 2008 Treatment of schizophrenia or schizoaffective disorder
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Bacon 1967 Duration of treatment only 2 months
Beyer 1980 Adults
Burgert 2008 Duration of follow-up < 6 months
Canlorbe 1976 Duration of follow-up only 12 weeks
Cannella 1968 Adults
Casteels 2010 Children had neurogenic or myogenic motor deficit
Cayir 2015 Not an RCT
CTRI/2011/10/002081 2011 Duration of follow-up < 6 months
Danielsson 2007 Aim was to treat hypothalamic obesity
Danilovich 2014 Duration of follow-up < 6 months
De Bock 2012 Duration of drug treatment only 6 weeks
Delitala 1977 Adults
Di Natale 1973 Not an RCT
Diaz 2013 Study aim, not all obese at baseline
Doggrell 2006 Not an RCT
EUCTR2009-016921-32-ES A dietary therapy, intervention not relevant for this review
EUCTR2012-000038-20-DE Duration of treatment only 6 weeks
Fanghänel 2001 Adults
Faria 2002 Adults
Ferguson 1986 Adults
Ferrara 2013 Duration of follow-up < 6 months
Fox 2015 Not an RCT
Freemark 2007 Not an RCT
Galloway 1975 Adults
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Gamski 1968 Adults
Garnett 2010 Not a pharmacological intervention
Genova 1967 Study aim not to treat to obesity
Gill 1977 Adults
Giovannini 1990 Duration of treatment only 90 days
Godefroy 1968 Adults
Goldrick 1973 Adults
Goldstein 1993 Adults
González Barranco 1974 Adults
Griboff 1975 Adults
Grube 2014 Adults
Guazzelli 1987 Adults
Gwinup 1967 Duration of follow-up in the placebo group only 13 weeks
Halpern 2006 Adults
Hamilton 2003 Duration of follow-up only 3 months
Hansen 2001 Adults
Haug 1973 Adults
Hawkins 2012 Not an RCT
Honzak 1976 Adults
Hooper 1972 Adults
Huston 1966 Adults
IRCT2013021012421N1 Aim of trial to treat fatty liver disease
IRCT2014020116435N1 Not an RCT
Israsena 1980 Duration of follow-up only 4 months
93Drug interventions for the treatment of obesity in children and adolescents (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
James 2000 Adults
Kasa-Vubu 2008 Not an RCT
Kay 2001 Duration of treatment only 10 weeks
Kelly 2012 1 arm of the cross-over trial was only followed up for 3 months after receiving the drug
Kelly 2013a Not an RCT
Kelly 2013b Not an RCT
Kendall 2014 Not an RCT
Klein 2006 Duration of follow-up < 6 months
Kneebone 1968 Adults
Knoll 1975 Not an RCT
Komarnicka 1975 Adults
Komorowski 1982 Duration of treatment only 8 weeks
Kreze 1967 Adults
Lamberto 1993 Not an RCT
Leite 1971 Adults
Lewis 1978 Adults
Libman 2015 Participants had type 1 diabetes - secondary cause of obesity
Liebermeister 1969 Adults
Liu 2013 Adults
Lorber 1966 Duration of treatment only 4 weeks
Love-Osborne 2008 The aim of the study was to treat insulin resistance, not all participants were obese
Maclay 1977 Adults
Malchow-Møller 1980 Duration of follow-up only 12 weeks
Marques 2016 Not an RCT
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McDuffie 2002 Not an RCT
Molnár 2000 Duration of follow-up only 20 weeks
Muls 2001 Adults
Nadeau 2015 Participants had type 1 diabetes - secondary cause of obesity
Nathan 2016 A description paper of 2 trials which do not meet the inclusion criteria of this review
NCT00076362 Aim of trial to treat hypothalamic obesity
NCT00284557 Not a pharmacological intervention
NCT00775164 Withdrawn prior to enrolment - inadequate enrolment
NCT00845559 Withdrawn prior to enrolment - no reason provided
NCT01023139 Not a pharmacological RCT - all participants were given drugs then randomised to lifestyle inter-
vention or control
NCT01061775 Aim to treat hypothalamic obesity
NCT01107808 Withdrawn prior to enrolment - poor recruitment to the study
NCT01169103 Intervention was a growth hormone therapy
NCT01242241 Aim of the study: not treatment of obesity
NCT01329367 Not a pharmacological intervention
NCT01332448 Not an RCT
NCT01410604 Duration of follow-up only 3 months
NCT01456221 Not a pharmacological intervention
NCT01910246 Not an RCT
NCT02022956 Not an RCT
NCT02063802 Duration of follow-up only 4 months
NCT02186652 Not an RCT
NCT02378259 Surgery intervention
NCT02398669 No control group
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NCT02438020 Duration of follow-up < 6 months
NCT02515773 Participants had bipolar disorder and were critically ill. They were all treated with anti-psychotics
which can cause obesity (potential secondary cause of obesity)
Nwosu 2015 Participants had type 1 diabetes - secondary cause of obesity
O’connor 1995 Adults
Park 2010 Not an RCT
Pedrinola 1994 Not an RCT
Persson 1973 Adults
Plauchu 1967a Adults
Plauchu 1967b Adults
Plauchu 1972 Adults
Pugnoli 1978 Adults
Rauh 1968 Duration of follow-up only 12 weeks
Resnick 1967 Adults
Rodos 1969 Adults
Rodriguez 2007 Not an RCT
Roed 1980 Adults
Roginsky 1966 Adults
Sabuncu 2004 Adults
Sainani 1973 Mainly adults
Scavo 1976 Not an RCT
Shutter 1966 Duration of treatment only 6 weeks
Spence 1966 Not an RCT
Spranger 1963 Duration of treatment only 4 weeks
Spranger 1965 Duration of treatment only 4 weeks
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Sproule 1969 Adults
Stewart 1970 Duration of follow-up only 16 weeks
Sukkari 2010 Not an RCT
TODAY study group 2013 The aim of the study was to treat diabetes, not obesity
Tong 2005 Adults
Toubro 2001 Adults
Tsai 2006 Not an RCT
Van Seters 1982 Adults
Warren-Ulanch 2008 Not an RCT
Weintraub 1984 Adults
Yanovski 2003 Not an RCT
Yu 2013 Duration of drug treatment only 10 weeks
RCT: randomised controlled trial.
Characteristics of studies awaiting assessment [ordered by study ID]
Golebiowska 1981
Methods
Participants
Interventions
Outcomes
Study identifier
Official title
Stated purpose of study
Notes Unable to source
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ISRCTN08063839
Methods Type of trial: interventional; randomised controlled trial
Allocation: randomised
Intervention model: parallel assignment
Masking: not reported
Primary purpose: treatment
Participants Condition: adolescent obesity
Enrolment: target 48
Inclusion criteria:
• aged 12 to 18 years
• BMI > 95th centile for age and sex
• pubertal stage ≥ 3
• ability for parent and child to read and understand written instructions in English; parents able to
give informed written consent in English; adolescent able to give verbal assent
• successfully completed a 6-month lifestyle intervention without a gain in BMI z-score
Exclusion criteria:
• renal disorders, diabetes, diagnosed psychological disorders
• taking stimulants or psychotropic medication or drugs known to alter metabolism including insulin
sensitisers, glucocorticoids, thyroxine, other weight loss medications
• taking any drugs known to be contraindicated with metformin therapy
• known adverse reactions to metformin
• pregnancy
Interventions Intervention: metformin + lifestyle intervention
Comparator: placebo + lifestyle intervention
Outcomes Primary outcome:
• BMI (pre and post intervention)
Secondary outcomes:
• subjective appetite sensations using a novel electronic appetite rating system (EARS), immediately
before and then hourly for 4 hours after a fixed-energy breakfast. Measured at baseline, day 1, week 2,
week 4, then monthly. This is a validated technique of measuring appetite which has been used in
appetite trials involving obese children
• food preferences will be measured using a novel ’liking and wanting’ (L&W) experimental
procedure. Measured at baseline, day 1, week 2, week 4, then monthly. This method has been validated
in several trials. The L&W procedure is sensitive to detect changes in nutrient and taste preferences
• we will measure fasting gastrointestinal hormones (at baseline, day 28, 2 months and 6 months) to
identify potential biomarkers which could explain any differences in appetite responses between the 2
groups. These will be correlated with fasting and postprandial subjective appetite sensations
• in a subset of participants (10 in each group), will measure gastrointestinal hormones and subjective
sensations of appetite, pre- and postprandially (by insertion of an intravenous cannula) and pre- and
postdosing with metformin (at baseline, each metformin dose increment (day 1, week 2, week 4), 2
months and 6 months)
Other outcomes: not reported
Study identifier ISRCTN number: ISRCTN08063839
Trial start date: 1 July 2010
Trial completion date: 30 June 2014
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Official title Investigating the use of pharmacotherapy in adolescents for weight loss maintenance: the role of appetite:
a randomised, placebo controlled trial
Stated purpose of study Quote: ”Eat Smart is a novel research study in which 2 dietary approaches to treat childhood obesity are
being tested.“
Notes Trial completed in 2014, no publication available and page not found on website
Trial sponsor: Royal Children’s Hospital (Australia)
Ethics approved by the Human Research Ethics Committee (HREC) of the Royal Children’s Hospital (ref:
HREC/10/QRCH/53)
Sources of funding are:
• Australian Paediatric Endocrine Care (APEC) Research Grant (Pfizer) (Australia) - (ref: E/09)
(contact: trudy.snape@pfizer.com)
• Royal Children’s Hospital (Australia)
Further information obtained from trial website: www2.som.uq.edu.au/som/Research/ResearchCentres/
cnrc/Pages/CNRCHome.aspx
Linquette 1971
Methods
Participants
Interventions
Outcomes
Study identifier
Official title
Stated purpose of study
Notes Unable to source
NCT00934570
Methods Type of trial: interventional; randomised controlled trial
Allocation: participants are randomised to metformin medication or placebo, and then randomised to en-
gage in a moderate or vigorous intensity exercise programme for the first 12 weeks of the 2-year programme
Intervention model: parallel assignment
Masking: single blind (participant)
Primary purpose: prevention
Participants Condition: obesity, type 2 diabetes
Enrolment: estimated 72
Inclusion criteria:
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• obese adolescents defined as BMI > 95th percentile for age and sex
• metformin-naive participants
Exclusion criteria:
• elevated fasting plasma glucose ≥ 6.0 mmol/L
• 2-hour plasma glucose ≥ 11.1 mmol/L after a standard glucose load
• HbA1c > 6.0%
• medication other than nonprescription drugs, oral contraceptive pill or thyroid hormone
replacement
• smoking
• pregnancy
• renal insufficiency (serum creatinine > the upper limit of normal)
• hepatic dysfunction (> 1.5 times the upper limit of normal for AST and ALT)
• latex allergy
• hypersensitivity to metformin or its ingredients
• breastfeeding
• participants with a history of lactic acidosis
• abnormal creatinine clearance
• HIV, HBV, and HCV infections
• drug and alcohol abuse
• severe mental disorders
• participants who are planning radiological examinations involving intravenous injection of
iodinated contract materials
• participation in another clinical trial
• significant history or presence of cardiovascular, pulmonary, gastrointestinal, immunological,
endocrine, neurological disorders
• malignant diseases
• previous exposure to any pharmaceutical antidiabetic agent
Interventions Interventions:
• metformin + standard exercise
• metformin + intensive exercise
Comparators:
• placebo + standard exercise
• placebo + intensive exercise
Outcomes Primary outcome:
• BMI
Secondary outcomes:
• body composition assessments (fat mass, fat free mass, and % body fat, waist circumference)
• metabolic assessments (glycaemic status, serum lipids, plasma adipocytokines)
• vascular assessments (blood pressure, endothelial function, vascular properties, heart variability)
• programme adherence (attendance, medication)
• physical performance assessments (aerobic fitness, strength)
• exercise intensity assessments (heart rate, rating of perceived exertion)
• physical activity assessments (self-reported physical activity, objective physical activity)
• psychosocial function assessments (quality of life, social support, outcome expectations, satisfaction,
enjoyment, self-efficacy, task self-efficacy, goal setting self-efficacy, planning self-efficacy, barriers self-
efficacy, behavioural intentions, group cohesion, collaboration)
• nutrition assessments (diet, 3-day food record)
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Other outcomes: not reported
Study identifier NCT number: NCT00934570
Other trial ID numbers: R-08-259, 15590
Trial start date: April 2009
Trial completion date: May 2012
Official title Reduction of Adolescent Risk Factors for Type 2 Diabetes and Cardiovascular Disease
Stated purpose of study Quote: ”Assess the sustainability of a two-year intervention aimed at improving body mass index (BMI)
and metabolic and vascular health in obese youth.“
Notes No full publication
Results were presented in a poster (Clarson et al 2013) - ”In the MXR [metformin] group, there were
significant differences in BMI z score at baseline (2.22 ± 037) and 6 months (2.08 ± 0.48, P < .001), 12
months (2.05 ± 0.49, P = .002) and 24 months (2.10 ± 0.46, P = 0.04)“
Author asked for additional results but none were provided
Sponsored by: Lawson Health Research Institute and Canadian Institutes of Health Research (CIHR)
Protocol:Wilson et al 2009
Further trial details are provided by Lawson Health Research Institute
The health authority associated with this trial: ”Canada: Health Canada“
NCT00940628
Methods Type of trial: interventional; randomised control trial
Allocation: randomised
Intervention model: parallel assignment
Masking: open label
Primary purpose: treatment
Participants Condition: obesity
Enrolment: 60
Inclusion criteria:
• adolescent participants, aged 12 to 14 years
• overweight or obese
Exclusion criteria:
• aged < 12 or > 14 years;
• BMI in normal range
Interventions Intervention: orlistat (Xenical) + diet and exercise programme
Comparator: diet and exercise programme
Outcomes Primary outcome:
• change in BMI (time frame: at each clinic visit, every 4 weeks)
Secondary outcomes:
• adverse events
• laboratory parameters (time frame: at each clinic visit, every 4 weeks
Other outcomes: not reported
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Study identifier NCT number: NCT00940628
Other trial ID number: ML19569
Trial start date: April 2008
Trial completion date: September 2010
Official title Open-label Comparative Randomized Study of the Efficacy and Safety of Orlistat (Xenical) in Complex
Therapy of Obesity and Metabolic Disorders in Adolescents
Stated purpose of study Quote: ”This 2 arm study will assess the effect of Xenical on body mass index (BMI) in obese or overweight
adolescents“
Notes Trial was completed in 2010, no publication is available
The health authority associated with this trial is ”Russia: Federal Service on Surveillance in Healthcare and
Social Development of RF“
NCT01487993
Methods Type of trial: interventional; randomised controlled trial
Allocation: randomised
Intervention model: parallel assignment
Masking: double blind (participant, carer, investigator)
Primary purpose: treatment
Participants Condition: obesity; insulin resistance
Enrolment: 127
Inclusion criteria:
• aged 10 to 16 years at trial entry
• white
• obesity defined as BMI-SDS > 2.3
• insulin resistance defined as HOMA-IR ≥ 3.4
• an obtained informed consent from participants and parents/carers
Exclusion criteria:
• presence of type 2 diabetes (American Diabetes Association criteria)
• presence of endocrine disorders with steroid therapy
• suspicion of polycystic ovarium syndrome
• height < -1.3 SD of target height
• syndrome disorders with or without mental retardation
• use of anti-hyperglycaemic drugs
• pregnancy (pregnancy test will be performed, if applicable)
• (history of ) alcohol abuse
• impaired renal or hepatic function (defined as GFR < 80 mL/min. GFR = 40 x length (cm) / serum
creatinine (µmol/L and ALT > 150% of normal value for age), or both
• use of ritonavir; use of ACE inhibitors
• insufficient knowledge of the Dutch language
Interventions Intervention: metformin + lifestyle intervention
Comparator: placebo + lifestyle intervention
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Outcomes Primary outcomes:
• change in BMI from baseline (time frame: 18 months and 36 months). Change in BMI after part 1
(double blind) and part 2 (follow-up)
• change in insulin resistance from baseline (time frame: 3, 6, 9, 12, 15, 18, 24, 30 and 36 months).
Calculated by the HOMA-IR
Secondary outcomes:
• renal and hepatic function (time frame: 3, 6, 9, 12, 15, 18, 24, 30 and 36 months), creatinine and
ALT
• tolerability (time frame: 3, 6, 9, 12, 15, 18, 24, 30 and 36 months), number of reported adverse
effects, in relation to the achieved dose level
• pharmacokinetic parameters: clearance (mL/min) (time frame: 9 months), clearance where
applicable expressed per bodyweight, age category, Tanner stage and sex, clearance will be determined
with a 2-compartment pharmacokinetic model using nonlinear mixed-effect modelling
• % body fat (time frame: 0, 9, 18 and 36 months)
• physical fitness (time frame: 0, 9, 18 and 36 months)
• quality of life (time frame: 0, 9, 18 and 36 months)
• long-term efficacy (time frame: 36 months). Based on BMI and HOMA-IR values
• long-term safety (time frame: 36 months). Renal and hepatic function after 36 months of
metformin use
• long-term tolerability (time frame: 36 months). The amount of adverse effects after 36 months
• microvascular complications (time frame: 36 months). Measured as microalbuminuria
• macrovascular complications (time frame: 36 months). Measured with pulse wave velocity and
augmentation Index
• development of type 2 diabetes mellitus (time frame: 36 months)
Other outcomes: not reported
Study identifier NCT number: NCT01487993
Other trial ID numbers: metformin 2011-6, 2010-023980-17
Official title An Efficacy, Safety and Pharmacokinetic Study on the Short-term and Long-term Use of Metformin in
Obese Children and Adolescents
Stated purpose of study Quote: ”The purpose of this study is to determine whether metformin is effective in reducing BMI and
insulin resistance in obese children and adolescents“
Notes The trial was sponsored by St. Antonius Hospital; Jeroen Bosch Ziekenhuis is a collaborator on the trial;
the health authority associated to this trial is ”Netherlands: The Central Committee on Research Involving
Human Subjects (CCMO)“
Results of trial are now published (see Van der Aa 2016 - NCT01487993): 62 participants randomised
(32 metformin, 30 placebo), 42 analysed (23 metformin, 19 placebo); 18 months’ intervention; median
change in BMI was +0.2 kg/m2 (95% CI -2.9 to 1.3) (metformin) versus +1.2 kg/m2 (95% CI -0.3 to 2.4)
kg/m2 (placebo) (P = 0.02). No serious adverse events reported. 2 out of 9 participants lost to follow-up in
the metformin group discontinued treatment because of adverse events. No placebo participants dropped
out due to adverse events (13 participants lost to follow-up)
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Methods Type of trial: interventional
Allocation: randomised
Intervention model: parallel assignment
Masking: unclear
Primary purpose: treatment
Participants Condition: overweight and obesity in children and adolescents
Enrolment: 145
Inclusion criteria:
• overweight (BMI SDS 1.0 to 2.0) or obese (BMI ≥ 2.0) (IOTF)
• children or adolescents
Exclusion criteria: -
Interventions Interventions:
• metformin combined with lifestyle changes
• metformin only
Comparators:
• lifestyle changes only
• no treatment controls
Outcomes Primary outcomes:
• BMI SDS
• waist circumference
• waist SDS
• adverse events
• lean mass
Secondary outcomes: none given
Other outcomes: none given
Study identifier -
Official title -
Stated purpose of study ”To assess the efficacy and safety ofMetformin use in combination with lifestyle changes or alone for weight
management in OW and OB children and adolescents“
Notes Project supported by Research Council of Lithuania (grant Nr MIP-039/2013) and Research Foundation
of Lithuanian University of Health Sciences (grants 2012 and 2013)
Results: reduction in BMI, waist circumference and waist circumference SDS adjusted by sex and puberty
stages was significantly greater in the metformin + lifestyle changes group compared to the controls no
treatment group. Change in BMI after 12 months’ intervention: controls = +0.18 kg/m2, lifestyle changes
only = +0.43 kg/m2, metformin only = -0.59 kg/m2, metformin + lifestyle changes = -1.07 kg/m2. Change
in waist circumference after 12 months’ intervention: controls = -1.8 cm, lifestyle changes only = -2.8 cm,
metformin only = -2.3 cm, metformin + lifestyle changes = -4.5 cm. Change in waist circumference SDS
after 12 months’ intervention: controls = -0.38, lifestyle changes only = -0.58, metformin only = -0.49,
metformin + lifestyle changes = -0.85. Initially, there were mild adverse effects with metformin (nausea,
diarrhoea) in 21.6% of participants from metformin only group and metformin + lifestyle changes group,
which disappeared within 1 week of metformin administration. Adjusted by sex and puberty status, lean
mass was significantly increased in lifestyle only group compared to controls no treatment and metformin
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only groups. Change in lean mass after 12 months’ intervention: controls = +1.6 kg, lifestyle changes only
= +3.98 kg, metformin only = -0.36 kg, metformin + lifestyle changes = -0.37 kg. 12 months’ metformin
treatment with lifestyle modification was effective and safe method reducing BMI and waist circumference
in overweight/obese children and adolescents, superior to that of lifestyle changes alone
Correspondence with author: the results presented in the poster are only partial results of a larger trial,
where these data are currently being analysed. They aim to publish the results in a publication and as part
of a PhD thesis
”-“ denotes not reported.
ACE: angiotensin converting enzyme; ALT: alanine transaminase; AST: aspartate transaminase; BMI: bodymass index; GFR: glomerular
filtration rate; HbA1c: haemoglobin A1c; HBV: hepatitis B virus; HCV: hepatitis C virus; HIV: human immunodeficiency virus;
HOMA-IR: homeostasis model assessment for insulin resistance; IOTF: International Obesity Task Force; min: minute; SD: standard
deviation; SDS: standard deviation score.
Characteristics of ongoing studies [ordered by study ID]
EUCTR2010-023061-21
Trial name or title Efectos de la metformina en la obesidad infantil: ”Effects of metformin on childhood obesity“
Methods Type of trial: interventional; randomised controlled trial
Allocation: randomised
Intervention model: parallel assignment
Masking: double blind
Primary purpose: treatment
Participants Condition: obesity in prepubertal and pubertal children
Enrolment: target 160
Inclusion criteria:
• obese children aged 7 to 14 years prepubertal and pubertal children, boys and girls, with exogenous
obesity
• basic or history of disease pathology
• not received medical treatment or diet (or both) that would interfere with the analytical results 12
months before
• inclusion of the same participant more than once not permitted
• not participated in a previous trial
Exclusion criteria:
• participants who do not meet the prescribed age
• submit or have submitted some underlying disease earlier
• receive or have received medication with metabolic adverse effects such as diuretics, beta-blockers,
beta-adrenergic agonists, corticosteroids
• children undergoing long periods of rest
Interventions Intervention: metformin
Comparator: placebo
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Outcomes Primary outcome:
• BMI (baseline, weeks 8, 16 and 24)
Secondary outcomes:
• blood pressure,
• blood analysis (lipid profile, hydrocarbon, inflammatory, oxidative)
• lifestyle survey (baseline, weeks 8, 16 and 24)
Other outcomes: not given
Starting date Trial start date: not given
Trial completion date: not given
Contact information Trial sponsor: Ramón Cañete Estrada
Name of organisation: Instituto de Salud Carlos III
Country: Spain
Contact details: Avda Menendez Pidal s/n, Córdoba, 14004, Spain. Tel: 34957011227. Email: cetico.hrs.
sspa@juntadeandalucia.es
Study identifier EU clinical trials register number: EUCTR2010-023061-21
Official title Original title: Ensayo clínico sobre efectos de la metformina en la obesidad pediátrica: efectos en el peso
corporal, perfil de biomarcadores inflamatorios y de riesgo cardiovascular, e impacto en factores relacionados
con el síndrome metabólico
English title: Clinical trial on the effect of metformin in pediatric obesity: effects on bodyweight, profile
and inflammatory biomarkers of cardiovascular risk, and impact on factors related to metabolic syndrome
Stated purpose of study To study the clinical and biochemical impact of metformin along with changing lifestyle (diet and exercise)
in obese children
Notes Majority of this online entry is in Spanish; sponsor status: noncommercial; trial was ongoingwhen identified
EUCTR2015-001628-45-SE
Trial name or title A study with lifestyle intervention and study medication once weekly or lifestyle intervention and placebo
in adolescents with obesity to explore differences between groups with regard to change in BMI
Methods Type of trial: interventional; randomised controlled trial
Allocation: randomised
Intervention model: parallel assignment
Masking: double blind
Primary purpose: treatment
Participants Condition: obesity in adolescents
Enrolment: 44
Inclusion criteria:
• signed informed consent prior to any trial-specific procedures
• males or females aged 10 to 18 years and 7 months
• obesity (BMI SDS > 2.0 or age-adapted BMI > 30 kg/m2), according to WHO
• not sexually active or usage of adequate contraception. Female participants must also have negative
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pregnancy tests. Methods that can achieve a failure rate of less than 1% per year (Pearl index < 1), when
used consistently and correctly, are considered as highly effective birth control methods. Such methods
include:
◦ combined (oestrogen and progestogen containing) hormonal contraception associated with
inhibition of ovulation: oral, intravaginal, transdermal
◦ progestogen-only hormonal contraception associated with inhibition of ovulation: oral,
injectable, implantable
◦ intrauterine device
◦ intrauterine hormone-releasing system
◦ bilateral tubal occlusion
◦ vasectomised partner
◦ sexual abstinence (if refraining from heterosexual intercourse during the entire period of risk
associated with the trial treatments. The reliability of sexual abstinence needs to be evaluated in relation
to the preferred and usual lifestyle of the participant)
• ability to understand and comply with the requirements of the trial
Exclusion criteria:
• known syndromal obesity, such as Prader-Willi syndrome, Laurence-Moon syndrome or Bardet-
Biedl syndrome
• pregnancy or lactation
• indigestion-causing diseases
• severe gastrointestinal disease
• total or partial gastric or small intestine resection
• type 1 or type 2 diabetes mellitus
• kidney disease (acute or chronic, according to physician (creatinine/urea/cystatin-C for Schwartz
calculation)
• hypo-/hyperthyroidism, unless under stable treatment
• severe vitamin D insufficiency, unless under stable treatment
• abnormal QT interval
• clinically significant abnormal laboratory values, e.g. triglycerides > 400 mg/dL (Salzburg) or > 4.5
mmol/L (Uppsala), amylase > 300 U/L (Salzburg) or > 5.1 µkat/L (Uppsala), lipase > 180 U/L (Salzburg)
or > 15 µkat/L (Uppsala) or calcitonin > 11.7 pg/mL (Salzburg) or > 3.4 pmol/L (Uppsala) for females
and > 17 pg/mL (Salzburg) or > 5.0 pmol/L (Uppsala) for males
• severe depression, severe anxiety or other psychiatric disorder referred to or undergoing special
treatment, as judged by the investigator
• severe sleep apnoea (defined clinically)
• chronic diseases, as judged by the investigator
• metformin treatment within 3 months prior to screening or concomitant medication influencing
blood glucose (e.g. metformin and acarbose), influencing other parameters of metabolic syndrome (e.g.
orlistat) or interfering with the investigational medicinal product
• steroid treatment (oral or injected)
• concomitant medication addressing attention disorders
• antidepressants that can lead to weight gain, as judged by the investigator
• hypersensitivity to exenatide or to any of the excipients
• pacemaker or metal implant that may interfere with MRI
• claustrophobia
• current or prior (within 3 months) participation in another clinical trial involving an investigational
medicinal product
• a personal or family history of medullary thyroid carcinoma
• a personal or family history of multiple endocrine neoplasia syndrome type 2
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Interventions Intervention: exenatide + lifestyle intervention
Comparator: placebo + lifestyle intervention
Outcomes Primary outcome:
• BMI SDS (according to WHO)
Secondary outcomes:
• adverse events, vital signs (blood pressure and pulse), electrocardiogram, tympanic body
temperature, glucose, clinical chemistry, haematology and urinalysis
• endpoints of insulin secretion and sensitivity derived from oral glucose tolerance test
• glucagon levels at specified time points
• triglycerides, high-density lipoprotein, low-density lipoprotein, total cholesterol, free fatty acids,
apolipoproteins, uric acid and blood pressure
• highly sensitive C-reactive protein
• bioimpedance assessments to calculate total and regional body composition and MRI assessments of
abdominal adipose tissue, organ fat characteristics and morphology (volume of visceral and abdominal
subcutaneous adipose tissue and liver fat content)
• waist, hip, upper thigh and neck circumference, waist-to-hip ratio, sagittal abdominal diameter and
skinfold calipre assessments of body fat
• standardised BMI
• interdisciplinary adiposity evaluation kit (AD-EVA), sleeping habits questionnaire, self-efficacy and
outcome expectations questionnaire, food frequency questionnaire, regular meals questionnaire, portion
size questionnaire, walking test (6 min), physical activity questionnaire and physical activity assessed by
accelerometry
• U-alpha1-microglobulin (protein HC)/creatinine and estimated GFR according to Schwartz
formula
• AST), ALT), gamma-glutamyl transpeptidase, lactate dehydrogenase and bilirubin
Starting date Trial start date: not given
Trial completion date: not given
Contact information Responsible party/principal investigator: Peter Bergsten, Department of Medical Cell Biology Uppsala
University
Study identifier EudraCT Number: 2015-001628-45
Official title A parallel, double-blinded, randomized, 6 months, two arms trial with lifestyle intervention and exenatide
2 mg once weekly or lifestyle intervention and placebo in adolescents with obesity to explore differences
between groups with regard to change in BMI SDS (according to WHO)
Stated purpose of study Quote: ”To compare the change from baseline to the 6 months visit at the end of treatment, between
lifestyle intervention + exenatide 2 mg once weekly and lifestyle intervention + placebo, in BMI SDS
(according to WHO) for adolescents with obesity“
Notes Trial registered on 27 July 2015. Trial status: ongoing (when identified). Trial sponsor: Department of
Medical Cell Biology Uppsala University. Monetary or material support provided by: European Commis-
sion’s Seventh Framework Programme (FP7) project Beta JUDO (grant 279153). Country: Sweden
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Trial name or title Effect of exercise or metformin on nocturnal blood pressure and other risk factors for CVD among obese
adolescents
Methods Type of trial: interventional; randomised controlled trial
Allocation: randomised
Intervention model: factorial assignment
Masking: open label
Primary purpose: treatment
Participants Condition: CVDs
Enrolment: 100
Inclusion criteria:
• aged 13 to 19 years at inclusion date
• obesity according to sex- and age-specific BMI (Cole 2000)
• reduced nocturnal systolic blood pressure fall (< 10%)
• signed informed consent by participant and parents
Exclusion criteria:
• CVD
• insulin-dependent diabetes mellitus
• participant on medications that are contraindicated during metformin treatment
• pregnancy
• mental or physical conditions limiting the ability to participate
Interventions Intervention: metformin
Comparator: exercise
Outcomes Primary outcome:
• normalisation of nocturnal blood pressure dipping
Secondary outcome:
• normalisation of insulin metabolism and cardiovascular structure and function
Starting date Trial start date: February 2009
Trial completion date: December 2012 (estimated)
Contact information Responsible party/principal investigator: Professor Claude Marcus, Karolinska Institutet, Karolinska
Institute
Study identifier NCT number: NCT00889876
Other trial ID numbers: 2008-000461-28
Official title Effect of Exercise or Metformin on Nocturnal Blood Pressure and Other Risk Factors for Cardiovascular
Disease (CVD) Among Obese Adolescents
Stated purpose of study Quote: ”The objective is to, among obese adolescents, study impact of regular physical activity ormetformin
therapy on nocturnal blood pressure and related cardiovascular disease risk factors“
Notes This trial has not been verified on the clinicaltrials.gov website since February 2011. We have attempted to
contact the principal investigator via email; however, have not received a response. Trial sponsor: Karolinska
Institutet
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Trial name or title Obesity in children and adolescents: associated risks and early intervention (OCA)
Methods Type of trial: interventional; randomised controlled trial
Allocation: randomised
Intervention model: parallel assignment
Masking: open label
Primary purpose: treatment
Participants Condition: obesity
Enrolment: 400 (estimated)
Inclusion criteria:
• aged 10 to 17 years
• weight > 85th percentile for age and sex (by IOTF)
• living in Kaunas and its region
• no obvious chronic diseases
• not on steroid or other long-term treatment
• informed consent of the participant and parents (official carers)
Exclusion criteria:
• aged < 10 or > 17 years
• diagnosis of type 1 diabetes
• chronic illness that may affect physical activity and metabolic profile
• insulin treatment
• steroid treatment
• planning to move from Kaunas or its region in the period of 1 year
• protocol refused by the participant or his/her parents
Interventions Interventions:
• metformin only
• intensive diet and physical activity group + metformin
Comparators:
• intensive diet and physical activity programme
• control
Outcomes Primary outcome:
• BMI changes (time frame: 12 months)
Secondary outcomes:
• glucose homeostasis (time frame: 12 month), insulin sensitivity increase, HOMA-IR decrease,
insulin and glucose concentrations normalisation
• lipid profile (time frame: 12 months), lipid profile normalisation
• metabolic syndrome (time frame: 12 months), metabolic syndrome prevalence and risks decrease
• hepatosteatosis (time frame: 12 months), hepatosteatosis prevalence decrease and liver function
improvement, hepatic enzymes normalisation
• PCOS and hyperandrogenism in females (time frame: 12 months), PCOS clinical symptoms
regression, menstrual cycle normalisation, hirsutism, androgens levels decreasing and oestrogen, sex
hormone-binding globulin levels increasing
Other outcomes:
• safety (time frame: 12 months). How many participants will have adverse events and withdraw the
metformin due to their intolerance or clinical/biochemical relapse
110Drug interventions for the treatment of obesity in children and adolescents (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT01677923 (Continued)
Starting date Trial start date: May 2013
Trial completion date: December 2015
Contact information Responsible party/principal investigator: Rasa Verkauskiene, Lithuanian University of Health Sciences.
rasa.verkauskiene@kaunoklinikos.lt. 00370-37-327097
Study identifier NCT number: NCT01677923
Other trial ID numbers: BE-2-1
Official title Phase 3: Effect of Diet, Physical Activity and Insulin SensitizerMetformin on Obesity and Associated Risks
in Children and Adolescents
Stated purpose of study Quote: ”The investigators hypothesize that Metformin decreases weight, normalizes lipid profile and in-
creases insulin sensitivity; the study team hope to get better effect of weight decrease and metabolic pro-
cesses repair in the intensive treatment group with intervention of physical activity, diet correction and
Metformin use“
Notes The health authorities associated with this trial are Lithuania: Bioethics Committee and Lithuania: State
Medicine Control Agency - Ministry of Health; the trial is sponsored by Lithuanian University of Health
Sciences; this trial was recruiting participants when identified
NCT01859013
Trial name or title Topiramate in Adolescents with Severe Obesity
Methods Type of trial: interventional; randomised controlled trial
Allocation: randomised
Intervention model: parallel assignment
Masking: double blind (participant, carer, investigator, outcomes assessor)
Primary purpose: treatment
Participants Condition: obesity, morbid obesity, weight loss
Enrolment: estimated 36
Inclusion criteria:
• BMI ≥ 1.2 times the 95th percentile (based on sex and age) or BMI ≥ 35 kg/m2
• aged 12 to 17 years
• Tanner stage IV or V by physical examination
Exclusion criteria:
• Tanner stage I, II, or III
• BMI ≥ 50 kg/m2
• type 1 or 2 diabetes mellitus
• previous (within 6 months) or current use of weight loss medication (participants may undergo
washout)
• previous (within 6 months) or current use of drugs associated with weight gain (e.g. steroids/anti-
psychotics)
• previous bariatric surgery
• recent initiation (within 3 months) of anti-hypertensive or lipid medication
• previous (within 6 months) or current use of medication to treat insulin resistance or
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hyperglycaemia (participants may undergo washout)
• major psychiatric disorder
• females: pregnant, planning to become pregnant, or unwilling to use ≥ 2 acceptable methods of
contraception when engaging in sexual activity throughout the trial
• tobacco use
• liver/renal dysfunction ALT or AST > 2.5 times the upper limit of normal. Bicarbonate < 18 mmol/
L. Creatinine > 1.2 mg/dL
• glaucoma
• obesity associated with genetic disorder (monogenetic obesity)
• hyperthyroidism or uncontrolled hypothyroidism
• history of suicidal thought/attempts
• history of kidney stones
• history of cholelithiasis
• current use of other carbonic anhydrase inhibitor
Interventions Intervention: topiramate
Comparator: placebo
Outcomes Primary outcome:
• % change from baseline in BMI at 28 weeks (time frame: baseline and 28 weeks)
Secondary outcomes:
• characterise the safety profile of topiramate for the treatment of adolescent obesity
• evaluate the effects of meal replacement therapy followed by topiramate vs meal replacement
therapy followed by placebo on risk factors for CVD and type 2 diabetes
• evaluate response to topiramate treatment based on baseline eating behaviour phenotype in
adolescents with severe obesity
Other outcomes: not reported
Starting date Trial start date: June 2013
Trial completion date: December 2015
Contact information Responsible party/principal investigator: Aaron S Kelly, PhD University of Minnesota - Clinical and
Translational Science Institute. Tel: 612-626-3492. Email: kelly105@umn.edu
Study identifier NCT number: NCT01859013
Other trial ID number: 1304M31241
Official title BMI Reduction with Meal Replacements + Topiramate in Adolescents with Severe Obesity
Stated purpose of study Quote: ”the goal of this pilot study is to evaluate the safety and efficacy of 24 weeks of topiramate therapy
with a 4-week run-in of meal replacement therapy in adolescents with severe obesity“
Notes The health authority associated with this trial: ”United States: Institutional Review Board“; the trial is
sponsored by University of Minnesota - Clinical and Translational Science Institute; the trial was recruiting
participants when identified; publication identified for retrospective analysis of participants who received
topiramate: Fox et al 2015
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Trial name or title Topiramate and Severe Obesity (TOBI)
Methods Type of trial: interventional
Allocation: randomised
Intervention model: parallel assignment
Masking: double blind (participant, carer, investigator, outcomes assessor)
Primary purpose: treatment
Participants Condition: obese children and adolescents
Enrolment: estimated 160
Inclusion criteria:
• aged 9 to 17 years
• BMI z-score ≥ 4 SD of French reference
• weight at enrolment > 50 kg
• therapeutic failure > 6 months
• for girls of childbearing age, willing to have an acceptable method of contraception (no oestrogens +
progestin)
• negative pregnancy test for girls of childbearing age
• agreeing to participate upon written informed consent
• appropriate understanding of the trial
Exclusion criteria:
• syndromic or secondary obesity
• major neurological or psychiatric disorder
• current or history of suicidal thought/attempts
• current or history of breakdown
• previous bariatric surgery
• severe hypercapnia
• renal dysfunction
• deformity in the urinary tract or solitary kidney
• history of renal lithiasis or glaucoma
• poorly controlled diabetic children or adolescents (HbA1c > 10%) and diabetic participants treated
with metformin or glibenclamide (or both)
• hepatic dysfunction
• bicarbonate < 16 mmol/L
• known hypersensitivity to the active substance or to 1 of the excipients
• intolerance to saccharose
• enrolment in another therapeutic trial
• high probability to fail to comply with treatment
• females: pregnant, planning to become pregnant
• no signature on consent form
• uncovered by the French national health insurance system (Sécurité sociale)
Interventions Intervention: topiramate
Comparator: placebo
Outcomes Primary outcome:
• % change from baseline in BMI (time frame: 9 months)
Secondary outcomes:
• adverse event outcome (time frame: up to 4.5 years of follow-up)
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• % change from baseline in BMI z-score (time frame: 9 months)
• % change from baseline in BMI and BMI z-score (time frame: 1, 3, 6 and 9 months)
• eating behaviour (time frame: 9 months). Self-administered questionnaires and scales: Binge Eating
Scale; State trait anxiety Inventory for Children; Child depression inventory
• physical activity (time frame: 6 and 9 months). Questionnaire from French Ministry of Health
• food intake (time frame: 6 and 9 months). High-fat, sugary, salted food intake and beverage other
than drinking water
• comorbidity outcome (time frame: 6 and 9 months). Comorbidities and metabolic and
cardiorespiratory complication
Other outcomes: none given
Starting date Trial start date: June 2015
Trial completion date: December 2020
Contact information Responsible party: Assistance Publique - Hôpitaux de Paris
Principal investigator: Marie-Laure Frelut, MD
Study identifier NCT number: NCT02273804
Official title Topiramate and Severe Obesity in Children and Adolescents
Stated purpose of study The purpose of this trial is to evaluate the efficacy of topiramate on the decrease of BMI compared to
placebo at 9 months
Notes The trial is sponsored by Assistance Publique - Hôpitaux de Paris; recruitment status when identified: not
yet recruiting
NCT02274948
Trial name or title Use of Metformin in Treatment of Childhood Obesity
Methods Type of trial: interventional
Allocation: randomised
Intervention model: parallel assignment
Masking: double blind (participant, carer, investigator, outcomes assessor)
Primary purpose: treatment
Participants Condition: paediatric obesity
Enrolment: estimated 120
Inclusion criteria:
• obese children (based on > +2 SD of BMI to age on WHO 2007 standards)
Exclusion criteria:
• children not of Sri Lankan origin
• children who are not planning to live in Sri Lanka during the next year
• children with a secondary underlying cause for the overweight/obesity
Interventions Intervention: metformin
Comparator: placebo
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NCT02274948 (Continued)
Outcomes Primary outcomes:
• improvement in childhood obesity (time frame: 1 year)
• improvement of obesity will be measured by reduction in body fat content and BMI
Secondary outcome:
• improvement in obesity-related metabolic derangements including insulin resistance (time frame: 1
year)
Other outcomes: none given
Starting date Trial start date: July 2014
Trial completion date: February 2016
Contact information Responsible party/principal investigator: Pujitha Wickramasinghe, University of Colombo
Study identifier NCT number: NCT02274948
Official title Effects of Metformin on Body Weight, Composition and Metabolic Derangements in Obese Children. A
Randomized Clinical Trial
Stated purpose of study This study expects to evaluate the use of metformin in themanagement of obese children. Insulin resistance
among obese Sri Lankan children (south Asian origin) is high, which had been shown in the investigators
previous work. This study will look at the effect of metformin on changes in insulin resistance, fatty liver
state, body fat content, BMI and other metabolic derangement
Notes Trial sponsored by University of Colombo; recruitment status when identified: this trial is currently re-
cruiting participants; location: Sri Lanka
NCT02496611
Trial name or title Enhancing Weight Loss Maintenance With GLP-1RA (BYDUREON™) in Adolescents with Severe
Obesity
Methods Type of trial: interventional
Allocation: randomised
Intervention model: parallel assignment
Masking: double blind (participant, carer, investigator, outcomes assessor)
Primary purpose: treatment
Participants Condition: severe obesity
Enrolment: estimated 100
Inclusion criteria:
• BMI ≥ 1.2 times the 95th percentile (based on sex and age) or BMI ≥ 35 kg/m2
• aged 12 to 17 years
Exclusion criteria:
• type 1 or 2 diabetes mellitus
• previous (within 6 months) or current use of medication(s) prescribed primarily for weight loss
(refer to appendix material for comprehensive list)
• if currently using weight altering drug(s) for nonobesity indication(s) (refer to appendix material for
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comprehensive list), any change in drug(s) or dose within the previous 6 months
• previous bariatric surgery
• if currently using anti-hypertensive medication(s), lipid medication(s), medication(s) to treat insulin
resistance (refer to appendix material for comprehensive list) (or a combination) any change in drug(s) or
dose within the previous 6 months
• if currently using continuous positive airway pressure/bilevel positive airway pressure (for sleep
apnoea), change in frequency of use or settings within the previous 6 months
• history of treatment with growth hormone
• neurodevelopmental disorder severe enough to impair ability to comply with trial protocol
• clinical diagnosis of bipolar illness, schizophrenia, conduct disorder, substance use/abuse, or a
combination
• females: currently pregnant, planning to become pregnant, or unwilling to use ≥ 2 acceptable
methods of contraception when engaging in sexual activity throughout the trial
• tobacco use
• liver/renal dysfunction
• ALT or AST > 2 times the upper limit of normal
• bicarbonate < 18 mmol/L
• creatinine > 1.2 mg/dL
• history of pancreatitis
• personal or family history (or both) of medullary thyroid carcinoma
• personal or family history (or both) of multiple endocrine neoplasia type 2
• calcitonin level > 50 ng/L
• bulimia nervosa
• neurological disorder
• hypothalamic obesity
• obesity associated with genetic disorder (monogenetic obesity)
• hyperthyroidism or uncontrolled hypothyroidism
• history of suicide attempt
• history of suicidal ideation or self-harm within the past year
• history of cholelithiasis
Interventions Intervention: exenatide extended-release for injectable suspension (BYDUREON™)
Comparator: placebo
Outcomes Primary outcomes:
• weight loss maintenance (time frame: 52 weeks)
• improvement of obesity will be measured by reduction in body fat content and BMI
Secondary outcomes:
• maintenance of body fat changes (time frame: 52 weeks)
• maintenance of blood pressure (time frame: 52 weeks)
• maintenance of improved insulin sensitivity (time frame: 52 weeks)
Other outcomes: none given
Starting date Trial start date: December 2015
Trial completion date: July 2020
Contact information Responsible party/principal investigator: University of Minnesota - Clinical and Translational Science
Institute
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NCT02496611 (Continued)
Study identifier NCT number: NCT02496611
Official title Enhancing Weight Loss Maintenance with GLP-1RA (BYDUREON™) in Adolescents with Severe Obe-
sity
Stated purpose of study Primary objective: evaluate the effect of GLP-1RA treatment on the maintenance of weight loss and
durability of cardiometabolic risk factor improvements among adolescents with severe obesity following a
meal replacement induction period
Secondary objectives: investigate the mechanisms by which glucagon-like peptide-1 receptor agonists treat-
ment facilitates weight loss maintenance and identify predictors of response to treatment
Notes Trial sponsored by University of Minnesota - Clinical and Translational Science Institute; recruitment
status when identified: this trial is currently recruiting participants; location: USA
ACE: angiotensin-converting enzyme; ALT: alanine transaminase; AST: aspartate transaminase; BMI: body mass index; CVD: cardio-
vascular disease; HbA1c: glycated haemoglobin; HOMA-IR: homeostasis model assessment-insulin resistance; IOTF: International
Obesity Task Force; SD: standard deviation; GFR: glomerular filtration rate; min: minute; MRI: magnetic resonance imaging; PK:
pharmacokinetics; PCOS: polycystic ovary syndrome; SDS: standard deviation score; WHO: World Health Organization.
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D A T A A N D A N A L Y S E S
Comparison 1. Body mass index (BMI): pharmacological interventions versus comparators
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in BMI (all trials) 16 1884 Mean Difference (IV, Random, 95% CI) -1.34 [-1.85, -0.83]
2 Change in BMI (drug type) 16 1884 Mean Difference (IV, Random, 95% CI) -1.34 [-1.85, -0.83]
2.1 Metformin 8 543 Mean Difference (IV, Random, 95% CI) -1.35 [0.00, -0.69]
2.2 Orlistat 3 773 Mean Difference (IV, Random, 95% CI) -0.79 [-1.08, -0.51]
2.3 Sibutramine 5 568 Mean Difference (IV, Random, 95% CI) -1.70 [-2.89, -0.51]
3 Change in BMI (dropout rate) 16 1862 Mean Difference (IV, Random, 95% CI) -1.34 [-1.85, -0.83]
3.1 Dropouts < 20% 9 597 Mean Difference (IV, Random, 95% CI) -1.11 [-1.78, -0.44]
3.2 Dropouts ≥ 20% 6 1145 Mean Difference (IV, Random, 95% CI) -1.42 [-2.34, -0.50]
3.3 Unclear dropout rate 1 120 Mean Difference (IV, Random, 95% CI) -2.73 [-3.74, -1.72]
4 Change in BMI
(intention-to-treat (ITT)
analysis)
16 1862 Mean Difference (IV, Random, 95% CI) -1.34 [-1.85, -0.83]
4.1 No ITT 5 282 Mean Difference (IV, Random, 95% CI) -1.56 [-2.52, -0.60]
4.2 ITT used 11 1580 Mean Difference (IV, Random, 95% CI) -1.25 [-1.86, -0.65]
5 Change in BMI (funding) 16 1862 Mean Difference (IV, Random, 95% CI) -1.34 [-1.85, -0.83]
5.1 Commercial 5 1009 Mean Difference (IV, Random, 95% CI) -1.50 [-2.69, -0.31]
5.2 Noncommercial 5 271 Mean Difference (IV, Random, 95% CI) -1.10 [-1.77, -0.44]
5.3 Commercial +
noncommercial
4 262 Mean Difference (IV, Random, 95% CI) -1.17 [-1.86, -0.47]
5.4 Unclear 2 320 Mean Difference (IV, Random, 95% CI) -1.79 [-3.54, -0.04]
6 Change in BMI (publication
date)
16 1862 Mean Difference (IV, Random, 95% CI) -1.34 [-1.85, -0.83]
6.1 2007 or before 8 1163 Mean Difference (IV, Random, 95% CI) -1.41 [-2.21, -0.60]
6.2 After 2007 8 699 Mean Difference (IV, Random, 95% CI) -1.26 [-1.90, -0.62]
7 Change in BMI (quality of trial) 16 1862 Mean Difference (IV, Random, 95% CI) -1.34 [-1.85, -0.83]
7.1 Low 6 322 Mean Difference (IV, Random, 95% CI) -1.40 [-2.28, -0.52]
7.2 Moderate 10 1540 Mean Difference (IV, Random, 95% CI) -1.31 [-1.95, -0.67]
8 Change in BMI (country) 16 1862 Mean Difference (IV, Random, 95% CI) -1.34 [-1.85, -0.83]
8.1 Middle income 3 216 Mean Difference (IV, Random, 95% CI) -2.39 [-3.08, -1.69]
8.2 High income 13 1646 Mean Difference (IV, Random, 95% CI) -1.09 [-1.62, -0.56]
9 Change in BMI (mean age) 16 1884 Mean Difference (IV, Random, 95% CI) -1.34 [-1.85, -0.83]
9.1 Mean age < 12 years 2 220 Mean Difference (IV, Random, 95% CI) -1.93 [-3.53, -0.34]
9.2 Mean age ≥ 12 years 14 1664 Mean Difference (IV, Random, 95% CI) -1.25 [-1.79, -0.71]
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Comparison 2. Weight: pharmacological interventions versus comparators
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in weight (all trials) 11 1180 Mean Difference (IV, Random, 95% CI) -3.90 [-5.86, -1.94]
2 Change in weight (drug type) 11 1180 Mean Difference (IV, Random, 95% CI) -3.90 [-5.86, -1.94]
2.1 Metformin 4 372 Mean Difference (IV, Random, 95% CI) -3.24 [-5.79, -0.69]
2.2 Sibutramine 5 568 Mean Difference (IV, Random, 95% CI) -4.71 [-8.10, -1.32]
2.3 Orlistat 2 240 Mean Difference (IV, Random, 95% CI) -2.48 [-4.31, -0.65]
Comparison 3. Adverse effects: pharmacological interventions versus comparator
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Serious adverse events 5 1347 Risk Ratio (M-H, Random, 95% CI) 1.43 [0.63, 3.25]
1.1 Metformin 1 76 Risk Ratio (M-H, Random, 95% CI) 5.00 [0.25, 100.80]
1.2 Orlistat 3 773 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.41, 2.67]
1.3 Sibutramine 1 498 Risk Ratio (M-H, Random, 95% CI) 3.53 [0.46, 27.33]
2 Discontinued trial because of
adverse events
10 1664 Risk Ratio (M-H, Random, 95% CI) 1.45 [0.83, 2.52]
2.1 Metformin 3 246 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.26, 5.48]
2.2 Orlistat 4 815 Risk Ratio (M-H, Random, 95% CI) 2.49 [0.74, 8.32]
2.3 Sibutramine 3 603 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.53, 2.46]
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Analysis 1.1. Comparison 1 Body mass index (BMI): pharmacological interventions versus comparators,
Outcome 1 Change in BMI (all trials).
Review: Drug interventions for the treatment of obesity in children and adolescents
Comparison: 1 Body mass index (BMI): pharmacological interventions versus comparators
Outcome: 1 Change in BMI (all trials)
Study or subgroup Drug intervention Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD)[kg/m2] N Mean(SD)[kg/m2] IV,Random,95% CI IV,Random,95% CI
Freemark 2001 14 -0.485 (1.38) 15 0.88 (1.61) 6.4 % -1.36 [ -2.45, -0.27 ]
Berkowitz 2003 43 -3.1875 (2.55) 39 -1.52 (2.052) 6.8 % -1.67 [ -2.67, -0.67 ]
Chanoine 2005 352 -1.08 (2.05) 181 -0.31 (1.68) 8.8 % -0.77 [ -1.10, -0.44 ]
Godoy-Matos 2005 30 -3.6 (2.5) 30 -0.9 (0.9) 6.9 % -2.70 [ -3.65, -1.75 ]
Maahs 2006 20 -1.3 (1.6) 20 -0.8 (3) 5.1 % -0.50 [ -1.99, 0.99 ]
Berkowitz 2006 281 -3.3934 (3.086247) 79 -0.43 (2.871776) 7.7 % -2.96 [ -3.69, -2.23 ]
Garc a-Morales 2006 23 -3.4 (1.965625) 23 -1.8 (1.965625) 6.3 % -1.60 [ -2.74, -0.46 ]
Van Mil 2007 11 -0.8 (1.1) 9 -1.4 (1.4) 6.3 % 0.60 [ -0.52, 1.72 ]
Atabek 2008 90 -2.08 (2.32) 30 0.65 (2.5) 6.7 % -2.73 [ -3.74, -1.72 ]
Clarson 2009 11 -1.8 (2.6533) 14 0.5 (1.122497) 4.6 % -2.30 [ -3.97, -0.63 ]
Wilson 2010 27 -0.9 (2.5980762) 27 0.2 (2.598076) 5.4 % -1.10 [ -2.49, 0.29 ]
Wiegand 2010 34 0.07 (3.4111069) 29 -0.31 (3.6619121) 4.4 % 0.38 [ -1.38, 2.14 ]
Yanovski 2011 53 -0.78 (2.7754182) 47 0.32 (2.929046) 6.3 % -1.10 [ -2.22, 0.02 ]
NCT00001723 100 -1.44 (2.6) 100 -0.5 (2) 8.0 % -0.94 [ -1.58, -0.30 ]
Mauras 2012 23 -2.4 (2.3979158) 19 -1.1 (2.179449) 5.4 % -1.30 [ -2.69, 0.09 ]
Kendall 2013 55 -0.25 (4.1901521) 55 0.21 (4.2494817) 4.9 % -0.46 [ -2.04, 1.12 ]
Total (95% CI) 1167 717 100.0 % -1.34 [ -1.85, -0.83 ]
Heterogeneity: Tau2 = 0.74; Chi2 = 65.88, df = 15 (P<0.00001); I2 =77%
Test for overall effect: Z = 5.16 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours drug intervention Favours comparator
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Analysis 1.2. Comparison 1 Body mass index (BMI): pharmacological interventions versus comparators,
Outcome 2 Change in BMI (drug type).
Review: Drug interventions for the treatment of obesity in children and adolescents
Comparison: 1 Body mass index (BMI): pharmacological interventions versus comparators
Outcome: 2 Change in BMI (drug type)
Study or subgroup Drug intervention Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD)[kg/m2] N Mean(SD)[kg/m2] IV,Random,95% CI IV,Random,95% CI
1 Metformin
Freemark 2001 14 -0.49 (1.38) 15 0.88 (1.61) 6.4 % -1.37 [ -2.46, -0.28 ]
Atabek 2008 90 -2.08 (2.32) 30 0.65 (2.5) 6.7 % -2.73 [ -3.74, -1.72 ]
Clarson 2009 11 -1.8 (2.6533) 14 0.5 (1.122497) 4.6 % -2.30 [ -3.97, -0.63 ]
Wiegand 2010 34 0.07 (3.4111069) 29 -0.31 (3.6619121) 4.4 % 0.38 [ -1.38, 2.14 ]
Wilson 2010 27 -0.9 (2.5980762) 27 0.2 (2.598076) 5.4 % -1.10 [ -2.49, 0.29 ]
Yanovski 2011 53 -0.78 (2.7754182) 47 0.32 (2.929046) 6.3 % -1.10 [ -2.22, 0.02 ]
Mauras 2012 23 -2.4 (2.3979158) 19 -1.1 (2.179449) 5.4 % -1.30 [ -2.69, 0.09 ]
Kendall 2013 55 -0.25 (4.1901521) 55 0.21 (4.2494817) 4.9 % -0.46 [ -2.04, 1.12 ]
Subtotal (95% CI) 307 236 44.2 % -1.35 [ -2.00, -0.69 ]
Heterogeneity: Tau2 = 0.42; Chi2 = 13.46, df = 7 (P = 0.06); I2 =48%
Test for overall effect: Z = 4.04 (P = 0.000054)
2 Orlistat
Chanoine 2005 352 -1.08 (2.05) 181 -0.31 (1.68) 8.8 % -0.77 [ -1.10, -0.44 ]
Maahs 2006 20 -1.3 (1.6) 20 -0.8 (3) 5.1 % -0.50 [ -1.99, 0.99 ]
NCT00001723 100 -1.44 (2.6) 100 -0.5 (2) 8.0 % -0.94 [ -1.58, -0.30 ]
Subtotal (95% CI) 472 301 21.9 % -0.79 [ -1.08, -0.51 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.37, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 5.46 (P < 0.00001)
3 Sibutramine
Berkowitz 2003 43 -3.1875 (2.55) 39 -1.52 (2.052) 6.8 % -1.67 [ -2.67, -0.67 ]
Godoy-Matos 2005 30 -3.6 (2.5) 30 -0.9 (0.9) 6.9 % -2.70 [ -3.65, -1.75 ]
Garc a-Morales 2006 23 -3.4 (1.965625) 23 -1.8 (1.965625) 6.3 % -1.60 [ -2.74, -0.46 ]
Berkowitz 2006 281 -3.3934 (3.086247) 79 -0.43 (2.871776) 7.7 % -2.96 [ -3.69, -2.23 ]
Van Mil 2007 11 -0.8 (1.1) 9 -1.4 (1.4) 6.3 % 0.60 [ -0.52, 1.72 ]
Subtotal (95% CI) 388 180 34.0 % -1.70 [ -2.89, -0.51 ]
Heterogeneity: Tau2 = 1.59; Chi2 = 30.30, df = 4 (P<0.00001); I2 =87%
-4 -2 0 2 4
Favours drug intervention Favours comparator
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(. . . Continued)
Study or subgroup Drug intervention Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD)[kg/m2] N Mean(SD)[kg/m2] IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 2.80 (P = 0.0051)
Total (95% CI) 1167 717 100.0 % -1.34 [ -1.85, -0.83 ]
Heterogeneity: Tau2 = 0.74; Chi2 = 65.89, df = 15 (P<0.00001); I2 =77%
Test for overall effect: Z = 5.16 (P < 0.00001)
Test for subgroup differences: Chi2 = 4.05, df = 2 (P = 0.13), I2 =51%
-4 -2 0 2 4
Favours drug intervention Favours comparator
Analysis 1.3. Comparison 1 Body mass index (BMI): pharmacological interventions versus comparators,
Outcome 3 Change in BMI (dropout rate).
Review: Drug interventions for the treatment of obesity in children and adolescents
Comparison: 1 Body mass index (BMI): pharmacological interventions versus comparators
Outcome: 3 Change in BMI (dropout rate)
Study or subgroup Drug intervention Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD)[kg/m2] N Mean(SD)[kg/m2] IV,Random,95% CI IV,Random,95% CI
1 Dropouts < 20%
Freemark 2001 15 -0.49 (1.38) 17 0.88 (1.61) 6.6 % -1.37 [ -2.41, -0.33 ]
Berkowitz 2003 43 -3.1875 (2.55) 39 -1.52 (2.052) 6.8 % -1.67 [ -2.67, -0.67 ]
Godoy-Matos 2005 28 -3.6 (2.5) 22 -0.9 (0.9) 6.8 % -2.70 [ -3.70, -1.70 ]
Maahs 2006 20 -1.3 (1.6) 20 -0.8 (3) 5.1 % -0.50 [ -1.99, 0.99 ]
Van Mil 2007 11 -0.8 (1.1) 9 -1.4 (1.4) 6.3 % 0.60 [ -0.52, 1.72 ]
Clarson 2009 11 -1.8 (2.6533) 14 0.5 (1.122497) 4.6 % -2.30 [ -3.97, -0.63 ]
Wiegand 2010 34 0.07 (3.4111069) 29 -0.31 (3.6619121) 4.4 % 0.38 [ -1.38, 2.14 ]
NCT00001723 100 -1.44 (2.6) 100 -0.5 (2) 8.0 % -0.94 [ -1.58, -0.30 ]
Yanovski 2011 45 -0.78 (2.7754182) 40 0.32 (2.929046) 6.0 % -1.10 [ -2.32, 0.12 ]
Subtotal (95% CI) 307 290 54.6 % -1.11 [ -1.78, -0.44 ]
-4 -2 0 2 4
Favours drug intervention Favours comparator
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(. . . Continued)
Study or subgroup Drug intervention Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD)[kg/m2] N Mean(SD)[kg/m2] IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 0.69; Chi2 = 25.66, df = 8 (P = 0.001); I2 =69%
Test for overall effect: Z = 3.23 (P = 0.0013)
2 Dropouts≥ 20%
Chanoine 2005 352 -1.08 (2.05) 181 -0.31 (1.68) 8.8 % -0.77 [ -1.10, -0.44 ]
Berkowitz 2006 281 -3.3934 (3.086247) 79 -0.43 (2.871776) 7.7 % -2.96 [ -3.69, -2.23 ]
Garc a-Morales 2006 23 -3.4 (1.965625) 23 -1.8 (1.965625) 6.3 % -1.60 [ -2.74, -0.46 ]
Wilson 2010 27 -0.9 (2.5980762) 27 0.2 (2.598076) 5.5 % -1.10 [ -2.49, 0.29 ]
Mauras 2012 23 -2.4 (2.3979158) 19 -1.1 (2.179449) 5.5 % -1.30 [ -2.69, 0.09 ]
Kendall 2013 55 -0.25 (4.1901521) 55 0.21 (4.2494817) 4.9 % -0.46 [ -2.04, 1.12 ]
Subtotal (95% CI) 761 384 38.6 % -1.42 [ -2.34, -0.50 ]
Heterogeneity: Tau2 = 1.00; Chi2 = 30.39, df = 5 (P = 0.00001); I2 =84%
Test for overall effect: Z = 3.02 (P = 0.0026)
3 Unclear dropout rate
Atabek 2008 90 -2.08 (2.32) 30 0.65 (2.5) 6.7 % -2.73 [ -3.74, -1.72 ]
Subtotal (95% CI) 90 30 6.7 % -2.73 [ -3.74, -1.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.27 (P < 0.00001)
Total (95% CI) 1158 704 100.0 % -1.34 [ -1.85, -0.83 ]
Heterogeneity: Tau2 = 0.73; Chi2 = 65.00, df = 15 (P<0.00001); I2 =77%
Test for overall effect: Z = 5.17 (P < 0.00001)
Test for subgroup differences: Chi2 = 6.93, df = 2 (P = 0.03), I2 =71%
-4 -2 0 2 4
Favours drug intervention Favours comparator
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Analysis 1.4. Comparison 1 Body mass index (BMI): pharmacological interventions versus comparators,
Outcome 4 Change in BMI (intention-to-treat (ITT) analysis).
Review: Drug interventions for the treatment of obesity in children and adolescents
Comparison: 1 Body mass index (BMI): pharmacological interventions versus comparators
Outcome: 4 Change in BMI (intention-to-treat (ITT) analysis)
Study or subgroup Drug intervention Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD)[kg/m2] N Mean(SD)[kg/m2] IV,Random,95% CI IV,Random,95% CI
1 No ITT
Freemark 2001 15 -0.49 (1.38) 17 0.88 (1.61) 6.6 % -1.37 [ -2.41, -0.33 ]
Atabek 2008 90 -2.08 (2.32) 30 0.65 (2.5) 6.7 % -2.73 [ -3.74, -1.72 ]
Clarson 2009 11 -1.8 (2.6533) 14 0.5 (1.122497) 4.6 % -2.30 [ -3.97, -0.63 ]
Wiegand 2010 34 0.07 (3.4111069) 29 -0.31 (3.6619121) 4.4 % 0.38 [ -1.38, 2.14 ]
Mauras 2012 23 -2.4 (2.3979158) 19 -1.1 (2.179449) 5.5 % -1.30 [ -2.69, 0.09 ]
Subtotal (95% CI) 173 109 27.8 % -1.56 [ -2.52, -0.60 ]
Heterogeneity: Tau2 = 0.72; Chi2 = 10.54, df = 4 (P = 0.03); I2 =62%
Test for overall effect: Z = 3.20 (P = 0.0014)
2 ITT used
Berkowitz 2003 43 -3.1875 (2.55) 39 -1.52 (2.052) 6.8 % -1.67 [ -2.67, -0.67 ]
Chanoine 2005 352 -1.08 (2.05) 181 -0.31 (1.68) 8.8 % -0.77 [ -1.10, -0.44 ]
Godoy-Matos 2005 28 -3.6 (2.5) 22 -0.9 (0.9) 6.8 % -2.70 [ -3.70, -1.70 ]
Garc a-Morales 2006 23 -3.4 (1.965625) 23 -1.8 (1.965625) 6.3 % -1.60 [ -2.74, -0.46 ]
Berkowitz 2006 281 -3.3934 (3.086247) 79 -0.43 (2.871776) 7.7 % -2.96 [ -3.69, -2.23 ]
Maahs 2006 20 -1.3 (1.6) 20 -0.8 (3) 5.1 % -0.50 [ -1.99, 0.99 ]
Van Mil 2007 11 -0.8 (1.1) 9 -1.4 (1.4) 6.3 % 0.60 [ -0.52, 1.72 ]
Wilson 2010 27 -0.9 (2.5980762) 27 0.2 (2.598076) 5.5 % -1.10 [ -2.49, 0.29 ]
NCT00001723 100 -1.44 (2.6) 100 -0.5 (2) 8.0 % -0.94 [ -1.58, -0.30 ]
Yanovski 2011 45 -0.78 (2.7754182) 40 0.32 (2.929046) 6.0 % -1.10 [ -2.32, 0.12 ]
Kendall 2013 55 -0.25 (4.1901521) 55 0.21 (4.2494817) 4.9 % -0.46 [ -2.04, 1.12 ]
Subtotal (95% CI) 985 595 72.2 % -1.25 [ -1.86, -0.65 ]
Heterogeneity: Tau2 = 0.76; Chi2 = 51.09, df = 10 (P<0.00001); I2 =80%
Test for overall effect: Z = 4.04 (P = 0.000052)
Total (95% CI) 1158 704 100.0 % -1.34 [ -1.85, -0.83 ]
Heterogeneity: Tau2 = 0.73; Chi2 = 65.00, df = 15 (P<0.00001); I2 =77%
Test for overall effect: Z = 5.17 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.29, df = 1 (P = 0.59), I2 =0.0%
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Analysis 1.5. Comparison 1 Body mass index (BMI): pharmacological interventions versus comparators,
Outcome 5 Change in BMI (funding).
Review: Drug interventions for the treatment of obesity in children and adolescents
Comparison: 1 Body mass index (BMI): pharmacological interventions versus comparators
Outcome: 5 Change in BMI (funding)
Study or subgroup Drug intervention Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD)[kg/m2] N Mean(SD)[kg/m2] IV,Random,95% CI IV,Random,95% CI
1 Commercial
Godoy-Matos 2005 28 -3.6 (2.5) 22 -0.9 (0.9) 6.8 % -2.70 [ -3.70, -1.70 ]
Chanoine 2005 352 -1.08 (2.05) 181 -0.31 (1.68) 8.8 % -0.77 [ -1.10, -0.44 ]
Berkowitz 2006 281 -3.3934 (3.086247) 79 -0.43 (2.871776) 7.7 % -2.96 [ -3.69, -2.23 ]
Garc a-Morales 2006 23 -3.4 (1.965625) 23 -1.8 (1.965625) 6.3 % -1.60 [ -2.74, -0.46 ]
Van Mil 2007 11 -0.8 (1.1) 9 -1.4 (1.4) 6.3 % 0.60 [ -0.52, 1.72 ]
Subtotal (95% CI) 695 314 36.0 % -1.50 [ -2.69, -0.31 ]
Heterogeneity: Tau2 = 1.63; Chi2 = 48.16, df = 4 (P<0.00001); I2 =92%
Test for overall effect: Z = 2.47 (P = 0.013)
2 Noncommercial
Maahs 2006 20 -1.3 (1.6) 20 -0.8 (3) 5.1 % -0.50 [ -1.99, 0.99 ]
Clarson 2009 11 -1.8 (2.6533) 14 0.5 (1.122497) 4.6 % -2.30 [ -3.97, -0.63 ]
Wilson 2010 27 -0.9 (2.5980762) 27 0.2 (2.598076) 5.5 % -1.10 [ -2.49, 0.29 ]
Mauras 2012 23 -2.4 (2.3979158) 19 -1.1 (2.179449) 5.5 % -1.30 [ -2.69, 0.09 ]
Kendall 2013 55 -0.25 (4.1901521) 55 0.21 (4.2494817) 4.9 % -0.46 [ -2.04, 1.12 ]
Subtotal (95% CI) 136 135 25.5 % -1.10 [ -1.77, -0.44 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.31, df = 4 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 3.24 (P = 0.0012)
3 Commercial + noncommercial
Freemark 2001 15 -0.49 (1.38) 17 0.88 (1.61) 6.6 % -1.37 [ -2.41, -0.33 ]
Berkowitz 2003 43 -3.1875 (2.55) 39 -1.52 (2.052) 6.8 % -1.67 [ -2.67, -0.67 ]
Wiegand 2010 34 0.07 (3.4111069) 29 -0.31 (3.6619121) 4.4 % 0.38 [ -1.38, 2.14 ]
Yanovski 2011 45 -0.78 (2.7754182) 40 0.32 (2.929046) 6.0 % -1.10 [ -2.32, 0.12 ]
Subtotal (95% CI) 137 125 23.8 % -1.17 [ -1.86, -0.47 ]
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(. . . Continued)
Study or subgroup Drug intervention Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD)[kg/m2] N Mean(SD)[kg/m2] IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 0.13; Chi2 = 4.07, df = 3 (P = 0.25); I2 =26%
Test for overall effect: Z = 3.29 (P = 0.00099)
4 Unclear
Atabek 2008 90 -2.08 (2.32) 30 0.65 (2.5) 6.7 % -2.73 [ -3.74, -1.72 ]
NCT00001723 100 -1.44 (2.6) 100 -0.5 (2) 8.0 % -0.94 [ -1.58, -0.30 ]
Subtotal (95% CI) 190 130 14.7 % -1.79 [ -3.54, -0.04 ]
Heterogeneity: Tau2 = 1.41; Chi2 = 8.53, df = 1 (P = 0.003); I2 =88%
Test for overall effect: Z = 2.00 (P = 0.045)
Total (95% CI) 1158 704 100.0 % -1.34 [ -1.85, -0.83 ]
Heterogeneity: Tau2 = 0.73; Chi2 = 65.00, df = 15 (P<0.00001); I2 =77%
Test for overall effect: Z = 5.17 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.76, df = 3 (P = 0.86), I2 =0.0%
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Analysis 1.6. Comparison 1 Body mass index (BMI): pharmacological interventions versus comparators,
Outcome 6 Change in BMI (publication date).
Review: Drug interventions for the treatment of obesity in children and adolescents
Comparison: 1 Body mass index (BMI): pharmacological interventions versus comparators
Outcome: 6 Change in BMI (publication date)
Study or subgroup Drug intervention Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD)[kg/m2] N Mean(SD)[kg/m2] IV,Random,95% CI IV,Random,95% CI
1 2007 or before
Freemark 2001 15 -0.49 (1.38) 17 0.88 (1.61) 6.6 % -1.37 [ -2.41, -0.33 ]
Berkowitz 2003 43 -3.1875 (2.55) 39 -1.52 (2.052) 6.8 % -1.67 [ -2.67, -0.67 ]
Chanoine 2005 352 -1.08 (2.05) 181 -0.31 (1.68) 8.8 % -0.77 [ -1.10, -0.44 ]
Godoy-Matos 2005 28 -3.6 (2.5) 22 -0.9 (0.9) 6.8 % -2.70 [ -3.70, -1.70 ]
Maahs 2006 20 -1.3 (1.6) 20 -0.8 (3) 5.1 % -0.50 [ -1.99, 0.99 ]
Garc a-Morales 2006 23 -3.4 (1.965625) 23 -1.8 (1.965625) 6.3 % -1.60 [ -2.74, -0.46 ]
Berkowitz 2006 281 -3.3934 (3.086247) 79 -0.43 (2.871776) 7.7 % -2.96 [ -3.69, -2.23 ]
Van Mil 2007 11 -0.8 (1.1) 9 -1.4 (1.4) 6.3 % 0.60 [ -0.52, 1.72 ]
Subtotal (95% CI) 773 390 54.5 % -1.41 [ -2.21, -0.60 ]
Heterogeneity: Tau2 = 1.08; Chi2 = 49.99, df = 7 (P<0.00001); I2 =86%
Test for overall effect: Z = 3.43 (P = 0.00060)
2 After 2007
Atabek 2008 90 -2.08 (2.32) 30 0.65 (2.5) 6.7 % -2.73 [ -3.74, -1.72 ]
Clarson 2009 11 -1.8 (2.6533) 14 0.5 (1.122497) 4.6 % -2.30 [ -3.97, -0.63 ]
Wilson 2010 27 -0.9 (2.5980762) 27 0.2 (2.598076) 5.5 % -1.10 [ -2.49, 0.29 ]
Wiegand 2010 34 0.07 (3.4111069) 29 -0.31 (3.6619121) 4.4 % 0.38 [ -1.38, 2.14 ]
Yanovski 2011 45 -0.78 (2.7754182) 40 0.32 (2.929046) 6.0 % -1.10 [ -2.32, 0.12 ]
NCT00001723 100 -1.44 (2.6) 100 -0.5 (2) 8.0 % -0.94 [ -1.58, -0.30 ]
Mauras 2012 23 -2.4 (2.3979158) 19 -1.1 (2.179449) 5.5 % -1.30 [ -2.69, 0.09 ]
Kendall 2013 55 -0.25 (4.1901521) 55 0.21 (4.2494817) 4.9 % -0.46 [ -2.04, 1.12 ]
Subtotal (95% CI) 385 314 45.5 % -1.26 [ -1.90, -0.62 ]
Heterogeneity: Tau2 = 0.43; Chi2 = 14.94, df = 7 (P = 0.04); I2 =53%
Test for overall effect: Z = 3.85 (P = 0.00012)
Total (95% CI) 1158 704 100.0 % -1.34 [ -1.85, -0.83 ]
Heterogeneity: Tau2 = 0.73; Chi2 = 65.00, df = 15 (P<0.00001); I2 =77%
Test for overall effect: Z = 5.17 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.08, df = 1 (P = 0.78), I2 =0.0%
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Analysis 1.7. Comparison 1 Body mass index (BMI): pharmacological interventions versus comparators,
Outcome 7 Change in BMI (quality of trial).
Review: Drug interventions for the treatment of obesity in children and adolescents
Comparison: 1 Body mass index (BMI): pharmacological interventions versus comparators
Outcome: 7 Change in BMI (quality of trial)
Study or subgroup Drug intervention Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD)[kg/m2] N Mean(SD)[kg/m2] IV,Random,95% CI IV,Random,95% CI
1 Low
Freemark 2001 15 -0.49 (1.38) 17 0.88 (1.61) 6.6 % -1.37 [ -2.41, -0.33 ]
Maahs 2006 20 -1.3 (1.6) 20 -0.8 (3) 5.1 % -0.50 [ -1.99, 0.99 ]
Atabek 2008 90 -2.08 (2.32) 30 0.65 (2.5) 6.7 % -2.73 [ -3.74, -1.72 ]
Clarson 2009 11 -1.8 (2.6533) 14 0.5 (1.122497) 4.6 % -2.30 [ -3.97, -0.63 ]
Wiegand 2010 34 0.07 (3.4111069) 29 -0.31 (3.6619121) 4.4 % 0.38 [ -1.38, 2.14 ]
Mauras 2012 23 -2.4 (2.3979158) 19 -1.1 (2.179449) 5.5 % -1.30 [ -2.69, 0.09 ]
Subtotal (95% CI) 193 129 32.9 % -1.40 [ -2.28, -0.52 ]
Heterogeneity: Tau2 = 0.71; Chi2 = 12.74, df = 5 (P = 0.03); I2 =61%
Test for overall effect: Z = 3.13 (P = 0.0018)
2 Moderate
Berkowitz 2003 43 -3.1875 (2.55) 39 -1.52 (2.052) 6.8 % -1.67 [ -2.67, -0.67 ]
Godoy-Matos 2005 28 -3.6 (2.5) 22 -0.9 (0.9) 6.8 % -2.70 [ -3.70, -1.70 ]
Chanoine 2005 352 -1.08 (2.05) 181 -0.31 (1.68) 8.8 % -0.77 [ -1.10, -0.44 ]
Berkowitz 2006 281 -3.3934 (3.086247) 79 -0.43 (2.871776) 7.7 % -2.96 [ -3.69, -2.23 ]
Garc a-Morales 2006 23 -3.4 (1.965625) 23 -1.8 (1.965625) 6.3 % -1.60 [ -2.74, -0.46 ]
Van Mil 2007 11 -0.8 (1.1) 9 -1.4 (1.4) 6.3 % 0.60 [ -0.52, 1.72 ]
Wilson 2010 27 -0.9 (2.5980762) 27 0.2 (2.598076) 5.5 % -1.10 [ -2.49, 0.29 ]
NCT00001723 100 -1.44 (2.6) 100 -0.5 (2) 8.0 % -0.94 [ -1.58, -0.30 ]
Yanovski 2011 45 -0.78 (2.7754182) 40 0.32 (2.929046) 6.0 % -1.10 [ -2.32, 0.12 ]
Kendall 2013 55 -0.25 (4.1901521) 55 0.21 (4.2494817) 4.9 % -0.46 [ -2.04, 1.12 ]
Subtotal (95% CI) 965 575 67.1 % -1.31 [ -1.95, -0.67 ]
Heterogeneity: Tau2 = 0.80; Chi2 = 50.38, df = 9 (P<0.00001); I2 =82%
Test for overall effect: Z = 4.00 (P = 0.000063)
Total (95% CI) 1158 704 100.0 % -1.34 [ -1.85, -0.83 ]
Heterogeneity: Tau2 = 0.73; Chi2 = 65.00, df = 15 (P<0.00001); I2 =77%
Test for overall effect: Z = 5.17 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.87), I2 =0.0%
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Analysis 1.8. Comparison 1 Body mass index (BMI): pharmacological interventions versus comparators,
Outcome 8 Change in BMI (country).
Review: Drug interventions for the treatment of obesity in children and adolescents
Comparison: 1 Body mass index (BMI): pharmacological interventions versus comparators
Outcome: 8 Change in BMI (country)
Study or subgroup Drug intervention Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD)[kg/m2] N Mean(SD)[kg/m2] IV,Random,95% CI IV,Random,95% CI
1 Middle income
Godoy-Matos 2005 28 -3.6 (2.5) 22 -0.9 (0.9) 6.8 % -2.70 [ -3.70, -1.70 ]
Garc a-Morales 2006 23 -3.4 (1.965625) 23 -1.8 (1.965625) 6.3 % -1.60 [ -2.74, -0.46 ]
Atabek 2008 90 -2.08 (2.32) 30 0.65 (2.5) 6.7 % -2.73 [ -3.74, -1.72 ]
Subtotal (95% CI) 141 75 19.8 % -2.39 [ -3.08, -1.69 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 2.66, df = 2 (P = 0.26); I2 =25%
Test for overall effect: Z = 6.71 (P < 0.00001)
2 High income
Freemark 2001 15 -0.49 (1.38) 17 0.88 (1.61) 6.6 % -1.37 [ -2.41, -0.33 ]
Berkowitz 2003 43 -3.1875 (2.55) 39 -1.52 (2.052) 6.8 % -1.67 [ -2.67, -0.67 ]
Chanoine 2005 352 -1.08 (2.05) 181 -0.31 (1.68) 8.8 % -0.77 [ -1.10, -0.44 ]
Maahs 2006 20 -1.3 (1.6) 20 -0.8 (3) 5.1 % -0.50 [ -1.99, 0.99 ]
Berkowitz 2006 281 -3.3934 (3.086247) 79 -0.43 (2.871776) 7.7 % -2.96 [ -3.69, -2.23 ]
Van Mil 2007 11 -0.8 (1.1) 9 -1.4 (1.4) 6.3 % 0.60 [ -0.52, 1.72 ]
Clarson 2009 11 -1.8 (2.6533) 14 0.5 (1.122497) 4.6 % -2.30 [ -3.97, -0.63 ]
Wiegand 2010 34 0.07 (3.4111069) 29 -0.31 (3.6619121) 4.4 % 0.38 [ -1.38, 2.14 ]
Wilson 2010 27 -0.9 (2.5980762) 27 0.2 (2.598076) 5.5 % -1.10 [ -2.49, 0.29 ]
Yanovski 2011 45 -0.78 (2.7754182) 40 0.32 (2.929046) 6.0 % -1.10 [ -2.32, 0.12 ]
NCT00001723 100 -1.44 (2.6) 100 -0.5 (2) 8.0 % -0.94 [ -1.58, -0.30 ]
Mauras 2012 23 -2.4 (2.3979158) 19 -1.1 (2.179449) 5.5 % -1.30 [ -2.69, 0.09 ]
Kendall 2013 55 -0.25 (4.1901521) 55 0.21 (4.2494817) 4.9 % -0.46 [ -2.04, 1.12 ]
Subtotal (95% CI) 1017 629 80.2 % -1.09 [ -1.62, -0.56 ]
Heterogeneity: Tau2 = 0.60; Chi2 = 45.43, df = 12 (P<0.00001); I2 =74%
Test for overall effect: Z = 4.05 (P = 0.000052)
Total (95% CI) 1158 704 100.0 % -1.34 [ -1.85, -0.83 ]
Heterogeneity: Tau2 = 0.73; Chi2 = 65.00, df = 15 (P<0.00001); I2 =77%
Test for overall effect: Z = 5.17 (P < 0.00001)
Test for subgroup differences: Chi2 = 8.39, df = 1 (P = 0.00), I2 =88%
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Analysis 1.9. Comparison 1 Body mass index (BMI): pharmacological interventions versus comparators,
Outcome 9 Change in BMI (mean age).
Review: Drug interventions for the treatment of obesity in children and adolescents
Comparison: 1 Body mass index (BMI): pharmacological interventions versus comparators
Outcome: 9 Change in BMI (mean age)
Study or subgroup Drug intervention Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD)[kg/m2] N Mean(SD)[kg/m2] IV,Random,95% CI IV,Random,95% CI
1 Mean age < 12 years
Atabek 2008 90 -2.08 (2.32) 30 0.65 (2.5) 6.7 % -2.73 [ -3.74, -1.72 ]
Yanovski 2011 53 -0.78 (2.7754182) 47 0.32 (2.929046) 6.3 % -1.10 [ -2.22, 0.02 ]
Subtotal (95% CI) 143 77 13.0 % -1.93 [ -3.53, -0.34 ]
Heterogeneity: Tau2 = 1.03; Chi2 = 4.46, df = 1 (P = 0.03); I2 =78%
Test for overall effect: Z = 2.37 (P = 0.018)
2 Mean age≥ 12 years
Freemark 2001 14 -0.485 (1.38) 15 0.88 (1.61) 6.4 % -1.36 [ -2.45, -0.27 ]
Berkowitz 2003 43 -3.1875 (2.55) 39 -1.52 (2.052) 6.8 % -1.67 [ -2.67, -0.67 ]
Chanoine 2005 352 -1.08 (2.05) 181 -0.31 (1.68) 8.8 % -0.77 [ -1.10, -0.44 ]
Godoy-Matos 2005 30 -3.6 (2.5) 30 -0.9 (0.9) 6.9 % -2.70 [ -3.65, -1.75 ]
Berkowitz 2006 281 -3.3934 (3.086247) 79 -0.43 (2.871776) 7.7 % -2.96 [ -3.69, -2.23 ]
Garc a-Morales 2006 23 -3.4 (1.965625) 23 -1.8 (1.965625) 6.3 % -1.60 [ -2.74, -0.46 ]
Maahs 2006 20 -1.3 (1.6) 20 -0.8 (3) 5.1 % -0.50 [ -1.99, 0.99 ]
Van Mil 2007 11 -0.8 (1.1) 9 -1.4 (1.4) 6.3 % 0.60 [ -0.52, 1.72 ]
Clarson 2009 11 -1.8 (2.6533) 14 0.5 (1.122497) 4.6 % -2.30 [ -3.97, -0.63 ]
Wilson 2010 27 -0.9 (2.5980762) 27 0.2 (2.598076) 5.4 % -1.10 [ -2.49, 0.29 ]
Wiegand 2010 34 0.07 (3.4111069) 29 -0.31 (3.6619121) 4.4 % 0.38 [ -1.38, 2.14 ]
NCT00001723 100 -1.44 (2.6) 100 -0.5 (2) 8.0 % -0.94 [ -1.58, -0.30 ]
Mauras 2012 23 -2.4 (2.3979158) 19 -1.1 (2.179449) 5.4 % -1.30 [ -2.69, 0.09 ]
Kendall 2013 55 -0.25 (4.1901521) 55 0.21 (4.2494817) 4.9 % -0.46 [ -2.04, 1.12 ]
Subtotal (95% CI) 1024 640 87.0 % -1.25 [ -1.79, -0.71 ]
Heterogeneity: Tau2 = 0.72; Chi2 = 56.98, df = 13 (P<0.00001); I2 =77%
Test for overall effect: Z = 4.53 (P < 0.00001)
Total (95% CI) 1167 717 100.0 % -1.34 [ -1.85, -0.83 ]
Heterogeneity: Tau2 = 0.74; Chi2 = 65.88, df = 15 (P<0.00001); I2 =77%
Test for overall effect: Z = 5.16 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.63, df = 1 (P = 0.43), I2 =0.0%
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Analysis 2.1. Comparison 2 Weight: pharmacological interventions versus comparators, Outcome 1
Change in weight (all trials).
Review: Drug interventions for the treatment of obesity in children and adolescents
Comparison: 2 Weight: pharmacological interventions versus comparators
Outcome: 1 Change in weight (all trials)
Study or subgroup Drug intervention Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD)[kg] N Mean(SD)[kg] IV,Random,95% CI IV,Random,95% CI
Berkowitz 2003 43 -7.8 (6.3) 39 -3.2 (6.1) 10.0 % -4.60 [ -7.29, -1.91 ]
Godoy-Matos 2005 30 -10.3 (6.6) 30 -2.4 (2.5) 10.2 % -7.90 [ -10.43, -5.37 ]
Garc a-Morales 2006 23 -7.7 (5.78125) 23 -3.8 (4.971875) 9.4 % -3.90 [ -7.02, -0.78 ]
Berkowitz 2006 281 -6.5593 (8.697846) 79 1.76 (8.171095) 10.8 % -8.32 [ -10.39, -6.25 ]
Maahs 2006 20 -5.5 (7.47557) 20 -1.6 (9.91254) 6.3 % -3.90 [ -9.34, 1.54 ]
Van Mil 2007 11 -0.18 (3.11) 9 -1.92 (3.88) 9.3 % 1.74 [ -1.39, 4.87 ]
Atabek 2008 90 -3.46 (11.1774) 30 3.53 (11.1455) 7.3 % -6.99 [ -11.60, -2.38 ]
Yanovski 2011 53 1.47 (6.439696) 47 4.85 (6.828763) 10.1 % -3.38 [ -5.99, -0.77 ]
NCT00001723 100 -2.9 (7) 100 -0.6 (7) 11.0 % -2.30 [ -4.24, -0.36 ]
Mauras 2012 23 -4.9 (4.795832) 19 -1.7 (4.794789) 9.7 % -3.20 [ -6.11, -0.29 ]
Kendall 2013 55 2.4 (16.2317) 55 0.4 (14.1603) 6.0 % 2.00 [ -3.69, 7.69 ]
Total (95% CI) 729 451 100.0 % -3.90 [ -5.86, -1.94 ]
Heterogeneity: Tau2 = 8.15; Chi2 = 47.85, df = 10 (P<0.00001); I2 =79%
Test for overall effect: Z = 3.90 (P = 0.000095)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Weight: pharmacological interventions versus comparators, Outcome 2
Change in weight (drug type).
Review: Drug interventions for the treatment of obesity in children and adolescents
Comparison: 2 Weight: pharmacological interventions versus comparators
Outcome: 2 Change in weight (drug type)
Study or subgroup Drug intervention Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD)[kg] N Mean(SD)[kg] IV,Random,95% CI IV,Random,95% CI
1 Metformin
Atabek 2008 90 -3.46 (11.1774) 30 3.53 (11.1455) 7.3 % -6.99 [ -11.60, -2.38 ]
Yanovski 2011 53 1.47 (6.439696) 47 4.85 (6.828763) 10.1 % -3.38 [ -5.99, -0.77 ]
Mauras 2012 23 -4.9 (4.795832) 19 -1.7 (4.794789) 9.7 % -3.20 [ -6.11, -0.29 ]
Kendall 2013 55 2.4 (16.2317) 55 0.4 (14.1603) 6.0 % 2.00 [ -3.69, 7.69 ]
Subtotal (95% CI) 221 151 33.1 % -3.24 [ -5.79, -0.69 ]
Heterogeneity: Tau2 = 3.17; Chi2 = 5.80, df = 3 (P = 0.12); I2 =48%
Test for overall effect: Z = 2.49 (P = 0.013)
2 Sibutramine
Berkowitz 2003 43 -7.8 (6.3) 39 -3.2 (6.1) 10.0 % -4.60 [ -7.29, -1.91 ]
Godoy-Matos 2005 30 -10.3 (6.6) 30 -2.4 (2.5) 10.2 % -7.90 [ -10.43, -5.37 ]
Berkowitz 2006 281 -6.5593 (8.697846) 79 1.76 (8.171095) 10.8 % -8.32 [ -10.39, -6.25 ]
Garc a-Morales 2006 23 -7.7 (5.78125) 23 -3.8 (4.971875) 9.4 % -3.90 [ -7.02, -0.78 ]
Van Mil 2007 11 -0.18 (3.11) 9 -1.92 (3.88) 9.3 % 1.74 [ -1.39, 4.87 ]
Subtotal (95% CI) 388 180 49.7 % -4.71 [ -8.10, -1.32 ]
Heterogeneity: Tau2 = 13.02; Chi2 = 32.59, df = 4 (P<0.00001); I2 =88%
Test for overall effect: Z = 2.72 (P = 0.0065)
3 Orlistat
Maahs 2006 20 -5.5 (7.47557) 20 -1.6 (9.91254) 6.3 % -3.90 [ -9.34, 1.54 ]
NCT00001723 100 -2.9 (7) 100 -0.6 (7) 11.0 % -2.30 [ -4.24, -0.36 ]
Subtotal (95% CI) 120 120 17.3 % -2.48 [ -4.31, -0.65 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 2.66 (P = 0.0078)
Total (95% CI) 729 451 100.0 % -3.90 [ -5.86, -1.94 ]
Heterogeneity: Tau2 = 8.15; Chi2 = 47.85, df = 10 (P<0.00001); I2 =79%
Test for overall effect: Z = 3.90 (P = 0.000095)
Test for subgroup differences: Chi2 = 1.31, df = 2 (P = 0.52), I2 =0.0%
-20 -10 0 10 20
Favours drug intervention Favours comparator
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Analysis 3.1. Comparison 3 Adverse effects: pharmacological interventions versus comparator, Outcome 1
Serious adverse events.
Review: Drug interventions for the treatment of obesity in children and adolescents
Comparison: 3 Adverse effects: pharmacological interventions versus comparator
Outcome: 1 Serious adverse events
Study or subgroup Drug intervention Comparator Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Metformin
Wilson 2010 2/38 0/38 7.5 % 5.00 [ 0.25, 100.80 ]
Subtotal (95% CI) 38 38 7.5 % 5.00 [ 0.25, 100.80 ]
Total events: 2 (Drug intervention), 0 (Comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
2 Orlistat
Chanoine 2005 11/352 5/181 62.2 % 1.13 [ 0.40, 3.21 ]
Maahs 2006 1/20 0/20 6.8 % 3.00 [ 0.13, 69.52 ]
NCT00001723 0/100 2/100 7.4 % 0.20 [ 0.01, 4.11 ]
Subtotal (95% CI) 472 301 76.4 % 1.04 [ 0.41, 2.67 ]
Total events: 12 (Drug intervention), 7 (Comparator)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.62, df = 2 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
3 Sibutramine
Berkowitz 2006 10/368 1/130 16.1 % 3.53 [ 0.46, 27.33 ]
Subtotal (95% CI) 368 130 16.1 % 3.53 [ 0.46, 27.33 ]
Total events: 10 (Drug intervention), 1 (Comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
Total (95% CI) 878 469 100.0 % 1.43 [ 0.63, 3.25 ]
Total events: 24 (Drug intervention), 8 (Comparator)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.46, df = 4 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.85 (P = 0.39)
Test for subgroup differences: Chi2 = 1.85, df = 2 (P = 0.40), I2 =0.0%
0.002 0.1 1 10 500
Favours drug intervention Favours comparator
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Analysis 3.2. Comparison 3 Adverse effects: pharmacological interventions versus comparator, Outcome 2
Discontinued trial because of adverse events.
Review: Drug interventions for the treatment of obesity in children and adolescents
Comparison: 3 Adverse effects: pharmacological interventions versus comparator
Outcome: 2 Discontinued trial because of adverse events
Study or subgroup Drug intervention Comparator Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Metformin
Wiegand 2010 1/36 3/34 6.3 % 0.31 [ 0.03, 2.88 ]
Wilson 2010 3/38 1/38 6.3 % 3.00 [ 0.33, 27.57 ]
Yanovski 2011 1/53 0/47 3.0 % 2.67 [ 0.11, 63.93 ]
Subtotal (95% CI) 127 119 15.6 % 1.20 [ 0.26, 5.48 ]
Total events: 5 (Drug intervention), 4 (Comparator)
Heterogeneity: Tau2 = 0.24; Chi2 = 2.30, df = 2 (P = 0.32); I2 =13%
Test for overall effect: Z = 0.23 (P = 0.81)
2 Orlistat
Ozkan 2004 7/22 0/20 3.9 % 13.70 [ 0.83, 225.43 ]
Chanoine 2005 12/352 3/181 19.6 % 2.06 [ 0.59, 7.20 ]
Maahs 2006 3/20 0/20 3.7 % 7.00 [ 0.38, 127.32 ]
NCT00001723 1/100 2/100 5.4 % 0.50 [ 0.05, 5.43 ]
Subtotal (95% CI) 494 321 32.6 % 2.49 [ 0.74, 8.32 ]
Total events: 23 (Drug intervention), 5 (Comparator)
Heterogeneity: Tau2 = 0.37; Chi2 = 3.87, df = 3 (P = 0.28); I2 =23%
Test for overall effect: Z = 1.48 (P = 0.14)
3 Sibutramine
Berkowitz 2003 0/42 1/39 3.1 % 0.31 [ 0.01, 7.39 ]
Berkowitz 2006 23/368 7/130 45.5 % 1.16 [ 0.51, 2.64 ]
Van Mil 2007 1/12 0/12 3.2 % 3.00 [ 0.13, 67.06 ]
Subtotal (95% CI) 422 181 51.8 % 1.14 [ 0.53, 2.46 ]
Total events: 24 (Drug intervention), 8 (Comparator)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.02, df = 2 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.33 (P = 0.74)
Total (95% CI) 1043 621 100.0 % 1.45 [ 0.83, 2.52 ]
Total events: 52 (Drug intervention), 17 (Comparator)
Heterogeneity: Tau2 = 0.0; Chi2 = 8.63, df = 9 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Chi2 = 1.19, df = 2 (P = 0.55), I2 =0.0%
0.002 0.1 1 10 500
Favours drug intervention Favours comparator
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A D D I T I O N A L T A B L E S
Table 1. Overview of trial populations
Trial Interven-
tion(s)
and com-
parator(s)
Descrip-
tion of
power and
sample
size calcu-
lation
Screened/
eligible
(N)
Ran-
domised
(N)
Safety
(N)
ITT
(N)
Finishing
trial
(N)
Ran-
domised
finishing
trial
(%)
Follow-up
timea
Atabek
2008b
I:
metformin
+ diet and
physical
activity ad-
vice
- - 90 90 - 90 100 6 months
C: placebo
+ diet and
physical
activity ad-
vice
30 30 - 30 100
total: 120 120 - 120 100
Berkowitz
2003
I: be-
havioural
pro-
gramme +
sibu-
tramine
Powered to
detect
a 4% dif-
ference in
% change
in BMI be-
tween
the 2 treat-
ment
groups
with an SD
of 5% (α =
0.05, β =
93%)c
146 43 43 43 40 93.0 6 months
(not in-
cluding the
6-month
open-
label period
where all
par-
ticipants re-
ceived sibu-
tramine)
C: be-
havioural
pro-
gramme +
placebo
39 39 39 34 87.2
total: 82 82 82 62 75.6
Berkowitz
2006
I: be-
havioural
pro-
gramme +
sibu-
tramine
”Planned
sample
size was
approx-
imately
400 par-
ticipants
with a 3:
1 random-
ization
ratio of
- 368 368 - 281 76.4 12 months
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Table 1. Overview of trial populations (Continued)
sibu-
tramine to
placebo.
On the
basis of
previous
12-month
adult trials,
we deter-
mined that
300 partic-
ipants in
the sibu-
tramine
group
would be
adequate
to assess
safety and
exposure,
allowing
an overall
dropout
rate of
approx-
imately
50% and
a proba-
bility that
approx-
imately
50% of
partic-
ipants
receiving
10 mg
of sibu-
tramine
would
lose 10%
or more
of initial
BMI at 6
months“
”Although
the proto-
col did not
document
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Table 1. Overview of trial populations (Continued)
a formal
sample size
calcula-
tion for
efficacy,
approx-
imately
132 ado-
lescents
(99 in
the sibu-
tramine
group and
33 in the
placebo
group)
would
allow a
between-
group
difference
in BMI of
2 kg/m2,
with 90%
power
(2-sided
level of 0.
05) to be
statistically
significant,
assuming a
common
SD of 3
kg/m2)“d
C: be-
havioural
pro-
gramme +
placebo
130 130 - 80 61.5
total: 498 498 - 361 72.5
Chanoine
2005
I: orlistat +
diet + ex-
ercise + be-
haviour
therapy
”We
planned to
enroll
at least 450
individ-
uals to pro-
vide more
than 80%
power
to detect a
differ-
ence of 1
BMI unit,
588 357 352 348 232 65.0 54 weeks
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Table 1. Overview of trial populations (Continued)
assuming a
30%
dropout
rate“
C: placebo
+ diet + ex-
ercise + be-
haviour
therapy
182 181 180 117 64.3
total: 539 533 528 349 64.7
Clarson
2009
I: met-
formin +
lifestyle in-
tervention
- 65 14 - - 11 78.6 6 months
C: lifestyle
interven-
tion only
17 - - 14 82.4
total: 31 - - 25 80.6
Franco
2014
(cross-
over trial)
I: sibu-
tramine +
dietary
guidance
- 73 - - - - - 13 months
C: placebo
+ dietary
guidance
− - - - -
total: 63 63 - 23 36.5
Freemark
2001
I:
metformin
- - 15 - - 14 93.3 6 months
C: placebo 17 - - 15 88.2
total: 32 - - 29 90.6
Garcia-
Morales
2006
I: sibu-
tramine +
diet + exer-
cise
13 partic-
ipants per
group (ex-
pectations:
mean loss
of 7.5 kg
(SD 5.3)
70 26 26 23 21 80.8 6 months
138Drug interventions for the treatment of obesity in children and adolescents (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Overview of trial populations (Continued)
in the sibu-
tramine
group vs 3.
6 kg (SD
4.5) in the
placebo
group)e
C: placebo
+ diet + ex-
ercise
25 25 23 19 76.0
total: 51 51 46 40 78.4
Godoy-
Matos
2005
I: sibu-
tramine +
hypocaloric
diet +
exercise
- - 30 30 30 28 93.3 24 weeks
C:
placebo +
hypocaloric
diet +
exercise
30 30 30 22 73.3
total: 60 60 60 50 83.3
Kendall
2013
I:
metformin
+ healthy
lifestyle
advice
”The
target re-
cruitment
was 140
patients,
based on
a power
calculation
using the
results of
a previous
study. A
standard
power
calculation
was used
to detect a
reduction
in BMI of
0.15 kg/m
2 (SD 0.
3). Sixty-
four par-
234 - 74 74 55 - 6 months
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Table 1. Overview of trial populations (Continued)
ticipants
in each
group give
a statistical
power of
80% for a
t test at the
5% signifi-
cance level.
This was
rounded
up to allow
for some
loss to
follow-up
but rec-
ognizing
that ad-
justment
using mul-
tifactorial
analysis
would
likely
enhance
the trial
power by
an unpre-
dictable
amount“f
C: placebo
+ healthy
lifestyle
advice
- 77 77 55 -
total: 155 151 151 110 71.0
Maahs
2006
I: orlistat +
diet and
exercise
therapy
”We deter-
mined that
a clinically
important
mean
difference
in decrease
in BMI
between
the orli-
stat and
placebo
groups
would be
2.0 kg/
m2 at 6
months
43 20 - 20 18 90.0 6 months
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Table 1. Overview of trial populations (Continued)
and used
an SD of
1.8. On
the basis
of this
approach,
a sample
size of 15
subjects
per group
would be
adequate
to detect a
2.0 kg/m2
difference
in Stu-
dent’s t test
with 80%
power and
alpha =
0.05. In
order to
allow for
a 25%
dropout
rate, 20
subjects
were ran-
domized
to each
group“g
C: placebo
+ diet and
exercise
therapy
20 - 20 16 80.0
total: 40 - 40 34 85.0
Mauras
2012
I:
metformin
+ diet/
exercise in-
tervention
”Differ-
ences in
hsCRP
and fib-
rinogen
concen-
trations at
6 months
were the
primary
outcomes.
An n = 42
completed
subjects
provided
> 90 %
- 35 35 - 23 65.7 6 months
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Table 1. Overview of trial populations (Continued)
power
to detect
significant
changes“
C: diet/
exercise in-
tervention
31 31 - 19 61.3
total: 66 66 - 42 63.6
NCT00001723
I: orlistat +
be-
havioural
weight loss
pro-
gramme
- - 100 100 100 87 87.0 6 months
C: placebo
+ be-
havioural
weight loss
pro-
gramme
100 100 100 84 84.0
200 100 100 171 85.5
Ozkan
2004
I: conven-
tional
treatment
(nutri-
tional and
lifestyle
modifi-
cation pro-
grammes)
+ orlistat
- - 22 - - 15 68.2 5 to 15
months
C: conven-
tional
treatment:
nutri-
tional and
lifestyle
modifi-
cation pro-
grammes
20 - - 15 75.0
total: 42 - - 30 71.4
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Table 1. Overview of trial populations (Continued)
Prado
2012
I: met-
formin +
nutritional
guide and
ex-
ercise pro-
gramme
8 partic-
ipants were
required
per inter-
vention
group (SD
0.4; differ-
ence of 0.
6, P < 0.
05, power
= 90%)
41/26 - 9 - 7 - 6 months
C: placebo
+
nutritional
guide and
ex-
ercise pro-
gramme
- 10 - 6 -
total: 26 19 - 13 50
Rezvanian
2010
I1:
metformin
+ diet and
physical
activity ad-
vice
”By con-
sidering al-
pha = 0.
05 and a
power level
of 0.8, the
sample size
was calcu-
lated
as 160, and
by consid-
ering the
attrition
dur-
ing the fol-
low-up, we
increased it
to 180“
180 45 - - 41 91.1 24 weeks
I2: fluoxe-
tine + diet
and physi-
cal activity
advice
45 - - 40 88.9
I3: met-
formin and
fluox-
etine + diet
and physi-
cal activity
advice
45 - - 41 91.1
C: placebo
+ diet and
physical
activity ad-
vice
45 - - 42 93.3
total: 180 - - 164 91.1
Srinivasan
2006
(cross-
I: met-
formin +
”standard-
- 34 − - - - - 12 months
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Table 1. Overview of trial populations (Continued)
over trial) ised infor-
mation
on healthy
eating and
exercise“
C: placebo
+
”standard-
ised infor-
mation
on healthy
eating and
exercise“
− - - - -
total: 28 - - 22 78.6
Van Mil
2007
I: sibu-
tramine +
energy-
restricted
diet and
exercise
plan
”The
number of
patients re-
quired per
treatment
group to
detect a
difference
between
treatment
groups
in mean
change in
BMI at
endpoint
interven-
tion of 1.
0 kg/m
2, based
on an
estimate
of variance
(sd) of
0.65, an
overall sig-
nificance
level of
5%, and
a power
of 90%,
was nine.
- 12 12 12 11 91.7 24 weeks
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Table 1. Overview of trial populations (Continued)
Allowing
a drop-
out rate of
25%, the
number of
patients
needed in
each group
was 12“h
C: placebo
+ energy-
restricted
diet and
exercise
plan
12 12 12 9 75.0
total: 24 24 24 20 83.3
Wiegand
2010
I: met-
formin +
lifestyle in-
tervention
”Since
a clinically
significant
effect was
defined as a
decrease in
HOMA-
IR by -1,
two groups
of 37 pa-
tients had
to be in-
cluded in
the study
to achieve
a power of
0.9 with a
α value of
0.05“
278 36 - - 34 94.4 6 months
C: placebo
+
lifestyle in-
tervention
34 - - 29 85.3
total: 70 - - 63 90
Wilson
2010
I: met-
formin +
lifestyle in-
tervention
”Assuming
an SDof 1.
9 for BMI
change, an
enrolled
sample of
72 pro-
vided 80%
power to
detect a
differential
92 39 39 39 19 48.7 100 weeks
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Table 1. Overview of trial populations (Continued)
of 1.46
between
treatment
arms or
between
sexes
and 1.75
between
white sub-
jects and
others“i
C: placebo
+
lifestyle in-
tervention
38 38 38 19 50.0
total: 77 76 76 38 49.4
Yanovski
2011
I:
metformin
+ dietitian-
adminis-
tered
weight-
reduction
pro-
gramme
”A total
sample size
of 60 par-
ticipants
would
detect a
between-
group
difference
of 0.09
BMI SD
score units
(approx-
imately
equivalent
to a 2
kg/m2
difference)
with 80%
power.
Participant
accrual
was set at
100 par-
ticipants
to allow as
much as
40% loss
to follow-
up“j
278 53 - 53 45 84.9 6 months
(not in-
cluding the
6-month
open-label
phase)
C: placebo
+ dietitian-
adminis-
tered
weight-
47 - 47 40 85.1
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Table 1. Overview of trial populations (Continued)
reduction
pro-
gramme
total: 100 - 100 85 85.0
Grand to-
tal
All inter-
ventionsk
1395 1153
All com-
paratorsk
817 665
All inter-
ventions
and com-
paratorsk
2484 1851
aDuration of intervention and follow-up under randomised conditions until end of trial.
bUnclear from the publication on the number which completed the trial and hence number of dropouts.
cActual treatment difference between intervention groups was 4.5% reduction in BMI.
dActual treatment difference between intervention groups at 12 months was 2.9 kg/m2.
eActual weight loss was 7.3 kg in the sibutramine group vs 4.3 kg in the placebo group.
fActual adjusted treatment difference at 6 months was -1.07 kg/m2.
gActual treatment difference between intervention groups at 6 months was 0.5 kg/m2.
hActual treatment difference between intervention groups at end of intervention (12 weeks) was 0.4 kg/m2 and at end of follow-up
(24 weeks) was 1.0 kg/m2.
iActual treatment difference between intervention groups after 48 weeks was 1.1 kg/m2.
jActual treatment difference between intervention groups at 6 months for BMI z score was 0.07.
kNumbers for interventions and comparators do not add up to ’all interventions and comparators’ because several trials did not provide
information on randomised participants per intervention/comparator group but only the total number of randomised participants.
”-“ denotes not reported.
BMI: body mass index; C: comparator; hsCRP: high sensitivity C-reactive protein; HOMA-IR: homeostasis model assessment for
insulin resistance index; I: intervention; ITT: intention-to-treat; n: number of participants; SD: standard deviation.
Table 2. Sensitivity analyses: BMI
Trials with data on mean change only
Number of trials 14
Point estimate (95% CI) (kg/m2) - 1.5 (-2.0 to -0.9) favouring drug intervention
Trials with concealment of allocation
Number of trials 12
Point estimate (95% CI) (kg/m2) -1.3 (-1.8 to -0.7) favouring drug interventions
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Table 2. Sensitivity analyses: BMI (Continued)
Trials with blinding of participants/personnel
Number of trials 10
Point estimate (95% CI) (kg/m2) -1.3 (-1.9 to -0.7) favouring drug interventions
Trials with blinding of outcome assessors
Number of trials 10
Point estimate (95% CI) (kg/m2) -1.3 (-1.9 to -0.7) favouring drug interventions
Trials without large sample size trials
Number of trials 14
Point estimate (95% CI) (kg/m2) -1.3 (-1.8 to -0.7) favouring drug interventions
Trials with trials with 6 months’ follow-up only
Number of trials 14
Point estimate (95% CI) (kg/m2) -1.2 (-1.7 to -0.7) favouring drug interventions
Trials without trials with higher drug dose
Number of trials 14
Point estimate (95% CI) (kg/m2) -1.2 (-1.7 to -0.7) favouring drug interventions
Trials with trials with a high dose/active lifestyle intervention
Number of trials 10
Point estimate (95% CI) (kg/m2) -1.3 (-1.9 to -0.7) favouring drug interventions
Trials without trials with high attrition
Number of trials 13
Point estimate (95% CI) (kg/m2) -1.4 (-2.0 to -0.8) favouring drug interventions
BMI: body mass index; CI: confidence interval.
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Table 3. Sensitivity analyses: weight
Trials with data on mean change only
Number of trials 8
Point estimate (95% CI) (kg) - 4.1 (-6.3 to -1.8) favouring drug intervention
Trials with concealment of allocation
Number of trials 9
Point estimate (95% CI) (kg) -3.5 (-5.8 to -1.2) favouring drug interventions
Trials with blinding of participants/personnel
Number of trials 7
Point estimate (95% CI) (kg) -4.2 (-6.8 to -1.5) favouring drug interventions
Trials with blinding of outcome assessors
Number of trials 7
Point estimate (95% CI) (kg) -4.2 (-6.8 to -1.5) favouring drug interventions
Trials without large sample size trials
Number of trials 10
Point estimate (95% CI) (kg) -3.4 (-5.2 to -1.6) favouring drug interventions
Trials with 6 months’ follow-up only
Number of trials 9
Point estimate (95% CI) (kg) -3.5 (-5.6 to -1.4) favouring drug interventions
Trials without trials with higher drug dose
Number of trials 10
Point estimate (95% CI) (kg) -3.4 (-5.2 to -1.6) favouring drug interventions
Trials with trials with a high dose/active lifestyle intervention
Number of trials 6
Point estimate (95% CI) (kg) -4.3 (-6.5 to -2.2) favouring drug interventions
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Table 3. Sensitivity analyses: weight (Continued)
Trials without trials with high attrition
Number of trials 9
Point estimate (95% CI) (kg) -4.4 (-6.6 to -2.2) favouring drug interventions
CI: confidence interval.
A P P E N D I C E S
Appendix 1. Search strategies
Cochrane Central Register of Controlled Trials (Cochrane Register of Studies)
Part I: Obesity
1. MESH DESCRIPTOR Obesity
2. MESH DESCRIPTOR Obesity, Morbid
3. MESH DESCRIPTOR Obesity, Abdominal
4. MESH DESCRIPTOR Pediatric Obesity
5. MESH DESCRIPTOR Overweight
6. MESH DESCRIPTOR Weight Loss
7. (adipos* or obes*):TI,AB,KY
8. (overweight* or over weight*):TI,AB,KY
9. (weight adj2 (reduc* or los* or control* or gain*)):TI,AB,KY
10. #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
Part II: Anti-obesity drugs
11. MESH DESCRIPTOR Anti-Obesity Agents
12. MESH DESCRIPTOR Appetite Depressants
13. ((anti obes* or antiobes* or weight loss) adj3 (agent* or drug* or medicine* or pharmac*)):TI,AB,KY
14. (appetite adj3 (suppress* or depress*)):TI,AB,KY
15. ((anorexi* or anorectic*) adj3 (agent* or drug*)):TI,AB,KY
16. anorectics:TI,AB,KY
17. metformin*:TI,AB,KY
18. exenatide*:TI,AB,KY
19. liraglutid*:TI,AB,KY
20. dulaglutid*:TI,AB,KY
21. albiglutid*:TI,AB,KY
22. taspoglutid*:TI,AB,KY
23. lixisenatid*:TI,AB,KY
24. semaglutid*:TI,AB,KY
25. orlistat*:TI,AB,KY
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(Continued)
26. cetilistat*:TI,AB,KY
27. sibutramin*:TI,AB,KY
28. fluoxetin*:TI,AB,KY
29. rimonabant*:TI,AB,KY
30. lorcaserin*:TI,AB,KY
31. benzphetamin*:TI,AB,KY
32. diethylpropion*:TI,AB,KY
33. phendimetrazin*:TI,AB,KY
34. mazindol*:TI,AB,KY
35. (phentermin* or chlorphentermin* or mephentermin*):TI,AB,KY
36. (phentermin* adj3 topiramat*):TI,AB,KY
37. (bupropion* adj3 naltrexon*):TI,AB,KY
38. (bupropion* adj3 zonisamid*):TI,AB,KY
39. beloranib*:TI,AB,KY
40. velneperit*:TI,AB,KY
41. tesofensin*:TI,AB,KY
42. #11 or #12 or #13 or #14 or #15 or#16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28
or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41
Part III: Part I + Part II
43. #10 and #42
44. MESH DESCRIPTOR Obesity WITH QUALIFIERS DT
45. MESH DESCRIPTOR Obesity, Morbid WITH QUALIFIERS DT
46. MESH DESCRIPTOR Weight Loss WITH QUALIFIERS DT
47. MESH DESCRIPTOR Overweight WITH QUALIFIERS DT
48. #43 or #44 or #45 or #46 or #47
Part IV: Population
49. MESH DESCRIPTOR Adolescent
50. MESH DESCRIPTOR Child
51. MESH DESCRIPTOR Pediatrics
52. minors:TI,AB,KY
53. (boy or boys or boyhood):TI,AB,KY
54. girl*:TI,AB,KY
55. (kid or kids):TI,AB,KY
56. (child* or schoolchild*):TI,AB,KY
57. adolescen*:TI,AB,KY
58. juvenil*:TI,AB,KY
59. youth*:TI,AB,KY
60. (teen* or preteen*):TI,AB,KY
61. (underage* or under age*):TI,AB,KY
62. pubescen*:TI,AB,KY
63. p?ediatric*:TI,AB,KY
64. #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 or #57 or #58 or #59 or #60 or #61 or #62 or #63
Part V: Part III AND IV
65. #48 and #64
66. MESH DESCRIPTOR Pediatric Obesity WITH QUALIFIERS DT
67. #65 or #66
MEDLINE (OvidSP)
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Part I: Obesity
1 Obesity/
2 Obesity, Morbid/
3 Obesity, Abdominal/
4 Pediatric Obesity/
5 Overweight/
6 Weight Loss/
7 (adipos* or obes*).tw.
8 (overweight* or over weight*).tw.
9 (weight adj2 (reduc* or los* or control* or gain*)).tw.
10 or/1-9
Part II: Anti-obesity drugs
11 Anti-Obesity Agents/
12 Appetite Depressants/
13 ((anti obes* or antiobes* or weight loss) adj3 (agent* or drug* or medicine* or pharmac*)).tw
14 (appetite adj3 (suppress* or depress*)).mp.
15 ((anorexi* or anorectic*) adj (agent* or drug*)).tw.
16 anorectics.tw.
17 metformin*.mp.
18 exenatide*.mp.
19 liraglutid*.mp.
20 dulaglutid*.mp.
21 albiglutid*.mp.
22 taspoglutid*.mp.
23 lixisenatid*.mp.
24 semaglutid*.mp.
25 orlistat*.mp.
26 cetilistat*.mp.
27 sibutramin*.mp.
28 fluoxetin*.mp.
29 rimonabant*.mp.
30 lorcaserin*.mp.
31 benzphetamin*.mp.
32 diethylpropion*.mp.
33 phendimetrazin*.mp.
34 mazindol*.mp.
35 (phentermin* or chlorphentermin* or mephentermin*).mp.
36 ((phentermin* adj3 topiramat*) or phentermine?topiramat*).mp
37 ((bupropion* adj3 naltrexon*) or bupropion?naltrexon*).mp
38 ((bupropion* adj3 zonisamid*) or bupropion?zonisamid*).mp
39 beloranib*.mp.
40 velneperit*.mp.
41 tesofensin*.mp.
42 or/11-41
Part III: Part I + Part II and additional MeSH/subheading combination
43 10 and 42
44 Obesity/dt [drug therapy]
45 Obesity, Morbid/dt [drug therapy]
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46 Weight Loss/dt [drug therapy]
47 Overweight/dt [drug therapy]
48 or/43-47
Part IV: Population [based on Leclercq 2013]
49 Adolescent/
50 Child/
51 Pediatrics/
52 minors.tw.
53 (boy or boys or boyhood).tw.
54 girl*.tw.
55 (kid or kids).tw.
56 (child* or schoolchild*).tw.
57 adolescen*.tw.
58 juvenil*.tw.
59 youth*.tw.
60 (teen* or preteen*).tw.
61 (underage* or under age*).tw.
62 pubescen*.tw.
63 p?ediatric*.tw.
64 or/49-63
Part V: Part III AND IV and additional MeSH/subheading combination
65 48 and 64
66 Pediatric Obesity/dt
67 65 or 66
Part VI: Study filter [Cochrane Handbook 2008 RCT filter - sensitivity max. version]
68 randomized controlled trial.pt.
69 controlled clinical trial.pt.
70 randomi?ed.ab.
71 placebo.ab.
72 drug therapy.fs.
73 randomly.ab.
74 trial.ab.
75 groups.ab.
76 or/68-75
77 exp animals/ not humans/
78 76 not 77
Part VII: Part V + Part VI
79 67 and 78
Embase (OvidSP)
Part I: Obesity
1 obesity/
2 morbid obesity/
3 abdominal obesity/
4 childhood obesity/
5 weight reduction/
6 (adipos* or obes*).tw.
7 (overweight* or over weight*).tw.
8 (weight adj2 (reduc* or los* or control* or gain*)).tw.
153Drug interventions for the treatment of obesity in children and adolescents (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
9 or/1-8
Part II: Anti-obesity drugs
10 antiobesity agent/
11 anorexigenic agent/
12 ((anti obes* or antiobes* or weight loss) adj3 (agent* or drug* or medicine* or pharmac*)).tw
13 (appetite adj3 (suppress* or depress*)).tw.
14 ((anorexi* or anorectic*) adj (agent* or drug*)).tw.
15 anorectics.tw.
16 metformin*.mp.
17 exenatide*.mp.
18 liraglutid*.mp.
19 dulaglutid*.mp.
20 albiglutid*.mp.
21 taspoglutid*.mp.
22 lixisenatid*.mp.
23 semaglutid*.mp.
24 orlistat*.mp.
25 cetilistat*.mp.
26 sibutramin*.mp.
27 fluoxetin*.mp.
28 rimonabant*.mp.
29 lorcaserin*.mp.
30 benzphetamin*.mp.
31 diethylpropion*.mp.
32 phendimetrazin*.mp.
33 mazindol*.mp.
34 (phentermin* or chlorphentermin* or mephentermin*).mp.
35 ((phentermin* adj3 topiramat*) or phentermine?topiramat*).mp
36 ((bupropion* adj3 naltrexon*) or bupropion?naltrexon*).mp
37 ((bupropion* adj3 zonisamid*) or bupropion?zonisamid*).mp
38 beloranib*.mp.
39 velneperit*.mp.
40 tesofensin*.mp.
41 or/10-40
Part III: Part I + Part II and additional MeSH/subheading combination
42 9 and 41
43 obesity/dt [drug therapy]
44 morbid obesity/dt [drug therapy]
45 weight reduction/dt [drug therapy]
46 or/42-45
Part IV: Population [adapted from Leclercq 2013]
47 juvenile/
48 adolescent/
49 child/
50 preschool child/
51 schoolchild/
52 pediatrics/
53 minors.tw.
54 (boy or boys or boyhood).tw.
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55 girl*.tw.
56 (kid or kids).tw.
57 (child* or schoolchild*).tw.
58 adolescen*.tw.
59 juvenil*.tw.
60 youth*.tw.
61 (teen* or preteen*).tw.
62 (underage* or under age*).tw.
63 pubescen*.tw.
64 p?ediatric*.tw.
65 or/47-64
Part V: Part III AND IV and additional MeSH/subheading combination
66 46 and 65
67 childhood obesity/dt
68 66 or 67
Part VI: Study filter [ Wong 2006afilter - BS version]
69 random*.tw. or clinical trial*.mp. or exp health care quality/
Part VII: Part V + Part VI
70 68 and 69
71 limit 70 to embase
LILACS (IAHx)
((MH:”Obesity“ OR MH:”Obesity, Morbid“ OR MH:”Obesity, Abdominal“ OR MH:”Pediatric Obesity“ OR MH:”Overweight“
ORMH:”Weight Loss“OR adipos$ORobes$OR overweight$OR”over weight“OR sobrepes$OR”exceso de peso“OR ”excesso de
peso“OR”weight reduction“OR”weight loss“OR”weight control“) AND(MH:”Obesity/drug therapy“ORMH:”Obesity,Morbid/
drug therapy“ ORMH:”Overweight/drug therapy“ ORMH:”Weight Loss/drug therapy“ ORMH:”Anti-Obesity Agents“ ORMH:
”Appetite Depressants“ OR ”farmacos antiobesidad“ OR ”farmacos antiobesidade“ OR ”depresores del apetito“ OR ”depressores
do apetite“ OR metformin$ OR exenatide$ OR liraglutid$ OR dulaglutid$ OR albiglutid$ OR taspoglutid$ OR lixisenatid$ OR
semaglutid$ OR orlistat$ OR cetilistat$ OR sibutramin$ OR fluoxetin$ OR rimonabant$ OR lorcaserin$ OR benzphetamin$ OR
diethylpropion$ OR phendimetrazin$ ORmazindol$ OR phentermin$ or chlorphentermin$ or mephentermin$ OR (phentermin$
AND topiramat$) OR (bupropion$ AND (naltrexon$ OR zonisamid$)) OR beloranib$ OR velneperit$ OR tesofensin$) AND
(MH:”Adolescent“ OR MH:”Child“ OR MH:”Pediatrics“ OR minors OR boy OR boys OR girl$ OR kid OR kids OR child$ OR
schoolchild$ OR escolar$ OR adolescen$ OR preadolescen$ OR juvenil$ OR juventud$ OR youth$ OR teen$ OR preteen$ OR
underage$ OR pubescen$ OR paediatri$ OR pediatri$ OR joven$ OR jovem$ OR niños OR niñas OR crianca$ OR menin$ OR
”menor de edad“ OR ”menores de edad“ OR ”menor de idade“ OR ”menores de idade“) ORMH:”Pediatric Obesity/drug therapy“)
+ Controlled Clinical Trial
PubMed (only subsets not available on Ovid)
#1 Part I: Obesity
adipos*[tw] OR obes*[tw] OR overweight*[tw] OR over weight*[tw] OR weight reduc*[tw] OR weight los*[tw] OR weight con-
trol*[tw] OR weight gain*[tw]
#2 Part II: Antiobesity drugs
anti obesity agent*[tw] OR antiobesity agent*[tw] OR anti obesity drug*[tw] OR antiobesity drug*[tw] ORweight loss agent[tw] OR
weight loss drug[tw] OR appetite suppress*[tw] OR appetite depress*[tw] OR anorexigenic agent*[tw] OR anorexigenic drug*[tw]
OR anorectics[tw] OR metformin*[tw] OR exenatide*[tw] OR liraglutid*[tw] OR dulaglutid*[tw] OR albiglutid*[tw] OR taspog-
lutid*[tw] OR lixisenatid*[tw] OR semaglutid*[tw] OR orlistat*[tw] OR cetilistat*[tw] OR sibutramin*[tw] OR fluoxetin*[tw] OR
rimonabant*[tw] OR lorcaserin*[tw] OR benzphetamin*[tw] OR diethylpropion*[tw] OR phendimetrazin*[tw] OR mazindol*[tw]
ORphentermin*[tw]ORchlorphentermin*[tw]ORmephentermin*[tw]OR topiramat*[tw]ORbupropion*[tw]ORnaltrexon*[tw]
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OR zonisamid*[tw] OR beloranib*[tw] OR velneperit*[tw] OR tesofensin*[tw]
#3 Part III: Part I + Part II
#1 AND #2
#4 Part IV: Population
minors[tw] OR boy[tw] OR boys[tw] OR boyhood[tw] OR girl*[tw] OR kid[tw] OR kids[tw] OR child*[tw] OR schoolchild*[tw]
OR adolescen*[tw] OR juvenil*[tw] OR youth*[tw] OR teen*[tw] OR preteen*[tw] OR underage*[tw] OR under age*[tw] OR
pubescen*[tw] OR paediatric*[tw] OR pediatric*[tw]
#5 Part V: Part III AND IV
#3 AND #4
#6 Part VI: Limiting to subsets not available on Ovid
#5 not medline[sb] not pmcbook
ICTRP Search Portal (Standard search)
obes* AND child* OR
obes* AND schoolchild* OR
obes* AND adolesc* OR
obes* AND young* OR
obes* AND pediatric* OR
obes* AND teen* OR
obes* AND preteen* OR
obes* AND juvenil* OR
obes* AND minors OR
obes* AND boy* OR
obes* AND girl* OR
obes* AND kids OR
obes* AND youth* OR
obes* AND underage* OR
obes* AND pube* OR
overweight* AND child* OR
overweight* AND schoolchild* OR
overweight* AND adolesc* OR
overweight* AND young* OR
overweight* AND pediatric* OR
overweight* AND teen* OR
overweight* AND preteen* OR
overweight* AND juvenil* OR
overweight* AND minors OR
overweight* AND boy* OR
overweight* AND girl* OR
overweight* AND kids OR
overweight* AND youth* OR
overweight* AND underage* OR
overweight* AND pube*
ClinicalTrials.gov (Expert search)
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( obese OR overweight OR obesity ) [DISEASE] AND ( drug or drugs OR agent OR agents OR appetite OR metformin OR
exenatide OR liraglutide OR dulaglutide OR albiglutide OR taspoglutide OR lixisenatide OR semaglutide OR orlistat OR cetilistat
OR sibutramine OR fluoxetine OR rimonabant OR lorcaserin OR benzphetamine OR diethylpropion OR phendimetrazine OR
mazindol OR phentermineOR chlorphentermineORmephentermineOR topiramate ORbupropion ORnaltrexoneOR zonisamide
OR beloranib OR velneperit OR tesofensine ) [TREATMENT] AND INFLECT EXACT ”Child“ [AGE-GROUP]
Appendix 2. Description of interventions
Trial Intervention(s): drug component (route, fre-
quency, total dose/day), behaviour changing com-
ponent
Comparator(s): drug component (route, fre-
quency, total dose/day), behaviour changing com-
ponent
Atabek 2008 Metformin: oral, twice daily, 500 mg x 2 (1 g)/d, 6
months
Diet and physical activity advice: individual con-
sultation sessions with a nutritionist, completed food
diary at beginning and end of trial, advised to per-
form 30 min of aerobic physical activity per day, 6
months
Placebo: oral, twice daily, 2 tablets/d, 6 months
Diet and physical activity advice: same as the in-
tervention group
Berkowitz 2003 Sibutramine: oral, 1 dose per day, placebo (week 1)
5 mg/d sibutramine (week 2) 10 mg/d (weeks 3 to
6) 15 mg/d (week 7 to month 6), length = 6 months
(plus an open-label phase for additional 6 months)
Behavioural programme: in phase 1 (drug-placebo
phase) participants attended 13 weekly group ses-
sions while in phase 2 (drug, open label) group ses-
sions were held biweekly then monthly. Parents met
separately from participants. Instructed to consume
1200 kcal/d to 1500 kcal/d and to engage in 120 min
of walking or similar activity per week. Eating and
activity logs kept daily. Length = 12 months
Placebo: oral, 1 dose per day, (months 1 to 6), 6
months
Behavioural programme: same as intervention
group
Berkowitz 2006 Sibutramine: oral, 1 dose per day, 10 mg/d (baseline
to month 6), 15 mg/d from month 6 in participants
who had not lost more than 10% of their initial BMI,
12 months
Behavioural therapy programme: each individ-
ual centre implemented flexible lifestyle modifica-
tion approaches that were specific to participants’
needs. This included self-monitoring of eating habits
and physical activity, stress management, stimulus
control, problem solving, contingency management,
cognitive restructuring and social support. Partici-
pants were given counselling at each visit and nutri-
Placebo: oral, 1 dose per day, placebo (baseline to
month 6), uptitrated after 6 months in participants
who had not lost more than 10% of their initial BMI,
12 months
Behavioural therapy programme: same as interven-
tion group
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tional counselling. Length = 12 months
Chanoine 2005 Orlistat: oral, dose 3 times per day, 120 mg x 3 (360
mg)/d, 1 year
Behavioural therapy: participants were prescribed a
nutritionally balanced, hypocaloric diet and at each
trial visit the dietitian spoke about compliance. Be-
havioural modification involved techniques to limit
calorie and fat intake, eating more slowly, avoid-
ing snacks and avoiding overeating. Guidelines were
given to encourage regular physical activity and re-
duce sedentary behaviour; compliance was moni-
tored by a behavioural psychologist at each visit.
Length = 54 weeks
Placebo: oral, dose 3 times per day, 1 year
Behavioural therapy: same as intervention group
Clarson 2009 Metformin: oral, 3 times daily, 500 mg x 3 (1.5 g),
6 months
Behaviour changing intervention: monthly indi-
vidual visits and 2 group sessions. Fitness special-
ist supervised participants in an individual 30-min
exercise sessions every 2 months. Diet advice and
physical activity advice given. Progress monitored by
weekly telephone calls and monthly visits. Length =
6 months
No placebo (N/A)
Behaviour changing intervention: same as inter-
vention group
Franco 2014 Sibutramine: oral, once daily, 10 mg, 6 months
Dietary guidance: the dietary guideline proposal was
of a low-calorie diet with restriction of 25% of the
total recommended calories for a teenager
Placebo: oral, once daily, 10 mg, 6 months
Dietary guidance: same as intervention group
Freemark 2001 Metformin: oral, 2 doses per day, 500 mg x 2 (1g)/
d, 6 months
No behaviour changing intervention
Placebo: oral, 2 doses per day, 6 months
No behaviour changing intervention
Garcia-Morales 2006 Sibutramine: oral, 1 dose per day, 10 mg/d, 6
months
Diet + exercise: diet and exercise advice was tai-
lored to each participant. Advice was given on recom-
mended food portions and possible combinations,
and all participants were advised to perform at least
30 min of aerobic physical activity per day. Each
participant also attended individual consultation ses-
sions with a registered paediatric nutritionist. A de-
tailed food consumption questionnaire was com-
pleted at the beginning and end of trial medication
period. Length = 6 months
Placebo: oral, 1 dose per day, 6 months
Diet + exercise: same as intervention group
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Godoy-Matos 2005 Sibutramine: oral, 1 dose per day, 10 mg/d, 6
months
Hypocaloric diet + exercise: participants were given
dietary counselling to achieve an energy deficit of 500
kcal/d at the start of the run-in phase (no further visits
after). Physical activity instructions were delivered
by the attendant doctors in a brief written protocol
aimed to obtain mainly aerobic moderate exercises
for at least 30 min/d. A lifestyle intervention was not
given during 6-month trial
Placebo: oral, 1 dose per day, 6 months
Hypocaloric diet + exercise: same as intervention
group
Kendall 2013 Metformin: oral, twice daily, 500 mg x 2 + 500 mg
(1.5 g), 6 months
Healthy lifestyle advice: participants provided with
a standardised healthy lifestyle advice at the start in a
1-to-1 sessions, including a healthy diet advice sheet
and increased levels of exercise (available upon re-
quest). A lifestyle intervention was not given during
the 6-month trial
Placebo: oral, twice daily, 2 + 1 (3) tablets/d, 6
months
Healthy lifestyle advice : same as intervention group
Maahs 2006 Orlistat: oral, 3 doses per day, 120 mg x 3 (360 mg)
/d, 6 months
Diet + exercise therapy: the goal caloric intake was
calculated using the Harris-Benedict equation with
ambulating activity factor (500 calories was sub-
tracted from the final number to obtain daily calorie
level). Participants were instructed to increase activ-
ity using a paediatric activity pyramid and encour-
aged to exercise for at least 30 min, 3 times per week.
Monthly follow-up visits with a dietitian reinforced
this advice. Log sheets anddiet recordswere also com-
pleted. Length = 6 months
Placebo: oral, 3 doses per day, 6 months
Diet + exercise therapy: same as intervention group
Mauras 2012 Metformin: oral, twice daily, 500 mg or 1000 mg
(dependent on age), 6 months
Diet + exercise intervention: dietary counselling
provided with recommended decrease of 250 calo-
ries/d to 500 calories/d. Intense follow-up provided
by dietitian. Participants given free membership to
YMCA or gym. Encouraged to exercise at least 3
times per week for 30 min per sessions. Activity diary
kept and pedometer worn. Length = 6 months
No placebo
Diet + exercise intervention: same as intervention
group
NCT00001723 Orlistat: 120 mg 3 times daily for 6 months
Behavioural weight loss programme: 12-week in-
tensive programme
Placebo: 120 mg 3 times daily for 6 months
Behavioural weight loss programme: same as in-
tervention group
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Ozkan 2004 Orlistat: oral, 3 doses per day, 120 mg x 3 (360 mg)
/d, mean 11.7 months - length of treatment was not
consistent across participants
Conventional treatment: the lifestyle modification
programme included reducing daily calories.Was ad-
ministered by a team comprising of a paediatric en-
docrinologist, paediatrician and a dietitian. Partici-
pants seen by dietitianmonthly and in the outpatient
clinic every 2 months. Length = between 6 and 17
months
No placebo
Conventional treatment: same as intervention
group; length between 6 and 17 months
Prado 2012 Metformin: oral, once daily, 500 mg, 3 months
Nutritional guide and exercise programme: ac-
cording to pattern 1500 kcal/d. Exercise classes once
per week and exercise guide to be practiced twice per
week. Length = 3 months
Placebo: oral, once daily, 3 months
Nutritional guide and exercise programme: same
as intervention group
Rezvanian 2010 Metformin: oral, once daily, 1500 mg/d, 12 weeks
Healthy eating and physical activity advice: phys-
ical activity advice included reducing sedentary time
and taking part in 30 min of enjoyable, moderate-in-
tensity physical activity per day. A registered dietitian
conducted a nutrition education session with recom-
mendations on diet such as increasing consumption
of fruit and vegetables and not using hydrogenated
fat
Placebo: oral, once daily, 12 weeks
Healthy eating and physical activity advice: same
as intervention group
Fluoxetine: oral, once daily, 20 mg/d, 12 weeks
Healthy eating and physical activity advice: same
as the other intervention groups
Metformin + fluoxetine: oral, once daily, dosage not
given, 12 weeks
Healthy eating and physical activity advice: same
as the other intervention groups
Srinivasan 2006 Metformin:oral, 2 doses per day, dose gradually built
up to 1g x 2 (2 g)/d, 6 months
”Standardised information on healthy eating and
exercise“: no further information given
Placebo: oral, 2 doses per day, dose gradually built
up to 1 g x 2 (2 g)/d, 6 months
”Standardised information on healthy eating and
exercise“: same as intervention group
Van Mil 2007 Sibutramine: oral, once daily, 5 mg/d, 12 weeks
Energy-restricted diet and exercise plan: the en-
ergy prescription calculated from measured basal
metabolic rate multiplied by an estimated physical
activity level minus 500 kcal. Physical activity pre-
scribed based on individual preferences and informa-
tion obtained by physical activity questionnaire. It
contained a daily bout of exercise of at least 30 min.
Placebo: oral, once daily, 5 mg/d, 12 weeks
Energy-restricted diet and exercise plan: same as
intervention group
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Length = 12 weeks
Wiegand 2010 Metformin: oral, twice daily, 2 x 500 mg (1 g)/d, 6
months
Multiprofessional behaviour changing interven-
tion: an interview was performed before randomi-
sation to determine 1 to 3 individually chosen
tasks (goals). Multiprofessional reinforcement ses-
sions took place every 4 to 8 weeks. Regarding phys-
ical activity, participants and their families attended
specialised sport classes (2 sport classes per week, 45
min each, was recommended) in addition to regular
sport classes at school. Length = 6 months
Placebo: oral, twice daily, 6 months
Multiprofessional behaviour changing interven-
tion: same as intervention group
Wilson 2010 Metformin: oral, 4 times daily, 4 x 500 mg (2 g)/d,
48 weeks
Behaviour changing intervention: used the Weigh
of Life LITE programme developed at Texas Chil-
dren’s Hospital, Houston. There were 10 individ-
ualised ”intensive“ sessions at weekly intervals and
monthly follow-up sessions for the reminder of the
trial. Sessions led by trained health specialist and par-
ent/guardians were invited. Length = 48 weeks
Placebo: oral, 4 times daily, 48 weeks
Behaviour changing intervention: same as inter-
vention group
Yanovski 2011 Metformin: oral, twice daily, 2 x 1000mg (2000 mg)
/d, 6 months
Dietitian-administered
weight-reduction programme: each participant and
parent/guardian met with a dietitian monthly, who
promoted a reduced-energy diet, increased physical
activity and decreased inactivity. Participants trained
to completed a 7-day food diary which was used to
prescribe a ”traffic light“ style 500 kcal/d deficit diet,
and exercisewas encouraged for 30min/d,monitored
by pedometers readings. Length = 6 months
Placebo: oral, twice daily, 6 months
Dietitian-administered weight-reduction
programme: same as intervention group
”-“ denotes not reported.
BMI: body mass index; /d: per day; kcal: kilocalories; min: minute; N/A: not applicable; YMCA: Young Men’s Christian Association
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Appendix 3. Baseline characteristics (I)
Trial Interven-
tion(s) and
comparator
(s)
Duration
of interven-
tion
(dura-
tion of fol-
low-up)
Descrip-
tion of par-
ticipants
Trial period
(year to
year)
Country Setting Ethnic
groups
(%)
Duration of
obesity
(mean years
(SD))
Atabek
2008
I:
metformin +
diet and
physical ac-
tivity advice
6 months (6
months)
Obese ado-
lescents with
hyperinsuli-
naemia
- Turkey Hospi-
tal in/outpa-
tient clinic/
other based
in Univer-
sity School
of Medicine
- -
C: placebo +
diet and
physical ac-
tivity advice
Berkowitz
2003
I:
behavioural
programme
+
sibutramine
6 months (6
months)
Obese ado-
lescent boys
and post-
menarchal
girls
March 1999
to August
2002
USA University
of Pennsyl-
vania School
of Medicine
White
49, black 49,
other 2
-
C:
behavioural
programme
+ placebo
White
62, black 33,
other 5
Berkowitz
2006
I:
behavioural
therapy pro-
gramme +
sibutramine
12 months
(12 months)
Obese ado-
lescents
July 2000 to
February
2002
USA 33 weight
loss clin-
ics and out-
patient
clinic based
in a Univer-
sity School
of Medicine
White
56, African-
Ameri-
can 22, His-
panic
or Mexican
American
16, other 6
-
C:
behavioural
therapy pro-
gramme +
placebo
White
59, African-
Ameri-
can 19, His-
panic
or Mexican-
American
14, other 9
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Chanoine
2005
I: orlistat +
diet + ex-
ercise + be-
havioural
therapy
54 weeks
(54 weeks)
Obese ado-
lescents
August
2000 to Oc-
tober 2002
USA and
Canada
32 clinical
centres
White
75, black 19,
other 6
-
C: placebo +
diet + ex-
ercise + be-
havioural
therapy
White
78, black 14,
other 8
Clarson
2009
I:
metformin +
lifestyle in-
tervention
6 months (6
months)
Obese ado-
lescents with
insulin resis-
tance
En-
rolled 2005
to 2007
Canada Participants
assessed in
community
clinic and
there were
monthly vis-
its to
clinic during
interven-
tion. Inter-
vention car-
ried out in
community
- at adoles-
cent’s home
- unclear
where group
sessions
took place
- -
C: lifestyle
intervention
only
Franco
2014
I:
sibutramine
+ dietary
guidance
6 months (6
months)
Obese ado-
lescents
- Brazil Paediatric
endocrinol-
ogy outpa-
tient clinic
in child-
hood obe-
sity group of
the Instituto
da
Crianca do
Hospital das
Clinicas de
Faculdade
de Medicina
de Universi-
dade de Sao
Paulo
- -
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C: placebo +
dietary
guidance
Freemark
2001
I:
metformin
6 months (6
months)
Obese ado-
lescents with
fasting
hyperinsuli-
naemia and
a family his-
tory of type
2 diabetes
- USA In-
patient and
outpatient
clinic of a
university
White 64,
black 36
-
C: placebo White 47,
black 53
Garcia-
Morales
2006
I:
sibutramine
+ diet + exer-
cise
6 months (6
months)
Obese Mex-
ican adoles-
cents
August
2001 to Au-
gust 2003
Mexico Out-
patients at-
tending the
endocrinol-
ogy depart-
ment of the
Fed-
ericoGomez
Children’s
Hospital of
Mexico
- -
C: placebo +
diet + exer-
cise
Godoy-
Matos 2005
I: sibu-
tramine +
hypocaloric
diet + exer-
cise
7 months (7
months)
Obese ado-
lescents
Jan-
uary 2002 to
April 2003
Brazil Reg-
ular clinical
setting
- -
C: placebo +
hypocaloric
diet + exer-
cise
Kendall
2013
I:
metformin +
healthy
lifestyle ad-
vice
6 months (6
months)
Obese
children and
ado-
lescents with
hyperinsuli-
naemia
or impaired
fasting glu-
cose or im-
paired glu-
cose
tolerance (or
both)
- UK UK paedi-
atric en-
docrine cen-
tres
White 80,
Asian 19,
Afro-
Caribbean
11
-
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C: placebo +
healthy
lifestyle ad-
vice
White 72,
Asian 26,
Afro-
Caribbean 1
Maahs
2006
I: orlistat +
diet and ex-
ercise ther-
apy
26 weeks
(26 weeks)
Obese ado-
lescents
Decem-
ber 2002 to
September
2003
USA General
clinical re-
search cen-
tre at Uni-
versity of
NewMexico
Hospital
Hispanic 60 -
C: placebo +
diet and ex-
ercise ther-
apy
Hispanic 65
Mauras
2012
I:
metformin +
diet/exercise
intervention
6 months (6
months)
Obese chil-
dren
with normal
glucose tol-
erance
but elevated
hsCRP or
fibrino-
gen concen-
trations (or
both)
- USA - White
51, African-
American
37, other 11
Uncom-
plicated (ex-
ogenous)
obesity for <
5 years
C: diet/exer-
cise
intervention
White
39, African-
American
42, other 19
NCT00001723
I: orlistat +
behavioural
weight loss
programme
6 months (6
months)
Obese
children and
ado-
lescents with
obesity-
related dis-
eases
RCT be-
gan in 1999
and ended in
2008
USA National In-
stitutes of
HealthClin-
ical Center
Non-His-
panic black
63,
non-His-
panic white
37
-
C: placebo +
behavioural
weight loss
programme
Non-His-
panic black
60,
non-His-
panic whites
40
Ozkan
2004
I: conven-
tional treat-
ment + orli-
stat
Intervention
group
was followed
for 5 to 15
months
(mean dura-
tion
of treatment
Adolescents
with se-
vere exoge-
nous obesity
- Turkey Outpatient
clinic
- -
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11.7, SD3.7
months)
C: conven-
tional treat-
ment
Control
group
was followed
for 6 to 17
months
(mean
10.2, SD3.7
months)
Prado 2012 I:
metformin +
nutri-
tional guide
and exercise
programme
3 months (6
months)
Obese fe-
male adoles-
cents at risk
of develop-
ing type 2
diabetes
June 2009 to
July 2010
Chile Conducted
at Center of
Adoles-
cent Health
Serjoven
- -
C: placebo +
nutri-
tional guide
and exercise
programme
Rezvanian
2010
I1:
metformin +
healthy eat-
ing and
physical ac-
tivity advice
12 weeks
(24 weeks)
Obese
children and
adolescents
- Iran Pediatric
Obesity and
Metabolic
Syndrome
Research
Clinic of the
Pedi-
atric Preven-
tive Cardiol-
ogy Depart-
ment, Isfa-
han Cardio-
vascular Re-
search Cen-
ter
- -
I2:
fluoxetine +
healthy eat-
ing and
physical ac-
tivity advice
I3: met-
formin and
fluoxetine +
healthy eat-
ing and
physical ac-
tivity advice
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C: placebo +
healthy eat-
ing and
physical ac-
tivity advice
Srinivasan
2006
I: met-
formin first
then placebo
+ standard-
ised infor-
mation on
healthy eat-
ing and exer-
cise
6 months
(12 months)
Obese chil-
dren
and adoles-
cents (aged 9
to 18) with
suspected
insulin resis-
tance
- Australia Outpatient
clinic of a
tertiary pae-
diatric hos-
pi-
tal (univer-
sity teaching
hospital)
64% were
from eth-
nic back-
grounds
with high
prevalence
of insulin
resistance
and the
metabolic
syndrome
(e.g. Indian
subconti-
nent, Pacific
Islands),
25% were
from a
northern
European
background,
and 11%
were from
a mixed
background
-
C: placebo
first then
metformin +
standardised
information
on
healthy eat-
ing and exer-
cise
Van Mil
2007
I:
sibutramine
+ energy-re-
stricted diet
and exercise
plan
12 weeks
(24 weeks)
Obese ado-
lescents
- The Nether-
lands
Outpatient
clinic
- -
C: placebo +
energy-re-
stricted diet
and exercise
plan
Wiegand
2010
I:
metformin +
multiprofes-
sional
lifestyle in-
tervention
6 months (6
months)
Obese in-
sulin-resis-
tant adoles-
cents
May 2006 to
December
2006
Germany
and Switzer-
land
Paedi-
atric obesity
centre
White 87,
other 13
-
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C: placebo +
multiprofes-
sional
lifestyle in-
tervention
White 92,
other 9
Wilson
2010
I:
metformin +
lifestyle in-
tervention
programme
52 weeks
(100 weeks)
Obese ado-
lescents
October
2003 to Au-
gust 2007
USA 6
Glaser pae-
diatric re-
search cen-
tres
White
56, African-
American
21, Asian 8,
other 15,
Hispanic
ethnicity 18
-
C: placebo +
lifestyle in-
tervention
programme
White
71, African-
American
16, Asian 0,
other 13,
Hispanic
ethnicity 29
Yanovski
2011
I:
metformin +
dietitian-ad-
ministered
weight-re-
duction pro-
gramme
6 months
(12 months)
Obese
insulin-re-
sistant chil-
dren
September
2000 to Au-
gust 2008
USA Trial took
place at the
NIH clini-
cal research
centre
Non-His-
panic white
42, Non-
His-
panic black
42, His-
panic white
11, other 5
-
-
C: placebo +
dietitian-ad-
ministered
weight-re-
duction pro-
gramme
Non-His-
panic white
49, Non-
His-
panic black
38, His-
panic white
11, other 2
”-“ denotes not reported.
C: comparator; hsCRP: high sensitivity C-reactive protein; I: intervention; RCT: randomised controlled trial; SD: standard deviation
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Appendix 4. Baseline characteristics (II)
Trial Interven-
tion(s) and
comparator
(s)
Sex
(female %)
Age
(mean years
(SD))
HbA1c
(mean %
(SD))
BMI
(mean kg/
m² (SD))
Body-
weight
(mean kg
(SD))
Comedica-
tions/coint-
erventions
Comor-
bidities
Atabek
2008
I:
metformin +
diet and
physical ac-
tivity advice
50 11.8 (2.8) - 28.5 (3.4) 67.16 (16.8) Diet and
physical ac-
tivity advice.
Individ-
ual consulta-
tion sessions
with a regis-
tered paedi-
atric nutri-
tionist
All partici-
pants had
hyperinsuli-
naemia
C: placebo +
diet and
physical ac-
tivity advice
50 11.6 (2.7) - 28.0 (3.4) 66.27 (16.9)
Berkowitz
2003
I:
behavioural
programme
+
sibutramine
72 14.1 (1.3) - 37.5 (4.0) 102 (14.7) Behavioural
therapy
-
C:
behavioural
programme
+ placebo
62 14.1 (1.2) - 38.0 (3.6) 105.3 (16.2)
Berkowitz
2006
I:
behavioural
therapy pro-
gramme +
sibutramine
66 13.6 (1.3) - 35.9 (4.1) 97.9 (14.7) Behavioural
therapy
50.5%
had dyslip-
idaemia, 1.
4% had hy-
pertension
C:
behavioural
therapy pro-
gramme +
placebo
62 13.7 (1.3) - 36.1 (3.8) 97.8 (14.6) 57.4%
had dyslip-
idaemia, 2.
3% had hy-
pertension
Chanoine
2005
I: orlistat +
diet + ex-
ercise + be-
havioural
therapy
65 13.6 (1.3) - 35.7 (4.2) 97.7 (15.0) Behavioural
modifica-
tion + diet +
exercise
counselling
In the orli-
stat group,
14 partici-
pants had
a baseline
abnormality
revealed by
gallbladder
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ultrasound,
including 8
participants
with fatty
liver infiltra-
tion or hep-
atomegaly
and 3 partic-
ipants with
gallstones;
25.3% of
participants
had the
metabolic
syndrome at
baseline
C: placebo +
diet + ex-
ercise + be-
havioural
therapy
71 13.5 (1.2) - 35.4 (4.1) 95.1 (14.2) -
Clarson
2009
I:
metformin +
lifestyle in-
tervention
- 13.1 - 36.4 (1.8) - Lifestyle in-
tervention
All partici-
pants
insulin resis-
tant. 15 par-
ticipants
had acan-
thosis nigri-
cans
C: lifestyle
intervention
only
- 13.1 - 33.9 (1.1) -
Franco
2014
I:
sibutramine
+ dietary
guidance
56 13.3 (1.8) - 33.9 (7.2) 85.5 (23.2) Dietary
guidance
-
C: placebo +
dietary
guidance
12.3 (1.7) - 32.8 (5.8) 83.1 (19.6)
Freemark
2001
I:
metformin
79 14.4 (0.6) 5.6 (0.1) 41.5 (0.9) - - All partici-
pants
had fasting
hyperinsuli-
naemia. 8
participants
had acan-
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thosis nigri-
cans
C: placebo 46 15.4 (0.5) 5.5 (0.1) 38.7 (1.3) -
Garcia-
Morales
2006
I:
sibutramine
+ diet + exer-
cise
61 15.2 (1.3) - 35.1 (5.3) 92.6 (14.6) Diet and ex-
ercise advice
8.7%
high blood
pressure, 8.
7% glu-
cose, 43.5%
high triglyc-
erides, 8.7%
high choles-
terol, 4.3%
high
LDL, 13%
high HDL
C: placebo +
diet + exer-
cise
52 14.7 (1.1) - 36.6 (5.2) 98.9 (22.7) 30.4% high
blood
pressure, 8.
7% glu-
cose, 52.2%
high triglyc-
erides, 34.
8%
high choles-
terol, 17.4%
high LDL
Godoy-
Matos 2005
I: sibu-
tramine +
hypocaloric
diet + exer-
cise
83 Females: 15.
9
(1.1) Males:
16.7 (0.6)
- Females: 37.
5 (3.8)
Males: 37.6
(4.3)
Females:
100.5 (14.2)
Males: 117.
1 (11.7)
Exercise ad-
vice
-
C: placebo +
hypocaloric
diet + exer-
cise
80 Females: 16.
3
(1.2) Males:
16.7 (0.6)
- Females: 35.
8 (4.2)
Males: 37.4
(1.9)
Females: 94.
0 (13.6)
Males: 113.
4 (10.0)
-
Kendall
2013
I:
metformin +
healthy
lifestyle ad-
vice
66 13.7 (2.3) - 37.1 (6.4) 100.3 (24.1) Standard-
ised healthy
lifestyle ad-
vice
All partici-
pants had
hyperinsuli-
naemia
or impaired
fasting glu-
cose or im-
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paired glu-
cose
tolerance (or
both)
C: placebo +
healthy
lifestyle ad-
vice
69 13.6 (2.2) - 36 (6.3) 96.4 (21.8)
Maahs
2006
I: orlistat +
diet and ex-
ercise ther-
apy
60 15.8 (1.5) 5.4 (0.1) 39.2 (5.3) 111.1 (22.9) Dietary and
exercise
counselling
-
C: placebo +
diet and ex-
ercise ther-
apy
75 15.8 (1.4) 5.4 (0.1) 41.7 (11.7) 114.3 (38.4) -
Mauras
2012
I:
metformin +
diet/exercise
intervention
57 12.3 (0.5) - 32 (1) - Di-
etary coun-
selling and
free mem-
bership to a
sports club/
gym
Elevated
hsCRP or
fib-
rinogen (or
both) con-
centrationsC: diet/exer-
cise
intervention
52 12.0 (0.4) - 33.2 (0.7) -
NCT00001723
I: orlistat +
behavioural
weight loss
programme
65 14.65 (1.38) - 41.7 (0.6) - Behavioural
therapy and
a multivita-
min for 6
months
All partici-
pants had at
least 1 of the
following:
systolic or
diastolic hy-
pertension
(determined
by age-spe-
cific charts)
; frank type
2 diabetes,
impaired
glucose
tolerance
assessed by
oral glucose
tolerance
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testing;
hyperin-
sulinaemia
(defined as
a fasting
insulin >
15 IU/mL)
; significant
hyperlip-
idaemia
(total
cholesterol
> 200 mg/
dL, LDL
cholesterol >
129 mg/dL
or fasting
triglycerides
> 200 mg/
dL); hepatic
steatosis
(ALT or
AST above
normal
range with
negative
hepatitis
studies) or
sleep apnoea
documented
by a sleep
trial
C: placebo +
behavioural
weight loss
programme
66 14.52 (1.46) - -
Ozkan
2004
I: conven-
tional treat-
ment + orli-
stat
67 12.9 (2.4) - 32.5 82.1 (20.9) Daily
oral multivi-
tamin
preparation,
lifestyle
modi-
fication pro-
gramme
-
C: conven-
tional treat-
ment
12.5 (2.2) - 31.2 73.9 (15.3) Lifestyle
modi-
fication pro-
gramme
-
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Prado 2012 I:
metformin +
nutri-
tional guide
and exercise
programme
100 15.6 (1.9) - 33.6 - Nutri-
tional guide
and exercise
programme
30% of par-
ticipants
had psychi-
atric comor-
bidities
C: placebo +
nutri-
tional guide
and exercise
programme
100 - 33.3 - 11.1% of
participants
had psychi-
atric comor-
bidities
Rezvanian
2010
I1:
metformin +
healthy eat-
ing and
physical ac-
tivity advice
- 13.1 (1.4) - 26.4 (0.5) - Physical ac-
tivity advice;
nu-
tritional ed-
ucation ses-
sion and di-
etary advice
-
I2:
fluoxetine +
healthy eat-
ing and
physical ac-
tivity advice
- 13.5 (1.2) - 26.5 (0.7) - -
I3: met-
formin and
fluoxetine +
healthy eat-
ing and
physical ac-
tivity advice
- 13.7 (1.1) - 26.6 (0.8) - -
C: placebo +
healthy eat-
ing and
physical ac-
tivity advice
- 13.4 (1.4) - 26.2 (0.6) - -
Srinivasan
2006
I: met-
formin first
then placebo
+ standard-
ised infor-
mation on
healthy eat-
ing and exer-
54 12.5 (2.2) - - - Information
on
healthy eat-
ing and exer-
cise
Suspicion of
insulin resis-
tance; 89%
participants
had acan-
thosis nigri-
cans
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cise
C: placebo
first then
metformin +
standardised
information
on
healthy eat-
ing and exer-
cise
- - -
Van Mil
2007
I:
sibutramine
+ energy-re-
stricted diet
and exercise
plan
45 14.1 (1.0) - 30.1 (4.5) 80.8 (15.6) Diet and ex-
ercise plan
-
C: placebo +
energy-re-
stricted diet
and exercise
plan
58 13.8 (1.5) - 33.3 (5.0) 89.2 (16.4) -
Wiegand
2010
I:
metformin +
multiprofes-
sional
lifestyle in-
tervention
72 15.1 - 34.3 (5) - Lifestyle in-
tervention
All had risk
factors for
developing
type 2 dia-
betes: acan-
tho-
sis nigricans,
signs of the
metabolic
syn-
drome, im-
paired fast-
ing glucose,
and positive
family his-
tory of type
2 diabetes,
or with im-
paired
glucose tol-
erance
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C: placebo +
multiprofes-
sional
lifestyle in-
tervention
62 15 - 35.5 (5.8) -
Wilson
2010
I:
metformin +
lifestyle in-
tervention
programme
67 14.8 (1.3) 5.4 (0.3) 35.9 (5.7) 95.9 (16.6) Lifestyle in-
tervention
given during
run-in pe-
riod and fol-
low-up
sessions pro-
vided
monthly for
the remain-
der of the
trial; a mul-
tivitamin
tablet and
calcium car-
bonate 1000
mg was
taken daily
-
C: placebo +
lifestyle in-
tervention
programme
66 15.0 (1.5) 5.3 (0.3) 35.9 (4.7) 101.8 (15.7) -
Yanovski
2011
I:
metformin +
dietitian-ad-
ministered
weight-re-
duction pro-
gramme
57 10.1 (1.6) - 34.2 (6.8) 76.4 (23.1) A monthly
dietitian ad-
ministered
weight-re-
duction pro-
gramme;
a daily chew-
able multivi-
tamin con-
taining
cyanocobal-
amin 6 mg
was also pre-
scribed
26.4% had
paediatric
metabolic
syn-
drome. 64%
showed
a presence of
acanthosis
nigricans; all
participants
had fast-
ing hyperin-
sulinaemia
C: placebo +
dietitian-ad-
ministered
weight-re-
duction pro-
gramme
64 10.4 (1.4) - 34.6 (6.2) 80.1 (20.5) 31.9% had
paediatric
metabolic
syn-
drome. 68%
showed
a presence of
acanthosis
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nigricans; all
participants
had fast-
ing hyperin-
sulinaemia
”-“ denotes not reported.
ALT: alanine transaminase; AST: aspartate transaminase; BMI: body mass index; C: comparator; HbA1c: glycosylated haemoglobin
A1c; HDL: high-density lipoprotein; HsCRP: high sensitivity C-reactive protein; I: intervention; LDL: low-density lipoprotein; SD:
standard deviation
Appendix 5. Matrix of study endpoints (publications and trial documents)
Trial Endpoints quoted in trial document(s)
(ClinicalTrials.gov, FDA/EMA document, manu-
facturer’s website, published design paper)a
Endpoints quoted in
publication(s)b
Time of measurement
Atabek 2008 N/T Primary outcome mea-
sures: -
6 months
Secondary outcome
measures : -
Other outcome mea-
sures:% change in BMI,
DBP, SBP,
pulse rate, lipids, triglyc-
erides, serum insulin,
serum glucose, HOMA,
HDL, BMI z score, LDL,
total cholesterol, weight
change, adverse events
Berkowitz 2003 Source: NCT00212173
(added 13 September
2005)
Primary outcome mea-
sure(s): BMI, weight
No trial results posted.
No link to Berkowitz
2003 publication but
links to 2 additional pub-
lications. A second pro-
tocol for an adolescent
lifestyle intervention also
included
Primary outcome mea-
sure:% change in BMI
3, 6, 9, 12 months
Sec-
ondary outcome mea-
sure(s): BP, lipids, glu-
cose, insulin
Secondary
outcome measures: BP,
pulse, hunger
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Other outcome mea-
sure(s): -
Other outcome
measures: lipids, triglyc-
erides, serum insulin,
serum glucose, HOMA,
HDL, BMI z score, LDL,
total cholesterol, weight
change, waist circumfer-
ence, adverse events
Berkowitz 2006 Source: NCT00261911
Primary outcome mea-
sure(s): absolute change
in BMI from baseline to
endpoint (12 months)
No trial results posted,
publications specified
Primary outcome mea-
sures:
absolute change from
baseline in BMI
0.25, 0.5, 1, 1.5, 2, 2.5,
3, 4, 5, 6, 7, 8, 9, 10, 11,
12 months
Sec-
ondary outcome mea-
sure(s): % change from
baseline in BMI, pro-
portions of participants
achieving ≥ 5% and ≥
10% BMI and body-
weight reduction, abso-
lute and % change from
baseline in waist circum-
ference, body composi-
tion (DEXA), lipid and
glycaemic variables (all:
12 months)
Secondary
outcome measures: %
change in BMI, pro-
portion of participants
achieving reductions in
BMI of≥ 5% or≥ 10%,
absolute and % changes
in bodyweight and lipid
and glycaemic variables,
absolute change in waist
circumference
Other outcome mea-
sure(s): -
Other outcome mea-
sures: DBP, SBP, pulse
rate, QTc interval, mat-
uration (Tanner staging),
adverse events
Chanoine 2005 N/T Primary outcome mea-
sures: change in BMI
from baseline to trial end
(or trial exit)
-0.5, 0.5, 1, 1.5, 2, 2.5,
3, 3.5, 4, 5, 6, 7, 8, 9, 10,
11, 12 months
Sec-
ondary outcome mea-
sures: change in body-
weight, levels of total,
HDL and LDL choles-
terol, LDL-to-
HDL cholesterol ratio,
triglyceride levels, SBP
and DBP,
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waist and hip circum-
ference, glucose and in-
sulin responses to an oral
glucose challenge, and
changes in body compo-
sition
Other outcome mea-
sures: beta carotene, vi-
tamin A, 25-hydroxyvi-
tamin D, vitamin E,
Tanner staging, adverse
events
Clarson 2009 N/T Primary outcome mea-
sures:
change in BMI andmod-
ificationofmetabolic risk
factors, including insulin
resistance, plasma lipids
and adipocytokines, as-
sessment of metformin
on the attainment of a
target metabolic profile
6 months
Secondary outcome
measures: -
Other outcome mea-
sures: BMI z score, BP,
adverse events, waist cir-
cumference
Franco 2014 N/T Primary outcome mea-
sures: -
On average every 40 days
for 13 months
Secondary outcome
measures: -
Other outcome mea-
sures:
% of participants loos-
ing 10% of their ini-
tial weight, weight, BMI,
SBP,
DBP, cholesterol, LDL,
HDL, triglycerides, lep-
tin, CRP, transaminases,
blood glucose, insulin,
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adverse events, waist cir-
cumference
Freemark 2001 N/T Primary outcome mea-
sures: -
6 months
Secondary outcome
measures: -
Other outcome mea-
sures:
BMI SDS, insulin, glu-
cose tolerance, leptin,
serum lipids, HbA1c,
IGF-1, lactate, choles-
terol, LDL, HDL, LDL/
HDL, triglycerides, ad-
verse events, ALT, AST
Garcia-Morales 2006 N/T Primary outcome mea-
sures:
baseline versus endpoint
absolute values for body-
weight, BMI, and % of
the initial BMI (%BMI)
-15, 30, 60, 90, 120, 150,
180 days
Secondary outcome
measures:
waist circumference and
% of the initial waist cir-
cumference (%waist)
Other out-
come measures: health-
related quality of life,
white blood cells, mono-
cytes, eosinophils, glu-
cose, uric acid, creati-
nine, albumin, chloride,
total choles-
terol, LDL, AST, alkaline
phosphatase, SBP, DBP,
heart rate, ST segment,
adverse events
Godoy-Matos 2005 N/T Primary outcome mea-
sures: change in weight
and BMI
-4, 4, 8, 12, 16, 20, 24
weeks
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Secondary out-
come measures: change
in waist, hip, and waist-
to-hip ratio
Other outcome mea-
sures: SBP, DBP,
heart rate, glucose, total
cholesterol, triglycerides,
HDL, LDL, VLDL, in-
sulin, total cholesterol/
HDL cholesterol,
left atrium diameter, left
ventricular mass, adverse
events, satiety score
Kendall 2013 Source:
ISRCTN19517475
Primary outcome mea-
sure: reduction in BMI
SDS
Prior to 16 December
2008:
80 participants aged 9 to
18 years
As of 16December 2008:
• pubertal and
postpubertal children:
fasting insulin > 26
mIU/L
• prepubertal
children: fasting insulin
> 15 mIU/L
• 120-minute insulin
> 89 mIU/L or impaired
glucose tolerance
(OGTT 2-hour plasma
glucose value ≥ 7.8 to <
11.1 (± impaired fasting
glucose ≥ 6.1 to < 7), or
both
Primary outcome mea-
sure: reduction of BMI
SDS
3, 6 months
Secondary outcome
measures: Added 16 De-
cember 2008: fasting and
2-hour insulin and glu-
cose levels on OGTT,
measures of insulin resis-
tance, fasting lipids,CRP,
adiponectin, leptin, re-
sistin, BP
Sec-
ondary outcome mea-
sures: BMI and waist-
to-hip ratio, fasting and
postprandial insulin and
glucose levels, metabolic
risk factors, adipokines
Other outcome mea-
sure(s): -
Other outcome mea-
sures: weight, height,
SBP, DBP, cholesterol,
HDL, LDL, triglyc-
erides, bilirubin, CRP,
lactate, resistin, adverse
events
Maahs 2006 N/T Primary outcome mea-
sures: change
in BMI from baseline to
6 months
1, 2, 3, 4, 5, 6 months
Sec-
ondary outcome mea-
sures: changes in weight,
lean body mass, results of
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blood chemistry studies
Other out-
come measures: health-
related quality of life, all-
cause mortality, vitamin
A, vitamin D, vitamin E,
adverse events
Mauras 2012 Source: NCT00139477
Primary outcome mea-
sures: change from base-
line
in hsCRP at 6 months,
change from baseline in
fibrinogen at 6 months,
change from baseline in
IL-6 at 6 months, change
from baseline in PAI-1 at
6 months
Trial results posted, pub-
lications specified
Primary outcome mea-
sures: hsCRP and fib-
rinogen concentrations
at 6 months
3, 6 months
Secondary outcome
measure(s): -
Secondary outcome
measures: -
Other outcome mea-
sure(s): -
Other outcome mea-
sures: weight, BMI per-
centile, systolic BP, di-
astolic BP, IL-6, PAI-1,
adiponectin, IGF-1, in-
sulin, total cholesterol,
LDL-cholesterol, HDL-
cholesterol, triglycerides,
free fatty acids, glucose
tolerance, resting energy
expenditure rates, ad-
verse events, waist cir-
cumference
NCT00001723 Source: NCT00001723
Primary outcome mea-
sure: change in BMI
SDS (time frame: base-
line to 6 months)
Trial
results posted, linked to
pilot trial but no link to
publication
No publication available 6 months
Sec-
ondary outcome mea-
sures: change in body-
weight (time frame: base-
line to 6 months)
, weight, change in BMI
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(time frame: baseline to 6
months), change in body
fat (time frame: base-
line to 6 months), body
fat distribution measures
obtainedDEXA, effect of
race on change in weight
(time frame: baseline to
6 months), difference in
change of weight accord-
ing to race (non-His-
panic white versus non-
Hispanic black)
Other outcome mea-
sure(s): -
Ozkan 2004 N/T Primary outcome mea-
sures: -
1 to 15 months
Secondary outcome
measures: -
Other outcome mea-
sures: weight change, %
weight change, BMI, ad-
verse events
Prado 2012 N/T Primary outcome mea-
sures: weight
1, 2, 3, 4, 5, 6 months
Secondary outcome
measures: -
Other out-
come measures: BMI,
motivational survey re-
sults, glycaemia, after-
load glucose, HDL, ad-
verse events, waist cir-
cumference
Rezvanian 2010 N/T Primary outcome mea-
sures: -
12, 24 weeks
Secondary outcome
measures: -
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Other outcome mea-
sures: BMI, BMI SDS,
waist circumference,
waist-to-height ratio, ad-
verse events
Srinivasan 2006 Source:
ISRCTN43267711
Primary outcome mea-
sures: -
No results posted or links
to publication
Retrospectively
registered
Primary outcome mea-
sures: -
6, 12 months
Secondary outcome
measures: -
Secondary outcome
measures: -
Other outcome mea-
sures: -
Other outcome mea-
sures: BMI, waist cir-
cumference z score, fast-
ing insulin, fasting glu-
cose, glu-
cose effectiveness, acute
insulin response, disposi-
tion index, glucose dis-
posal, acanthosis nigri-
cans neck score, Tan-
ner staging, weight loss,
weight z score, BMI z
score, adverse events
Van Mil 2007 N/T Primary outcome mea-
sure: change in BMI
between the 2 periods
(12 weeks’ randomised
treatment period and 12
weeks’ follow-up)
1, 2, 3, 4, 5, 6, 7, 8, 9,
10, 11, 12, 13, 14, 16,
18, 20, 22, 24 weeks
Secondary outcome
measures: -
Other outcome mea-
sures: height, weight,
sleeping metabolic rate,
basal metabolic rate, to-
tal energy expenditure,
physical activity level,
basal metabolic rate ad-
justed, total energy ex-
penditure residuals, ad-
verse events
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Wiegand 2010 Found in the references of included trials section:
EudraCT Nr. 2004-003816-47 (but currently not
available at EU CTR. We contacted EMA and re-
ceived the following answer “Note that this trial is
not in the public domain due to missing information
from Ethics Committee therefore we recommend
you to contact the National Competent Authority
concerned by this application.”; in the dissertation
byHübel it is specified “Vor Beginn der Studie wurde
die Zustimmung der jeweils zuständigen Ethikkom-
missionen eingeholt (Charité Berlin, Deutschland;
St. Gallen, Schweiz)” - “before start of the study ap-
proval of the appropriate ethics committees was obtained
(Charité Berlin, Germany; St. Gallen, Switzerland))
Primary outcome mea-
sures: HOMA-IR
-6, 3, 6 months
Secondary outcome
measures: anthropomet-
ric measurements (BMI
and waist-to-hip ratio)
, cardiovascular risk pa-
rameters (SBP and DBP)
, lipid profile (total,
LDL, HDL cholesterol
and triglycerides), and
other metabolic param-
eters (glucose tolerance
and fasting insulin)
Other outcome mea-
sures: adverse events
Wilson 2010 Source: NCT00209482
and NCT00120146
Primary outcome mea-
sures: NCT00209482:
mean change from base-
line in individual BMIs
between the 2 groups
(compared at 2 time
points: at week 52 and
week 100)
NCT00120146: change
in BMI, BMI
No trial results posted,
publications specified
Primary outcome mea-
sures: BMI change, BMI
z score
-4, 12, 24, 36, 48, 60, 72,
84, 96 weeks
Sec-
ondary outcome mea-
sures: NCT00209482: -
NCT00120146: change
in insulin sensitivity; fast-
ing insulin concentra-
tions; characterisation of
insulin dynamics and in-
sulin sensitivity; charac-
terisation of fat distri-
bution and fatty infiltra-
tion of the liver; use of
CT to characterise ab-
dominal fat distribution;
use of CT and ALT lev-
els to assess fatty in-
filtration of the liver;
Secondary outcome
measures: fat mass, lean
mass, fat area, HOMA-
IR, area under insulin
curve, area under glucose
curve, corrected insulin
release at glucose peak,
LDL cholesterol, HDL
cholesterol, triglycerides,
triglyceride-to-HDL
cholesterol ratio, adverse
events
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characterisation of body
composition; characteri-
sation of dietary amino
acids; characterisation of
the insulin-to-glucagon
ratio; characterisation of
the impact of sex on re-
sponse tometformin XR;
characterisation of the
impact of race/ethnic-
ity on response to met-
formin XR; characteri-
sation of health-related
quality of life
Other outcome mea-
sures: NCT00209482: -
NCT00120146: -
Other outcome mea-
sures: waist circumfer-
ence
Yanovski 2011 Source: NCT00005669
Primary outcome mea-
sures: changes in body-
weight as determined by
BMI SDS (6 months)
Trial results posted, pub-
lications specified
Primary outcome mea-
sures: change in BMI SD
score (BMI z score), as
determined at the end of
the 6-month randomised
treatment phase
1, 2, 3, 4, 5, 6 months
Sec-
ondary outcome mea-
sures: change in body-
weight as determined
by BMI (6 months),
change in bodyweight (6
months), change in body
fat by DEXA (6 months)
, change in body fat by
Bod Pod (6 months)
Secondary out-
come measures: changes
in BMI, bodyweight and
fatmass at the conclusion
of the randomised phase
Other outcome mea-
sures: -
Other outcome mea-
sures: changes in skin-
fold thickness, body cir-
cumferences, visceral adi-
pose tissue, insulin re-
sistance and laboratory
components
of the metabolic syn-
drome - SBP,DBP, serum
insulin, plasma glucose,
total cholesterol, HDL
cholesterol, LDL choles-
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terol, LDL-to-
HDL cholesterol ratio,
triglycerides, ALT, AST,
hsCRP, vitamin B12, ad-
verse events
- denotes not reported.
aTrial document(s) refers to all available information from published design papers and sources other than regular publications (e.g.
FDA/EMA documents, manufacturer’s websites, trial registers).
bPublication(s) refers to trial information published in scientific journals (primary reference, duplicate publications, companion
documents or multiple reports of a primary trial)
ALT: alanine transaminase; AST: aspartate transaminase; BMI: body mass index; BMI SDS: body mass index standardised deviation
score; BP: blood pressure; CDC: Centers for Disease Control and Prevention; CRP: C-reactive protein; CT: computed tomography;
DBP: diastolic blood pressure; DEXA: dual-energy X-ray absorptiometry; EMA: European Medicines Agency; EU CTR: European
Clinical Trials Register; FDA: Food and Drug Administration (US); HbA1c: glycosylated haemoglobin A1c; HDL: high-density
lipoprotein; HOMA(-IR): homeostasis model assessment (insulin resistance); hsCRP: high sensitivity C-reactive protein; IGF-1:
insulin-like growth factor 1; IL-6: interleukin-6; LDL: low-density lipoprotein; N/T: no trial document available; OGTT: oral glucose
tolerance test; PAI-1: plasminogen activator inhibitor-1; QTc: heart-rate corrected QT interval; SBP: systolic blood pressure; VLDL:
very low density lipoprotein; XR: extended release
Appendix 6. Examination of outcome reporting bias
Trial Outcome Clear that outcome
was measured and
analyseda (trial re-
port
states that outcome
was analysed but
only reports that
result was not sig-
nificant)
Clear that outcome
was measured and
analysedb (trial re-
port states that
outcome was anal-
ysed but no results
reported)
Clear that
outcome was mea-
suredc (clear that
outcome was mea-
sured but not nec-
essarily analysed
(judgement
says likely to have
been analysed but
not reported be-
cause of nonsignif-
icant results))
Un-
clear whether the
outcome was mea-
suredd (not men-
tioned but clinical
judgement
says likely to have
been measured and
analysed but not
reported on the ba-
sis of nonsignifi-
cant results)
Atabek 2008 Behaviour change - - Yes -
Berkowitz 2003 N/A
Berkowitz 2006 N/A
Chanoine 2005 N/A
Clarson 2009 Body fat distribu-
tion
Yes - - -
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Franco 2014 Body fat distribu-
tion
- - Yes -
Freemark 2001 N/A
Garcia-Morales
2006
Behaviour change - - Yes -
Godoy-Matos
2005
N/A
Kendall 2013 Behaviour change - - Yes -
Maahs 2006 Behaviour change - - Yes -
Health-related qual-
ity of life and self es-
teem
Yes - - -
Mauras 2012 N/A
NCT00001723 N/A
Ozkan 2004 N/A
Prado 2012 Measured BMI Yes - - -
Body fat distribu-
tion
Yes - - -
Rezvanian 2010 N/A
Srinivasan 2006 Measured BMI - Yes - -
Body fat distribu-
tion
- Yes - -
Van Mil 2007 N/A
Wiegand 2010 Body fat distribu-
tion
Yes - - -
Wilson 2010 Body fat distribu-
tion
- Yes - -
Yanovski 2011 N/A
BMI: body mass index; N/A: not applicable.
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Appendix 7. Definition of endpoint measurementa (I)
Trial Measured BMI Adverse events Health-re-
lated quality of life
and self-esteem
All-causemortality Morbidity
Atabek 2008 Expressed as
BMI (kg/m2). Obe-
sity defined as≥ the
95th percentile for
age and sex based on
the standards of the
CDC (IO)
Participants were
asked to report any
adverse effects every
month. Serious ad-
verse events defined
as vomiting or lactic
acidosis (SO)
N/I N/I Hyperinsuli-
naemia was defined
from norms for pu-
bertal stages 2 to 4:
mid-puberty > 30
mU/L, and postpu-
bertal hyperinsulin-
ism was defined by
adult WHO crite-
ria (> 20 mU/L)
. Insulin sensitivity
was estimated using
FGIR, HOMA-IR
and QUICKI (IO)
Berkowitz 2003 The change in raw
BMI is not given.
Instead it is ex-
pressed as % reduc-
tion in BMI (kg/m
2).
BMI also used
to calculate BMI z
score (calculated us-
ing CDC standards)
Obesity defined as
BMI 32 to 44 kg/m
2 (IO)
Adverse events were
recorded
at eachmedical visit.
In addition, blood
pressure and heart
rate were monitored
closely, and any ab-
nor-
malities were con-
sidered as adverse
events. A serious ad-
verse event was not
defined (AO, IO,
SO)
N/I N/I N/I
Berkowitz 2006 Expressed as BMI
(kg/m2) in graphi-
cal format and %
change in BMI in
text and tabular for-
mat. Used Rosner
1998 to define obe-
sity (IO)
The inves-
tigator recorded all
adverse events, both
observed and volun-
teered. The only se-
rious event defined
as excessive nausea
and vomiting. Un-
clear whether sui-
cide attempt and de-
pression were de-
fined as serious (AO,
IO, SO)
N/I 2 suicide attempts
- did not result in
mortality (AO, IO)
N/I
189Drug interventions for the treatment of obesity in children and adolescents (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Chanoine 2005 Expressed as
BMI (kg/m2). Used
Barlow 1998 to de-
fine obesity (IO)
Gastrointestinal
tract adverse effects
assessed at each visit
by a specially de-
signed dictionary of
standard terms for
defecation patterns
for reproducibility
and consistency of
reporting.Other ad-
verse events were
noted and followed
by questioning. Se-
rious adverse events
included acute de-
myelinating en-
cephalomyelitis, fa-
cial palsy, pneumo-
nia, worsen-
ing of asthma, pain
in the right side, pi-
lonidal abscess, de-
pression, asthma at-
tack, seizure, admis-
sion for repair of de-
viated nasal septum,
appen-
dicitis, cholelithia-
sis, gallbladder dis-
order followed by
cholecystec-
tomy, adenoidal hy-
pertrophy and asep-
tic meningitis. The
trial also used elec-
trocardiograms to
detect abnormalities
and measured gall-
bladder ultrasounds
to detect gallstones
(AO, IO, SO)
N/I N/I Gallstones and fatty
liver infiltration or
hepatomegaly iden-
tified by gallbladder
ultrasound (IO)
Clarson 2009 Expressed as
BMI (kg/m2). Obe-
sity defined as BMI
> 95th percentile
for age and sex (no
reference). BMI z
scores calculated us-
No adverse events
reported, trial
highlights that met-
formin was well tol-
erated by all partici-
pants - unclear how
this was assessed
N/I N/I Insulin re-
sistance was defined
using HOMA > 3
(IO)
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ing the CDC refer-
ence data (IO)
Franco 2014 Weight and height
used to calculate
BMI. Obesity de-
fined byWHO clas-
sification (IO)
Adverse effects were
investigated on a
preset questionnaire
and described vol-
untarily by the par-
ticipant at each con-
sultation (on aver-
age every 40 days)
. A serious adverse
event was not de-
fined (AO, SO)
N/I N/I N/I
Freemark 2001 Expressed change in
BMI. Also expressed
as BMI SDS. Used
Rosner 1998 to ad-
justing for age, sex
and race (IO)
Unclear how and
when adverse events
were assessed
N/I N/I Hyperinsulinaemia
defined as fasting in-
sulin concentration
exceeding 15 µU/
mL. Insulin sensi-
tiv-
ity assessed by fast-
ing insulin-to-glu-
cose concentration
ratio, QUICKI and
HOMA-IR (IO)
Garcia-Morales
2006
Expressed as
BMI (kg/m2). Used
CDC growth charts
(Kuczmarski 2000)
(IO)
Adverse events were
reported as they
were detected by the
participant or inves-
tigator. They were
also assessed during
visits. Severe adverse
events de-
fined as life-threat-
ening or those re-
sulting in hospital-
isation or produc-
ing long-term dis-
abilities (AO, IO,
SO)
Health-related qual-
ity of life assessed
by a 36-item Short-
Form Health Sur-
vey (SF-36) ques-
tionnaire (Alonso
1995) (SO)
N/I Comorbidities were
accessed at baseline
and
follow-up. These in-
cluded high blood
pressure, high glu-
cose, high triglyc-
erides, high choles-
terol, high LDL and
high HDL (IO)
Godoy-Matos
2005
Expressed as
BMI (kg/m2). Obe-
sity defined as BMI
between 30 and 45
(no reference) (IO)
Adverse events were
as-
sessed and recorded
at each visit. A sig-
nificant event was
defined as a serious
N/I N/I N/I
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or rare event - se-
rious event not de-
fined (AO, IO, SO)
Kendall 2013 Expressed as BMI
(kg/m
2). Obesity defined
by UK BMI centile
charts. No reference
for how BMI SDS
was calculated (IO)
How and when trial
authors assessed ad-
verse events was not
described.No expla-
nation to how they
defined a severe/se-
ries event
N/I N/I Participants had hy-
perinsulinaemia,
impaired fasting
glucose or impaired
glucose tolerance
In-
sulin resistance/sen-
sitivity was assessed
using:
HOMA-IR,
QUICKI, whole-
body insulin sensi-
tivity
index, adiponectin-
to-leptin ratio (IO)
Maahs 2006 Expressed as
BMI (kg/m2). Obe-
sity defined as BMI
that exceeded the
85th percentile for
age and sex (assume
this from the CDC
standards) (IO)
Adverse events as-
sessed at each
monthly visit. Se-
rious/severe adverse
events not defined
(AO, IO, SO)
Health-related qual-
ity of life assessed
by 4 questionnaires:
Brief Symptom In-
ventory (Derogatis
1983), Parents and
Children’s KINDL (
Ravens-Sieberer
2001), IWQOL-
Kids (Kolotkin
1997; Kolotkin
2001), and a global
ratings scale (SO)
Defined as suicide -
1 participant in the
orlistat group (AO,
IO)
N/I
Mauras 2012 Expressed as
BMI (kg/m2). BMI
% determined us-
ing CDC standards
(Kuczmarski 2000)
(IO)
Trial authors did not
describe how and
when adverse events
were assessed. Did
not report number
or type of adverse
events
N/I N/I Elevated hsCRPand
fibrogen concentra-
tions were measured
by immuno-neph-
elometry (IO)
NCT00001723 BMI SDS calcu-
lated for age and sex
according to CDC
standards (IO)
Events were col-
lected by systematic
assessment. Trial au-
thors did not define
what a serious ad-
verse event was (IO,
SO)
N/I N/I N/I
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Ozkan 2004 Expressed
as BMI (kg/m2). Se-
vere obesity defined
as weight for height
index > 140% (no
reference) (IO)
Unclear how and
when adverse events
were assessed. All
with mild gastroin-
testinal complaints
apart from 2 (mild
diffuse hair loss and
another withmuscle
cramps). A serious/
severe event was not
defined
N/I N/I N/I
Prado 2012 Expressed as
BMI (kg/m2). Obe-
sity defined as BMI
> 95th percentile for
age and sex (no ref-
erence) (IO)
Adverse events
monitored by ALT,
AST and haemoglo-
bin levels (IO)
N/I N/I Risk factors for di-
abetes mellitus type
2:
high glycaemia fast-
ing, high postload
glucose or high in-
sulin sensitivity. In-
sulin sensitivity ac-
cessed by HOMA
Rezvanian 2010 Expressed as BMI
(kg/m2). Gave base-
line BMI SDS (cal-
culated using re-
vised CDC growth
charts: Kuczmarski
2000 but did not
give follow-up mea-
surements (IO)
Partic-
ipants and parents
educated on possi-
ble signs of symp-
toms of hypogly-
caemia. They were
also given a 24-hour
mobile phone num-
ber to call if any
adverse events oc-
curred. No defini-
tion of severe/seri-
ous adverse events
(SO)
N/I N/I N/I
Srinivasan 2006 Raw BMI (kg/m2)
data not provided
BMI z score (pre-
sented
only on a graph) was
calculated from the
CDC reference data
2000. Obesity de-
fined by the Interna-
tional Obesity Task
Force (Cole 2000)
(IO)
Unclear how and
when adverse events
were assessed. No
definition for seri-
ous/severe events
N/I N/I Clin-
ical suspicion of in-
sulin resistance de-
fined by fasting in-
sulin-to-glucose ra-
tio or presence of
acanthosis nigricans
(assessed by severity
at the neck by a val-
idated scale)
Insulin sen-
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sitivity was accessed
by SI clamp (mini-
mal model), fasting
insulin and fasting
glucose (IO)
Van Mil 2007 Expressed as BMI
(kg/m2). BMI SDS
was determined us-
ing the Dutch age-
and sex-ad-
justed BMI curves
(Hansen 1998)
. Obesity defined as
≥ 97th percentile
(no reference) (IO)
Adverse events were
determined
at each visit. Heart
rate, DBP, SBP were
monitored through-
out the trial. No def-
inition of a serious/
severe event (AO,
IO, SO)
N/I N/I N/I
Wiegand 2010 Ex-
pressed as BMI (kg/
m2) - reference: Park
2009. Also provided
BMI SDS, no refer-
ence (IO)
Adverse events de-
termined at the 3-
month
and 6-month visit
by a clinical and
biochemical assess-
ment. No definition
of a serious/severe
event (AO, IO, SO)
N/I N/I Risk factors for type
2 diabetes: acantho-
sis nigricans, signs
of metabolic syn-
drome and impaired
fasting glucose
In-
sulin sensitivity was
assessed byHOMA-
IR and insulin sen-
sitivity index (IO)
Wilson 2010 Expressed as
BMI (kg/m2). Used
CDC charts to con-
vert BMI to BMI
z score (Kuczmarski
2000) (IO)
Adverse events as-
sessed at each visit.
An appendectomy
was defined as a
serious/severe event
(AO, IO, SO)
N/I N/I N/I
Yanovski 2011 Expressed as BMI
(kg/m2). Also ex-
pressed as BMI SDS
(no reference) (IO)
Adverse events ac-
cessed at each visit
and by laboratory
analysis. A serious/
severe event was not
defined (AO, IO,
SO)
N/I N/I Insulin sensi-
tivity was calculated
(from a SI clamp)
using the metabolic
rate-to-steady-state
insulin ratio. Insulin
resistance estimated
using HOMA-IR
(IO)
aIn addition to definition of endpointmeasurement, descriptionwhomeasured the outcome (AO: adjudicated outcomemeasurement;
IO: investigator-assessed outcome measurement; SO: self-reported outcome measurement)
ALT: alanine transaminase; AST: aspartate transaminase; BMI: body mass index; BMI SDS: body mass index standard deviation score;
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CDC: Centers for Disease Control and Prevention; DBP: diastolic blood pressure; FGIR: fasting insulin concentration/fasting glucose
concentration; HbA1c: glycosylated haemoglobin A1c; HDL: high-density lipoprotein; HOMA(-IR): homeostasis model assessment
(insulin resistance); hsCRP: high sensitivity C-reactive protein; IWQOL: Impact of Weight on Quality of Life questionnaire; LDL:
low-density lipoprotein; N/I: not investigated; OGTT: oral glucose tolerance test; QUICKI: quantitative insulin check index; SBP:
systolic blood pressure; SI clamp: insulin sensitivity clamp; WHO: World Health Organization
Appendix 8. Definition of endpoint measurementa (II)
Trial Body fat distribution Behaviour change Participants views of
the intervention
Socioeconomic effects
Atabek 2008 N/I Food consumption was
assessed by the comple-
tion of a detailed ques-
tionnaire at the begin-
ning and end of the trial
(no reference or results
given) (SO)
N/I N/I
Berkowitz 2003 Waist cir-
cumferencemeasured us-
ing reference: Calloway
1988 (IO)
Hunger was evaluated
by the Eating Inventory
(range 0 to 14) (Stunkard
1985) (SO)
N/I N/I
Berkowitz 2006 Waist circumference - no
description (IO)
N/I N/I N/I
Chanoine 2005 Waist circumference - no
description on how it was
measured. Body compo-
sition measured by whole
body DEXA (IO)
N/I N/I N/I
Clarson 2009 Waist circumference was
measured in the standing
position at the level of
the umbilicus to the near-
est 0.1 cm using a con-
stant tension tape (no ref-
erence) (IO)
N/I N/I N/I
Franco 2014 Waist circumference and
hip circumference mea-
sured at the smallest and
largest diameter. Arm cir-
cumference at themiddle
N/I N/I N/I
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third of the left arm (no
reference) (IO)
Freemark 2001 N/I N/I N/I N/I
Garcia-Morales 2006 Waist circumference -
measured with a flexible
tape between the high-
est point of the iliac crest
and the lowest part of the
costal margin at the mi-
daxillary line (no refer-
ence) (IO)
A detailed questionnaire
on food consumption
was completed at the be-
ginning and end of the
trial (no reference) (SO)
N/I N/I
Godoy-Matos 2005 Waist circumference -
measured at the min-
imal circumference be-
tween iliac crest and
last rib edge. Hip cir-
cumference assessed at
the greatest circumfer-
ence through the ma-
jor trochanters (no refer-
ence) (IO)
N/I N/I N/I
Kendall 2013 Waist-to-hip ratio (no
reference) (IO)
3 previously validated
questionnaires (food fre-
quency, diet and eating
behaviour, and physical
activity) were completed
by each child at the start
and end of the trial. No
results presented (SO)
N/I N/I
Maahs 2006 BIA Diet records recorded be-
fore enrolment and at 3
and 6 months. No refer-
ence or results provided
(SO)
N/I N/I
Mauras 2012 Waist
circumference measured
at umbilicus (no ref-
erence). Intrahepatic fat
content measured using
fast MRI. References:
Fishbein 2001; Fishbein
2003. Body composition
was measured DEXA.
N/I N/I N/I
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Also measured waist-to-
height ratio (no refer-
ence) (IO)
NCT00001723 N/I N/I N/I N/I
Ozkan 2004 N/I N/I N/I N/I
Prado 2012 Waist circumference -
measured with a cen-
tral flexible tape, corre-
sponding to the perime-
ter less between the il-
iac crest and the bottom
edge last rib, then ex-
hale with arms relaxed on
both sides (no reference)
(IO)
N/I N/I N/I
Rezvanian 2010 Waist circumference -
measured at a point mid-
way between the lower
border of the rib cage and
the iliac crest at the end
of normal expiration (no
reference) (IO)
N/I N/I N/I
Srinivasan 2006 Raw waist circumference
data not reported. Waist
circumference was calcu-
lated from the mean of
3 measures at the level
of the umbilicus (no ref-
erence). Waist circum-
ference z scores calcu-
lated from recent mul-
tiracial American refer-
ence data (Fernandez
2004). Raw body com-
position data were not re-
ported. DEXA scans also
used. MRI whole-body
scans (IO)
N/I N/I N/I
Van Mil 2007 Body composition was
assessed using a 4-com-
ponent reference model:
total bodyweight = fat
mass + total body wa-
ter + total bone mineral
Physical activity level was
estimated using an activ-
ity questionnaire. A 7-
day dietary record was
given to each participant.
N/I N/I
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content and remaining
fat-free mass (references:
Fuller 1992; VanMarken
Lichtenbelt 1999). To
calculate this they used
densitometry, deuterium
dilution (Maastricht pro-
tocol) with labelledwater
test and DEXA (IO)
Only the food quotient
used in the assessment
(respiratory exchange ra-
tio to calculate TEE).
Rest of the data not pre-
sented (IO, SO)
Wiegand 2010 Waist-to-hip ratio and
body composition (BIA)
weremeasured but no ex-
planation to how and no
results given (apart from
saying they were not sig-
nificant) (IO)
N/I N/I N/I
Wilson 2010 Abdominal CT
scans evaluated abdomi-
nal fat content and dis-
tribution (Borkan 1982).
Whole body DEXA used
to measure % body fat
and lean body mass (von
Scheven 2006). Waist
circumference measured
at the smallest circumfer-
ence below the rib cage
and above the umbilicus
(Wang 2003) (IO)
N/I N/I N/I
Yanovski 2011 Abdominal and hip cir-
cumferences (assessed in
triplicate) and tri-
ceps skinfold thickness.
Whole-body fat mass by
DEXA and by air dis-
placement plethysmog-
raphy; and intra-abdom-
inal and subcutaneous
abdominal adipose tissue
by MRI at L2 to L3 and
L4 to L5 (IO)
N/I N/I N/I
aIn addition to definition of endpointmeasurement, descriptionwhomeasured the outcome (AO: adjudicated outcomemeasurement;
IO: investigator-assessed outcome measurement; SO: self-reported outcome measurement)
BIA: bioelectrical impedance analysis; CT: computed tomography; DEXA: dual-energy X-ray absorptiometry; MRI: magnetic reso-
nance imaging; n: number of participants; N/I: not investigated; TEE: total energy expenditure
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Appendix 9. Adverse events (I)
Trial Interven-
tion(s) and
comparator
(s)
Par-
ticipants in-
cluded in
analysis
(N)
Deaths
(N)
Deaths
(% of par-
ticipants)
Partici-
pants
with at least
one adverse
event
(N)
Partici-
pants
with at least
one adverse
event
(%)
Partic-
ipants with
at least one
severe/seri-
ous adverse
event
(N)
Partic-
ipants with
at least one
severe/seri-
ous adverse
event
(%)
Atabek
2008
I:
metformin +
diet and
physical ac-
tivity advice
90 0 0 2 2.2 0 0
C: placebo +
diet and
physical ac-
tivity advice
30 0 0 0 0.0 0 0
Berkowitz
2003
I:
behavioural
programme
+
sibutramine
43 0 0 6 14.0 - -
C:
behavioural
programme
+ placebo
39 0 0 3 7.7 - -
Berkowitz
2006
I:
behavioural
therapy pro-
gramme +
sibutramine
368 0 0 327 88.9 10 2.7
C:
behavioural
therapy pro-
gramme +
placebo
130 0 0 111 85.4 1 0.8
Chanoine
2005
I: orlistat +
diet + ex-
ercise + be-
havioural
therapy
352 0 0 341 97 11 3
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C: placebo +
diet + ex-
ercise + be-
havioural
therapy
181 0 0 170 94 5 3
Clarson
2009
I:
metformin +
lifestyle in-
tervention
14 0 0 0 0 0 0
C: lifestyle
intervention
only
17 0 0 0 0 0 0
Franco
2014
I:
sibutramine
+ dietary
guidance
63 - - 8 13.4 0 0
C: placebo +
dietary
guidance
63 - - 3 4.9 0 0
Freemark
2001
I:
metformin
15 0 0 4 26.7 0 0
C: placebo 17 0 0 1 5.9 0 0
Garcia-
Morales
2006
I:
sibutramine
+ diet + exer-
cise
23 0 0 10 43.5 0 0
C: placebo +
diet + exer-
cise
23 0 0 10 43.5- 0 0
Godoy-
Matos 2005
I: sibu-
tramine +
hypocaloric
diet + exer-
cise
30 0 0 -a - 0 0
C: placebo +
hypocaloric
diet + exer-
cise
30 0 0 -a - 0 0
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(Continued)
Kendall
2013
I:
metformin +
healthy
lifestyle ad-
vice
74 0 0 20 27.0 0 0
C: control +
healthy
lifestyle ad-
vice
77 0 0 8 10.4 0 0
Maahs
2006
I: orlistat +
diet and ex-
ercise ther-
apy
20 1 5.0 - - 1 5.0
C: placebo +
diet and ex-
ercise ther-
apy
20 0 0 - - 0 0
Mauras
2012
I:
metformin +
diet/exercise
intervention
35 0 0 - - 0 0
C: diet/exer-
cise
intervention
31 0 0 - - 0 0
NCT00001723
I: orlistat +
behavioural
weight loss
programme
100 0 0 95 95 0 0
C: placebo +
behavioural
weight loss
programme
100 0 0 94 94 2 2
Ozkan
2004
I: conven-
tional treat-
ment + orli-
stat
22 0 0 22 100 - -
C: conven-
tional treat-
ment
20 0 0 0 0 - -
201Drug interventions for the treatment of obesity in children and adolescents (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Prado 2012 I:
metformin +
nutri-
tional guide
and exercise
programme
10 0 0 - - 0 0
C: placebo +
nutri-
tional guide
and exercise
programme
9 0 0 - - 0 0
Rezvanian
2010
I1:
metformin +
healthy eat-
ing and
physical ac-
tivity advice
45 0 0 7 15.6 0 0
I2:
fluoxetine +
healthy eat-
ing and
physical ac-
tivity advice
45 0 0 - - 0 0
I3: met-
formin and
fluoxetine +
healthy eat-
ing and
physical ac-
tivity advice
45 0 0 - - 0 0
C: placebo +
healthy eat-
ing and
physical ac-
tivity advice
45 0 0 - - 0 0
Srinivasan
2006
I: met-
formin first
then placebo
+ ”standard-
ised infor-
mation on
healthy eat-
13 0 0 -b - 0 0
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ing and exer-
cise“
C: placebo
first then
metformin
+ ”standard-
ised infor-
mation on
healthy eat-
ing and exer-
cise“
15 0 0 -b - 0 0
Van Mil
2007
I:
sibutramine
+ energy-re-
stricted diet
and exercise
plan
12 0 0 12 100 - -
C: placebo +
energy-re-
stricted diet
and exercise
plan
12 0 0 9 75 - -
Wiegand
2010
I:
metformin +
multiprofes-
sional
lifestyle in-
tervention
36 0 0 8 22.2 - -
C: placebo +
multiprofes-
sional
lifestyle in-
tervention
34 0 0 13 38.2 - -
Wilson
2010
I:
metformin +
lifestyle in-
tervention
38 0 0 -c - 2 5.3
C: placebo +
lifestyle in-
tervention
38 0 0 -c - 0 0
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Yanovski
2011
I:
metformin +
dietitian-ad-
ministered
weight-re-
duction pro-
gramme
53 0 0 -d - 0 0
C: placebo +
dietitian-ad-
ministered
weight-re-
duction pro-
gramme
47 0 0 -d - 0 0
”-“ denotes not reported.
aNumber of participants with one or multiple adverse events: sibutramine group 47 events in 30 participants; placebo group 45
events in 30 participants.
bTwo participants were unable to tolerate metformin 1000 mg twice daily because of nausea and were switched to metformin 750
mg twice daily with slower dose increments.
cNumber of participants with one or multiple adverse events: metformin group: 52 events in 38 participants; placebo group: 43
events in 38 participants.
dA total of 9/53 (17%) metformin-treated children were unable to take the highest dose of 2000 mg/d and were prescribed doses
ranging from 500 mg/d to 1500 mg/d; number of participants with one or multiple adverse events: metformin group: 64 events in
53 participants; placebo group: 25 events in 47 participants
C: comparator; I: intervention; n: number pf participants.
Appendix 10. Adverse events (II)
Trial Interven-
tion(s) and
comparator
(s)
Par-
ticipants in-
cluded in
analysis
(N)
Partic-
ipants dis-
continu-
ing trial due
to an ad-
verse event
(N)
Partic-
ipants dis-
continu-
ing trial due
to an ad-
verse event
(%)
Partic-
ipants with
at least one
hospitalisa-
tion
(N)
Partic-
ipants with
at least one
hospitalisa-
tion
(%)
Partic-
ipants with
at least one
outpatient
treatment
(N)
Partic-
ipants with
at least one
outpatient
treatment
(%)
Atabek
2008
I:
metformin +
diet and
physical ac-
tivity advice
90 0 0 0 0 0 0
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C: placebo +
diet and
physical ac-
tivity advice
30 0 0 0 0 0 0
Berkowitz
2003
I:
behavioural
programme
+
sibutramine
42 0 0 - - - -
C:
behavioural
programme
+ placebo
39 1 2.5 - - - -
Berkowitz
2006
I:
behavioural
therapy pro-
gramme +
sibutramine
368 23 6 - - - -
C:
behavioural
therapy pro-
gramme +
placebo
130 7 5 - - - -
Chanoine
2005
I: orlistat +
diet + ex-
ercise + be-
havioural
therapy
352 12 3 10 2.8 0 0
C: placebo +
diet + ex-
ercise + be-
havioural
therapy
181 3 2 5 2.8 0 0
Clarson
2009
I:
metformin +
lifestyle in-
tervention
14 0 0 0 0 0 0
C: lifestyle
intervention
only
17 0 0 0 0 0 0
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(Continued)
Franco
2014
I:
sibutramine
+ dietary
guidance
63 0 0 0 0 0 0
C: placebo +
dietary
guidance
63 0 0 0 0 0 0
Freemark
2001
I:
metformin
15 0 0 0 0 0 0
C: placebo 17 0 0 0 0 0 0
Garcia-
Morales
2006
I:
sibutramine
+ diet + exer-
cise
23 0 0 - - - -
C: placebo +
diet + exer-
cise
23 0 0 - - - -
Godoy-
Matos 2005
I: sibu-
tramine +
hypocaloric
diet + exer-
cise
30 0 0 0 0 0 0
C: placebo +
hypocaloric
diet + exer-
cise
30 0 0 0 0 0 0
Kendall
2013
I:
metformin +
healthy
lifestyle ad-
vice
74 0 0 - - - -
C: control +
healthy
lifestyle ad-
vice
77 0 0 - - - -
Maahs
2006
I: orlistat +
diet and ex-
ercise ther-
apy
20 3 15 - - - -
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C: placebo +
diet and ex-
ercise ther-
apy
20 0 0 - - - -
Mauras
2012
I:
metformin +
diet/exercise
intervention
35 0 0 0 0 0 0
C: diet/exer-
cise
intervention
31 0 0 0 0 0 0
NCT00001723
I: orlistat +
behavioural
weight loss
programme
100 1 1 - - - -
C: placebo +
behavioural
weight loss
programme
100 2 2 - - - -
Ozkan
2004
I: conven-
tional treat-
ment + orli-
stat
22 7 32 - - - -
C: conven-
tional treat-
ment
20 0 0 - - - -
Prado 2012 I:
metformin +
nutri-
tional guide
and exercise
programme
10 0 0 0 0 0 0
C: placebo +
nutri-
tional guide
and exercise
programme
9 0 0 0 0 0 0
Rezvanian
2010
I1:
metformin +
healthy eat-
45 0 0 0 0 0 0
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ing and
physical ac-
tivity advice
I2:
fluoxetine +
healthy eat-
ing and
physical ac-
tivity advice
45 0 0 0 0 0 0
I3: met-
formin and
fluoxetine +
healthy eat-
ing and
physical ac-
tivity advice
45 0 0 0 0 0 0
C: placebo +
healthy eat-
ing and
physical ac-
tivity advice
45 0 0 0 0 0 0
Srinivasan
2006
I: met-
formin first
then placebo
+ ”standard-
ised infor-
mation on
healthy eat-
ing and exer-
cise“
13 0 0 0 0 0 0
C: placebo
first then
metformin
+ ”standard-
ised infor-
mation on
healthy eat-
ing and exer-
cise“
15 0 0 0 0 0 0
Van Mil
2007
I:
sibutramine
+ energy-re-
stricted diet
12 1 8 0 0 0 0
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and exercise
plan
C: placebo +
energy-re-
stricted diet
and exercise
plan
12 0 0 0 0 0 0
Wiegand
2010
I:
metformin +
multiprofes-
sional
lifestyle in-
tervention
36 3 8.3 - - - -
C: placebo +
multiprofes-
sional
lifestyle in-
tervention
34 1 2.9 - - - -
Wilson
2010
I:
metformin +
lifestyle in-
tervention
38 3 7.9 - - - -
C: placebo +
lifestyle in-
tervention
38 1 2.6 - - - -
Yanovski
2011
I:
metformin +
dietitian-ad-
ministered
weight-re-
duction pro-
gramme
53 1 1.9 - - - -
C: placebo +
dietitian-ad-
ministered
weight-re-
duction pro-
gramme
47 0 0 - - - -
”-“ denotes not reported.
C: comparator; I: intervention; n: number of participants.
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Appendix 11. Adverse events (III)
Trial Intervention(s)
and comparator(s)
Participants in-
cluded in analysis
(N)
Participants with a
specific adverse
event
(description)
Participants with
at least one specific
adverse events
(N)
Participants with
at least one specific
adverse event
(%)
Atabek 2008 I: metformin + diet
and physical activity
advice
90 1.
Diarrhoea and mild
abdominal pain
2. Mild discomfort
from the abdomen
1. 1
2. 1
1. 1.1
2. 1.1
C: placebo + diet
and physical activity
advice
30 - - -
Berkowitz 2003 I: behavioural
programme + sibu-
tramine
42 1. High blood pres-
sure and pulse rate
2. High blood pres-
sure only
3. High pulse rate
only
4. Knee surgery
5. Ventricular pre-
mature beats
6. Cholelithiasis/
cholecystectomy
7. Rash, viral
1. 3
2. 1
3. 1
4. 1
5. 1
6. 1
7. 1
1. 7.1
2. 2.4
3. 2.4
4. 2.4
5. 2.4
6. 2.4
7. 2.4
C: behavioural pro-
gramme + placebo
39 1. Elevated blood
pressure and pulse
rate*
2. Elevated pulse
rate only*
3. Atrial premature
beats
4. Tonsillectomy
5. Ventricular pre-
mature beats*
6. Ecchymoses*
1. 1
2. 1
3. 1
4. 2
5. 1
6. 2
1. 2.6
2. 2.6
3. 2.6
4. 5.1
5. 2.6
6. 5.1
Berkowitz 2006 I: behavioural ther-
apy programme +
sibutramine
368 1. Infection
2. Headache
3. Pharyngitis
4. Tachycardia
5. Accidental injury
6. Dry mouth
7. Pain
8. Hypertension
1. 167
2. 113
3. 49
4. 46
5. 41
6. 41
7. 42
8. 39
1. 45.3
2. 30.7
3. 13.3
4. 12.5
5.11.1
6.11.1
7. 11.4
8. 10.6
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9. Rhinitis
10. Abdominal pain
11.Dysmenorrhoea
12. Vomiting
13. Cough
increased
14. Nausea
15. Dizziness
16. Rash
17. Sinusitis
18. Constipation
19. Flu syndrome
20. Insomnia
21. Viral infection
22.Allergic reaction
23. Suicide attempt
24. Depression
25. Syncope
26. Chest pain
27. Arrhythmia
28. Extra systoles
9. 41
10. 37
11. 21
12. 32
13. 28
14. 31
15. 28
16. 25
17. 24
18. 24
19. 23
20. 23
21. 20
22. 18
23. 1
24. 5
25. -
26. -
27. -
28. -
9. 11.1
10. 10.1
11. 5.7
12. 8.7
13. 7.6
14. 8.4
15. 7.6
16. 6.8
17. 6.5
18. 6.5
19. 6.3
20. 6.3
21. 5.4
22. 4.9
23. 0.3
24. 1.4
25. ≤ 1.5
26. ≤ 1.5
27. ≤ 1.5
28. ≤ 1.5
C: behavioural ther-
apy programme +
placebo
130 1. Infection
2. Headache
3. Pharyngitis
4. Tachycardia
5. Accidental injury
6. Dry mouth
7. Pain
8. Hypertension
9. Rhinitis
10. Abdominal pain
11.Dysmenorrhoea
12. Vomiting
13. Cough
increased
14. Nausea
15. Dizziness
16. Rash
17. Sinusitis
18. Constipation
19. Flu syndrome
20. Insomnia
21. Viral infection
22.Allergic reaction
23. Suicide attempt
24. Depression
1. 53
2. 39
3. 23
4. 8
5. 8
6. 8
7. 12
8. 11
9. 17
10. 12
11. 13
12. 7
13. 12
14. 12
15. 5
16. 7
17. 6
18. 3
19. 7
20. 4
21. 2
22. 7
23. 1
24. 1
25. -
1. 41
2. 30
3. 18
4. 6.2
5. 6.2
6. 6.2
7. 9.2
8. 8.5
9. 13.1
10. 9.2
11. 10
12. 5.4
13. 9.2
14. 9.2
15. 3.8
16. 5.4
17. 4.6
18. 2.3
19. 5.4
20. 3.1
21. 1.5
22. 5.4
23. 0.8
24. 0.8
25. ≤ 1.5
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25. Syncope
26. Chest pain
27. Arrhythmia
28. Extra systoles
26. -
27. -
28. -
26. ≤ 1.5
27. ≤ 1.5
28. ≤ 1.5
Chanoine 2005 I: orlistat + diet + ex-
ercise + behavioural
therapy
352 1. Fatty/oily stool
2. Oily spotting
3. Oily evacuation
4. Abdominal pain
5. Fecal urgency
6. Flatus with dis-
charge
7. Soft stool
8. Nausea
9. Increased defeca-
tion
10. Flatulence
11. Fecal inconti-
nence
12. Headache
13. Upper respira-
tory tract infection
14. Nasopharyngi-
tis
15. Sore throat
16. Sinusitis
17. Joint sprain
18. Nasal conges-
tion
19. Back pain
20. Gastroenteritis
21. Seasonal rhinitis
22. Limb injury
23. Asymptomatic
gallstones
24. Pilonidal ab-
scess
25. Depression
26. Asthma attack
27. Seizure
28. Admission for
repair of deviated
nasal septum
29. Appendicitis
30. Cholelithiasis
31. Gallbladder dis-
order followed by
1. 177
2. 102
3. 82
4. 77
5. 73
6. 70
7. 53
8. 52
9. 48
10. 32
11. 31
12. 134
13. 114
14. 99
15. 59
16. 40
17. 35
18. 31
19. 28
20. 23
21. 21
22. 18
23. 6
24. 1
25. 2
26. 1
27. 1
28. 1
29. 1
30. 1
31. 1
32. 1
33. 1
34. 10
1. 50.3
2. 29.0
3. 23.3
4. 21.9
5. 20.7
6. 19.9
7. 15.1
8. 14.8
9. 13.6
10. 9.1
11. 8.8
12. 38.1
13. 32.4
14. 28.1
15. 16.8
16. 11.4
17. 9.9
18. 8.8
19. 8.0
20. 6.5
21. 6.0
22. 5.1
23. 1.7
24. 0.3
25. 0.6
26. 0.3
27. 0.3
28. 0.3
29. 0.3
30. 0.3
31. 0.3
32. 0.3
33. 0.3
34. 2.8
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cholecystectomy
32. Adenoidal hy-
pertrophy
33. Aseptic menin-
gitis
34. Electrocardio-
gram abnormalities
C: placebo + diet
+ exercise + be-
havioural therapy
181 1. Fatty/oily stool
2. Oily spotting
3. Oily evacuation
4. Abdominal pain
5. Fecal urgency
6. Flatus with dis-
charge
7. Soft stool
8. Nausea
9. Increased defeca-
tion
10. Flatulence
11. Fecal inconti-
nence
12. Headache
13. Upper respira-
tory tract infection
14. Nasopharyngi-
tis
15. Sore throat
16. Sinusitis
17. Joint sprain
18. Nasal conges-
tion
19. Back pain
20. Gastroenteritis
21. Seasonal rhinitis
22. Limb injury
23. Acute demyeli-
nating
encephalomyelitis
24. Facial palsy
25. Pneumonia
26. Worsening of
asthma
27. Pain in the right
side
28. Electrocardio-
gram abnormalities
1.15
2. 7
3. 3
4. 20
5. 20
6. 5
7. 19
8. 23
9. 16
10. 8
11. 1
12. 56
13. 48
14. 46
15. 29
16. 19
17. 17
18. 11
19. 11
20. 8
21. 9
22. 5
23. 1
24. 1
25. 1
26. 1
27. 1
28. 1
1. 8.3
2. 3.9
3. 1.7
4. 11.0
5. 11.0
6. 2.8
7. 10.5
8. 12.7
9. 8.8
10. 4.4
11. 0.6
12. 30.9
13. 26.5
14. 25.4
15. 16.0
16. 10.5
17. 9.4
18. 6.1
19. 6.1
20. 4.4
21. 5.0
22. 2.8
23. 0.6
24. 0.6
25. 0.6
26. 0.6
27. 0.6
28. 0.6
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Clarson 2009 I: met-
formin + lifestyle in-
tervention
14 - - -
C: lifestyle interven-
tion only
17 - - -
Franco 2014 I: sibutramine + di-
etary guidance
63 1. Anorexia
2. Dry mouth
3. Headache
4. Constipation
5. Changing the
mood
6. Dyspnoea
7. Epigastralgia
8. Hypertension
9. Insomnia
10. Nausea
11. Tachycardia
12. Dizziness
13. Tremors
14. Vomiting
- 1. 0.9
2. 1.7
3. 6.8
4. 3.8
5. 1.3
6. 0.4
7. 0.9
8. 0.9
9. 1.3
10. 2.1
11. 1.3
12. 3.4
13. 0.4
14. 0.4
C: placebo + dietary
guidance
63 1. Change in taste
2. Headache
3. Diarrhoea
4. Hypertension
5. Irritability
6. Tachycardia
7. Dizziness
- 1. 0.9
2. 3.3
3. 2.8
4. 0.5
5. 1.4
6. 0.5
7. 0.9
Freemark 2001 I: metformin 15 1.Transient abdom-
inal discomfort or
diarrhoea
2. Intermittent nau-
sea
1. 3
2. 1
1. 20
2. 6.7
C: placebo 17 1.Transient abdom-
inal discomfort or
diarrhoea
1. 1 1. 5.9
Garcia-Morales
2006
I: sibutramine + diet
+ exercise
23 1. Headache
2. Dry mouth
3. Headache with
nausea
4. Headache with
weakness
5. High DBP
6. High heart rate
1. 1
2. 1
3. 1
4. 1
5. 1
6. 3
7. 2
8. 2
1. 4.3
2. 4.3
3. 4.3
4. 4.3
5. 4.3
6. 13.0
7. 8.7
8. 8.7
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7. High blood pres-
sure (baseline)
8. High blood pres-
sure (end of trial)
C: placebo + diet +
exercise
23 1. Headache
2. Headache with
somnolence
3. Headache with
dry mouth
4. High DBP
5. High heart rate
6. High blood pres-
sure (baseline)
7. High blood pres-
sure (end of trial)
1. 2
2. 1
3. 1
4. 2
5. 2
6. 7
7. 2
1. 8.7
2. 4.3
3. 4.3
4. 8.7
5. 8.7
6. 30.4
7. 8.7
Godoy-Matos
2005
I: sibutramine
+ hypocaloric diet +
exercise
30 1. Dry mouth
2. Headache
3. Constipation
4. Abdominal pain
5. Cold
6. Dizzy
7. Tonsillitis
8.Menstrual cramp
9. Nausea
10. Toothache
11. Otitis
12. Hair loss
13. Rhinitis
14. Sinusitis
15. Sleepiness
16. Dry cough
17.Myalgia
18. Viral infection
19. Lumbago
1. 7
2. 13
3. 12
4. 3
5. 9
6. 3
7. 2
8. 8
9. 3
10. 3
11. 3
12. 2
13. 1
14. 1
15. 1
16. 1
17. 1
18. 2
19. 2
1. 23.3
2. 43.3
3. 40.0
4. 10.0
5. 30.0
6. 10.0
7. 6.7
8. 26.7
9. 10.0
10. 10.0
11. 10.0
12. 6.7
13. 3.3
14. 3.3
15. 3.3
16. 3.3
17. 3.3
18. 6.7
19. 6.7
C: placebo
+ hypocaloric diet +
exercise
30 1. Dry mouth
2. Headache
3. Constipation
4. Abdominal pain
5. Cold
6. Dizzy
7. Tonsillitis
8.Menstrual cramp
9. Nausea
10. Toothache
11. Otitis
1. 3
2. 21
3. 4
4. 4
5. 11
6. 2
7. 2
8. 6
9. 1
10. 1
11. 1
1. 10.0
2. 70.0
3. 13.3
4. 13.3
5. 36.7
6. 6.7
7. 6.7
8. 20.0
9. 3.3
10. 3.3
11. 3.3
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12. Hair loss
13. Rhinitis
14. Sinusitis
15. Sleepiness
16. Dry cough
17.Myalgia
18. Bronchitis
19. Inguinal der-
matitis
20. Fever
12. 1
13. 2
14. 2
15. 2
16. 2
17. 2
18. 2
19. 2
20. 2
12. 3.3
13. 6.7
14. 6.7
15. 6.7
16. 6.7
17. 6.7
18. 6.7
19. 6.7
20. 6.7
Kendall 2013 I: metformin +
healthy lifestyle ad-
vice
74 - - -
C: control + healthy
lifestyle advice
77 - - -
Maahs 2006 I: orlistat + diet and
exercise therapy
20 - - -
C: placebo + diet
and exercise therapy
20 - - -
All: 40 1. Soft stools
2. Oily spotting
3.Fatty or oily stools
4. Oily evacuation
5. Liquid stools
6. Cramping
7. Flatus with dis-
charge
8. Fecal
incontinence
- -
Mauras 2012 I: metformin + diet/
exercise
intervention
35 - - -
C: diet/exercise in-
tervention
31 - - -
NCT00001723 I: orlistat +
behavioural weight
loss programme
100 1. Hypoglycaemia
2. Left lower quad-
rant pain and vom-
iting
3.
Ear disorders (otitis,
earache, ear pain)
4. Eye dis-
1. 0
2. 0
3. 7
4. 8
5.16
6. 18
7. 6
8. 1
1. 0
2. 0
3. 7
4. 8
5.16
6. 18
7. 6
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orders (change in vi-
sion, conjunctivitis,
styes)
5. Abdominal pain
or cramping
6. Bloating or gas
7. Borborygmi
8. Constipation
9. Controlled dis-
charge of oil with-
out stool
10. De-
creased frequency of
bowel movements
11. Diarrhoea
12. Fatty-appearing
stools
13. Flatulence (pas-
sage of gas)
14. Flatus with dis-
charge
15. Frequent urge
for bowel
movement
16. Hiccups
17. In-
creased frequency of
bowel movements
18. Nausea
19. Oily spotting
20. Rectal bleeding
- haemorrhoids
21. Soft or deliques-
cent stools
22. Stomach pain or
cramps
23. Stools almost all
liquid with very few
solid parts
24. Stools hard and
in the shape of small
pellets
25. Stools mixed
with fat or with a
separate oily layer
26. Uncontrolled
passage of stool or
9. 56
10. 25
11. 21
12. 61
13. 60
14. 43
15. 19
16. 1
17. 68
18. 10
19. 6
20. 4
21. 68
22. 8
23. 64
24. 11
25. 83
26. 60
27. 44
28. 7
29. 4
30. 5
31. 5
32. 14
33. 3
34. 5
35. 2
36. 1
37. 6
38. 1
39. 11
40. 16
41. 3
42. 1
43. 1
44. 0
45. 5
46. 0
47. 14
48. 5
8. 1
9. 56
10. 25
11. 21
12. 61
13. 60
14. 43
15. 19
16. 1
17. 68
18. 10
19. 6
20. 4
21. 68
22. 8
23. 64
24. 11
25. 83
26. 60
27. 44
28. 7
29. 4
30. 5
31. 5
32. 14
33. 3
34. 5
35. 2
36. 1
37. 6
38. 1
39. 11
40. 16
41. 3
42. 1
43. 1
44. 0
45. 5
46. 0
47. 14
48. 5
217Drug interventions for the treatment of obesity in children and adolescents (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
oil
27. Urgent,
but controlled, need
to produce stools
28. Vomiting
29. Dizziness
30. Epistaxis
31. Feeling cold
32. Headache
33. Increased sweat-
ing
34. Increased thirst
35. Sinusitis, post-
nasal drip or nasal
stuffiness
36. Unusual tired-
ness or weakness (fa-
tigue)
37. Pharyngitis
38. Sinusitis, post-
nasal drip or nasal
stuffiness
39. Decrease in ap-
petite
40. Muscle pain,
stiffness, cramps or
ache
41. Migraine
headaches
42. Mental depres-
sion
43. Dysuria or UTI
44. Nocturia
45. Asthma symp-
toms
46. Cough
47. Upper respira-
tory infection
48. Skin rash
C: placebo +
behavioural weight
loss programme
100 1. Hypoglycaemia
2. Left lower quad-
rant pain and vom-
iting
3.
Ear disorders (otitis,
earache, ear pain)
4. Eye dis-
1. 1
2. 1
3. 7
4. 9
5. 21
6. 5
7. 2
8. 7
1. 1
2. 1
3. 7
4. 9
5. 21
6. 5
7. 2
8. 7
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orders (change in vi-
sion, conjunctivitis,
styes)
5. Abdominal pain
or cramping
6. Bloating or gas
7. Borborygmi
8. Constipation
9. Controlled dis-
charge of oil with-
out stool
10. De-
creased frequency of
bowel movements
11. Diarrhoea
12. Fatty-appearing
stools
13. Flatulence (pas-
sage of gas)
14. Flatus with dis-
charge
15. Frequent urge
for bowel
movement
16. Hiccups
17. In-
creased frequency of
bowel movements
18. Nausea
19. Oily spotting
20. Rectal bleeding
- haemorrhoids
21. Soft or deliques-
cent stools
22. Stomach pain or
cramps
23. Stools almost all
liquid with very few
solid parts
24. Stools hard and
in the shape of small
pellets
25. Stools mixed
with fat or with a
separate oily layer
26. Uncontrolled
passage of stool or
9. 11
10. 22
11. 8
12. 6
13. 47
14. 11
15. 3
16. 3
17. 45
18. 9
19. 0
20. 2
21. 42
22. 9
23. 34
24. 10
25. 18
26. 11
27. 18
28. 7
29. 4
30. 2
31.2
32. 17
33. 4
34. 4
35. 5
36. 5
37. 12
38. 3
39. 9
40. 12
41. 0
42. 3
43. 5
44. 3
45. 3
46. 7
47. 17
48. 2
9. 11
10. 22
11. 8
12. 6
13. 47
14. 11
15. 3
16. 3
17. 45
18. 9
19. 0
20. 2
21. 42
22. 9
23. 34
24. 10
25. 18
26. 11
27. 18
28. 7
29. 4
30. 2
31.2
32. 17
33. 4
34. 4
35. 5
36. 5
37. 12
38. 3
39. 9
40. 12
41. 0
42. 3
43. 5
44. 3
45. 3
46. 7
47. 17
48. 2
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oil
27. Urgent,
but controlled, need
to produce stools
28. Vomiting
29. Dizziness
30. Epistaxis
31. Feeling cold
32. Headache
33. Increased sweat-
ing
34. Increased thirst
35. Sinusitis, post-
nasal drip or nasal
stuffiness
36. Unusual tired-
ness or weakness (fa-
tigue)
37. Pharyngitis
38. Sinusitis, post-
nasal drip or nasal
stuffiness
39. Decrease in ap-
petite
40. Muscle pain,
stiffness, cramps, or
ache
41. Migraine
headaches
42. Mental depres-
sion
43. Dysuria or UTI
44. Nocturia
45. Asthma symp-
toms
46. Cough
47. Upper respira-
tory infection
48. Skin rash
Ozkan 2004 I: conventional
treatment + orlistat
22 1. Frequent stools
2. Soiling, frequent
defecation
3.Mild hair loss
4. Reported muscle
cramps
1. 22
2. 5
3. 1
4. 1
1. 100
2. 22.7
3. 4.5
4. 4.5
C: conventional
treatment
20 - - -
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Prado 2012 I: metformin + nu-
tritional guide and
exercise programme
10 1. Increase levels of
ALT
2. Increase levels of
AST
3.Reduction in hae-
moglobin
- -
C: placebo + nutri-
tional guide and ex-
ercise programme
9 1. Increase levels of
ALT
2. Increase levels of
AST
3.Reduction in hae-
moglobin
- -
Rezvanian 2010 I1: metformin
+ healthy eating and
physical activity ad-
vice
45 1. Headache
2. Abdominal pain
3. Loose stool
1. 2
2. 2
3. 3
1. 4.4
2. 4.4
3. 6.6
I2: fluoxetine
+ healthy eating and
physical activity ad-
vice
45 1. Dry mouth
2. Loose stool
1. 3
2. 2
1. 6.6
2. 4.4
I3: metformin and
fluoxetine + healthy
eating and physical
activity advice
45 - - -
C: placebo + healthy
eating and physical
activity advice
45 - - -
Srinivasan 2006 I: metformin
first then placebo +
”standardised infor-
mation on healthy
eating and exercise“
13 - - -
C: placebo first then
metformin + ”stan-
dardised informa-
tion on healthy eat-
ing and exercise“
15 - - -
Van Mil 2007 I: sibutramine + en-
ergy-restricted diet
and exercise plan
12 1. Clinical depres-
sion
2. Flu syndrome
3. Headache
1. 1
2. 6
3. 2
4. 7
1. 8.3
2. 50
3. 16.6
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4. Abdominal com-
plaints
5. Agitation
6. Increased
appetite
7. Rash
8. Dizziness
9. Dysmenorrhoea
10. Joint problem
11.Heart rate > 100
bpm on 2 occasions
12. DBP >
85 mmHg on 2 oc-
casions
5. 3
6. 4
7. 2
8. 3
9. 3
10. 2
11. 4
12. 1
4. 58.3
5. 25
6. 33.3
7. 16.6
8. 25
9. 25
10. 16.6
11. 33.3
12. 8.3
C: placebo + energy-
restricted diet and
exercise plan
12 1. Flu syndrome
2. Headache
3. Agitation
4. Increased
appetite
5. Dizziness
6. Joint problem
7.DBP> 85mmHg
on 2 occasions
1. 6
2. 3
3. 1
4. 2
5. 1
6. 2
7. 1
1. 50
2. 25
3. 8.3
4. 16.6
5. 8.3
6. 16.6
7. 8.3
Wiegand 2010 I:
metformin + multi-
professional lifestyle
intervention
36 1. Gastrointestinal
symptoms
2. Unspecific (e.g.
weakness or fatigue)
1. 5
2. 3
1. 13.9
2. 8.3
C: placebo + multi-
professional lifestyle
intervention
34 1. Gastrointestinal
symptoms
2. Unspecific (e.g.
weakness or fatigue)
1. 9
2. 4
1. 26.5
2. 11.8
Wilson 2010 I: met-
formin + lifestyle in-
tervention
38 1. Headache
2. Nausea
3. Vomiting
4.Upper respiratory
tract infection
5. Musculoskeletal
complaints
6. Elevated ALT lev-
els
7. Appendectomy
8. Leg vein throm-
bosis
1. 18
2. 9
3. 6
4. 18
5. 5
6. 2
7. 1
8. 1
1. 47
2. 24
3. 16
4. 47
5. 13
6. 5
7. 3
8. 3
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C: placebo
+ lifestyle interven-
tion
38 1. Headache
2. Nausea
3. Vomiting
4.Upper respiratory
tract infection
5. Musculoskeletal
complaints
6. Elevated ALT lev-
els
1. 13
2. 3
3. 1
4. 23
5. 7
6. 1
1. 34
2. 8
3. 3
4. 61
5. 18
6. 3
Yanovski 2011 I: metformin
+ dietitian-adminis-
tered weight-reduc-
tion programme
53 1. Liquid or loose
stools
2. Vomiting
3. Fatigue
4. Lost interest in
usual pleasurable ac-
tivities
1. 22
2. 22
3. 20
4. 1
1. 41.5
2. 41.5
3. 37.7
4. 1.9
C: placebo
+ dietitian-adminis-
tered weight-reduc-
tion programme
47 1. Liquid or loose
stools
2. Vomiting
3. Fatigue
1. 8
2. 10
3. 7
1. 17
2. 21.3
3. 14.9
*Berkowitz 2003: these adverse events occurred during the open-label phase where all participants received sibutramine
ALT: alanine transaminase; AST: aspartate transaminase; bpm: beats per minute; DBP: diastolic blood pressure; n: number of
participants; UTI: urinary tract infection
Appendix 12. Survey of authors providing information on included trials
Trial Date trial author con-
tacted
Date trial author
replied
Date trial author was
asked for additional in-
formation
(short summary)
Date trial author pro-
vided data
(short summary)
Atabek 2008 24 January 2014
15 May 2014
No 24 January 2014 - asked
for additional unpub-
lished data and other on-
going trials
15 May 2014 - asked for
further details about the
trial including funding,
allocation concealment,
randomisation method,
dropout rates and adverse
events
N/A
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Berkowitz 2003 20 January 2014
15 May 2014
No 20 January 2014 - asked
for additional unpub-
lished data and other on-
going trials
15 May 2014 - asked for
further details about the
trial including randomi-
sation method, alloca-
tion concealment and ad-
verse events
N/A
Berkowitz 2006 20 January 2014
15 May 2014
No 20 January 2014 - asked
for additional unpub-
lished data and other on-
going trials
15 May 2014 - asked
for further details on the
trial’s adverse events
N/A
Chanoine 2005 20 January 2014
25 March 2014
15 May 2014
20 January 2014
25 March 2014
15 May 2014
03/06/2014
20 January 2014 - asked
for additional unpub-
lished data and other on-
going trials
25 March 2014 - asked
for raw BMI and SD val-
ues at 6 months’ follow-
up
15 May 2014 - asked for
further details about the
trial including blinding
and adverse events
20 January 2014 - au-
thor replied with confir-
mation the data of the
trial was correct and at-
tached an addition paper
for the trial
25 March 2014 - author
provided the raw data at
6 months
15 May 2014 - provided
further details on blind-
ing
3 June 2014 - gave addi-
tional results on adverse
events
Clarson 2009 24 January 2014
15 May 2014
31 January 2014
19 May 2014
24 January 2014 - asked
for additional unpub-
lished data and other on-
going trials
15 May 2014 - asked
for further details about
the trial including alloca-
tion concealment, blind-
ing and adverse events
31 January 2014 - author
confirmed there was no
further data for the trial
and provided a protocol
for an ongoing trial
19 May 2014 - author
provided further details
about the trial
Franco 2014 24 February 2015 9 March 2015 24 February 2015 9 March 2015 - authors
replied with further de-
tails on the trial such
as funding source, ran-
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domisation method and
blinding
Freemark 2001 20 January 2014
25 March 2014
15 May 2014
16 May 2014 20 January 2014 - asked
for additional unpub-
lished data and other on-
going trials
25 March 2014 - asked
for BMI raw data and as-
sociated SDs
15 May 2014 - asked
for further details about
the trial including alloca-
tion concealment, blind-
ing and adverse events
16 May 2014 - author
provided further details
about the trial
Garcia-Morales 2006 21 January 2014
15 May 2014
No 21 January 2014 - asked
for additional unpub-
lished data and other on-
going trials
15 May 2014 - asked for
further details about the
trial including the run-in
period, blinding and ad-
verse events
N/A
Godoy-Matos 2005 20 January 2014
15 April 2014
17 May 2014 20 January 2014 - asked
for additional unpub-
lished data and other on-
going trials
15 April 2014 - asked for
further details about the
trial including allocation
concealment, randomi-
sation method, blinding
and adverse events
17 May 2014 - author
provided further details
about the trial
Kendall 2013 24 January 2014
15 May 2014
29 January 2014 24 January 2014 - asked
for additional unpub-
lished data and other on-
going trials
15 May 2014 - asked for
further details about the
trial including blinding
and adverse events
29 January 2014 - author
confirmed no additional
datawere available for the
trial
Author did not reply to
the follow-up email (15
May 2014)
Maahs 2006 20 January 2014
09 May 2014
15 May 2014
20 January 2014
09 May 2014
15 May 2014
20 January 2014 - asked
for additional unpub-
lished data and other on-
20 January 2014 - au-
thor confirmed no fur-
ther data were available
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going trials
09 May 2014 - asked to
confirmed if the data pre-
sented were SDs or SEs
15 May 2014 - asked
for further details on the
trial’s adverse events
for the trial
09 May 2014 - author
confirmed the data were
SDs
15 May 2014 - author
could not provide further
information on the ad-
verse events
Mauras 2012 24 January 2014
15 May 2014
16 May 2014
15 May 2014
27 May 2014
24 January 2014 - asked
for additional unpub-
lished data and other on-
going trials
15 May 2014 - asked for
further details on the trial
including allocation con-
cealment, randomisation
method, number of trial
centres, blinding and ad-
verse events
16 May 2014 - asked for
further information on
adverse events
15 May 2014 - author
provided further details
on the trial
27 May 2014 - author
said she would try to ob-
tain the data; however,
we received no further
emails
NCT00001723 30 October 2015 30 October 2015 30 October 2015 - asked
for further details on the
trial: blinding, allocation
concealment, randomi-
sation process, funding,
publications and lifestyle
programme
30 October 2015 - au-
thor replied and gave fur-
ther details
Ozkan 2004 No - was unable to send
emails to the address
given in the publication
N/A N/A N/A
Prado 2012 17 January 2014
24 January 2014
15 May 2014
28 January 2014
18 May 2014
17 January 2014 - asked
for raw BMI data
24 January 2014 - asked
for additional unpub-
lished data and other on-
going trials
15 May 2014 - asked for
further details on the trial
including blinding, allo-
cation concealment and
adverse events
28 January 2014 - author
was unable to provide
any unpublished data
18 May 2014 - author
provided further infor-
mation about the trial
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Rezvanian 2010 24 January 2014
15 May 2014
24 January 2014
15 May 2014
24 January 2014 - asked
for additional unpub-
lished data and other on-
going trials
15 May 2014 - asked
for further details on the
trial including allocation
concealment and adverse
events
24 January 2014 - author
confirmed there were no
further details to give on
the trial and provided ref-
erences to other poten-
tially relevant trials
15 May 2014 - author
provided further details
about the trial
Srinivasan 2006 20 January 2014
15 May 2014
15 May 2014 20 January 2014 - asked
for additional unpub-
lished data and other on-
going trials
15 May 2014 - asked
for further details on the
trial including allocation
concealment and adverse
events
15 May 2014 - author
provided further details
about the trial
Van Mil 2007 20 January 2014
15 May 2014
20 January 2014
30 May 2014
20 January 2014 - asked
for additional unpub-
lished data and other on-
going trials
15 May 2014 - asked
for further details on the
trial including randomi-
sation, blinding and ad-
verse events
20 January 2014 - author
confirmed findings were
correct and highlighted
the main finding of their
trial
30 May 2014 - author
provided further details
about the trial
Wiegand 2010 24 January 2014
15/04/2014
27 January 2014 24 January 2014 - asked
for additional unpub-
lished data and other on-
going trials
15 May 2014 - asked
for further details on the
trial including allocation
concealment, randomi-
sation, blinding and ad-
verse events
27 January 2014 - author
confirmed there was no
further data available for
the trial
Author did not reply to
the follow-up email
Wilson 2010 24 January 2014
15 May 2014
24 January 2014
15 May 2014
24 January 2014 - asked
for additional unpub-
lished data and other on-
going trials
15 May 2014 - asked for
further details on the trial
including dropouts and
adverse events
24 January 2014 - au-
thor confirmed there was
no unpublished data on
themain outcomes of the
trial
15 May 2014 - author
said he would try to ob-
tain the data; however, I
227Drug interventions for the treatment of obesity in children and adolescents (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
did not receive any fur-
ther emails
Yanovski 2011 24 January 2014
15 May 2014
24 January 2014 24 January 2014 - asked
for additional unpub-
lished data and other on-
going trials
15 May 2014 - asked
for further details on the
trial’s adverse events
24 January 2014 - author
confirmed the trial was
over and there is no fur-
ther information avail-
able
Author did not reply to
the follow-up email
BMI: body mass index; N/A: not applicable; SD: standard deviation; SE: standard error
Appendix 13. Checklist to aid consistency and reproducibility of GRADE assessments
Questions BMI Weight Adverse
events
(serious ad-
verse events
/ adverse
events caus-
ing discon-
tinuation of
trial)
Health-re-
lated qual-
ity of life
All-cause
mortality
Morbidity Socioe-
conomic ef-
fects
Trial limita-
tions
(risk of
bias)a
1. Was ran-
dom se-
quence gen-
era-
tion used (i.
e. no poten-
tial for selec-
tion bias)?
Yes Yes Yes / Yes N/A N/A N/A N/A
2. Was allo-
cation con-
cealment
used (i.e. no
potential for
selection
bias)?
Yes Yes Yes / Yes
3. Was there
blinding of
participants
and person-
Yes Yes Yes / Yes
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nel (i.e. no
potential for
perfor-
mance bias)?
4. Was there
blinding of
outcome as-
sessment (i.
e. no poten-
tial for de-
tection bias)
?
Yes Yes Yes / Yes
5.
Was an ob-
jective out-
come used?
Yes Yes Yes / Yes
6. Were
more than
80% of par-
ticipants en-
rolled in tri-
als included
in the anal-
ysis (i.e. no
potential re-
porting bias)
?e
Yes Yes Yes / No ()
7. Were data
re-
ported con-
sistently for
the outcome
of interest (i.
e. no poten-
tial selective
reporting)?
Yes Yes No () / No ()
8. No other
biases
reported (i.
e. no poten-
tial of other
bias)?
No () No () Unclear /
Unclear
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9. Did the
trials end up
as scheduled
(i.e.
not stopped
early)?
Yes Yes Yes / Yes
Inconsis-
tencyb
1. Point esti-
mates
did not vary
widely?
Yes Yes Yes / Yes
2.
To what ex-
tent did con-
fidence in-
tervals over-
lap (substan-
tial: all con-
fi-
dence inter-
vals overlap
at least one
of the in-
cluded stud-
ies point es-
timate;
some: confi-
dence inter-
vals overlap
but
not all over-
lap at least
one point es-
timate;
no: at least
one outlier:
where the
confi-
dence inter-
val of some
of the stud-
ies do not
overlap with
those
of most in-
cluded stud-
ies)?
Some Some Substantial /
Substantial
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3. Was the
direc-
tion of effect
consistent?
No () No () No () / No ()
4. What was
the magni-
tude of sta-
tistical het-
erogeneity
(asmeasured
by I2) - low
(I2 < 40%)
,moderate (I
2 = 40% to
60%), high
(I2 > 60%)?
High () High () Low / Low
5. Was the
test for het-
ero-
geneity sta-
tistically sig-
nificant (P <
0.1)?
Statistically
significant ()
Statistically
significant ()
Not statisti-
cally signifi-
cant /
Not statisti-
cally signifi-
cant
Indirect-
nessa
1. Were the
popu-
lations in in-
cluded stud-
ies applica-
ble to the de-
cision con-
text?
Applicable Applicable Applicable /
Applicable
2. Were the
inter-
ventions in
the included
studies
applicable to
the decision
context?
Applicable Applicable Applicable /
Applicable
3. Was
the included
outcomenot
a surrogate
outcome?
Yes Yes Yes / Yes
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4. Was
the outcome
time frame
sufficient?
Sufficient Sufficient Sufficient /
Sufficient
5. Were the
conclusions
based on di-
rect compar-
isons?
Yes Yes Yes / Yes
Impreci-
sionc
1. Was the
confi-
dence inter-
val for the
pooled
estimate not
consistent
with benefit
and harm?
Yes Yes No () / No ()
2. What is
the magni-
tude of the
me-
dian sample
size (high: >
300 partici-
pants, inter-
me-
diate: 100 to
300 partici-
pants, low: <
100 partici-
pants)?e
Low () Low () Intermedi-
ate / Low ()
3. What was
the magni-
tude
of the num-
ber of in-
cluded stud-
ies (large:
> 10 studies,
moderate: 5
to 10 stud-
ies, small: <
5 studies)?e
Large Large Moderate /
Moderate
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4. Was
the outcome
a common
event (e.g.
occurs more
than 1/100)
?
N/A N/A Yes / Yes
Publication
biasd
1.
Was a com-
prehensive
search con-
ducted?
Yes Yes Yes / Yes
2. Was grey
literature
searched?
No () No () No () / No ()
3. Were no
restrictions
applied to
study selec-
tion on the
basis of lan-
guage?
Yes Yes Yes / Yes
4. There was
no industry
influence on
studies
included in
the review?
No () No () No () / No ()
5. There was
no evidence
of
funnel plot
asymmetry?
No () No () Unclear /
Unclear
6. There was
no dis-
crepancy in
findings be-
tween pub-
lished
and unpub-
lished trials?
Unclear Unclear Unclear /
Unclear
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aQuestions on risk of bias are answered in relation to most of the aggregated evidence in the meta-analysis rather than to individual
studies.
bQuestions on inconsistency are primarily based on visual assessment of forest plots and the statistical quantification of heterogeneity
based on I2 statistic.
cWhen judging the width of the confidence interval it is recommended to use a clinical decision threshold to assess whether the
imprecision is clinically meaningful.
dQuestions address comprehensiveness of the search strategy, industry influence, funnel plot asymmetry and discrepancies between
published and unpublished trials.
eDepends on the context of the systematic review area.
(): key item for potential downgrading the certainty of the evidence (GRADE) as shown in the footnotes of the ’Summary of finding’
table
BMI: body mass index; N/A: not applicable.
Appendix 14. Health-related quality of life: instruments
Instrument
Short-Form health survey (SF-36, generic questionnaire) - employed in García-Morales 2006.
Brief Symptom Inventory (BSI, generic questionnaire), parent and children’s KINDL (generic questionnaire), Impact of Weight on
Quality of Life - Kids (IWQOL-Kids, specific questionnaire) and global ratings scale - all employed in Maahs 2006.
WH A T ’ S N E W
Last assessed as up-to-date: 15 March 2016.
Date Event Description
1 September 2016 New citation required and conclusions have changed Given the rapid growth in the treatment of child and
adolescent obesity, we have split the original review (’In-
terventions for treating obesity in children and adoles-
cents’) into six separate reviews, with a specific inter-
vention and age focus
(1) Diet, physical activity, and behavioural interven-
tions for the treatment of overweight or obesity in ado-
lescents aged 12 to 17 years.
(2) Diet, physical activity, and behavioural interven-
tions for the treatment of overweight or obesity in
schoolchildren from the age of 6 to 11 years.
(3) Diet, physical activity, and behavioural interven-
tions for the treatment of overweight or obesity in
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preschool children up to the age of 6 years.
(4) Drug interventions for the treatment of obesity in
children and adolescents.
(5) Parent-only interventions for childhood overweight
or obesity in children aged 5 to 11 years.
(6) Surgery for the treatment of obesity in children and
adolescents
1 September 2016 New search has been performed This is an update of the former Cochrane review ’In-
terventions for treating obesity in children and adoles-
cents’
C O N T R I B U T I O N S O F A U T H O R S
EM: search strategy development, acquiring trial reports, trial selection, data extraction, data analysis, data interpretation, review draft
and future review updates.
GA: data extraction, data analysis, data interpretation, review draft and future review updates.
BR: data analysis, data interpretation and review draft
MIM: search strategy development and review draft.
LB: data extraction, data interpretation, review draft and future review updates.
NF: data extraction, data interpretation, review draft and future review updates.
EC: data extraction, data interpretation, review draft and future review updates.
CO: acquiring trial reports, trial selection, data extraction, data interpretation, review draft and future review updates.
LE: search strategy development, acquiring trial reports, trial selection, data extraction, data analysis, data interpretation, review draft
and future review updates.
D E C L A R A T I O N S O F I N T E R E S T
EM: none known.
GA: none known.
BR: none known.
MIM: none known.
LB: none known.
NF: has provided medical consultancy to several pharmaceutical companies developing and marketing (outside of the UK at present)
treatments for obesity. Since March 2016 he is employed by Novo Nordisk, Denmark in Global Medical Affairs.
EC: none known.
CO: none known.
LE: none known.
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• University Medical Center, Groningen, Netherlands.
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• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Given the rapid growth in the treatment of child and adolescent obesity, the original review has now been split into six separate reviews,
with a specific intervention and age focus. Whilst the other reviews in this series utilised an updated version of the original search
strategy, we developed a new search strategy (see Appendix 1) to reflect advances in pharmacological therapies that may not have been
adequately captured in the original search strategy. We decided to exclude trials which included growth hormone therapies to avoid
including trials which treated conditions such as Cushing’s syndrome. In addition, some subgroup analyses were not possible due to a
limited number of trials.
We included only randomised controlled trials that were specifically designed to treat obesity in children and observed participants
for a minimum of six months. The rationale for introducing this criterion arose from the belief that many interventions appear to be
effective in the short term (up to three months), but not in the long term (Glenny 1997). It seemed to be more important to evaluate
the longer-term effects of treatments, as this would provide a more valuable indication of effectiveness, given the chronic nature of
obesity.
N O T E S
Portions of the methods sections, the appendices, additional tables and figures 1 to 3 of this review are based on a standard template
established by the Cochrane Metabolic and Endocrine Disorders Group.
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